Dubai Final-v20.indd - World Allergy Organization

Final Program 

5–8 December 2010 • WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE 

Dubai, UAE 

Asthma and Co-morbid Conditions: 

Expanding the Practice of Allergy for Optimal Patient Care 

A World Federation of Allergy, Asthma 

& Clinical Immunology Societies 

www.worldallergy.org

CANCÚN, MÉXI 

World Allergy Congress 

Registration 

Open! 

Register between now and January 1, 2011 to 

receive 10% off of your registration rate! 

Just enter the code: WISC2010 

when prompted during the 

registration process. 

http://www.worldallergy.org/ 

wac2011/registration/ 

OOOOORR 

The World Allergy Organization (WAO) holds its World Allergy 

Congress (WAC) every two years. Each Congress attracts over 

4,000 professionals working and interested in the field 

of allergy, asthma, and clinical immunology and 

WORLD ALLERGY 

HOTEL ACCOMMODATIONS 

CANCÚN, MÉXICO 

www.worldallergy.org/wac 20 1 1 

Hotels, Travel, and Social 

Program Information 

other related fields. 

WAO will offer a variety of discounted hotel accommodations for attendees. Cancún offers some 

of the most comfortable hotels with easy access to the Convention Center. 

TRAVEL 

The Cancún International Airport (CUN) is served by a large number of international airline 

carriers that provide direct service from several major cities, making Cancún one of the easiest 

and most affordable destinations to visit. 

SOCIAL PROGRAM 

Following in the tradition of previous World Allergy Congresses, an exciting social program is 

being planned by members of the Congress Organizing and Local Organizing Committees. 

Events will include the Opening Ceremony, Welcome Reception and All Congress Event. Optional 

tours will also be available for delegates and accompanying persons.

CO 

COImportant Dates 

30 June 2011 Early Registration Deadline 

30 June 2011 Abstract Submission Deadline 

15 July 2011 Late-Breaking Abstract Submission Deadline 

31 October 2011 Late Registration Deadline 

3 December 2011 On-Site Registration Begins 

4-8 December 2011 2011 World Allergy Congress 

CONGRESS 

CONGRESS 2011 2011 

4-8 4-8 DECEMBER DECEMBER 2011 2011 

ICO ICO 

Scientific Program 

The World Allergy Congress 2011will feature 

a variety of topics and session types 

TOPIC SESSION TYPE 

Asthma & co-morbid conditions Breakfast Symposia 

Debates Plenary Sessions 

Drug allergy Meet the Experts 

Immunetherapy Hands-On Workshops 

Pediatric allergy & asthma New Horizon Sessions 

Primary & secondary immunedeficiencies 

and allergic diseases 

For a full listing and more information about the Scientific Program visit the WAC2011 website. 

You may start submitting abstracts to be a part of the program, starting in February 2011! 

Keep checking http://www.worldallergy.org/wac2011/abstracts for more information. 

A meeting of the 

In collaboration with 

WAO-1010--417

WElCOmE lEttErs 

ruby Pawankar 

President Elect, WAO 

Conference Organizing 

Chair 

WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE 

Asthma and Co-morbid Conditions: Expanding the Practice of Allergy for Optimal Patient Care 

Dear Colleagues, 

Welcome to Dubai and the World Allergy Organization’s 1st international scientific Conference! 

the theme of this Conference, “Asthma and Co-morbid Conditions: Expanding the Practice of Allergy for Optimal Patient Care,” is 

one that, as President of the WAO, i have promised to promote through research and education. As a member of the worldwide 

specialty of allergy, asthma and clinical immunology, i would like to encourage a culture in which allergists/immunologists are first 

knowledgeable primary care physicians, internists, and pediatricians, and then specialists. Physicians trained in this way should 

be able to provide patients with more complete, cost-effective care for asthma and allied allergic and immunologic diseases. they 

should be able to diagnose and treat co-morbid conditions. thus, the theme of this Conference is to capture and reflect this vision. 

Your participation in this inaugural event will help transform this vision of how we manage allergic diseases into everyday practice. 

i wish you a most successful Conference. 

richard F. lockey 

President, World Allergy Organization (WAO) 

On behalf of the WAO Board of Directors 

Dear Friends, 

We join richard lockey in warmly welcoming you to this meeting. it has been a most rewarding experience organizing this Conference 

and developing its scientific program. We are confident that as a participant your experience will be equally energizing for you. the 

scientific and educational program is designed to provide a forum for the latest research, reviews of current theory and practice, and 

importantly, “hands-on” problem-based learning. it is our hope, that as practitioners, educators, and researchers, you will take away 

from this Conference valuable insight into the most effective advances in the diagnosis and management of asthma and its comorbidities 

as well as broader aspects of related allergic disorders to meet the challenges of the global unmet needs in this area. 

We want to take this opportunity also to thank the exceptionally skilled and committed faculty who are a truly international and 

versatile group. A majority of the faculty is presenting more than once covering different session-types and several co-morbidities 

– demonstrating in this range the true meaning of the theme of this Conference: “Asthma and Co-morbid Conditions: Expanding the 

Practice of Allergy for Optimal Patient Care”. 

An equally important part of learning occurs outside the sessions when we have the important opportunity to meet up with 

colleagues to exchange ideas, make new connections and continue old conversations. We hope you will do plenty of all this. Please 

share with us your feedback and ideas so that we can continue to promote excellence in the field of allergy and asthma. 

Once again: Welcome! 

sincerely, 

g. Walter Canonica 

Past President, WAO 

Executive Chair, 

scientific Program 

Committee 

Eric Bateman 

Co-Chair, 


Committee 

Stephen T. Holgate 

member-at-large, 

WAO Board 

Co-Chair, 


Committee 

robert lemanske 

Co-Chair, 


Committee 

www.worldallergy.org 2 

FinAl PrOgrAm



On behalf of the Dubai Health Authority, i would like to welcome you to the World Allergy Organisation’s (WAO’s) inaugural 

international scientific Conference that is taking place in Dubai from the 5th to the 8th of December, 2010 at the Dubai international 

Convention and Exhibition Centre 

As a strategic and principle health authority for the Emirate of Dubai, the DHA is responsible for securing and policing the very best 

healthcare standards in Dubai and is also responsible for developing the future direction of health policy here in Dubai. 

Hosting, attending and speaking at congresses such as this are an important part of our vision as we continue to develop 

healthcare policies that meet the requirements of our population, now and in the future. 

the Conference programme highlights a range of issues and areas of interests that will be explored over the next few days. this 

is reflected in the number of eminent healthcare professionals from around the world who will be joining and speaking at the 

Conference. 

this is a platform where international and local eminent speakers will get an opportunity to discuss and understand the latest in the 

diagnosis and management of asthma and its co-morbidities. 

the forum shall help healthcare professionals interact with colleagues, regional leaders and world experts in the field, thus updating 

their knowledge. 

With this, i wish you all the best and i hope you enjoy the Conference. 

His Excellency Qadhi saeed Al murooshid 

Director general of the Dubai Health Authority 


FinAl PrOgrAm

tABlE OF COntEnts 

About the World Allergy Organization (WAO) . . . . . . . . . . . . 5-6 

WAO member societies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 

Welcome to Dubai!. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 

general information, A-Z . . . . . . . . . . . . . . . . . . . . . . . . 10-11 

Conference information, A-Z . . . . . . . . . . . . . . . . . . . . . 13-16 

Dubai international Convention and 

Exhibition Centre Floorplans. . . . . . . . . . . . . . . . . . . . . . 16-17 

Hotels map . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 

Optional tours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 

Exhibition Floorplan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 

Exhibitor Directory . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23-26 

Program-at-a-glance. . . . . . . . . . . . . . . . . . . . . . . . . . . 29-32 

scientific Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33-52 

Posters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54-76 

Abstracts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78-162 

speaker and Chairperson index . . . . . . . . . . . . . . . . . 163-164 

Poster Author index . . . . . . . . . . . . . . . . . . . . . . . . . . 165-169 

sponsors & Partners . . . . . . . . . . . . . . . . . . . . . . . Back Cover 

World allergy organization (Wao) Secretariat 

555 E. Wells st., suite 1100 

milwaukee, Wi 53202 UsA 

Phone: +1 414 276 1791 

Fax: +1 414 276 3349 

E-mail: info@worldallergy.org 



COmmittEEs 

WAO BOArD OF DirECtOrs 2010-2011 

richard F. lockey, President 

mario sanchez Borges, treasurer 

lanny J. rosenwasser, secretary-general 

ruby Pawankar, President-Elect 

g. Walter Canonica, Past-President 

michael A. Kaliner, Historian 

ignacio Ansotegui 

michael Blaiss 

thomas B. Casale 

motohiro Ebisawa 

Yehia El-gamal 

sandra gonzalez-Diaz 

tari Haahtela 

stephen t. Holgate 

Juan Carlos ivancevich 

marek l. Kowalski 

Hae-sim Park 

Paul C. Potter 

tatiana slavyanskaya 

myron Zitt 

2010 WAO intErnAtiOnAl sCiEntiFiC COnFErEnCE 

OrgAniZing COmmittEEs 

Conference President 


Conference organizing 

Chair 

ruby Pawankar 

Scientific Program 

Executive Committee 

g. Walter Canonica, Executive 

Chair 

Eric Bateman, Co-Chair 

stephen t. Holgate, Co-Chair 

robert lemanske, Co-Chair 

local organizing 

Committee 

ruby Pawankar, Chair 

Bassam mahboub, Co-Chair 

mona Al Ahmad, Co-Chair 

suleiman Al Hammadi 

saleh Al muhsen 

salem Al tamemi 

Abdulla ibrahim 

regional advisor 

Yehia El-gamal 

regional advisory Committee 

Hani Ababneh 

malek Abdulalim 

Yousef Abdulrazzaq 

Abdulrahman Al Frayh 

Harb Al Harfi 

Jamil Al mughales 

mirza Al sayegh 

Adel Al Wahadneh 

shirina Al souwaidi 

Zeinab Awad 

Zeina Baz 

Abdenour Benyounes 

Habib Douagui 

mohamad Ehlayel 

Ahmed Elbousify 

Youness El gueddari 

Kamal Hanna 

syed Hasnain 

Elham Hossny 

lubna Hwejeh 

Omer Kalayci 

Ali Ben Kheder 

Andreas liveris 

Yousser mohamed 

mostafa moin 

mohammad reza masjedi 

menachem rottem 

Fadhel saleh 

Zineb sayah 

Arzu Yorgancioglu 

Fares Zaitoun 


FinAl PrOgrAm

ABOUt WAO 

the World Allergy Organization (WAO) is a global federation 

of 84 regional and national allergy, asthma and clinical 

immunology societies. through collaboration with its member 

societies, WAO provides a wide range of educational and 

outreach programs to WAO individual members around the 

globe. these programs, relating to the clinical practice of 

allergy and asthma, allergy and asthma service provision, and 

physician training in allergy and asthma help better understand 

and address the challenges facing allergists worldwide. 

missiOn 

WAO’s mission is to be a global resource and advocate in the 

field of allergy, advancing excellence in clinical care through 

education, research and training as a worldwide alliance of 

allergy, asthma and clinical immunology societies. 

mEEtings 

World allergy Congress (WaC) 

WAO hosts the World Allergy Congress (WAC) – its main 

scientific meeting – biennially in different regions of the world. 

Please join us in Cancún, méxico in 2011, rome, italy in 2013 

and seoul, Korea in 2015. For more details on WAC 2011 in 

Cancún, please visit www.worldallergy.org/wac2011 

Wao international Scientific Conference 

WAO is excited to launch its theme-based scientific Conference, 

alternating with and complementing WAO’s biennial Congress. 

it is with great pleasure that we welcome you to the 1st WAO 

international scientific Conference on Asthma and Co-morbid 

Conditions: Expanding the Practice of Allergy for Optimal Patient 

Care in Dubai, UAE, 5-8 December 2010. 

WAO WEBsitE 

www.worldallergy.org 

As a leading global online destination for allergy, asthma and 

clinical immunology, www.worldallergy.org supports and 

enhances all WAO educational activities and provides materials 

specifically designed for continued medical training. Popular 

resources include the specially commissioned educational 

synopses on major topics posted in the Allergic Diseases 

Resource Center, interactive case studies that challenge 

allergists to diagnose unusual cases, an archive of webinars 

recorded at major meetings, and audio recordings of interviews 

with key opinion leaders around the world. the WAO website is 

now HOncode certified. 

tHE WOrlD AllErgY OrgAniZAtiOn JOUrnAl 

www.waojournal.org 

The World Allergy Organization Journal (WAO Journal) is the 

official publication of WAO and underscores WAO’s commitment 

to raising awareness and advancing excellence in clinical care, 

education, research and training. this international, peerreviewed 

journal covers a broad spectrum of the interdisciplinary 

fields of allergy and clinical immunology. As an online-only 

journal, the publication process of the WAO Journal is efficient 

and quick, with articles posted each month on schedule. All WAO 

members have free access to the WAO Journal. 



the primary goals of the WAO Journal are: 

• to be a premier journal of original scientific and clinically 

relevant information for practicing allergists/immunologists 

and other physicians concerned with the practice of allergy 

and clinical immunology 

• to publish state-of-the-art review articles and editorials on 

translational and clinical medicine in the field of allergy and 

immunology 

• to present a forum for scientific interaction between 

allergists and immunologists worldwide 

WAO PrOgrAms FOr EDUCAtiOn, 

rEsEArCH AnD PAtiEnt CArE 

global resources in allergy (gloria) 

glOriA promotes best practices in the management of allergic 

disease through didactic programs developed by international 

experts. glOriA is presented at national and regional allergy 

society meetings throughout the world and also at regional, 

state and local society meetings within the United states. All 

current glOriA modules are available for free download at 

www.worldallergy.org/gloria 

World allergy Forum ® (WaF) 

WAF brings cutting edge symposia to major allergy meetings 

throughout the world. Developed by international expert 

advisory panels, the symposia provide up-to-the minute 

presentations on scientific and clinical developments in the 

field of allergic disease. WAF placements attract up to 1,000 

attendees. WAF is supported by an unrestricted educational 

grant from novartis. View presentations for free at 

www.worldallergy.org/waf 

Emerging Societies Program (ESP) 

EsP advances the WAO mission by supporting developments 

that enable allergists to better serve patients now and in the 

future. EsP aims to disseminate information on and share 

experiences about new treatments for allergic disease and 

about new indications for available therapies. All EsP meetings 

and training schools are conducted with the help and support 

of WAO member societies. the American College of Allergy, 

Asthma and immunology (ACAAi) partners with WAO on EsP. 

View all EsP activities at www.worldallergy.org/esp 

WAO PrOJECts AnD PUBliCAtiOns 

www.worldallergy.org/publications 

anaphylaxis: 

• “Epinephrine: the drug of choice for anaphylaxis.” Kemp 

st, lockey rF, simons FEr, was published in 2008 (Allergy, 

2008, 63:1061-1070), and reproduced as an e-supplement 

to the WAO Journal. Available at www.waojournal.org 

• “Epinephrine auto-injectors: first-aid treatment still out of 

reach for many at risk of anaphylaxis in the community.” 

simons FEr, et al, for the World Allergy Organization. (Ann 

Allergy Asthma Immunol, 2009, 102: 403-409) 

• “global availability of medications, supplies and equipment 

for the assessment and management of anaphylaxis by 

physicians in healthcare settings.” simons, FEr, for World 

Allergy Organization, in preparation, 2010 


FinAl PrOgrAm

ABOUt WAO 

Cow’s milk allergy: “the evidence-based WAO global 

guidelines on the Diagnosis & rationale for Action Against 

Cow’s milk Allergy,” authored by the WAO Food Allergy special 

Committee. (WAO Journal. 2010;3(4):57-161) 

immunotherapy: “sub-lingual immunotherapy (slit) - 

WAO Position Paper 2009.” slit is an exciting therapeutic 

strategy on the delivery of immunotherapy and is gradually 

being adopted by allergy communities throughout the world. 

Following a first meeting in genoa in november 2008 to review 

experience of Us trials of slit, WAO hosted a meeting in Paris 

in January 2009 to develop the first global consensus on slit. 

All WAO regional & Affiliate member societies were invited to 

send representative delegates to this meeting and the majority 

were represented. they were joined by delegates representing 

non-member organizations including niH, gA2lEn, EFA, iCPrg, 

and AriA. A WAO Position Paper based on the Paris meeting was 

published in the WAO Journal, and in Allergy. (WAO Journal. 

2009;2(11):223-281) 

the first State of World allergy report (SoWar) appeared in 

the WAO Journal in June 2008. sOWAr stresses the importance 

of providing national allergy services for the burgeoning 

numbers of allergy patients in the world. this downloadable, 

on-line report is a useful resource for allergists and allergy 

societies wishing to make the case for improved local allergy 

service provision. Available at: www.waojournal.org. (WAO 

Journal. 2008;1(6):51-517) 

WAO Position Papers support and promote the specialty of 

allergy and help set standards for clinical practice and training: 

• “What is an allergist? A position statement of the WAO 

specialty and training Council.” 2008 Available at: www. 

waojournal.org 

• “requirements for physician competencies in allergy: Key 

clinical competencies appropriate for the care of patients 

with allergic or immunologic diseases—a position statement 

of the World Allergy Organization.” 2008 Available at: www. 

waojournal.org 

• “recommendations for competency in allergy training 

for undergraduates qualifying as medical practitioners – 

A position paper of the World Allergy Organization.” 2009 

Available at: www.waojournal.org 



Wao White Book on allergy is being prepared for launch in 

2011. the Executive summary to the WAO White Book is being 

launched during the Conference in Dubai. the WAO White Book 

will be an important resource to help individual allergists and 

allergy/immunology societies promote allergic diseases as a 

major global public health issue. 

WAO mEmBEr sOCiEtY sUrVEYs 

WAO’s federal structure provides a unique network to conduct 

effective global surveys about allergy and asthma. A number of 

projects have taken place over the last two years: 

• the WAO specialty and training Council conducted surveys 

on general/adult and pediatric clinical allergy services and 

training to obtain global information on current and future 

allergy service provision. 

• Building on the WAO’s 2007 international survey on the 

availability of epinephrine auto-injectors worldwide, in 2008 

the WAO special Committee on Anaphylaxis conducted 

a survey of member societies to gather data on how 

anaphylaxis is diagnosed and treated in healthcare settings 

in their respective countries. the combined results of 

these surveys will form the basis of the WAO international 

guidelines for the assessment and management of 

anaphylaxis, which was introduced at WAC 2009 and will 

launch in 2010. 

• the Asthma special Committee conducted a survey of 

member societies to find out about the major allergens 

involved in exacerbations of severe and chronic asthma, 

and to learn whether national definitions of severe asthma 

exist. the information obtained will form a WAO educational 

program based on the 2009 World Health Organization’s 

definition of severe Asthma. 

• the Drug Allergy special Committee conducted a survey on 

in-vivo methods used in the diagnosis of allergic reactions 

to major drug classes. the information obtained will be the 

first step to reaching a global consensus about the best way 

to diagnose drug hypersensitivity reactions, and to sharing 

expertise on this clinical problem. 

• the Evidence Based medicine and methodology special 

Committee developed a survey to establish allergists’ 

educational needs in evidence-based medicine. 

World allergy organization 

555 E. Wells st., suite 1100 

milwaukee, Wi 53202-3823 UsA 

Phone: +1 414 276 1791 

Fax: +1 414 276 3349 

E-mail: info@worldallergy.org 



FinAl PrOgrAm

WAO mEmBEr sOCiEtiEs 

Albanian society of Allergology and Clinical immunology 

American Academy of Allergy, Asthma and immunology 

American College of Allergy, Asthma and immunology 

Argentine Association of Allergy and Clinical immunology 

Argentine society of Allergy and immunopathology 

Australasian society of Clinical immunology and Allergy 

Austrian society of Allergology and immunology 

Azerbaijan society for Asthma, Allergy and Clinical immunology 

Bangladesh society of Allergy and immunology 

Belgian society of Allergy and Clinical immunology 

Brazilian society of Allergy and immunopathology 

British society for Allergy and Clinical immunology 

Bulgarian society of Allergology 

Canadian society of Allergy and Clinical immunology 

Chilean society of Allergy and immunology 

Chinese society of Allergology 

(Chinese) Hong Kong institute of Allergy 

Colombian Allergy, Asthma, and immunology Association 

Croatian society of Allergology and Clinical immunology 

Cuban society of Allergology 

Czech society of Allergology and Clinical immunology 

Danish society of Allergology 

Egyptian society of Allergy and Clinical immunology 

Egyptian society of Pediatric Allergy and immunology 

Finnish society of Allergology and Clinical immunology 

French society of Allergology 

georgian Association of Allergology and Clinical immunology 

german society for Allergology and Clinical immunology 

Hellenic society of Allergology and Clinical immunology 

Honduran society of Allergy and Clinical immunology 

Hungarian society of Allergology and Clinical immunology 

icelandic society of Allergy and immunology 

indian College of Allergy, Asthma and Applied immunology 

indonesian society for Allergy and immunology 

israel Association of Allergy and Clinical immunology 

italian Association of territorial and Hospital Allergists 



the World Allergy Organization (WAO), a world federation of allergy, asthma and clinical immunology societies, consists of 

84 member societies. 

All active members of dues-paying member societies are individual members of the World Allergy Organization (WAO). 

AssOCiAtE mEmBEr sOCiEtiEs 

national Association for Private Algerian 

Allergists 

Ecuadorian society of Allergy and 

immunology 

Ecuadorian society of Allergology and 

Affiliated sciences 

Jordanian society for Allergy and Clinical 

immunology 

Kuwait society of Allergy and Clinical 

immunology 

moroccan society of Allergology and 

Clinical immunology 

swedish Association for Allergology 

rEgiOnAl OrgAniZAtiOns 

Asia Pacific Association of Allergy, Asthma 

and Clinical immunology 

Commonwealth of independent states 

society of immunology and Allergology 

European Academy of Allergy and Clinical 

immunology 

latin American society of Allergy and 

immunology 

italian society of Allergy and Clinical immunology 

Japanese society of Allergology 

Korean Academy of Allergy, Asthma and Clinical immunology 

latvian Association of Allergists 

lebanese society of Allergy and immunology 

malaysian society of Allergy and immunology 

mexican College of Clinical immunology and Allergy 

mexican College of Pediatricians specialized in Allergy and 


mongolian society of Allergology 

netherlands society of Allergology 

norwegian society of Allergology and immunopathology 

Panamanian Association of Allergology and Clinical immunology 

Paraguayan society of immunology and Allergy 

Peruvian society of Allergy and immunology 

Philippine society of Allergy, Asthma and immunology 

Polish society of Allergology 

Portuguese society of Allergology and Clinical immunology 

romanian society of Allergology and Clinical immunology 

russian Association of Allergology and Clinical immunology 

serbian Association of Allergologists & Clinical immunologists 

Allergy and Clinical immunology society (singapore) 

slovenian Association for Allergology and Clinical immunology 

Allergy society of south Africa 

spanish society of Allergology and Clinical immunology 

Allergy & immunology society of sri lanka 

swiss society for Allergology and immunology 

Allergy, Asthma and immunology society of thailand 

turkish national society of Allergy and Clinical immunology 

Ukrainian Association of Allergologists and Clinical 

immunologists 

Uruguayan society of Allergology 

Venezuelan society of Allergy and immunology 

Vietnam Association of Allergy, Asthma and Clinical immunology 

Zimbabwe Allergy society 

AFFiliAtE OrgAniZAtiOns 

gA²lEn (global Allergy and Asthma 

European network) 

international Association of Asthmology 

international Primary Care respiratory 

group 

southern European Allergy societies 

Apply for your national Allergy society to become a WAO member society at www.worldallergy.org/wao_societies/apply.php 


FinAl PrOgrAm



WElComE To THE WorlD allErgY organiZaTion (Wao) 

inTErnaTional SCiEnTiFiC ConFErEnCE! 

5–8 DECEmBEr 2010 

VEnUE 

the venue for the Conference is the Dubai international 

Convention and Exhibition Centre (DiCEC). the DiCEC 

offers world class exhibition and convention facilities and 

is centrally located. 

Dubai international Convention and Exhibition Centre 

(DiCEC) 

sheikh Zayed road 

PO Box 9292 

Dubai 

United Arab Emirates 

tel: +971 4 332 1000 

Fax: +971 4 318 8741 

Website: www.dwtc.com 

WElComE To DUBai, UaE! 

Dubai is the second largest of the seven emirates that make up the United Arab Emirates. located on the southern shore 

of the beautiful Arabian gulf, Dubai is a city-state, replete with clean, sandy beaches and clear, blue-green waters. it has 

an ancient islamic heritage that survives amidst the skyscrapers and highways of a modern, cosmopolitan city of almost 

1.4 million people. this ‘Pearl of the Arabian gulf,’ concentrated mainly on its exquisite Creek, the fi nest natural shelter in 

1600 km (1000 miles) of coastline, ranks as the United Arab Emirates’ most important port and commercial center. 

With great underwater visibility and lots of sea life, snorkeling is a popular pastime in Dubai, as is quad biking in the 

desert, camel riding, and deep-sea fi shing and windsurfi ng. With a number of challenging golf courses, some with 

gorgeous views of the Creek, and the desert, there is plenty of choice in Dubai for the avid golfer. 

the several large shopping malls in Dubai provide an exciting variety of shops to choose from. shoppers can fi nd the best 

in designer labels and some fantastic bargains. there are local souks for those who do not wish to go to the malls, which 

offer local merchandise ranging from clothes and fabrics to regional food and fruit, woodcarvings and handicrafts. 


FinAl PrOgrAm

gEnErAl inFOrmAtiOn, A-Z 

BAnKs/Atm (AUtOmAtiC tEllEr mACHinEs): 

HOW DO YOU PAY? 

many international banks are represented by branches in Dubai. 

Bank hours vary but in general are 08:00 to 14:00, sunday to 

thursday and 08:00 to 12:00, saturday. 

Credit cards (American Express, Diners Club, master Card and 

Visa) and debit cards (Visa Electron) are widely accepted in all 

the shopping malls, supermarkets and many of the stand-alone 

shops. However, most of the smaller grocery stores and shops 

in the souks generally take cash. should you need to convert 

foreign currency into local currency, there are money exchanges 

and banks all over the city and in hotels. Atms are also located 

in most hotels and malls. 

Emirates Bank international ltd and national Bank of Dubai are 

located within the Dubai international Convention and Exhibition 

Centre (DiCEC), hours are 08:00 to 13:00 for Emirates Bank and 

national Bank of Dubai, daily except Fridays. Atm machines can 

be found on Concourses 1 and 2. 

BArgAining 

Bargaining is expected in the souk (market) and is quite usual 

elsewhere. Vendors will usually drop the price and often quite 

substantially, particularly for a cash sale. 

BUsinEss HOUrs 

Business: 08:00-13:00 and 16:00-19:30, sunday to thursday. 

most of the multinational companies work from 09:00-18:00 

with a one-hour lunch break. 

Government offices: 07:30-14:30, sunday to thursday. 

Exchange houses: 10:00-22:00. 

Shopping malls: 10:00-22:00, sunday to Wednesday and 

10:00-00:00, thursday and Friday. 

ClimAtE 

Dubai has a sub-tropical, arid climate. sunny, blue skies can be 

expected most of the year. rainfall is infrequent and irregular, 

falling mainly in winter. temperatures range from a low of about 

10.5°C/50°F to a high of 48°C/118°F. 

COmmUniCAtiOns 

the international dialing code for in-coming calls is +9714. 

Calls to and from land-lines within Dubai are free of charge 

and direct dialing is possible to more than 170 countries. 

gPrs and WAP services are also available. A gsm international 

roaming service for mobile phones is available for more than 

60 countries. if your country isn’t one of them, then a service 

known as “Wasel” is available. Bring your phone or buy it here 

and purchase a sim card (available at most supermarkets, 

petrol stations and hotels), which enables you to make and 

receive calls from the UAE. internet services are also available 

for nonsubscribers from regular phone lines. 



CUrrEnCY 

the currency in Dubai is the UAE Dirham (AED). notes are in 

denominations of AED 1,000, 500, 200, 100, 50, 20, 10 and 5. 

Coins are in denominations of AED 1, and 50, 25, 10 and 5 fils. 

Exchange rates, as of October 2010: 

£1.00 = AED 5.78 

$1.00 = AED 3.67 

€1.00 = AED 5.13 

ElECtriCitY 

the voltage in the United Arab Emirates is 220 / 240 volts A / C 

at 50 cycles. 

lAngUAgE 

Arabic is the official language of Dubai, although English, 

malayalam, Hindi, Urdu, Bengali, tamil, Persian, tagalog, 

Chinese and other languages are also spoken. 

rEstAUrAnts 

there are many restaurants/cafés located in the DiCEC 

including: 

• loop Café: Exhibition Hall 8, Concourse 2 

(opposite Emirates bank) 

Hours: 07:00 to 18:00 - saturday to thursday 

• Hub: Opposite Hall 6, Concourse 2, in between both sheikh 

rashid Hall’s entrances 


• Za’abeel Bistro & Za’abeel Café: Za’abeel Hall 


• round table Pizza: Exhibition Hall 2, Concourse 1 

Hours: 07:00 to 23:00 - saturday to Friday 

• tea leaf & Coffee bean: Exhibition Hall 1, Concourse 1 


• Café nero: trade Centre Plaza 


• Japengo: trade Centre Plaza 


• Pizza Express: trade Centre Plaza (Opening soon) 


refreshment carts serving a variety of lebanese, Chinese 

and indian food as well as sandwiches are available in the 

concourse. 

For a complete listing of restaurants in Dubai city with location, 

phone and type of cuisine, please visit the Dubai Convention 

bureau’s web site: 

http://www.definitelydubai.com/im-visiting/where-do-i-eat/ 

restaurants-dubai 

trAVEl 

the city is served by Dubai international Airport (DXB)—host 

to the world’s largest duty free shopping area—situated in the 

north central part of the city. Dubai international Airport provides 

regular flights to and from the UK, Australia, America, Asia and 

Europe. more than 80 airlines take advantage of Dubai’s open 

skies policy, and operate to and from Dubai international Airport 

to more than 130 destinations, making it one of the world’s 

busiest airports. 


FinAl PrOgrAm

gEnErAl inFOrmAtiOn, A-Z 

tiPPing AnD grAtUitiEs 

tipping practices are similar to most other parts of the world. 

most restaurants include a 10 percent service charge, but 

tipping in general is at the customer’s discretion. 

tOUrist inFOrmAtiOn 

Please visit the Dubai Department of tourism and Commerce 

marketing in the Exhibit Hall, sheikh rashid F. they can answer 

questions about Dubai. 

Website: http://www.dubaitourism.ae 

trAnsPOrtAtiOn WitHin tHE CitY 

to experience this spectacular city to the fullest, you’ll want to 

explore. the advanced public transport system means you and 

your party can transition effortlessly from business to leisure. 

Dubai has an advanced public transport system including a 

new state-of-the-art metro system, buses and taxis on their 

WAO Small Airways Working Group Steering Committee 

Lanny J. Rosenwasser, Chair – USA 

Monica Kraft, Vice Chair – USA 

Leif Bjermer – Sweden 

Thomas B. Casale – USA 

Leonardo Fabbri – Italy 

Qutayba Hamid – Canada 

Peter H. Howarth – United Kingdom 

Charles Irvin – USA 

J. Christian Virchow – Germany 



multi-lane highways. the newly opened Dubai metro will be the 

longest fully automated rail network in the world when it is fully 

completed in 2010. the red line ‘trade Centre station’ serves 

DiCEC, delivering maximum convenience to millions of visitors. 

Bus services operate on 62 routes linking various residential 

and industrial areas with the two central business districts. 

there are fi ve major taxi companies - Dubai transport, Cars 

taxis, national taxis, metro taxis and Arabia taxis, all equipped 

with the latest gPs systems. 

About 150 Abras (traditional boats made of wood), transport 

people across the Dubai Creek seating around 20 passengers 

each. they transport approximately 15 million passengers every 

year. For yet another option of travel, choose the waterbus 

system, a collection of comfortable and stylish boats stopping 

at all major tourist attractions along the Dubai Creek. 

www.worldallergy.org/small_airways_group 

Small Airways Disease 

Working Group 

Search a database of scientific literature 

Stay informed with announcements of upcoming live events 

Expand your knowledge base with educational resources 

on all aspects of small airways disease 


FinAl PrOgrAm 

WAO-1110-385

ONBREZ ® BREEZHALER ® 

Important note: Before prescribing, consult full prescribing information. Presentation: Inhalation powder hard capsules containing indacaterol maleate equivalent to 150 microgram 

(mcg) indacaterol; inhalation powder hard capsules containing indacaterol maleate equivalent to 300 mcg indacaterol. Indications: ONBREZ ® BREEZHALER ® is a long-acting beta2-agonist 

indicated for longterm, once-daily, maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Dosage: Adults: 

recommended dosage is the once-daily inhalation of the content of one 150 mcg capsule using the ONBREZ BREEZHALER inhaler. The dosage should only be increased on medical 

advice. Once-daily inhalation of the content of one 300 mcg capsule using the ONBREZ BREEZHALER inhaler, has been shown to provide additional clinical benefit to some patients, 

e.g. with regard to breathlessness, particularly for patients with severe COPD. The maximum dose is 300 mcg once-daily. Children (

COnFErEnCE inFOrmAtiOn, A-Z 

ABstrACts 

Abstracts for the WAO international scientific Conference were 

submitted under a variety of different topics related to the theme 

of the Conference. All accepted abstracts have been placed in 

Poster sessions on 6, 7 and 8 December and are printed in the 

back of this Final Program. Poster numbers are listed in the 

‘Posters’ section of the Final Program (pages 54-76). this Poster 

number also corresponds to the abstract, which is printed in the 

‘Abstract’ section (pages 78-162) of the Final Program. For more 

information, see “Poster sessions” section. 

BADgEs 

Each participant will receive a name badge upon check-in at the 

registration Desk. the badge will be the official meeting document 

and should be worn at all times in order to gain entry to the 

Conference rooms. Please note that access to any of the Conference 

areas or events will not be possible without an official badge. 

in order to comply with security requirements, participants 

are expected to wear their badges at all times in all areas. 

if you lose your badge, a new one can be purchased at the 

registration Desk for $50 UsD with photo identification. 

BUsinEss CEntEr 

the DiCEC offers a business center, spectrum-Digital Print, for 

various business needs. it offers a range of services including printing 

and internet access along with internet cards for WiFi access. 

Spectrum – Digital Print 

DWtC Dubai World trade Centre 

Concourse 1, Between Hall 2 & 3 

tel: +971 4 327 5900 

Fax: +971 4 327 5166 

Email: dwtc@spectrumdubai.com 

www.spectrumdubai 


CErtiFiCAtE OF AttEnDAnCE 

Certificates of Attendance will be available on 7th and 8th 

December at the registration Desk. After the Conference is 

over, you may request a Certificate of Attendance by emailing a 

request to lori@actionreg.com. Your request should include your 

name badge number. 

COntinUing mEDiCAl EDUCAtiOn (CmE) CrEDits 

the WAO international scientific Conference is accredited by 

the European Accreditation Council for Continuing medical 

Education (EAAACmE) and the Faculty of medicine & Health 

sciences (FmHs) at the UAE University. All CmE Certificates will 

be distributed by email after the Conference. Please be sure to 

fill out the CmE self-reporter with your correct email address, 

which is included in your registration bag. 

European accreditation Council for Continuing medical 

Education (EaaCmE) 

the WAO international scientific Conference is accredited by 

the European Accreditation Council for Continuing medical 

Education (EAACmE) to provide a CmE activity for medical 

specialists attending the Conference. the goal of a CmE system 

is to assure a high level of theoretic and clinical competence 

throughout the working life of medical specialists. 



the WAO international scientific Conference has been 

designated for a maximum of 24 hours of European external 

CmE credits. 

Division of CmE Credits: 

sunday, 5 December: 6 hours 

monday, 6 December: 6 hours 

tuesday, 7 December: 6 hours 

Wednesday, 8 December: 6 hours 

EACCmE credits are recognized by the American medical 

Association (AmA) toward the Physician’s recognition Award. 

to convert EACCmE to AmA PrA category 1 credit, contact the 

AmA, telephone 1-800-621-8335 or 1-312-464-4941. Us 

doctors do not automatically earn CmE credits unless they 

contact the AmA. 

noTE: in order to receive your CmE certificate by email, please 

fill out the CmE self-reporter Form that is included in your 

Conference bag. CmE self-reporter Forms should be returned 

to the registration Desk, located outside sheikh rashid E. 

United arab Emirates Continuing medical Education Credits 

UAE CmE will be provided by the Faculty of medicine & Health 

sciences (FmHs), UAE University. 

FmHs accredits CmE events for CmE providers in the UAE. 

these are recognized by all the medical bodies in the UAE. 

the WAO international scientific Conference has been 

designated for a maximum of 33 hours of UAE CmE. 

Division of CmE Credits: 

sunday, 5 December: 7 hours 

monday, 6 December: 9.5 hours 

tuesday, 7 December: 9 hours 

Wednesday, 8 December: 7.5 hours 

noTE: in order to receive your CmE certificate by email, please 

fill out the CmE self-reporter Form that is included in your 

Conference bag. CmE self-reporter Forms should be returned 

to the registration Desk, located outside sheikh rashid E. 

COAt/PACKAgE CHECK 

the cloakroom is located near the Convention gate Entrance. 

Hours 

sunday, 5 December: 07:00 – 22:00 

monday, 6 December: 07:00 – 18:30 

tuesday, 7 December: 07:00 – 18:30 

Wednesday, 8 December: 07:00 – 16:00 

Price 

AED 20.00 per item 

no item should be left in the luggage room overnight. Any items 

not collected within the opening hours will be kept overnight at 

the DWtC lost & Found Office at an additional charge of AED 

50.00 per day per item. 

COFFEE BrEAKs 

Coffee breaks are included in the registration fee for Delegates, 

students, nurses and Accompanying Persons. morning and 

afternoon coffee breaks will take place in the 1 st floor foyer on 

5 December and in sheikh rashid F on 6, 7, and 8 December. 


FinAl PrOgrAm


DisClAimEr 

WAO will not be held liable for personal injuries or for loss 

or damage to property incurred by participants or guests at 

the WAO international scientific Conference, including those 

participating in tours and social events. Participants and guests 

are encouraged to purchase insurance to cover loss incurred 

in the event of cancellation, medical expenses or damage to 

or loss of personal effects when traveling outside of their own 

countries. 

WAO cannot be held liable for any hindrance to or disruption of 

the international scientific Conference proceedings arising from 

natural, political, social or economic events or other unforeseen 

incidents beyond its control. registration of a participant implies 

acceptance of this condition. 

the materials presented at this continuing medical education 

activity are made available for educational purposes only. the 

materials are not intended to represent the only, nor necessarily 

best, methods or procedures appropriate for the medical 

situations discussed, but rather are intended to present an 

approach, view, statement, or opinion of the faculty that may be 

helpful to others who face similar situations. 

DrEss 

Dress for the Conference is business casual. 

EmErging sOCiEtiEs PrOgrAm-WOrlD AllErgY 

trAining sCHOOl (EsP-WAts) lEVEl 2 

the Emerging societies Program (EsP), a joint initiative of 

the WAO and the American College of Allergy, Asthma and 

immunology (ACAAi), is hosting a level 2 World Allergy training 

school (WAts) Course at the WAO international scientific 

Conference on 5 December 2010. this WAts level 2 is a 

follow-up to the very successful WAts level 1 held in Dubai 

in march 2009. the EsP Council has identified specific 

Postgraduate Courses as WAts level 2 Courses. these courses 

are denoted in the preliminary program with “WAts 2.” 

the objectives of the WAts are the following: 

• to educate and update young physicians in the practice 

of allergic diseases by disseminating state-of-the-art 

knowledge on the basic and clinical aspects of allergic 

diseases and enhancing practical knowledge and skills in the 

diagnosis and treatment of allergic diseases 

• to help in capacity building by training representatives 

from various countries in the diagnosis and management of 

allergic diseases 

• to provide a platform where world class experts can lecture 

and interact with young physicians 

• to stimulate interest in young physicians to pursue the 

specialty of allergy and thus increase the number of allergists 

WAts Postgraduate Courses are available to all registered 

delegates. 

EVAlUAtiOns 

Conference evaluation forms are included in the registration bag. 

Your feedback is very important to us and we encourage you to 

complete your evaluation. Please fill out your form and return it to 

the registration Desk, located outside sheikh rashid E. 



EXHiBitiOn 

A commercial exhibition will take place on the following dates 

and times in sheikh rashid F: 

sunday, 5 December: 20:00 - 22:00 

monday, 6 December: 09:00 - 18:30 

tuesday, 7 December: 09:00 - 17:00 

Wednesday, 8 December: 09:00 - 13:30 

the Exhibit Hall map and Directory are listed on pages 22-26 of 

the Final Program. 

Admittance into the Exhibit Hall is included in the registration rate 

for Delegates, nurses, students and Accompanying Persons. An 

official badge is required for entry into the Exhibit Hall. 

intErnEt 

Please visit the DiCEC Business Centre for internet access or to 

purchase Wi-Fi internet cards. see “Business Centre” for more 

information. 

lAngUAgE 

the official language of the Conference is English. 

lOst AnD FOUnD 

the lost and Found office is located next to the cloakroom, near 

the Convention gate Entrance. Please see the detailed map of 

the DiCEC on page 17 for exact location. Please call +971 4 

308 4600 if the office is closed. 

lUnCH 

lunch boxes are included in the registration fee for Delegates, 

students, nurses and Accompanying Persons. lunch boxes 

will be distributed in Al multaqua on 5 December and in sheikh 

rashid C & D on 6, 7, and 8 December. 

Delegates are encouraged to pick up their lunches in sheikh 

rashid C & D on 6, 7 and 8 December and bring the lunch into 

sheikh rashid E to attend the Keynote lunch symposium. 

mEDiCAl HElP & PHArmACY 

Emergency and first-aid office is located near the Exhibition 

gate reception between Halls 4 and 5. For emergencies, please 

call +971 4 306 4040. 

Dubai life Pharmacy is located in Concourse 2, between Halls 

5 and 6. 

mEEting POint 

the Conference meeting Point is the registration Area outside 

sheikh rashid E. 

mOBilE PHOnEs 

Use of mobile phones is strictly prohibited within the scientific 

session rooms. Please ensure that you have your mobile phone 

silenced while attending sessions. 

PArKing – FrEE 

Free outdoor parking is available at Car Park B, C & D. 

PHOtOgrAPHing 

Kindly respect that taking photos in the session rooms is strictly 

forbidden. 


FinAl PrOgrAm


POstEr sEssiOns 

All accepted abstracts will be presented as posters in Poster 

sessions on 6, 7, and 8 December in the Exhibition Hall (sheikh 

rashid F). Each Poster session will focus on posters in 3-4 

topic categories. Chairpersons are assigned to each category 

and will stimulate discussion between the audience and 

Presenting Authors. Presenting Authors will stand next to their 

posters, answer questions and discuss their research. 

Poster Session 1 

Includes networking session with faculty and WAO leadership 

monday, 6 December 

17:00 – 18:30 

Allergens and risk factors 

Asthma education and management 

Asthma epidemiology and mechanisms 

rhinitis, rhinosinusitis and conjunctivitis 


Includes Outstanding Poster Awards announcement 

tuesday, 7 December 

13:00 – 14:15 


Drug and food allergy 

skin and other diseases 


Wednesday, 8 December 

09:30 – 10:30 

immune mechanisms of allergy 

immunotherapy 

Pediatric allergies 

Posters must be set up on monday, 6 December between 

09:00 – 16:00. Posters will remain on display throughout the 

Conference, and must be dismantled between 10:30 – 13:00 on 

Wednesday, 8 December. Posters not dismantled by 13:00 on 

Wednesday, 8 December will be discarded. 

Poster numbers are listed in the ‘Posters’ section of the Final 

Program (pages 54-76). this Poster number also corresponds 

to the abstract number, which is printed in the ‘Abstracts’ 

section (pages 78-162) of the Final Program. All posters will 

remain on display throughout the conference. 

outstanding Poster awards 

Abstracts that scored highly in the review process and have 

exceptional posters will be given WAO Outstanding Poster 

Awards. Awards will be announced at the beginning of Poster 

session 2 on tuesday, 7 December. Posters that receive this 

award will have a ribbon displayed on the poster board. 

POstgrADUAtE COUrsEs – 5 DECEmBEr 

Postgraduate Courses will take place on 5 December in the 

DiCEC in the 1st and 2nd floor meeting rooms. Please refer to the 

DiCEC floorplan on page 17 for exact locations. 

since attendance is limited, all Postgraduate Courses require 

pre-registration. At the time of check in at the registration 

Desk, all pre-registered attendees will be provided with a ticket 

for each registered session. 

All attendees must provide a ticket to gain entry to a 

Postgraduate Course. 



rEgistrAtiOn 

the registration Desk will be located outside sheikh rashid E 

and will be open during the following hours: 

saturday, 4 December: 16:00 – 19:00 





if you lose your badge, a new one can be purchased at the 

registration Desk for $50 UsD with photo identification. 

The registration fee for Delegates, nurses and Students 

includes: 

* Admission to all scientific sessions 

* Conference bag and meeting materials 

* Free access to exhibition area 

* Certificate of attendance 

* CmE 

* invitation to social events 

* Keynote lunch lectures 

The registration fee for accompanying Persons includes: 

* Free access to exhibition area 

* invitation to social events 

* Keynote lunch lectures 

Registration for Accompanying Persons does not include: 

Admission to the scientific sessions or conference bag and 

meeting materials 

smOKing POliCY 

smoking is not permitted during any meeting activity or event in 

the DiCEC. 

sOCiAl EVEnts: 

Name badges are strictly required for all Social Events 

opening Ceremony and Welcome reception 

sunday, 5 December 2010 

19:00 – 22:00 

DiCEC, sheikh rashid E & F 

Join fellow delegates, faculty and the WAO leadership in 

sheikh rashid E for the Opening Ceremony to launch the 

Conference. Following the Opening Ceremony, we will move to 

a hosted reception in the Exhibit Hall, sheikh rashid F, featuring 

hors d’oeuvres, and the opportunity to network with colleagues 

and friends. 

Included in registration fee for Delegates, Students, Nurses and 

Accompanying Persons. 

Poster Session 1 and networking with Faculty and Wao 

leadership 

monday, 6 December 2010 

17:00 – 18:30 

DiCEC, sheikh rashid F 

Junior delegates will have the opportunity to discuss and 

view posters in an informal setting, as well as network with 

Conference faculty and the WAO leadership. light refreshments 

will be served. 

Included in registration fee for Delegates, Students, Nurses and 

Accompanying Persons. 


FinAl PrOgrAm


sPEAKErs’ PrEViEW rOOm 

the speakers’ Preview room is located in Ajman A, on the 

1st floor of the sheikh rashid area. speakers are requested to 

check-in, drop off and finalize their slide presentations here. 

it is requested that speakers visit the Preview room at least 

3 hours before the beginning of their session. speakers making 

presentations in the early morning sessions should ensure that 

they have checked in the previous day. 

the speakers’ Preview room will be open during the following 

hours: 

saturday, 4 December: 10:00 – 17:00 





C - Location Map 

Sheikh rashid area 

Trade 

Centre 

Tower 



DUBAi intErnAtiOnAl COnVEntiOn AnD EXHiBitiOn CEntrE 

Venue Map 

Za’abeel park 

F 

Trade Centre 

Roundabout 

Parking 

A 

312 Road 

Za'abeel Hall 

Hall 

1 2 3 4 

Convention 

Tower 

Sheikh Saeed Halls 

Arena 

3 2 1 

D 

Hall 8 

7 

6 

5 

D C 

A Za’abeel Entrance 

B Convention Gate Entrance 

VEnUE 

the venue for the Conference is the Dubai international 

Convention and Exhibition Centre (DiCEC). the DiCEC offers 

world class exhibition and convention facilities and is centrally 

located. 

Dubai international Convention and Exhibition Centre (DiCEC) 

sheikh Zayed road 

PO Box 9292 



tel: +971 4 332 1000 

Fax: +971 4 318 8741 

Website: www.dwtc.com 


FinAl PrOgrAm 

B 

Novotel 

Hotel 

Ibis Hotel 

B C 

Dubai Trade Centre Hotel Apartments 

Metro 

Sheikh 

Maktoum 

Hall 

Block A 

Sheikh 

Rashid 

Hall 

Sheikh Zayed Road (E11) Abu Dhabi > 

Multi-storey car park 

Block B 

C Plaza Entrance 

D Arena Entrance 

Dubai Trade Centre 

District 

Block C 

E 

NORTH 

Emirates 

Towers



DUBAi intErnAtiOnAl COnVEntiOn AnD EXHiBitiOn CEntrE 

SHEiKH raSHiD arEa 

Floor Color Key: 

ground Floor 

al multaqua 

Ballroom 

1st Floor 

2nd Floor 

speakers’ Preview room 

Ajman A 

Postgraduate Courses 

Sharjah D 


Sharjah A 

lunch on 

5 December 

to Free Car Park 

Convention gate Entrance 

Exhibition gate Entrance 

to taxi stations 

LIFT LIFT 

- 

registration 

Area 


FinAl PrOgrAm 

- 

- 

- 

A 

- 

Cloakroom and lost & Found Offi ce 

A B 

F 

E 

Sheikh rashid Hall 

D C 

lunch 

Boxes 


Abu Dhabi A 


Abu Dhabi B 


Ras Al Khaimah 


Umm Al Qwain 

LIFT 

- 

- - - 

- - 

- 

- 

- 

symposia 

Plenary sessions 

Opening 

Ceremony 

Exhibition Hall & 

Poster sessions 

Welcome reception 

Coffee Breaks

Helping to control asthma 

throughout the year 1 

 

SINGULAIR is indicated in the treatment of asthma 

as add-on therapy in those patients with mild to 

moderate persistent asthma who are inadequately 

controlled on inhaled corticosteroids and in whom “as 

needed” short-acting Beta-agonists provide inadequate 

clinical control of asthma. In those asthmatic 

patients in whom SINGULAIR is indicated in asthma, 

SINGULAIR can also provide symptomatic relief of 

seasonal allergic rhinitis. 

SINGULAIR is also indicated in the prophylaxis of asthma 

in which the predominant component is exercise-induced 

bronchoconstriction. 

SINGULAIR is contraindicated in patients with hypersensitivity 

to the active substance or to any of the excipients. 

Patients should be advised to continue taking SINGULAIR 

even if their asthma is under control, as well as during 

periods of worsening asthma. 

In clinical studies in asthmatic patients 15 years of age and 

older, the following drug-related adverse reactions, abdominal 

t y p e i s f r u t i g e r b l a c k i t a l i c 

pain and headache, were reported commonly (≥1/100 to

HOtEls mAP 

7 

7 

5 

1 

2 

3 

4 

5 

6 

6 

4 

3 

4 

3 



2 

Dubai International Convention & Exhibition Centre 

Grand Hyatt Dubai 

Al Gharoud, Dubai, United Arab Emirates 

Tel: +971 4 317 1234, Fax: +971 4 317 1235 

Novotel World Trade Center 

Zabeel Road 2nd, Dubai, United Arab Emirates 

Tel: +971 4 3320000, Fax: +971 4 3320001 

Ibis World Trade Center 

Sheikh Zayed Road, Dubai, United Arab Emirates 

Tel: +971 4 3324444, Fax: +971 4 3311220 

Fairmont Dubai 


Tel +971 332 5555, Fax +971 4 332 4555 

HOtEl inFOrmAtiOn 

mCi middle East, the local Professional Congress Organizer 

for the Conference will be handling all hotels on-site. For hotel 

information, please visit the Hotels & tours Desk, which is 

located in the registration Area outside sheikh rashid E. 

2 


FinAl PrOgrAm 

5 

6 

7 

1 

Towers Rotana Hotel 


Tel: +971 4 343 8000, Fax: +971 4 343 5111 

Rose Rayhaan by Rotana 


Tel: +971 4 323 0111, Fax: +971 4 323 0222 

Shangri-La Dubai 


Tel: +971 4 343 8888, Fax: +971 4 343 8886 

1

OPtiOnAl tOUrs 

CitY OF COntrAsts - sHArJAH CUltUrAl tOUr 

35 USD Per Person 

Sunday, 5 December 9:00 – 13:00 

Tuesday, 7 December 10:30 – 14:30 

sharjah was crowned by UnEsCO Cultural Capital of the Arab 

World in 1998. With a reputation for artistic excellence, the 

emirate boasts over 15 museums, an aquarium and a center for 

Arabian wildlife. 

Anyone who has an interest in local history, culture and 

architecture will enjoy exploring sharjah’s old city. A visit to souq 

Al Arsah, sharjah’s oldest market, is a must. 

the next stop is the sharjah Heritage museum, beginning a 

journey of discovery through sharjah’s rich and diverse heritage 

with handcrafted works of art and 

objects that date back to a time 

when local people relied solely on 

fi shing and pearling. Discover the 

traditional skills and crafts relating 

to jewelry, costumes, and herbal 

medicines, music and folklore. 

CitY OF mErCHAnts - DUBAi OriEntAtiOn tOUr 


Sunday, 5 December 14:30 – 18:00 

monday, 6 December 14:30 – 18:00 

Tueday, 7 December 14:30 – 18:00 

Wednesday, 8 December 14:30 – 18:00 

Experience the historic sites and lively multi-ethnic life of Dubai. 

From the famous Burj Al Arab to the gold souk, you’ll see all the 

famous sights of Dubai on this leisurely tour. 

Your excursion begins with a drive on sheikh Zayed road to 

view the city’s skyscrapers with a photo stop at Dubai’s most 

famous landmark and tallest tower in the world - Burj Khalifa. the 

tour proceeds to Jumeirah, where we can witness the worldrenowned 

luxury hotel Burj Al Arab – with the unique billowing 

sail design. the hotel is a must see for all visitors to Dubai. 

see some of the palaces of the royal Family and residential areas 

with a stop at the eminent Jumeirah mosque and a drive by the 

palace of the ruler of Dubai. We 

then proceed to 

Al Bastakiya, Dubai’s atmospheric 

old quarter by the Creek. then it’s 

all aboard the Abra (water taxi) to 

cross the Creek to the spice souk. 

You’ll then have time to shop in 

another famous Dubai landmark, 

the glittering gold souk. 



mCi middle East, the local Professional Congress Organizer for the Conference, will be handling all local tours for the 2010 WAO 

international scientifi c Conference. You can purchase tickets on-site at the Hotel & Tours Desk located in the registration 

area outside Sheikh rashid E. 

important Tour information: 

1. All tours are conducted in English. 

2. tours’ duration and date of operation are subject to change. the tour can be cancelled if a minimum number of participants is 

not achieved. 

3. For all tours, the pick up and drop off point is the Hotels & tours Desk located in the registration Area outside sheikh rashid E. 

Kindly report to the pick up point 15 minutes prior to the start of the tour. 

DEsErt sAFAri WitH BBQ DinnEr 



this tour departs in the afternoon by four-wheel drive vehicles 

across the desert of Dubai with several photo stops. A camel 

farm is the fi rst destination of this exciting dune drive. the drive 

continues across the desert, stopping to watch the beautiful 

sunset before reaching the campsite where you have the 

opportunity for a camel ride, sand boarding and trying out a 

henna design on your hands or feet. Enjoy a delicious barbecue 

dinner and shisha (the famous Arabic water pipe). Before 

returning to Dubai, watch our belly dancer performing her show 

around the campfi re by starlight. 

sUnsEt CrUisE 


Wednesday, 8 December 16:00 – 18:00 

What could be more enchanting than to marvel at the sunset 

aboard a dhow as it slips silently along Dubai Creek? Your cruise 

aboard traditional wooden vessels offers an intriguingly different 

view of this amazing city – a portrait of the true character of 

Dubai, the intertwining of the traditional and modern. 

see old wooden dhows, luxury yachts and spectacular modern 

architecture. Offering a selection of two select beverages, this 

tour refl ects a delicious taste of true Arabian hospitality. 

CAmEl riDing & sAnDBOArDing sAFAri 



travel with our experienced safari guides in four-wheel drive 

vehicles to the desert for a thrilling journey over the rolling dunes. 

After an exhilarating drive, enjoy a camel ride just like the 

nomadic Bedouin have 

done for centuries. Abandon 

tradition for a breathtaking 

mode of transport: 

strapping on a sand board 

for an exhilarating ride 

down the steep-sided 

dunes to the valley fl oor 

below. 


FinAl PrOgrAm

Online Learning Content 

for Practitioners — and Trainees 

Webinar Archive 

Asthma and Co-Morbid Conditions 

Risk Assessment in Anaphylaxis 

Respiratory Syncytial Virus Illness: A Gateway to Asthma? 

Gastroesophageal Reflux Disease (GERD) and Asthma 

Dedicated to Reaching Allergists Everywhere 

Symposia and 

Training Schools 

Materials and schedules 

free to download 

Educational Resources 

Major Medical Journal Article Summaries 

Medical Book Reviews 

Allergic Disease Resource Center, Synopses 

Interactive Teaching Case Reports 

Conversations with Experts 

Clinical Allergy Tips 

Passport to expert resources in allergy, asthma 

and clinical immunology 

Continuing Education 

www.worldallergy.org/educational _programs/online_learning.php 

Asthma and Allergic Rhinitis Online Lecture Series 

Drug Allergy Interactive Module 

Immunology Online Lecture Series 

Food Allergy Interactive Module 

Small Airways Disease Working Group 

www.worldallergy.org/small_airways_group 

Podcasts, Case Studies, Clinical Pearls and more… 

http://www.worldallergy.org/educational_programs/ 


Member Resources 

Worldwide Allergy Meetings, Interactive Calendar 

Global Allergy Web Links 

Research and Training Resources 

WAO News & Notes Monthly Electronic Newsletters 

World Allergy Organization Journal 


WAO-1110-385

EXHiBitiOn FlOOrPlAn 

sHEiKH rAsHiD F 

Poster Board Poster Board Poster Board 

EXHiBit HAll HOUrs 

sunday, 5 December: 20:00 - 22:00 

monday, 6 December: 09:00 - 18:30 

tuesday, 7 December: 09:00 - 17:00 

Wednesday, 8 December: 09:00 - 13:30 



Coffee Break 

19 

Future 

meetings 

table 

20 

Cis 

21 16 

Dubai Bedfont 

Convention scientific 

Bureau limited 

22 14 

mEAAAiC lg life 

sciences 

slAAi 

EAACi 

World Allergy 

Organization 

2011 World 

Allergy Congress 

Coffee Break 

sheikh rashid Hall F 

Entrance 


FinAl PrOgrAm 

23 

24 

18 


Health 

Authority 

17 

nycomed 

13 

HAE: learn 

About it, talk 

About it 

6 

Allergy Julphar 

therapeutics 

7 

First Defense 

nasal screen 

Corp 

8 

HVD 

sanofi- 

Aventis 

9 

10 

novartis 

msD 

5 

4 

stallergenes 

CiPlA - 

ntPE 

3 

2 

Omron 

Healthcare 

12 

gsK 

1

EXHiBitOr DirECtOrY 

allergy Therapeutics Booth 6 

Dominion Way 

Worthing, West sussex Bn14 8sA 

United Kingdom 

Phone: +44 1903 844 700 

Website: www.allergytherapeutics.com 

Allergy therapeutics is a fully integrated specialty pharmaceutical 

company with a profitable core business and a patent protected 

development pipeline of allergy vaccines with the potential to 

transform allergy treatment. 

Bedfont Scientific Booth 16 

105 laker road 

rochester 

Kent mE1 3QX 

United Kingdom 

Phone: +44 1634 673 720 

Fax: +44 1634 673 721 

Website: www.bedfont.com 

Bedfont scientific ltd is a world leader in developing innovative, 

non-invasive breath analysis monitors for a number of medical 

applications. their newest innovation is the nObreath FEnO 

monitor, a breakthrough in providing portable airway inflammation 

management for asthmatics. measuring FEnO enables the 

health professional to prescribe and measure steroid response 

as an alternative harsh or invasive testing such as blood tests or 

spirometry, demonstrating Bedfont’s commitment to their company 

slogan: “breath analysis is the new blood test”. 

CiPla-nTPE Booth 3 

PO Box 3139 

ntDE House 

street 9 Umm ramool 

Phone: +9714 285 2222 

Fax: +9714 222 2900 

CiPlA is the largest pharmaceutical manufacturer in india (ims- 

Org ’10 report), exporting its 1200 formulations in 65 therapeutic 

categories to 180 countries in the world including UsA, UK, germany, 

Australia, south Africa, gCC etc. CiPlA has manufacturing facilities 

approved by UsFDA, UK mHrA, tgA Australia, PiC germany etc. 

CiPlA’s innovative patented respiratory devices like Zerostat spacer, 

transparent DP halers; revolizer, etc are distributed in UAE by their 

agents national trading & Pharmaceutical Est. (ntPE). 



CiS - Commonwealth of independent 

States Society of immunology and allergology Booth 20 

World immunopathology Organization 

4 Ostrovityanova street 

117513 moscow 

russia 

Phone: +7 (495) 735-1414 

Fax: +7 (495) 735-1441 

E-mail: info@wipocis.org 

Please join us for the following meetings: 

Cis society of Allergology and immunology 

iV World Asthma and COPD Forum 

Paris, France 

may 1-3,2011 

www.wipocis.org 

Vi World Congress on immunopathology & respiratory allergy 

moscow, russia 

september 15-18,2011 

Dubai Convention Bureau Booth 21 

PO Box 594 


UAE 

Phone: + 0097 1420 10220 

Website: www.dcb.ae 

the Dubai Convention Bureau is a division of the Department of 

tourism and Commerce marketing, a non-profit government funded 

organization, whose aim is to further develop and increase Dubai’s 

share of the international miCE and special events markets, whilst 

maximizing the economic prospects of Dubai. the DCB is dedicated 

to pursue and win events through national and international 

promotions to advance the position of the Emirate as a leading 

business tourism destination. 

Dubai Health authority Booth 18 

the Dubai Health Authority (DHA) was created in June 2007, by 

law 13 issued by His Highness sheikh mohammed bin rashid Al 

maktoum, Vice President and Prime minister of the UAE, ruler of 

Dubai. As the strategic health authority for the Emirate of Dubai, the 

DHA is empowered to set policies and strategies for health and to 

assure the application of those health policies and strategies. His 

Excellency Qadhi saeed Al murooshid is the Director general of the 

Dubai Health Authority (DHA). 

the DHA’s aim in Dubai is to provide an accessible, effective and 

integrated healthcare system, protect public health and improve 

the quality of life within the Emirate. this is a direct translation of 

the objectives of the Dubai strategic Plan 2015 launched by His 

Highness sheikh mohammed bin rashid Al maktoum. Keeping the 

strategic plan in mind, the DHA’s mission is to ensure access to 

health services, maintain and improve the quality of these services, 

improve the health status of nationals, residents and visitors and 

oversee a dynamic, efficient and innovative health sector. 


FinAl PrOgrAm


EaaCi - European academy of 

allergy and Clinical immunology Booth 24 

genferstrasse 21 

Zurich 8002 

switzerland 

Phone: +41 44 205 55 33 

Fax: +41 44 205 55 39 

Website: www.eaaci.net 

Email: info@eaaci.net 

the European Academy of Allergy and Clinical immunology is a 

non-profit organization active in the field of allergic and immunologic 

diseases such as asthma, rhinitis, eczema, occupational allergy, food 

and drug allergy and anaphylaxis. EAACi was founded in 1956 in 

Florence and has become the largest medical association in Europe 

in the field of allergy and clinical immunology. it includes 6,100 

individual members from 107 countries as well as 41 national Allergy 

societies. 

First Defense nasal Screen Corp Booth 7 

7143 state rd 54, #117 

new Port richey, Fl 34653 

UsA 

Phone: 877.mY.Air.09 

Fax: 800.616.0258 

Email: customerservice@nasalscreens.com 

Website: http://www.filteryourlife.com/contact.htm 

Our product is the first ever invented light weight, almost non visible, 

non inserted allergy nasal screen that is a self adhesive, hypo 

allergenic, latex free, nasal screen that reduces the inhalation of 

allergens by up to 99% by completely and individually sealing each 

nasal passage and can be worn for extended periods of time and has 

no side effects. 

Future meetings Table Booth 19 

glaxoSmithKline Booth 1 

gulf & near East 

P.O. Box 50199 


Website: www.gsk.com 

gsK is one of the world’s leading producers of prescription 

medicines, vaccines and consumer healthcare products leading the 

way in respiratory , anti-viral medications, anti-infectives, Allergy, 

rhinitis and Cns diseases. the spirit of gsK is to improve the quality 

of human life by enabling people to do more, feel better and live 

longer through its’ responsibility to improve access to medicines, 

contributing to community programs around the world and supporting 

improvement in science education. 



HaE: learn about it, Talk about it Booth 13 

730 stockton Drive 

Exton, PA 

UsA 

Phone: +1 610 321 2333 

Fax: +1 610 321 3868 

Website: www.viropharma.com 

‘HAE: learn About it, talk About it’ is a peer-driven campaign 

designed to foster communication between physicians on the front 

lines of the diagnosis and treatment of hereditary angioedema 

(HAE), a rare and potentially fatal swelling disease. the program 

is led by the World Allergy Organization (WAO), the American 

College of Asthma, Allergy & immunology (ACAAi) and the American 

gastroenterological Association (AgA) institute, and supported by 

ViroPharma incorporated. 

HVD life Sciences Booth 8 

16, Vouliagmenis Avenue 

glyfada gr-16610 

greece 

Phone: +30 210 9600 687 

Fax: +30 210 9600 693 

Website: www.hvdlifesciences.com 

Email: office@hvdgmbh.com 

HVD lifesciences is a marketing and distribution company 

representing PHADiA, with 8 offices and over 45 partner companies 

in middle East, Africa, latin America and Europe we provide top 

quality service. Phadia develops, manufactures and markets blood 

test systems for clinical diagnosis and monitoring of allergy, asthma 

and autoimmune diseases to more than 3,000 laboratories in 

60 countries. supplying seven out of ten allergy laboratory tests 

worldwide, the company is world leader for 25 years. 

Julphar Booth 5 

P.O. Box 997, 

ras Al Khaimah 

Degdaga - Airport road 

United Arab Emirates, 

Phone: +971 7 2461461 

Fax: +971 7 2462462 

E-mail: Julphar@emirates.net.ae / info@Julphar.net 

since gulf Pharmaceutical industries (JUlPHAr) has been 

established in 1980 as the first UAE company specialized in 

pharmaceuticals manufacturing in the region, it has worked on 

strengthening its leading and distinguished role and adopted the 

method of renewal and innovation depending on the application 

of the highest quality standards and international standards in all 

pharmaceutical manufacturing aspects. As a result of the company’s 

commitment to strict quality and benefits, it has been able to have a 

distinct presence in more than 50 countries around the world. 

latin american Society of allergy 

and immunology (Slaai) Booth 23 

Jose Benitez 2704 (302) 

Col. Obispado 

monterrey, n.l. 64060 

méxico 

Phone: +52 (81) 834 824 59 

Fax: +52 (81) 834 824 59 

Website: www.slaai.org 


FinAl PrOgrAm


lg life Sciences, ltd Booth 14 

20 lg twin towers 

Yoido-Dong 

Youngdungpo-gu 

seoul 150-721 

south Korea 

Phone: +82 2 3773 7296 

Fax: +82 2 3773 7329 

Website: www.lgls.com 

in a bid to find the next-generation diagnostic methodologies, lgls 

is developing seminal technology and products related to automated 

allergy system for screening, DnA analysis and lab-on-a-chip 

technology, which can be used to simultaneously find multiple 

disease markers in a short time. We will continue our efforts to 

emerge as a top global brand in the diagnostic field. 

Allergy screening Products 

test items intended Use 

Alloscreen screening of 42 kinds of specific allergen 

Alloscan 2.0 strip scanner for Alloscreen kit 

Allostation s Fully automated allergy system for screening 

for Alloscreen kit 

mEaaaiC - middle East asia allergy, asthma 

and immunology Congress Booth 22 

middle East Asia Allergy Asthma immunology Congress (mEAAAiC) is 

a regional congress that presents a valuable and unique 

opportunity for both specialists and general physicians, to update 

their knowledge and advance their skills. mEAAAiC generally 

attracts key opinion leaders from the region as well as world 

renowned international faculty. the 1st mEAAAiC in march 2009 was 

held in collaboration with international organizations like the WAO, 

EAACi, AAAAi and ACAAi. the congress attracted around 1,500 

participants from over 43 countries. With the resounding success 

in 2009, mEAAAiC is now an established biennial congress with the 

next edition to be held in April 2011. For more information, please 

visit www.meaaaic.org 

merck Booth 12 

1 merck Drive 

Whitehouse station, nJ 08889-3497 

UsA 

Phone: (908) 423-1000 

Website: www.msd.com 

today’s msD is a global healthcare leader working to help the world 

be well. msD is a tradename of merck & Co., inc., with headquarters 

in Whitehouse station, n.J., U.s.A. through our prescription 

medicines, vaccines, biologic therapies, and consumer care and 

animal health products, we work with customers and operate in 

more than 140 countries to deliver innovative health solutions. We 

also demonstrate our commitment to increasing access to healthcare 

through far-reaching policies, programs and partnerships. msD. Be 

well. For more information, visit www.msd.com. 



novartis Booth 10 

novartis international Ag 

CH-4002 Basel 

switzerland 

Phone: +41 61 324 11 11 

Fax: +41 61 324 80 01 

Website: www.novartis.com 

At novartis Booth, there will be a display of videos discussing: 

• the quality of life of patients living with severe allergic asthma 

• the impact Xolair has on changing the way patients live with 

severe allergic asthma 

• the mode of action of Xolair 

As well, novartis will distribute at the booth some booklets about real 

adults case studies treated with Xolair. 

to insure that visiting physicians get all the inquiries answered, at 

the booth we’ll have product specialists that can answer physician 

questions or record their queries in order to answer them at a later 

time. 

All this aside from other promotional activities that abide by the 

Pharma Code of Conduct. 

nycomed Booth 17 

Dubai Healthcare City 

PO Box 1586 


UAE 

Phone: +0097 1438 34207 

Fax: +0097 1435 72839 

Website: www.nycomed.com 

Email: sheriff.hassan@nycomed.ae 

Alvesco: 

o Has a novel mechanism of action for exceptional balance of safety 

and efficacy. 

o Efficacy comparable with the leading iCs. 

o safety and tolerability comparable with placebo. 

o Once-daily dosing helps to improve compliance. 

Alvesco is: 

lUng tArgEtED 

• smaller particle size for greater lung deposition and less oral 

exposure. 

• greater than 50% of the inhaled dose is delivered directly to the 

lung. 

lUng ACtiVAtED 

• Converted to its active form by esterases in the lung. 

• lipid conjugation for prolonged anti-inflammatory effects and 

once-daily dosing. 

lUng limitED 

• High protein binding for systemic safety. 

• Only 1% is available for systemic exposure. 

• Quickly metabolized in the liver for first-pass inactivation. 


FinAl PrOgrAm


omron Healthcare Europe B.V. Booth 2 

Kruisweg 577 

Hoofddrop 2132 nA 

netherlands 

Phone: +31 20 354 8200 

Fax: +31 20 354 8201 

Website: www.omrom-healthcare.com 

Email: info.omronhealthcare@eu.omron.com 

Omron Healthcare, an innovative global medical devices company, 

develops and manufactures high quality products for respiratory care. 

Omron’s further product line is dedicated to preventing, monitoring 

and treating lifestyle-related diseases such as cardiovascular, 

hypertension, diabetes and obesity. 

Sanofi-aventis Booth 9 

182 Avenue de France 

Paris 75013 

France 

Phone: +33 1 55 71 51 76 

Fax: +33 1 55 71 51 80 

Website: www.sanofi-aventis.com 

telfast®/Allegra® (fexofenadine hydrochloride) is a selective, 

non-sedating, H1-receptor antagonist indicated in seasonal Allergic 

rhinitis and Chronic idiopathic Urticaria in children and adults. it does 

not cross the blood-brain barrier. 

nasacort® AQ (triamcinolone acetonide) nasal spray is indicated 

for the treatment of the nasal symptoms of seasonal and Perennial 

Allergic rhinitis in adults and children 2 years of age and older. 

Formulated with no fragrance and no alcohol. 

Before prescribing the product always refer to the prescribing 

information available in your country. 

Stallergenes Booth 4 

6 rue Alexis de tocqueville 

Antony 92183 

France 

Phone: +33 1 55 59 20 00 

Fax: +33 1 55 59 21 29 

Website: www.stallergenes.com 

Email: contact@stallergenes.com 

stallergenes is a European biopharmaceutical company dedicated to 

allergen immunotherapy for the prevention and treatment of allergyrelated 

respiratory diseases, e.g. allergic rhinitis, rhinoconjunctivitis 

and asthma. 

leader in sublingual immunotherapy treatments, stallergenes 

reached a turnover of 193 million euros in 2009 (24%, being devoted 

to research and Development) and is actively involved in the 

development of sublingual immunotherapy tablets. 

stallergenes markets its products in 50 countries via 10 subsidiaries 

throughout Europe and distribution and partnership agreements 

around the globe. 



World allergy organization (Wao) 

555 East Wells street, suite 1100 

milwaukee, Wi 53202 

UsA 

Phone: +1 414 276 1791 

Fax: +1 414 276 3349 

Email: info@worldallergy.org 

Website: www.worldallergy.org 

Please visit the WAO Exhibit to learn more about WAO: Educational 

Programs, Online learning, and the World Allergy Organization 

Journal (WAOJ) 

2011 World allergy Congress (WaC) 

555 East Wells street, suite 1100 

milwaukee, Wi 53202 

UsA 

Phone: +1 414 276 1791 

Fax: +1 414 276 3349 

Email: WAC2011@worldallergy.org 

Website: www.worldallergy.org/wac2011 

Please visit the WAC Exhibit to learn more about the 2011 World Allergy 

Congress from 4 – 8 December in Cancún, méxico and receive a 

special registration discount code for use by 1 January 2011. 


FinAl PrOgrAm

PrOgrAm-At-A-glAnCE 

registration 

Outside Sheikh Rashid E 



sUnDAY, 5 DECEmBEr 2010 


07:00 

07:15 

07:30 

07:45 

08:00 

08:15 

08:30 

08:45 

09:00 Pg1: 

Pg2: 

Pg3: 

09:15 

spirometry Exhaled nO and managing smoking 

09:30 

Sharjah A other markers of cessation clinics 

09:45 

10:00 

10:15 

infl ammation 

WAts2 

Sharjah D 

Umm Al Qwain 

10:30 Coffee Break 

1st 10:45 

Floor Foyer 

11:00 Pg7: 

Pg8: 

Pg9: 

11:15 

inhalation devices investigating and Asthma self- 

11:30 

Sharjah A managing upper management plans 

11:45 

12:00 

12:15 

12:30 

airway disorders 

Sharjah D 

WAts2 

Umm Al Qwain 

12:45 

lunch Break 

13:00 

13:15 

Al Multaqua 

13:30 Pg13: 

Pg14: 

Pg15: 

13:45 

Practical aspects of role of bone Asthma control 

14:00 

managing rhinitis and scanning in asthma measures in 

14:15 

14:30 

14:45 

asthma in children 

WAts2 

Sharjah A 

and osteoporosis 

Sharjah D 

research and clinical 

practice 

Umm Al Qwain 


1st 15:15 

Floor Foyer 

15:30 Pg19: 

Pg20: 

Pg21: 

15:45 

When and how to Bronchial Asthma education 

16:00 

use epinephrine provocation tests in Umm Al Qwain 

16:15 

16:30 

16:45 

17:00 

/ treatment of 

anaphylaxis 

Sharjah A 

adults and children 

Sharjah D 

17:15 Special Session: 

17:30 

Hereditary Angioedema (HAE): 

17:45 

spotlight on the latest advances in diagnosis and treatment 

18:00 

18:15 

18:30 

18:45 

19:00 

Abu Dhabi B 

19:15 

opening Ceremony 

19:30 

19:45 

20:00 

20:15 

20:30 

Sheikh Rashid E 

20:45 

Welcome reception 

21:00 

21:15 

21:30 

21:45 

22:00 

Sheikh Rashid F 

Exhibition 


Pg4: 

nasal endoscopy 

and challenge tests 

WAts2 

Abu Dhabi A 

Pg10: 

CPAP and sleep 

disorders 

WAts2 

Abu Dhabi A 

Pg16: 

Food allergy: 

Diagnosis and 

treatment 

WAts2 

Abu Dhabi A 

Pg22: 

skin testing: theory 

and practice 

Abu Dhabi A 

Pg5: 

Aspirin 

desensitization 

WAts2 

Abu Dhabi B 

Pg11: 

Clinical methods for 

distinguishing COPD 

and asthma 

WAts2 

Abu Dhabi B 

Pg17: 

managing chronic 

cough 

Abu Dhabi B 

Pg23: 

Practical aspects of 

immunotherapy 

WAts2 

Abu Dhabi B 

Pg6: 

sputum analysis/ 

BAl analysis 


Pg12: 

Dietary factors and 

weight management 


Pg18: 

Optimizing asthma 

management & 

treatment through 

behavior modifi cation 

WAts2 


Pg24: 

Preventing asthma 

exacerbations 

WAts2 


KEY 

Css Company sponsored symposium 

Kn Keynote lunch symposium 

Pg Postgraduate Course 

Ps Plenary session 

sY symposium 


FinAl PrOgrAm



WisC 2010 PrOgrAm-At-A-glAnCE 

mOnDAY, 6 DECEmBEr 2010 


06:30 

06:45 

07:00 

07:15 

07:30 

07:45 

08:00 PS 1: 

08:15 

08:30 

08:45 

09:00 

09:15 

09:30 

09:45 



10:15 

10:30 SY1: 

10:45 

11:00 

11:15 

11:30 

11:45 

registration 


Exhibition 


Update on asthma and lower airway co-morbidities 


Update on asthma research and clinical 

practice 

Sheikh Rashid A 

SY2: 

Asthma and co-morbidities 

Sheikh Rashid B 

12:00 lunch Break 

12:15 

Sheikh Rashid C&D 

12:30 Kn1: Presidential Keynote lunch symposium: Asthma and co-morbid conditions 

12:45 


13:00 PS2: 

13:15 

13:30 

13:45 

14:00 

14:15 

14:30 

14:45 



15:15 

15:30 SY4: 

15:45 

16:00 

16:15 

16:30 

16:45 

Asthma & upper airway co-morbidities 


Asthma in the elderly 


17:00 Poster Session 1: 

17:15 

17:30 

17:45 

18:00 

18:15 

18:30 

18:45 

19:00 

19:15 

19:30 

19:45 

20:00 

20:15 

20:30 

20:45 

21:00 

Poster session and networking with 

Faculty and WAO leadership 


SY5: 

mEAAAiC: Asthma and upper airway comorbidities 

in the gulf and near East 


SY3: 

Asthma and upper airway co-morbidities: 

research and clinical practice updates 


SY6: 

Asthma and upper airway co-morbidities: 

looking ahead 


KEY 





sY symposium 


FinAl PrOgrAm


registration 


Exhibition 




tUEsDAY, 7 DECEmBEr 2010 


07:00 

07:15 

07:30 

07:45 

08:00 PS3: 

08:15 

Asthma and endocrine co-morbidities 

08:30 

08:45 

09:00 

09:15 

09:30 

09:45 



10:15 


10:30 SY7: 

SY8: 

SY9: 

10:45 

An overview of pediatric asthma Asthma, endocrine disorders and new concepts in severe asthma 

11:00 


iatrogenesis 


11:15 

11:30 

11:45 



12:15 


12:30 Kn2: Use of antimicrobials to treat acute exacerbations of chronic bronchitis, asthma and COPD 

12:45 


13:00 Poster Session 2: outstanding Poster awards 

CSS: 

13:15 


sanofi Aventis: 

13:30 

Allergic airways diseases: From the 

13:45 

14:00 

14:15 

evidence to clinical practice 


14:30 PS4: 

14:45 

Asthma and COPD: Present and future therapies 

15:00 

15:15 

15:30 

15:45 

16:00 

16:15 



16:45 


17:00 SY10: 

SY11: 

SY12: 

17:15 

immunotherapy and immune modulators in EAACi: the multiple faces of asthma Asthma and COPD 

17:30 

asthma and allergic rhinitis 



17:45 

18:00 

18:15 

18:30 

18:45 

19:00 

19:15 

19:30 

19:45 

20:00 


20:15 

20:30 

KEY 

20:45 

21:00 





sY symposium 


FinAl PrOgrAm


registration 


Exhibition 




WEDnEsDAY, 8 DECEmBEr 2010 


07:00 

07:15 

07:30 

07:45 

08:00 PS5: 

08:15 

Asthma and atopic eczema, food allergy, anaphylaxis 

08:30 

08:45 

09:00 

09:15 


09:30 Poster Session 3: 

09:45 

10:00 

10:15 



10:45 


11:00 SY14: 

SY15: 

11:15 

Asthma and viral infections 

Asthma and chest co-morbidities 

11:30 


in the middle East 

11:45 

12:00 

12:15 

12:30 



13:00 


13:15 Kn3: Asthma and immunotherapy: Past, present and future 

13:30 

13:45 


14:00 PS6: 

14:15 

Psychological and societal dimensions of asthma 

14:30 

14:45 

15:00 

15:15 

15:30 

15:45 

16:00 

16:15 

16:30 

16:45 

17:00 


SY13: 

Asthma and ocular allergy co-morbidity 


SY16: 

Asthma and concomitant chest diseases 


KEY 





sY symposium 


FinAl PrOgrAm



sCiEntiFiC PrOgrAm—sUnDAY, 5 DECEmBEr 2010 

POstgrADUAtE COUrsEs 

since attendance is limited, all Postgraduate Courses require pre-registration. At the time of check in at the registration Desk, all 

pre-registered attendees will be provided with a ticket for each registered session. 

Please provide your ticket to gain entry to a Postgraduate Course. 

09:00 – 10:30 PoSTgraDUaTE CoUrSE 1 Sharjah a 

Spirometry 

learning objectives: 

• to define what constitutes accurate and adequate spirometric assessment 

• to discuss how spirometry performance and interpretation differ depending on age 

• to review how pulmonary-function assessment compares with other outcome measures in asthma 

Speakers: Omar Al rawas 

thomas B. Casale 

stephen Peters 

09:00 – 10:30 PoSTgraDUaTE CoUrSE 2 Sharjah D 

Exhaled no and other markers of inflammation - WaTS2* 


• to highlight the importance of monitoring airway inflammation for improved asthma control 

• to show how exhaled nitric oxide serves as a biomarker for airway inflammation 

• to review the clinical applications of measuring exhaled nitric oxide 

Speaker: myron Zitt 

09:00 – 10:30 PoSTgraDUaTE CoUrSE 3 Umm al Qwain 

managing smoking cessation clinics 


• to review best practices on how and where to set up such clinics 

• to discuss what management approaches work best and why 

• to discuss effective ways to ensure adherence to non-smoking 

Speakers: Bassam mahboub 

riccardo Polosa 

giovanni Viegi 

09:00 – 10:30 PoSTgraDUaTE CoUrSE 4 abu Dhabi a 

nasal endoscopy and challenge tests - WaTS2* 


• to demonstrate how to use these practical procedures to yield reproducible results 

• to show how to assess the outcomes of these tests and best use them in the clinic 

• to explain when to opt for a challenge test 

Speakers: Abdulla ibrahim 

Dennis ledford 

ruby Pawankar 

09:00 – 10:30 PoSTgraDUaTE CoUrSE 5 abu Dhabi B 

aspirin desensitization - WaTS2* 


• to understand the principles of aspirin desensitization 

• to demonstrate how to assess correctly when it is indicated 

• to review the mechanisms of aspirin desensitization and what are its short and long-term outcomes 

Speakers: marek l. Kowalski 

Hae-sim Park 

*World allergy Training School 2 


FinAl PrOgrAm 

sUnDAY, 5 DECEmBEr 2010





09:00 – 10:30 PoSTgraDUaTE CoUrSE 6 ras al Khaimah 

Sputum analysis/Bal analysis 


• to explain the advantages and disadvantages of sputum versus BAl analyses 

• to present data regarding what biomarkers in either sputum or BAl may be useful for clinical monitoring 

• to discuss the age groups in which sputum induction can be performed and interpreted 

Speakers: neil Barnes 

louis-Philippe Boulet 

Paul O’Byrne 

10:30 – 11:00 CoFFEE BrEaK 1st Floor Foyer 


inhalation devices 


• to review various asthma medication delivery systems relevant to age 

• to show how HFA propellants may affect drug delivery from mDis 

• to provide insight into spacers and their importance in drug delivery 

Speakers: suleiman Al Hammadi 

sandra gonzález-Díaz 

Pramod Kelkar 


investigating and managing upper airway disorders 


• to demonstrate examination techniques, including rhinolaryngoscopy, for upper airway disorders 

• to illustrate common pathologies, including the causes of sleep-disordered breathing of upper airway disorders 

Speakers: g. Walter Canonica 

Omer Kalayci 

michael A. Kaliner 


asthma self-management (Sm) plans - WaTS2* 


• to emphasize the importance of patient self-management plans for asthma 

• to provide examples of sm plans for use in children, adolescents and adults in different practice settings 

• to review the impact of illiteracy, resource limitation and other barriers to self-management 

Speakers: ignacio J. Ansotegui 

tari Haahtela 

nizar Kherallah 


CPaP and sleep disorders - WaTS2* 


• to explain better the physiology and pathophysiology of obstructive sleep apnea and its consequences 

• to emphasize the magnitude of the clinical problem 

• to make familiar the practical aspects of treatment techniques 

• to identify unmet needs 

Speaker: Fulvio Braido 



FinAl PrOgrAm





Clinical methods for distinguishing CoPD and asthma - WaTS2* 


• to review different methods for distinguishing asthma from COPD in different practice settings, including the role of screening 

questionnaires, and lung function and allergy tests 

• to review and discuss the role of clinical trials of therapy and monitoring of outcomes in asthma/COPD 

Speakers: Hatem Al Ameri 

stephen Peters 

Eric Bateman 


Dietary factors and weight management 


• to review appropriate dietary management in preschool children 

• to provide updates on the use of probiotics in disease prevention 

• to present information regarding what dietary and/or behavioral interventions are most successful in achieving appropriate weight 

control 

Speakers: michael s. Blaiss 

Paul greenberger 

12:30 – 13:30 lUnCH BrEaK al multaqua 

Beginning at 12:30, lunch boxes may be picked up in al multaqua. 


Practical aspects of managing rhinitis and asthma in children - WaTS2* 


• to explain the process of diagnosis of rhinitis and asthma in children 

• to make familiar the specifics of treatment of rhinitis and asthma in children, especially in relation to safety, efficacy and easy 

administration toward better compliance 

• to identify specifics of disease that may be related to region 

Speakers: salem Al tamemi 

Carlos E. Baena-Cagnani 

michael s. Blaiss 


role of bone scanning in asthma and osteoporosis 


• to review the different methods used to assess bone density 

• to review the risks and benefits of bone density assessments 

Speakers: Dennis ledford 



asthma control measures in research and clinical practice 


• to review and compare validated measures for assessing asthma control 

• to provide practical advice on their use in clinical research and in various clinical care settings 

• to show the relationship between current control and “future” risk and its implications for care and setting treatment goals 

Speakers: sergio Bonini 

Paul O’Byrne 



FinAl PrOgrAm 

sUnDAY, 5 DECEmBEr 2010






Food allergy: Diagnosis and treatment - WaTS2* 


• to provide insight into diagnosing food allergy (igE testing and food challenge) 

• to explain how to cope with allergic reactions (including anaphylaxis) induced by food allergy 

• to understand the role of “oral immunotherapy” for food allergy 

Speakers: sami Bahna 

motohiro Ebisawa 

Alessandro Fiocchi 


managing chronic cough 

learning objective: 

• to demonstrate the combined diagnostic/therapeutic approach to chronic cough 

Speakers: Pramod Kelkar 

riccardo Polosa 


optimizing asthma management & treatment through behavior modification - WaTS2* 


• to provide insight into reasons for non-compliance in asthma therapy, including patient fears 

• to review effective ways of enhancing treatment compliance at different ages 

Speakers: Fulvio Braido 

Harold nelson 

mario sanchez-Borges 

15:00 – 15:30 CoFFEE BrEaK 1st Floor Foyer 


When and how to use epinephrine / Treatment of anaphylaxis 


• to review the mechanisms by which epinephrine reduces the symptoms of anaphylaxis 

• to present appropriate dosing and route of administration of epinephrine 

• to discuss when epinephrine should or should not be given to school children with a history of “anaphylaxis” 

Speakers: richard F. lockey 

myron Zitt 


Bronchial provocation tests in adults and children 


• to describe different forms of bronchial provocation tests and their uses 

• to provide practical advice on their selection and conduct 

• to review the safety and interpretation of bronchial provocation tests 

Speakers: Omer Kalayci 

lanny rosenwasser 


asthma education 


• to review the definitions of asthma severity and control 

• to reinforce the concept of current asthma impairment versus future asthma risk 

• to identify communication barriers that impair both short and long term asthma education 

Speakers: tari Haahtela 

michael A. Kaliner 

tatiana slavyanskaya 



FinAl PrOgrAm





Skin testing: Theory and practice 


• to review the use of skin testing for allergy 

• to review the approved methods of skin testing 

• to discuss ways to improve skin testing 

Speakers: sami Bahna 


Fares Zaitoun 


Practical aspects of immunotherapy - WaTS2* 


• to review the process of how to select patients for immunotherapy 

• to explain the methodology of immunotherapy and who should administer it to the patient 

• to review the risks and benefits of the different types of immunotherapy 

Speakers: g. Walter Canonica 

Harold nelson 


Preventing asthma exacerbations - WaTS2* 


• to address the question: What defines an asthma exacerbation versus loss of asthma control? 

• to discuss which patients may be at increased risk for exacerbations 

• to review why reducing exacerbation frequency may be important in terms of long term consequences (i.e., loss of lung function) 

Speakers: thomas B. Casale 


marek l. Kowalski 

17:15 – 18:15 Special Session abu Dhabi B 

Hereditary angioedema (HaE): Spotlight on the latest advances in diagnosis and treatment 

Chairperson: lanny rosenwasser 

17:15 Welcoming remarks 

17:20 Clinical presentation and differential diagnosis |




sCiEntiFiC PrOgrAm—mOnDAY, 6 DECEmBEr 2010 

8:00 – 10:00 PlEnarY SESSion 1 Sheikh rashid E 

Update on asthma and lower airway co-morbidities 


• to provide an overview of recent advances in asthma pathophysiology and treatment 

• to show the relationship of lower airway co-morbidities to asthma severity and control 

• to review new approaches to treatments directed toward lower airway co-morbidities 

Chairpersons: Hassan Alrayes 

Ali Ben Kheder 

Ashok shah 


08:05 Epidemiology and risk factors for asthma and CoPD |




11:15 asthma exacerbation and reducing emergency room visits |





11:15 asthma and nasal polyps |




15:00 – 15:30 CoFFEE BrEaK Sheikh rashid F 

15:30 – 17:00 SYmPoSiUm 4 Sheikh rashid a 

asthma in the elderly 


• to recognize the importance and high prevalence of asthma in the elderly 

• to consider clinical presentations and management issues of asthma in the elderly 

• to consider diagnostic challenges presented by co-morbid conditions 

Chairpersons: Young-Koo Jee 

Yousser mohamed 

Fadhel saleh 


15:35 asthma and co-morbidities in the elderly |





15:30 – 17:00 SYmPoSiUm 6 Sheikh rashid E 

asthma and upper airway co-morbidities: looking ahead 


• to review functional upper airway disorders and their relationship with asthma 

• to investigate the contribution of gErD to asthma morbidity 

• to evaluate the relationship(s) between obstructive sleep apnea and asthma 

Chairpersons: Carla irani 

Ho Joo Yoon 


15:35 asthma and vocal cord dysfunction |



sCiEntiFiC PrOgrAm—tUEsDAY, 7 DECEmBEr 2010 


asthma and endocrine co-morbidities 


• to describe endocrine factors related to obesity that may contribute to asthma pathophysiology 

• to review how weight gain or loss may influence asthma severity and/or control 

• to consider the effects of pregnancy on asthma control and approaches to treatment 

Chairpersons: Abdulrahman Al Frayh 

Waleed Al-Herz 

Young Joo Cho 


08:05 Dietary factors, obesity and pediatric asthma |





11:15 Prevention of pediatric asthma and allergies |




11:15 Small airways disease in asthma 

Wao Small airways Diseases Working group lecture* |





13:00 – 14:30 ComPanY SPonSorED SYmPoSiUm Sheikh rashid B 

Sanofi-aventis Symposium – allergic airways diseases: From the evidence to clinical practice 

Chairperson: mario sanchez-Borges 


13:05 Burden of allergic diseases in middle East countries |




17:00 – 18:30 SYmPoiSUm 10 Sheikh rashid a 

immunotherapy and immune modulators in asthma and allergic rhinitis 


• to explain the mechanisms of and indications for immunotherapy 

• to review the available immunotherapy approaches 

• to review when and how to use immunotherapy and assess its success 

Chairpersons: Ahmed Elbousify 

nagata makoto 


17:05 Subcutaneous immunotherapy |





17:00 – 18:45 SYmPoiSUm 12 Sheikh rashid E 

asthma and CoPD 


• to provide insight into how disordered cell and molecular processes in these diseases can be used as diagnostic and prognostic tests 

• to provide updates on new methods that help in diagnosis of lung diseases 

• to review allergen avoidance strategies: those that work and those that do not 

Chairpersons: Hasan Al-Dhekri 

Kamal Hanna 


17:05 Biomarkers in the assessment of asthma and CoPD |



sCiEntiFiC PrOgrAm—WEDnEsDAY, 8 DECEmBEr 2010 


asthma and atopic eczema, food allergy, anaphylaxis 


• to explain the clinical presentation of atopic dermatitis and its management 

• to present information regarding the natural history of food allergy 

• to review the management of anaphylaxis in the asthmatic patient 

Chairpersons: Hani Ababneh 

mK Agarwal 


08:05 atopic eczema and respiratory allergy |





09:55 asthma and rhinoconjunctivitis co-morbidity and quality-of-life |




11:45 The impact of olive pollens on allergy and asthma in Jordan |





14:00 – 16:00 Plenary Session 6 Sheikh rashid E 

Psychological and societal dimensions of asthma 


• to highlight the links between the mind and body in asthma 

• to identify the impact of psychological factors upon attitudes regarding compliance and the implications for treatment 

• to describe the influence of socioeconomic factors on the prevalence and management of asthma 

• to consider special behavioral and developmental issues affecting children with asthma 

Chairpersons: mirza Al-sayegh 

noel rodriguez-Perez 


14:05 Developmental and behavioral problems in children and adolescents |

30 th Congress of the 

European Academy of 

Allergy and Clinical Immunology 

11 – 15 June 2011 

Istanbul, Turkey 

EAACI Congress 2011 

www.eaaci2011.com 

Bridging Science and Culture 

Abstract 

Submission 

Deadline: 

18 January 

2011

POstErs 

POstErs 



POstEr sEssiOns 

All accepted abstracts will be presented as posters in Poster sessions on 6, 7, and 8 December in the Exhibition Hall (sheikh rashid 

F). Each Poster session will focus on posters in 3-4 topic categories. Chairpersons are assigned to each category and will stimulate 

discussion between the audience and Presenting Authors. Presenting Authors will stand next to their posters, answer questions and 

discuss their research. 

Posters must be set up on monday, 6 December between 09:00 – 16:00. Posters will remain on display throughout the Conference, 

and must be dismantled between 10:30 – 13:00 on Wednesday, 8 December. Posters not dismantled by 13:00 on Wednesday, 

8 December will be discarded. 

the Poster number listed above the abstract title corresponds to the abstract number, which is printed in the ‘Abstracts’ section 

(pages 78-162) of this program. it also corresponds to the Poster Board number, placed on the boards in the Exhibition Hall (sheikh 

rashid F). 

All posters will remain on display throughout the conference. 

monday, 6 December 2010 – Poster Session 1 

Poster Session and networking with Faculty and Wao leadership 

Junior delegates will have the opportunity to discuss and view posters in an informal setting, as well as network with Conference 

faculty and the WAO leadership. light refreshments will be served. 

included in the registration fee for Delegates, students, nurses and Accompanying Persons. 

17:00 - 18:30 PO1-1: Allergens and risk factors sheikh rashid F 

To view full abstracts from this session, please reference pages 78-87 of the ‘Abstracts’ section in this program. 

Chairpersons: syed m. Hasnain 

noel rodriguez-Perez 

1100 

allErgiC aSTHma in SYrian aDUlTS 

A. Khoury, m. merrawi and A. H. Joukaj 

Chest Diseases, Aleppo Faculty of Medicine, Aleppo, Syria. 

1101 

oCCUPaTional aSTHma in PETroCHEmiSTrY WorKErS WiTH PErSiSTanT EXPoSUrE 

A. Eatemadi 

Immunology & Infectious disease, Ahvaz University of Medical Sciences, Ahvaz, Iran. 

1102 

SPECiFiC igE SEnSiTiZaTion To CEPHaloSPorinS in HoSPiTal PErSonnEl 

J. E. Kim, s. H. Kim, H. J. Jin, J. H. Kim, Y. m. Ye and H. s. Park 

Department of Allergy & Rheumatology, Ajou University School of Medicine, Suwon, South Korea. 

1103 

HoUSE DUST miTE allErgY – inDian PErSPECTiVE 

g. K. saha, Professor 

Zoology, Department of Zoology, University of Calcutta, Kolkata, India. 

1104 

SEnSiTiZaTion raTE anD riSK FaCTorS For SEnSiTiZaTion To DigESTiVE EnZYmES in HoSPiTal PErSonnEl 

J. E. Kim, H. J. Jin, J. H. Kim, Y. m. Ye and H. s. Park 

Department of Allergy & Rheumatology, Ajou University School of Medicine, Suwon, South Korea. 

1105 

SKin TEST rEaCTiViTY in THE EaSTErn ProVinCE oF SaUDi araBia 

r. KHOUQEEr 

Allergy and Immunology, Saad Specialist Hospital, Alkhobar, Saudi Arabia. 


FinAl PrOgrAm

POstErs 



1106 

QUanTiFiCaTion oF a 24 KD maJor allErgEn oF CULEX QUINQUEFASCIATUS WHolE BoDY EXTraCT BY immUnologiCal 

TECHniQUES 

m. A. Kausar, Ph.D. 1 , V. Vijayan, Ph.D. 2 , s. Bansal, Ph.D. 3 , m. Vermani, Ph.D. 4 , W. siddiqui, Ph.D. 5 and m. Agarwal, Ph.D. 6 

1 Departments of Respiratory Allergy and Applied Immunology, VP Chest Institute, University of Delhi, New Delhi, India. 2 Department 

of Respiratory Medicine, V.P. Chest Institute, Delhi, India. 3 Department of Biochemistry, V.P. Chest Institute, Delhi, India. 4 Department 

of Respiratory Allergy and Applied Immunology, V.P. Chest Institute, Delhi, India. 5 Department of Biochemistry, Jamia Hamdard,, New 

Delhi, India. 6 Department of Respiratory Allergy and Applied Immunology, Formerly at V.P. Chest Institute, Delhi, India. 

1107 

PrEValEnCE oF aSTHma in ElEmEnTarY SCHool STUDEnTS aFTEr an oil lEaK in THE WESTErn CoaST oF KorEa 

Y. K. Jee, mD, PhD 1 , K. m. Kim 1 , D. H. Kim 1 , Y. s. Kim 1 , J. s. Park 1 , W. C. Jeong 2 , J. i. Hur 2 , s. C. Jung, mD 3 and s. C. roh, mD, mPH, 

PhD 3 

1 Internal Medicine, Dankook University College of Medicine, Cheonan, South Korea. 2 Taean Institute of Environmental Health, Taean, 

South Korea. 3 Occupational and Environmental Medicine, Dankook University College of Medicine, Cheonan, South Korea. 

1108 

PrEValEnCE oF CHroniC oBSTrUCTiVE PUlmonarY DiSEaSE anD iTS aSSoCiaTion WiTH ToBaCCo SmoKing anD 

EnVironmEnTal ToBaCCo SmoKE EXPoSUrE among rUral PoPUlaTion 

P. B g 1 , n. Huliraj 2 , P. K. s P 1 , r. B m 1 , g. Dr 1 , r. m. n r 1 and s. B. C r 3 

1 Department of Community Medicine, Kempegowda Institute of Medical Sciences, Bangalore, India. 2 Department of Thoracic 

Medicine, Kempegowda Institute of Medical Sciences, Bangalore, India. 3 Department of Radiology, Kempegowda Institute of Medical 

Sciences, Bangalore, India. 

1109 

aSSESSmEnT oF lUna-air oaSiS air PUriFiErS in PrEVEnTing inHalanT allErgiES in DogS BY rEDUCing 

aEroallErgEnS anD VoCS 

n. ghosh, Ph.D. 1 , A. Aranda, Bs 1 , J. Bennert, Ph.D., Ctn 2 , J. Chudasama, Bs 2 , A. B. Das, D.sc. 3 and C. saadeh, mD, FACP, FACr 4 

1 Life, Earth and Environmental Sciences, West Texas A&M University, Canyon, TX. 2 Air Oasis, Amarillo. 3 Dept. of Agricultural 

Biotechnology, College of Agriculture, Orissa University of Agricultutre & Technology, India. 4 Allergy A.R.T.S., Amarillo, TX. 

1110 

EFFECT oF mUlTiWallED CarBon nanoTUBE in oVa-inDUCED aSTHma moDEl 

i. s. Yun, mD 1 , J. Y. Kim, PhD 2 , i. H. Choi, PhD 3 , C. s. Hong, mD, PhD 1 and J. W. Park, mD, PhD 4 

1 Division of Allergy & Immunology Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. 

2 Institute of Allergy Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. 3 Department 

of Microbiology, Yonsei University College of Medicine, South Korea. 4 Division of Allergy & Immunology Department of Internal 

Medicine, Yonsei University College of Medicine, Seoul. 

1111 

PollEn CoUnTS ProFilE in gEorgia EValUaTED BY THE BUrKHarD PollEn TraP 

m. V. Chikhladze 1 and r. i. sepiashvili 2 

1 National Institute of Allergology, Asthma & Clinical Immunology, Georgian Academy of Sciences, Tskhaltubo, Georgia. 2 Department 

of Allergology and Clinical Immunology, Institute of Immunophysiology, Moscow, Russia. 

1112 

air PUriFiEr THaT USES PHoTo CaTalYTiC oXiDaTion rEDUCED THE PoPUlaTion oF mrSa 

n. ghosh, Ph.D. 1 , C. Pratt, Bs 1 , J. Bennert, Ph.D., Ctn 2 , J. Chudasama, Bs 2 and A. B. Das, D.sc. 3 

1 Life, Earth and Environmental Sciences, West Texas A&M University, Canyon, TX. 2 Air Oasis, Amarillo. 3 Dept. of Agricultural 

Biotechnology, College of Agriculture, Orissa University of Agriculture & Technology, India. 

1113 

inCrEaSing oF allErgY PoTEnCY oF PollEn grainS in HElianTHUS annUUS l. UnDEr BEnZo(Á) PYrEnE (BaP) 

EXPoSUrE 

Z. Baghali 1 , A. majd 2 , A. Chehregani 3 , Z. Pourpak 4 and m. Vatanchian 3 

1 Dept. of Biology, Tarbiat Moallem University, Hamedan, Iran. 2 Dept. of Biology, Tarbiat Moallem University, Tehran, Iran. 3 Dept. of 

Biology, Bu-Ali Sina University, Hamedan, Iran. 4 Immunology, Asthma and Allergy Research Institute, Tehran University, Tehran, Iran. 


FinAl PrOgrAm 

POstErs

POstErs 

POstErs 



1114 

rElaTionSHiP BETWEEn ToTal SErUm igE anD BoDY maSS inDEX in PaTiEnTS WiTH nonaToPiC rESPiraTorY allErgY 

s. H. Kim, W. Y. lee, s. J. Yong, K. C. shin, s. n. lee, s. J. lee and m. K. lee 

Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea. 

1115 

PollEn STUDY in inDonESia 

i. rengganis 

Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia. 

1116 

inHalanT allErgEnS SEnSiTiZaTion in PaTiEnTS WiTH aSTHma anD allErgiC rHiniTiS; rEViEW oF SKin TEST rESUlTS 

oVEr TWo YEarS PErioD aT SUlTan QaBooS UniVErSiTY HoSPiTal, mUSCaT – oman 

s. W. sharef, mD. and s. H. Al-tamemi, mD., FrCPC. 

Department of Child Health, Sultan Qaboos University Hospital, Muscat, Oman. 

1117 

SKin PriCK TEST in CHilDrEn rESiDing in a rUral CommUniTY in BanDUng, WEST JaVa, inDonESia 

g. sapartini 1 , C. B.Kartasasmita 1 , B. setiabudiawan 1 , r. g. D. majangsari 1 , W. saptaputra 2 and n. irwan 2 

1 Department of Child Health, School of Medicine Padjadjaran University, Bandung, Indonesia. 2 Health Research Unit, School of 

Medicine Padjadjaran University, Bandung, Indonesia, Bandung, Indonesia. 

1118 

ProTEin EXPrESSion ProFilE oF inDigEnoUS anD CommErCial EXTraCTS oF amaranTHUS PollEn in allErgY 

PaTiEnTS 

s. m. Hasnain, PhD, FACAAi, FAAAAi 1 , H. Al sini 1 , A. Al-Qassim 1 , A. Al Frayh, prof., allergy/pulmonology 2 , m. O. gad-El-rab 3 and A. 

Alaiya 1 

1 Biological and Medical Research, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. 2 king saud University 

&King Khalid Hospital Riadh K S ARiyadh, Riyadh. 3 College of Medicine, King Saud University. 

1119 

naTUral rUBBEr laTEX-rElaTED oCCUPaTional aSTHma: SUCCESSFUl SUBlingUal DESEnSiTiZaTion 

D. schiavino 

Allergy Department, Catholic University, Rome, Italy. 

1120 

ToTal igE SEnSiTiViTY ComParED WiTH SPECiFiC igE rESUlTS againST miTES anD molDS For THE SCrEEning oF TYPE 

1 allErgY in WorKErS oF a PoliCE inSTiTUTE in CaraCaS, VEnEZUEla 

n. A. silva, Esp., C. monterrey, n. Camacho and g. nirsen 

Laboratory of Production and Quality Control, Corpodiagnostica, Caracas, Venezuela. 

17:00 - 18:30 PO 1-2: Asthma education and management sheikh rashid F 


Chairpersons: Eric Bateman 

mohammed nizam iqbal 

1200 

omaliZUmaB ProVing To BE EFFECTiVE in PaTiEnTS WiTH normal igE lEVElS & rEFraCTorY aSTHma, 

B. mahboub, Head, of, Pulmonary, medicine1 , r. mohamed, Pulmonologist2 and n. mohamed, Pulmonologist3 1 2 ,Rashid hospital, Dubai, United Arab Emirates. Department of Pulmonary Medicine, Rashid hospital, Dubai, United Arab Emirates. 

3 ,Department of Pulmonary medicine ,Rashid hospital, Dubai, United Arab Emirates. 

1201 

From TEmPEramEnT To PErSonaliTY: DoES aSTHma aFFECT DEVEloPmEnT? 

C. grønnerød, Dr.psychol. 

Department of Psychology, University of Oslo, Oslo, Norway. 


FinAl PrOgrAm

POstErs 



1202 

THE TrEaTmEnT oF PaTiEnTS WiTH BronCHial aSTHma anD arTErial HYPErTEnSion 

E. A. latysheva1 , O. m. Kurbacheva1 and g. E. gendlin2 1 2 Allergology and Clinical Immunology, Institute of Immunology FMBA Russia, Moscow, Russia. Cardiology, Russian Medical 

University. 

1203 

aDUlT aToPiC DiSorDErS anD aDHD: a nEED oF BlaCK SPoT Program 

m. Afifi, mBChB, mmed, DrPH 

Primary Health Care, Ministry of Health (HQ), Dubai, United Arab Emirates. 

1204 

THE QUaliTY oF liFE in aSTHmaTiC PaTiEnTS TrEaTED WiTH omaliZUmaB 

F. della torre 1 , A. limonta 1 , V. gaffuri riva 1 and E. Della torre 2 

1 General Pneumology, INRCA-IRCCS, Milan, Italy. 2 Internal Medicine, San Raffaele Hospital, Milan, Italy. 

1205 

aToPiC aSTHma anD BronCHiECTaSiS 

A. Khoury 1 and F. Ahmed 2 

1 Chest Diseases, Aleppo Faculty of Medicine, Aleppo, Syria. 2 Pulmonology Department, Faculty of Medicine of Aleppo, Aleppo, Syria. 

1206 

EFFECT oF omaliZUmaB in JaPanESE PaTiEnTS WiTH SEVErE allErgiC aSTHma anD rHiniTiS 

F. nishihara, Y. takaku, K. nakagome, A. masumoto, t. Yamaguchi and m. nagata 

Allergy Center , Department of Respiratory Medicine, Saitama Medical University, Moroyama-Machi, Japan. 

1207 

managEmEnT oF mUCUS rElaTED rESPiraTorY HEalTH ProBlEmS THroUgH SinUSES anD airWaYS ClEaning 

EXErCiSES 

m. Prakash rao, B.Com., ll.m. 

Advocate, Hyderabad, India. 

1208 

THE rolE oF inTErlEUKin-13 in aSTHma 

A. Vafa 

Azerbaijan Medical University, Baku, Azerbaijan. 

1209 

imProVED HEalTH oUTComES For aDolESCEnTS WiTH aSTHma in JorDan: a ClUSTEr ranDomiZED ConTrollED 

Trial 

n. A. Al-sheyab 1 , r. gallagher 2 , J. Crisp 2 and s. shah, Dr 3 

1 Maternal and Child Health, Jordan University of Science and Technology, Irbid, Jordan. 2 University of Technology, Sydney, Sydney, 

Australia. 3 University of Sydney, Westmead, Australia. 

1210 

imPlEmEnTaTion oF gUiDElinES in rEal-WorlD UK aSTHma managEmEnT 

D. ryan, mD 1 , J. Haughney, mD 2 , m. thomas, mD 2 , H. Pinnock, mD 3 , D. Price, Prof, mD 2 , s. Ellis 4 and A. Chisholm 4 

1 Woodbrook Medical Centre, Loughborough, United Kingdom. 2 Centre of Academic Primary Care, University of Aberdeen, Aberdeen, 

United Kingdom. 3 Allergy and Respiratory Research Group, Centre for Population Health Sciences: GP Section, The University of 

Edinburgh, Edinburgh, United Kingdom. 4 Research in Real Life, Cawston, United Kingdom. 

1211 

iS THErE SUFFiCiEnT nEED For an aDUlT SEVErE aSTHma SErViCE in THE UK? a rEViEW oF 11 UK FamilY 

PraCTiTionErS 

D. Price, Professor, medical, Doctor 1 , m. Britton, Consultant, Physician 2 , l. mascarenhas 3 , V. Knowles 4 , E. J. sims 5 and s. Blagbrough 5 

1 Centre of Academic Primary Care,, University of Aberdeen, Aberdeen, United Kingdom. 2 Postgraduate Medical School, Faculty 

Health & Medical Sciences, University of Surrey, Guildford, United Kingdom. 3 NHS Surrey, Leatherhead. 4 SW Locality, Surrey 

Community Health, Farnham, United Kingdom. 5 Optimum Patient Care, Norwich, United Kingdom. 


FinAl PrOgrAm 

POstErs

POstErs 

POstErs 



1212 

CHooSing ComBinaTion THEraPY For aSTHma: rESUlTS oF a Pan-EUroPEan aTTiTUDinal SUrVEY 

D. Price, Professor, mD 

Centre of Academic Primary Care, University of Aberdeen, Aberdeen, United Kingdom. 

1213 

ComBinaTion THEraPY For aSTHma: rESUlTS oF a DElPHi ProCESS 

D. Price, Professor, mD 1 and J. Bousquet, Professor 2 

1 Centre of Academic Primary Care, University of Aberdeen, Aberdeen, United Kingdom. 2 University of Montpellier, Montpellier, France. 

1214 

CorrElaTion BETWEEn aSTHma-rElaTED QUaliTY oF liFE anD aSTHma ConTrolS in aDUlT aSTHmaTiCS 

B. Anıl, P. Yıldız, E. Aynacı, E. Yıldırım, F. Şahin and F. seçik 

Pulmonology, Yedikule Chest Disease and Surgery Training and Research Hospital, İstanbul, İstanbul, Turkey 

1215 

aSTHma ComPliCaTion in PrEgnanCY 

n. H. Al shammari, O. randa, K. muna 

AL Qassimi Hospital, Sharjah, United Arab Emirates. 

1216 

THE ValUE oF aSPirin DESEnSiTiSaTion in THE managEmEnT oF aSTHma anD rHinoSinUSiTiS: EViDEnCE–BaSED 

E. Arafa, mBChB, Dip, allergy, msc, allergy, fellow, southampton, UK 1 and D. P. Howarth, Bsc, mBBs, Dm, FrCP 2 

1 Allergy Department, N M C Specialty Hospital, Dubai, United Arab Emirates. 2 Infection,Inflammation and Immunity research 

division,School of medicine, Southampton General Hospital, Southampton, United Kingdom. 

1217 

ESoPHagEal CanDiDiaSiS SUCCESSFUllY TrEaTED WiTH rEPlaCEmEnT oF inHalED CorTiCoSTEroiD 

A. P. Castro-Coelho, m. V. Aun, F. g. montenegro, D. B. Borges, r. C. Agondi, J. Kalil and P. giavina-Bianchi 

Clinical Immunolgy and Allergy, Sao Paulo University, Sao Paulo, Brazil. 

1218 

DEmograPHiC anD CliniCal CHaraCTEriSTiCS aSSoCiaTED WiTH THE aTTriTion in a CoHorT oF aDUlT aSTHma 

s. H. Kim 1 , t. B. Kim 2 , Y. s. Chang 3 , s. H. Kim 3 , H. W. Park 4 , s. W. Park 5 , Y. s. Cho 2 , J. W. Park 6 , D. H. nahm 7 , Y. J. Cho 8 , s. H. Cho 4 , B. W. 

Choi 9 , H. B. moon 2 and H. J. Yoon 1 

1 Department of Internal Medicine, Hanyang University College of Medicine, Seoul, South Korea. 2 Department of Allergy and Clinical 

Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 3 Department of Internal Medicine, 

Seoul National University Bundang Hospital, Seongnam, South Korea. 4 Department of Internal Medicine, Seoul National University 

College of Medicine, Seoul, South Korea. 5 Division of Respiratory and Allergy Medicine, Soonchunhyang University Hospital, College 

of Medicine, Bucheon, South Korea. 6 Division of Allergy & Immunology Department of Internal Medicine, Yonsei University College of 

Medicine, Seoul, South Korea. 7 Allergy & Rheumatology, Ajou University School of Medicine, Seoul, South Korea. 8 Allergy and Clinical 

Immunology, Internal Medicine, Ewha Womans University Mockdong Hospital, Seoul, South Korea. 9 Department of Internal Medicine, 

Chung-Ang University College of Medicine, Seoul, South Korea. 

1219 

EFFECT oF anTirEFlUX TrEaTmEnT on CoUgH FrEQUEnCY in STaBlE aDUlT aSTHmaTiCS 

m. n. Hamed, mD 1 , H. sliem, mD 2 and m. F. Hassan, mD 3 

1 Chest Diseases, Suez Canal University, Faculty of Medicine, Isamilia, Egypt. 2 Internal medicine, Suez Canal University, Faculty of 

Medicine, Ismailia, Egypt. 3 Infectious and tropical diseases, Suez Canal University, Faculty of Medicine, Ismailia, Egypt. 

1220 

PoTEnTial maSKing oF airWaY inFlammaTion BY ComBinaTion THEraPY in aSTHma 

B. J. lee, m.D., PhD., J. Y. lee and D. C. Choi 

Allergy and Clinical Immunology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 

Seoul, South Korea. 


FinAl PrOgrAm

POstErs 



1221 

THE USEFUlnESS oF Pram SCorE in aSSESSing THE SEVEriTY anD oUTComE oF an aCUTE EXaCErBaTion oF WHEEZE 

in CHilDrEn 

m. K. nagaraju, D. r, s. n and g. r 

Pediatric allergy and immunology, Kanchi Kamakoti CHILDS Trust Hospital, Chennai, India. 

17:00 - 18:30 PO 1-3: Asthma epidemiology and mechanishms sheikh rashid F 


Chairpersons: Paul greenberger 

Carla irani 

1300 

rElaTion oF PErimEnSTrUal aSTHma WiTH DiSEaSE SEVEriTY anD oTHEr allErgiC Co-morBiDiTiES-THE FirST 

rEPorT oF PErimEnSTrUal aSTHma PrEValEnCE in SaUDi araBia 

E. Y. sabry 

Chest OPD- Internal Medicine, Saudi German Hospital, Riyadh, Saudi Arabia. 

1301 

non-EoSinoPHiliC aSTHma: imPorTanCE anD PoSSiBlE mECHaniSmS 

s. raj and r. shah 

Bioinformatics, Sathyabama University, Chennai 73, India. 

1302 

aSTHma inCiDEnCE aFTEr agE 6 YEarS BY gEnDEr anD aToPiC STaTUS in THE CHilDHooD allErgY STUDY 

s. Ahmed, m.D. 1 , g. Wegienka, Ph.D. 1 , s. Havstad, mA 1 , C. Johnson, Ph.D., mPH 1 , D. Ownby, m.D. 2 , C. nageotte, m.D. 1 and E. Zoratti, 

m.D. 1 

1 Allergy and Immunology, Henry Ford Health System, Detroit, MI. 2 Allergy and Immunology, Medical College of Georgia, Augusta, GA. 

1303 

PrEVElanCE, TrEaTmEnT PaTTErnS anD riSK FaCTorS oF aSTHma anD rHiniTS among aDUlTS in THE UaE 

B. mahboub, Head, of, Pulmonary, medicine 1 , r. Pawankar, mD, Ph.D 2 , m. rafique 3 , n. sulaiman 4 , s. Al Hammadi, mBBs 5 and A. 

ibrahim 6 

1 Department of Pulmonary Medicine, Rashid Hospital, Dubai, United Arab Emirates. 2 Allergy and Rhinology, NIPPON MEDICAL 

SCHOOL, Tokyo, Japan. 3 Pulmonologist ,Dept of Pulmonary Medicine, Rashid Hospital, Dubai, United Arab Emirates. 4 Dept of family 

& community medicine& Behavioural sciences, Sharjah University, Sharjah, United Arab Emirates. 5 UAE University, United Arab 

Emirates. 6 Otorhinolaryngology, Al barha Hospital, Dubai, United Arab Emirates. 

1304 

PollEn rElaTED aSTHma: THE moST FrEQUEnT aSTHma PHEnoTYPE in KUWaiTi SCHoolCHilDrEn 

m. s. Al-Ahmad, mBBCh, FrCPC 1 , n. Arifhodzic, Phd 2 , n. Al-Ahmed 1 , A. Al-Onizi 1 , r. Panicker 1 and n. Fakim 1 

1 Allergy Department, Kuwait Allergy Center, Kuwait, Kuwait. 2 Allergy, AL-Rashed allergy Centre, Kuwait, Kuwait. 

1305 

CYSTEinYl-lEUKoTriEnS oVErProDUCTion anD THE aSTHma SEVEriTY in PaTiEnTS WiTH aSPirin-inDUCED aSTHma 

C. mitsui, mD, m. taniguchi, n. Higashi, E. Ono, K. Kajiwara, Y. Hukutomi, t. tsuburai, K. sekiya, H. tanimoto, t. ishii, A. mori, H. mita, 

m. Hasegawa and K. Akiyama 

Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, 

Sagamihara,Kanagawa, Japan. 

1306 

CorrElaTion BETWEEn SPiromETrY rESUlTS anD BoDY maSS inDEX in PaTiEnTS WiTH aSTHma 

r. C. Agondi, C. Bisaccioni, m. ribeiro, J. Kalil and P. giavina-Bianchi 



FinAl PrOgrAm 

POstErs

POstErs 

POstErs 



1307 

PrEValEnCE oF BronCHial aSTHma anD iTS aSSoCiaTion WiTH SmoKing HaBiTS among aDUlT PoPUlaTion in rUral 

arEa 

B. g. Parasuramalu, m.B.B.s., m.D. 1 , n. Huliraj 2 , r. B m 1 , P. K. s P 1 , g. Dr 1 and r. m. n r 1 

1 Department of Community Medicine, Kempegowda Institute of Medical Sciences, Bangalore, India. 2 Department of Thoracic 

Medicine, Kempegowda Institute of Medical Sciences, Bangalore, India. 

1308 

analYSiS oF PUBmED- inDEXED aSTHma rESEarCH From THE araB WorlD in THE laST TEn YEarS 

m. Afifi, mBChB, mmed, DrPH1 and W. A. Hameed, mBChB2 1 2 Primary Health Care, Ministry of Health (HQ), Dubai, United Arab Emirates. Primary Health Care, Ministry of Health, Ajman, United 

Arab Emirates. 

1309 

THE imPaCT oF ConComiTanT allErgiC rHiniTiS anD aSTHma on QUaliTY oF liFE in iTalian PaTiEnTS oF gEnEral 

PraCTiTionErS: arga STUDY 

s. maio1 , s. Baldacci1 , m. Borbotti1 , A. Angino1 , F. martini1 , B. Piegaia1 , P. silvi1 , g. sarno1 , s. Cerrai1 , m. simoni1 , F. Di Pede1 and g. 

Viegi, mD2 1 2 Institute of Clinical Physiology, National Research Council, Pisa, Italy. CNR Institute of Biomedicine and Molecular Immunology, 

Palermo, Italy. 

1310 

19 YEarS raTE oF HoSPiTaliZaTion oF CHroniC BronCHial aSTHma in BaHrain; QUaliTY oF HEalTH CarE in mEDiCal 

DEParTmEnT oF SmC 

m. m. Jahromi 

Quality Assurance, Salmaniya Medical Complex,, Manama, Bahrain. 

1311 

PrEValEnCE oF allErgiC DiSEaSES in THE CiS CoUnTriES 

t. A. slavyanskaya and r. i. sepiashvili 

Department of Allergology and Clinical Immunology, Institute of Immunophysiology, Moscow, Russia. 

1312 

gUiDElinES aPPliCaTion For aSTHma anD rHiniTiS managEmEnT: arga (rESPiraTorY allErgiC DiSEaSES: 

moniToring STUDY oF gina anD aria gUiDElinES) ProJECT 

s. Baldacci1 , s. maio1 , s. Cerrai1 , g. sarno1 , m. Borbotti1 , A. Angino1 , F. martini1 , l. Carrozzi1 , F. Di Pede1 and g. Viegi, mD2 1 2 Institute of Clinical Physiology, National Research Council, Pisa, Italy. CNR Institute of Biomedicine and Molecular Immunology, 

Palermo, Italy. 

1313 

inHalED SoDiUm CromoglYCaTE rEDUCES THE EXPrESSion oF aSTHma-rElEVanT CYToKinES BY PEriPHEral BlooD T 

CEll in CHilD aSTHma. THiS SUPPorTS iTS PoSSiBlE USE aS PrEVEnTaTiVE THEraPY in CHilD aSTHma 

V. gemou-Engesaeth, mD., PhD1, 5, 6 1 , Q. Hamid, mD, PhD 2 , E. A. roedland, Dsc3 3 , H. E. Heier, mD., PhD4 4 , P. i. gaarder 4 , J. B. 

grogaard 1 , s. Halvorsen 1 and C. J. Corrigan, mD., PhD.5 5 

1 1Dept. of Pediatrics, Oslo Univers. Hospital5King’s College London School of Medicine and 6Athens University, A Pediatric Clinic, 

Oslo, Norway. 2 McGill University, Meakins-Christie Laboratories, Montreal, QC, Canada. 3 3Institute of Medical Microbiology, 

Rikshospitalet, Molecular Biology, Oslo, Norway. 4 Dept. of Immunology and Transfussion Medicine, Oslo University Hospital, Oslo, 

Norway. 5 Centre for Allergic Mechanisms of Asthma, King’s College London School of Medicine and MRC and Asthma, Centre for 

Allergic Mechanisms of Asthma, London, United Kingdom. 


FinAl PrOgrAm

POstErs 



1314 

EConomiC CoST oF aDUlT aSTHmaTiCS in THE TErTiarY HoSPiTal oF KorEa 

s. H. lee 1 , t. W. Kim 1 , H. r. Kang 1 , s. H. Kim 2 , s. s. Kim 1 , Y. W. lee 3 , t. B. Kim 4 , s. H. Kim 5 , H. W. Park 1 , s. W. Park 6 , Y. s. Chang 2 , Y. s. 

Cho 4 , J. W. Park, mD., PhD. 7 , Y. J. Cho 8 , H. J. Yoon 5 , s. H. Cho 1 , B. W. Choi 9 , H. B. moon 4 and K. U. min 1 

1 Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea. 2 Department of Internal 

Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea. 3 Department of Internal Medicine, Yonsei University 

College of Medicine, Seoul, South Korea. 4 Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan 

College of Medicine, Seoul, South Korea. 5 Department of Internal Medicine, Hanyang University College of Medicine, Seoul, South 

Korea. 6 Division of Respiratory and Allergy Medicine, Soonchunhyang University Hospital, College of Medicine, Bucheon, South 

Korea. 7 Division of Allergy & Immunology Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South 

Korea. 8 Allergy and Clinical Immunology, Internal Medicine, Ewha Womans University Mockdong Hospital, Seoul, South Korea. 

9 Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea. 

1315 

aSSoCiaTion BETWEEn SUBCUTanEoUS aBDominal FaT anD airWaY HYPErrESPonSiVEnESS 

K. m. Kim 

Internal Medicine, Dankook University College of Medicine, Cheonan, South Korea. 

1316 

CHLAMYDOPHILA PNEUMONIAE-inFECTED HUman PEriPHEral mononUClEar CEllS rESiST CorTiCoSTEroiD- inDUCED 

SUPPrESSion oF mETalloProTEinaSE-9 anD TiSSUE inHiBiTor mETalloProTEinaSE-1 SECrETion 

C. s. Park 1 , t. B. Kim 2 , K. A. moon 3 , Y. J. Bae 2 , Y. s. lee 2 , m. K. Jang 3 , H. B. moon 2 and Y. s. Cho 2 

1 Department of Internal Medicine, Inje university Heaundae Paik Hospital, Busan, South Korea. 2 Department of Allergy and Clinical 

Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 3 Asan Institute for Life Science, 

Seoul, South Korea. 

1317 

EFFECTS oF TraFFiC air PollUTion on rESPiraTorY HEalTH anD allErgiES in EgYPTian SCHoolCHilDrEn 

m. shamssain, Ph.D 1 , W. Al Qerem, B.sc 2 , K. mcgarry, Ph.D 1 and l. neshat, m.sc 1 

1 Pharmacy, Health and Wellbeing, University of Sunderland, U.K, Sunderland, United Kingdom. 2 Pharmacy, Health and Wellbeing, 

University of Sunderland, Sunderland, United Kingdom. 

1318 

aSSoCiaTion BETWEEn aToPiC ECZEma anD CHilDHooD aSTHma in SCHoolCHilDrEn From THE norTH EaST oF 

EnglanD 

m. shamssain, Ph.D 

Pharmacy, Health and Wellbeing, University of Sunderland, U.K, Sunderland, United Kingdom. 

1319 

TrEnDS in PrESCriBing inHalED CorTiCoSTEroiDS alonE anD in ComBinaTion WiTH long-aCTing β2-agoniSTS in 

EUroPE in 2004–2009 

D. Price, Professor, mD1 and C. Virchow, Professor2 1 2 Centre of Academic Primary Care, University of Aberdeen, Aberdeen, United Kingdom. Zentrum für Innere Medizin, Universität 

Rostock, Rostock, Germany. 

1320 

il-17 DriVES THE rECrUiTmEnT oF B CEllS To THE BronCHial TiSSUE oF SEVErE aSTHmaTiC PaTiEnTS 

r. Halwani, msc;, Ph.D 1 , s. Al-muhsen, mD, FrCPC, FAAP 2 and Q. Hamid, mD, PhD 3 

1 Asthma Research Chair and Prince Naif Center for Immunological Research, College of Medicine, King Saud University., Riyadh, 

Saudi Arabia. 2 Department of Pediatrics, College of Medicine, King Saud University. 3 McGill University, Meakins-Christie Laboratories, 

Montreal, Canada. 

1321 

EoSinoPHilS EnHanCE airWaY SmooTH mUSClE CEll ProliFEraTion 

r. Halwani, msc;, Ph.D 1 , s. Al-muhsen, mD, FrCPC, FAAP 2 and Q. Hamid, mD, PhD 3 

1 Asthma Research Chair and Prince Naif Center for Immunological Research, College of Medicine, King Saud University., 

Riyadh, Saudi Arabia. 2 Department of Pediatrics, College of Medicine, King Saud University. 3 McGill University, 2 Meakins-Christie 

Laboratories, Montreal, Canada. 


FinAl PrOgrAm 

POstErs

POstErs 

POstErs 



1322 

EPiTHElial CEll DEriVED CHEmoKinES EnHanCE THE ProliFEraTion anD SUrViVal oF airWaY SmooTH mUSClE CEllS 

Via THE aCTiVaTion oF ErK1/2 Signaling PaTHWaY 

s. Al-muhsen, mD, FrCPC, FAAP 1 , r. Halwani, msc;, Ph.D 2 , H. Al-Jahdali, mD, FrCPC, FCCP 3 and Q. Hamid, mD, PhD 4 

1 Department of Pediatrics, College of Medicine, King Saud University. 2 Asthma Research Chair and Prince Naif Center for 

Immunological Research, College of Medicine, King Saud University., Riyadh, Saudi Arabia. 3 King Saud University for health sciences, 

Riyadh, Saudi Arabia. 4 McGill University, Meakins-Christie Laboratories, Montreal, Canada. 

1323 

TH-17 CYToKinE moDUlaTion oF STEroiD inSEnSiTiViTY in PEriPHEral BlooD mononUClEar CEllS 

A. Vazquez tello, Ph.D. 1 , r. Halwani, msc;, Ph.D 2 , s. Al-muhsen, mD, FrCPC, FAAP 3 and Q. Hamid, mD, PhD 4 

1 Asthma Research Chair and Prince Naif center for Immunology Research, College of Medicine, King Saud University, Riyadh, Saudi 

Arabia. 2 Asthma Research Chair and Prince Naif Center for Immunological Research, College of Medicine, King Saud University., 

Riyadh, Saudi Arabia. 3 Department of Pediatrics, College of Medicine, King Saud University. 4 McGill University, Meakins-Christie 

Laboratories, Montreal, QC, Canada. 

1324 

molD allErgEnS SEnSiTiZaTion in aSTHma PaTiEnTS iS aSSoCiaTED WiTH SEVEriTY oF DiSEaSE 

C. Bisaccioni, m. V. Aun, A. P. Castro-Coelho, F. g. montenegro, r. C. Agondi, J. Kalil and P. giavina-Bianchi 


1325 

imPaCT oF allErgiC rHiniTiS on PaTiEnTS WiTH BronCHial aSTHma in aBU DHaBi 

s. g. Bodi, mD, FCCP 1 , m. Ohri 2 , J. mn 2 , B. tn 2 and m. Khare 2 

1 Pulmonology, AHALIA HOSPITAL, ABU DHABI, United Arab Emirates. 2 Ent, AHALIA HOSPITAL, ABU DHABI, United Arab Emirates. 

1326 

analYSiS oF gEnE EXPrESSion ProFilES oF PEriPHEral BlooD B lYmPHoCYTES in VarioUS CliniCal PHEnoTYPES oF 

aSTHma 

n. E. Q. Ahmad 1 , r. Harun 2 and r. Othman 2 

1 Institute of Medical Science Technology (MESTECH), Universiti Kuala Lumpur (UniKL), Kajang, Malaysia. 2 UKM Medical Molecular 

Biology Institute (UMBI), Universiti Kebangsaan Malaysia (UKM), Cheras, Malaysia. 

1327 

aSTHma anD aToPY in CHilDrEn 7 To 9 YEarS aFTEr Viral rESPiraTorY inFECTionS 

C. B. Kartasasmita, Prof/PhD, B. setiabudiawan, g. sapartini, r. ghrahani, W. saptaputra, n. irwan, K. mutyara and E. A. simoes 

Department of Child Health, Hasan Sadikin/School of Medicine Padjadjaran University, Bandung, Indonesia, Bandung, Indonesia. 

1328 

aETiologY oF CHroniC oBSTrUCTiVE PUlmonarY DiSEaSE (CoPD) in non SmoKing WomEn oF KanDY DiSTriCT , Sri 

lanKa 

A. siribaddana, mBBs mD mrCP, P. C. Wanigasekara and K. senevirathne 

Respiratory Medicine Unit, Teaching Hospital, Kandy, Sri Lanka. 

17:00 - 18:30 PO1-4: rhinitis, rhinosinusitis and conjunctivitis sheikh rashid F 


Chairpersons: michael A. Kaliner 

Philip rouadi 

1400 

SElECT ParamETErS rElaTing To THE maXimal inSPiraTorY anD EXPiaTorY FloW raTE among THE rUral 

PoPUlaTionS inHaBiTing THE arEaS aroUnD ZamoSC, PolanD – a FolloW-UP To THE mUlTi-CEnTEr STUDY ECaP 

(EPiDEmiologY oF allErgiC DiSEaSES in PolanD) 

E. Krzych-Falta Jr. 1 , B. samoliñski2 , A. lusawa1 , B. rojek1 and W. Kapalczynski3 1Department of Prevention of Environmental Hazards and Allergology, Warsaw Medical University, Department of Clinical Allergol, 

Medical Uniwersity of Warsaw, Warsaw, Poland. 2Department of Prevention of Environmental Hazards and Allergology, Warsaw 

Medical University, Department of Clinical Allergol, M, Medical Uniwesity of Warsaw, Warsaw, Poland. 3University of Louisville School 

of Medicine, Louisville, United States, University of Louisville School of Medicine,, United States. 


FinAl PrOgrAm

POstErs 



1401 

THE aSSoCiaTion BETWEEn DEgrEE oF SEnSiTiZaTion To allErgEn anD SEVEriTY oF allErgiC rHiniTiS 

n. s. mohd Ashari, W. m. Wm, n. K. Y, s. sah and C. m. CH 

Immunology, Universiti Sains Malaysia, Kota Bharu, Malaysia. 

1402 

Co-aDminiSTraTion oF CHEnoPoDiUm alBUm allErgEnS anD CPg oligoDEoXYnUClEoTiDES EFFECTS on PEriPHEral 

BlooD mononUClEar CEllS oF PaTiEnTS WiTH allErgiC rHiniTiS TrEaTED WiTH inTranaSal CorTiCoSTEroiDS anD 

anTiHiSTaminES 

s. Farrokhi sr., mD 1 , t. mousavi 1 , s. Arshi 1 , A. salekmoghadam 1 , A. Varasteh, PhD 2 and n. rezaei, mD, PhD 3 

1 Department of Immunology, Iran University of Medical Sciences, Tehran, Iran. 2 6. Immunobiochemistry Lab, Immunology Research 

Center, Avicenna Research Institute, 6. Immunobiochemistry Lab, Immunology Research Center, Avicenna Research Institute, 

Mashhad, ID, Iran. 3 Growth and Development Research Center, Children’s Medical Center, Tehran, Iran. 

1403 

TrEaTmET oF CHroniC allErgiC rHiniTiS:inTranaSal VS. oral THEraPY? 

A. Eatemadi 

Immunology & Infectious disease, Ahvaz university of medical sciences, Ahvaz, Iran. 

1404 

EFFiCaCY oF FEXoFEnaDinE in DiFFErEnT DoSagES For TrEaTmnET oF SEaSonal allErgiC rHiniTiS 

A. Eatemadi 

Immunology & Infectious disease, Ahvaz university of medical sciences, Ahvaz, Iran. 

1405 

THE moDiFiED SnoT-20 QUESTionnairE: rEPEaTaBiliTY anD aPPliCaBiliTY To rHiniTiS 

A. s. sami, mBBs, Bsc, ODtC, mCPs, mA, msc 

Ent, Royal National Throat, Nose and Ear Hospital, London, United Kingdom. 

1406 

a CommUniTY BaSED SUrVEY on THE PrEValEnCE oF rHiniTiS 



1407 

EFFiCaCY oF mUlTiFaCETED aVoiDanCE mEaSUrES in THE managEmEnT oF PaTiEnTS WiTH PErSiSTEnT allErgiC 

rHiniTiS anD HoUSE DUST miTE allErgY 

s. s. Chao, FrCs and D. Y. Wang 

Department of Otolaryngology Head and Neck Surgery, National Univeristy of Singapore, Singapore, Singapore. 

1408 

EliminaTion oF oCUlar iTCHing BY oloPaTaDinE HCl oPHTHalmiC SolUTion, 0.2% 

m. s. Blaiss, mD1 , D. Amin, ms2 and m. tort, PhD3 1 2 3 University of Tennessee Health Science Center`, Memphis, TN. Global Medical Affairs, Alcon Research, Fort Worth, TX. Alcon 

Research ,Ltd, Fort Worth, TX. 

1409 

momETaSonE FUroaTE naSal SPraY inCrEaSES THE nUmBEr oF DaYS WiTH minimal SYmPTomS in PaTiEnTS WiTH 

aCUTE rHinoSinUSiTiS 

m. Danzig 1 , E. O. meltzer, mD 2 , D. gates 1 and g. gopalan, mD 3 

1 Schering-Plough Research Institute (now Merck Research Laboratories), Kenilworth, NJ. 2 Allergy and Asthma Medical Group & 

Research Center, San Diego, CA. 3 Merck & Co., Kenilworth, NJ. 

1410 

THE rECalCiTranT PoSTnaSal-DriP SYnDromE: THE grEaT CHallEngE For THE allErgiST-immUnologiST 

s. nsouli, mD, AnD, sEniOr, CliniCAl, rEsEArCH, AssOCiAtE 

Asthma and Allergy, DANVILLE ASTHMA AND ALLERGY CLINIC, CALIFORNIA, USA, Danville, CA. 


FinAl PrOgrAm 

POstErs

POstErs 

POstErs 



1411 

USEFUlnESS oF PEaK EXPiraTorY FloW raTE aSSESSmEnT in THE SCrEEning For BronCHial HYPEr rESPonSiVEnESS 

in CHilDrEn WiTH allErgiC rHiniTiS 

m. K. nagaraju, m. r iii, s. n and g. r 

Pediatric allergy and immunology, Kanchi Kamakoti CHILDS trust Hospital, Chennai, India. 

1412 

FoXP-3, a rEgUlaTorY T CEll SPECiFiC marKEr, anD iTS EXPrESSion in naSal PolYPS 

K. roongrotwattanasiri 1 , r. Pawankar, mD, Ph.D 2 , s. Kimura 3 , s. mori 3 and t. Yagi 3 

1 Otolaryngology, Chiang Mai University and Nippon Medical School, Chiang Mai, Thailand. 2 Allergy and Rhinology, NIPPON MEDICAL 

SCHOOL, Tokyo, Japan. 3 Rhinology and Allergy, Otorhinolaryngology, Nippon Medical School, Tokyo, Japan. 

1413 

DoES THE SinUS mUCoSa rESPonD To allErgEn ProVoCaTion? 

E. El Hassan, mBBs 1 , r. mösges, m.D., Ph.D., FAAAAi 2 and m. Kleiner, msc 1 

1 Faculty of Medicine, University of Cologne, Institute of Medical Statistics, Informatics und Epidemiology, University Hospital of 

Cologne, Cologne, Germany. 2 IMSIE, Cologne, Germany. 


FinAl PrOgrAm

POstErs 



Tuesday, 7 December 2010 – Poster Session 2 

outstanding Poster awards 

Abstracts that scored highly in the review process and have exceptional posters will be given WAO Outstanding Poster Awards. 

Awards will be announced at the beginning of this Poster session. 

Posters that receive this award will have a ribbon displayed on the poster board. 

13:00 - 14:15 PO2-1: Clinical immunology sheikh rashid F 


Chairpersons: Hani Ababneh 

lanny rosenwasser 

2100 

a rarE CaSE oF aTaXia TElangiECTaSia in malaYSia 

n. s. mohd Ashari, K. s. Ar and W. Z. Wah 

Immunology, Universiti Sains Malaysia, Kota Bharu, Malaysia. 

2101 

CHroniC EoSinoPHiliC PnEUmonia in PaTiEnT WiTH DiFFiCUlT-To-TrEaT aSTHma 

n. Pauk 

3rd Faculty of Charles University, Dept of Pneumology, Faculty Hospital Na Bulovce, Prague, Czech Republic. 

2102 

CliniCal CHaraCTEriSTiCS oF EoSinoPHiliC organ inVolVEmEnT DiSTingUiSHing From mETaSTaSiS in CanCEr 

PaTiEnTS WiTH EoSinoPHilia 

t. B. Kim, t. lee, Y. s. lee, Y. J. Bae, Y. s. Cho and H. B. moon 

Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 

2103 

oPPoSiTE EFFECT oF ETanErCEPT anD inFliXimaB on THE DEVEloPmEnT oF CUTanEoUS VaSCUliTiS 

J. g. Kim 

Pediatrics, Seoul National University College of Medicine and Rheumatology Research Institute, SNU Hospital, Seoul, South Korea. 

2104 

BronCHoalVEolar laVagE anD SErUm EoSinoPHil CaTioniC ProTEin lEVElS in CHroniC aSTHma anD BronCHial 

CarSinoma 

s. Kose 1 , m. Arici 2 , g. Cavdar 1 , s. Yavas 1 and g. Camci 1 

1 Infectious Diseases and Clinical Microbiology, Clinical Allergy and Immunology, Tepecik Educational and Research Hospital, Izmir, 

Turkey. 2 Pulmonery Diseases, Tepecik Educational and Research Hospital, Izmir, Turkey. 

2105 

SUlFaTED moDiFiCaTion oF lYCiUm BarBarUm PolYSaCCHariDE UnDEr miCroWaVE irraDiaTion anD THEir anTi-HiV 

aCTiViTiES 

X. Zhu and H. Zhang 

Beijing University of Technology, Beijing, China. 

2106 

THE lEVEl oF THE TUmor nECroSiS FaCTor in PaTiEnTS WiTH FEmoral nECK FraCTUrES 

O. Popova 1 , t. nurpeisov 2 and n. Batpenov 3 

1 Laboratory, Research Institute of Traumatology and orthopedy, Astana, Kazakhstan. 2 Research Institute of Cardiology, Almaty, 

Kazakhstan. 3 Research Institute of Traumotology and orthopedy, Astana, Kazakhstan. 

2107 

STUDY oF il-8 inDiCES in ElDErlY PEoPlE WiTH FEmoral nECK FraCTUrES 

O. Popova1 and t. nurpeisov 2 

1 2 Laboratory, Research Institute of Traumatology and Orthopedy, Astana, Kazakhstan, Astana, Kazakhstan. Research Institute of 

Cardiology, Almary, Kazakhstan. 


FinAl PrOgrAm 

POstErs

POstErs 

POstErs 



2108 

EXPrESSion oF il-17a anD il-17F CYToKinES in B lYmPHoCYTES 

A. Vazquez tello, Ph.D. 1 , r. Halwani, msc;, Ph.D 2 , r. li, Ph.D. 3 , A. Bar-Or, mD 4 , B. mazer, mD 5 , s. Al-muhsen, mD, FrCPC, FAAP 6 and 

Q. Hamid, mD, PhD 7 

1 College of Medicine, Asthma Research Chair and Prince Naif center for Immunology Research, King Saud University, Riyadh, Saudi 

Arabia. 2 Asthma Research Chair and Prince Naif Center for Immunological Research, College of Medicine, King Saud University., 

Riyadh, Saudi Arabia. 3 Montreal Neurological Institute and McGill University, Montreal, QC, Canada. 4 5 Montreal Neurological Institute 

and McGill University, Montreal, QC, Canada. 5 Meakins-Christie Laboratories and Respiratory Division, Department of Medicine, 

McGill University, Montreal, QC, Canada. 6 Department of Pediatrics, College of Medicine, King Saud University. 7 McGill University, 

Meakins-Christie Laboratories, Montreal, QC, Canada. 

2109 

CaSE rEPorT oF rElaPSing PolYCHonDriTiS in CHilDrEn 

B. setiabudiawan1 , s. F. Boesoerie2 , r. g. D. majangsari1 , g. sapartini1 and D. rosifah1 1 2 Child Health, Padjadjaran University, Bandung, Indonesia. Otorhinolaryngology Head & Neck, Padjadjaran University, Bandung, 

Indonesia. 

2110 

PEriPHEral EoSinoPHilia 

m. restrepo 1 , s. Diez 1 , J. sanchez 1 , C. Chinchilla 2 and r. Cardona 3 

1 Allergology, Universidad de Antioquia, Medellín, Colombia. 2 University of Antioquia - Grupo de Alergología Clínica y Experimental 

(GACE), Medellin, Colombia. 3 University of Antioquia, Medellin, Colombia. 

13:00 - 14:15 PO2-2: Drug and food allergy sheikh rashid F 


Chairpersons: suleiman Al Hamadi 


2200 

PoTEnTial aDVErSE rEaCTionS From ComPlEmEnTarY anD alTErnaTiVE mEDiCinE (Cam) anD DiETarY SUPPlEmEnT 

(DS) in norTH amEriCa 

H. C. g. Wong, mD, FrCPC, FACP, FAAAAi, FCCP 

Department of Medicine, University of British Columbia & Vancouver General Hospital, Vancouver, BC, Canada. 

2201 

inTErim FinDingS From ESTaBliSHing THE EFFECTiVEnESS, CoST-EFFECTiVEnESS anD SaFETY oF oral anD 

SUBlingUal immUnoTHEraPY For FooD allErgY: a SYSTEmaTiC rEViEW 

U. nurmatov 1 , g. Devereux 2 and A. sheikh 1 

1 Allergy & Respiratory Research Group, Centre for Population Health Sciences, The University of Edinburgh, Edinburgh, United 

Kingdom. 2 Department of Child Health, Royal Aberdeen Children’s Hospital, The University of Aberdeen, Aberdeen, United Kingdom. 

2202 

CiSPlaTin aDminiSTraTion FolloWing aCUTE HYPErSEnSiTiViTY To oTHEr PlaTinUm ComPoUnDS: a PHaSE ii STUDY 

E. syrigou, n. makrilia, K. Politi, g. Kaklamanos, l. manolopoulos and K. n. syrigos 

Oncology Unit, 3rd Department of Medicine, Sotiria General Hospital, Athens School of Medicine, Greece, Athens, Greece. 

2203 

FooD allErgY anD aToPiC DErmaTiTiS 

A. Hekmatdoost Jr. 

Dep Clinical Nutrition and Dietetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 

2204 

CliniCal CHaraCTEriSTiCS oF raniTiDinE inDUCED HYPErSEnSiTiViTY 

Y. J. Cho 

Allergy and Clinical Immunology, Internal Medicine, Ewha Womans University Mockdong Hospital, Seoul, South Korea. 


FinAl PrOgrAm

POstErs 



2205 

PangaSiUS HYPoPHTHalmUS HYPErSEnSiTiViTY 

m. t. Palomeque sr. 1 , m. torrecillas 1 , B. Bartolome 2 , n. martínez Borque 1 , m. r. gonzález mendiola 1 , E. martín Casáñez 1 , P. lara de la 

rosa 1 , g. soto Vargas 1 and D. martínez Bohigas 1 

1 Alergología, Complejo Hospitalario Universitario Albacete, Albacete, Spain. 2 Departamento I+D, Bial-Arístegui, Bilbao, Spain. 

2206 

FiXED DrUg ErUPTion inDUCED BY iBUProFEn anD aCETaminoPHEn 

m. torrecillas sr., m. t. Palomeque, E. martín, n. martínez, P. lara, g. soto, D. martínez and m. r. gonzález 

Alergología, Complejo Hospitalario Universitario Albacete, Albacete, Spain. 

2207 

FrEQUEnCY oF immEDiaTE, laTE anD DElaYED TYPE FooD HYPErSEnSiTiViTY in ProVoCaTion TEST For Egg allErgY 

anD iTS CorrElaTion WiTH Egg-WHiTE igE raST SCorE 

t. noma 1 , n. Ogawa 1 , n. Ogawa 2 , K. mikami 2 , t. saeki 1 , A. isozaki 3 , Y. Kawano 3 and H. Oshiba 4 

1 Pediatrics, Kitasato Univ, Sagamihara, Japan. 2 Pediatrics, Chiba Aiyukai Memorial Hospital, Japan. 3 Pediatrics, Yokohama City 

Minato Red Cross Hospital, Japan. 4 Pediatrics, Tokyo Kousei-Nenkin Hospital, Japan. 

2208 

anTi-igE anTiBoDY anD FooD igE-mEDiaTED DiSEaSES in SEVErE aSTHmaTiC PaTiEnTS 

g. Florio 1 , C. Oricchio 2 , m. Palmieri 1 , g. marone 3 and V. Patella 1 

1 Division of Allergy and Clinical Immunology, Agropoli General Hospital, Department of Medicine ASL Salerno, Salerno, Italy. 2 Unit of 

Transfusion Medicine, Agropoli General Hospital, ASL Salerno, Salerno, Italy. 3 Division of Allergy and Clinical Immunology and Center 

for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy. 

2209 

EFFECTS oF DiETarY CoUnSElling on ProTEin inTaKE anD PlaSmaTiC ProTEin ProFilE in CHilDrEn WiTH FooD allErgY 

E. D’Auria, m. mandelli, g. Cagnoli, A. m. lammardo, J. Zuvadelli, E. salvatici and m. giovannini 

Department of Pediatrics, San Paolo Hospital-University of Milan, Italy, Milan, Italy. 

2210 

THE rolE oF SKin PriCK TEST in DiagnoSiS oF CroSS –allErgY 

Z. Bartuzi 1 and K. napiórkowska 2 

1 Department Allergology, Clinical Immunology and Internal Diseases, Collegium Medicum Nicolaus Copernicus University, 

Bydgoszcz, Poland. 2 Allergology, Clinical Immunology and Internal Diseases, Collegium Medicum Nicolaus Copernicus University, 

Bydgoszcz, Poland. 

2211 

THE EFFECTiVEnESS oF THE mEaSUrEmEnT oF ToTal anD SPECiFiC igE in DiagnoSiS oF CroSS allErgY 

Z. Bartuzi 1 and K. napiórkowska 2 

1 Department Allergology, Clinical Immunology and Internal Diseases, Collegium Medicum Nicolaus Copernicus University, 

Bydgoszcz, Poland. 2 Allergology, Clinical Immunology and Internal Diseases, Collegium Medicum Nicolaus Copernicus University, 


2212 

aSSESSing PoTEnTial DETErminanTS oF PoSiTiVE ProVoCaTion TESTS in SUBJECTS WiTH nSaiD HYPErSEnSiTiViTY 

m. Viola, g. rumi, r. l. Valluzzi, F. gaeta, C. Caruso and A. romano 

Allergy Unit, Complesso Integrato Columbus, Rome, Italy. 

2213 

CoW milK SEnSiTiZaTion in a groUP oF EgYPTian allErgiC inFanTS anD CHilDrEn 

E. Hossny, mD, PhD, FAAAAi 1 , A. shehab, mD, PhD 2 , s. saad, mD, PhD 3 and m. Borick 3 

1 Pediatric Allergy and Immunology Unit, Children’s Hospital,, Ain Shams University, Cairo, Egypt. 2 Clinical Pathology Department, Ain 

Shams University, Cairo, Egypt. 3 Pediatric Allergy and Immunology Unit, Ain Shams University, Cairo, Egypt. 

2214 

EPiDEmiologiCal STUDY oF FooD allErgY in THE ToWn oF ConSTanTinE (algEria) 

H. Boughellout and m. n. Zidoune 

Nutrition and Food TECHNOLOGY Institute, UNIVERSITY MENTOURI CONSTANTINE, Constantine, Algeria. 


FinAl PrOgrAm 

POstErs

POstErs 

POstErs 



2215 

anaPHYlaCTiC rEaCTion inDUCED BY HomEoToXiC DrUg 

m. naime, Estudiante, m. sofia and P. Elizabeth 

Escuela De Ciencias De La Salud, Universidad de oriente, Puerto La Cruz, Venezuela. 

2216 

anaPHYlaXiS aFTEr naSal ProVoCaTion TEST WiTH alTErnaria alTErnaTa EXTraCT 

C. gomez-garcia1 , s. sus-Carrizosa1 , m. Olivares1 , C. Chinchilla1 , r. ramirez1 , r. Cardona-Villa1 and m. restrepo2 1 2 University of Antioquia - Grupo de Alergología Clínica y Experimental (GACE), Medellin, Colombia. Allergology, Universidad de 

Antioquia, Medellín, Colombia. 

2217 

PaTiEnT WiTH PEanUT allErgY WiTH nEgaTiVE CUTanEoUS anD in ViTro TESTS, ConFirmED BY oral ConTrollED 

FooD CHallEngE 

s. Diez 1 , m. restrepo 1 , J. sanchez 1 and r. Cardona 2 

1 Allergology, Universidad de Antioquia, Medellín, Colombia. 2 University of Antioquia, Medellin, Colombia. 

2218 

ECZEma inDUCED BY FooD allErgY: CoUlD iT mimiC an immUnE DEFiCiEnCY? 

s. Arshi, m. nabavi, D. Babaie and B. ghalehbaghi 

Allergy and Clinical Immunology, hazrat-e rasool Hospital, Iran University of Medical Sciences, Tehran, Iran. 

13:00 - 14:15 PO2-3: skin and other diseases sheikh rashid F 


Chairpersons: salem H. Al-tamami 

Barbara rogala 

2300 

ComParaTiVE EValUaTion oF EPiDEmiologiCal FaCTorS anD ComPliCaTionS oF CaTaraCT SUrgErY in DiaBETiC 

PaTiEnTS VErSUS non DiaBETiC PaTiEnTS 

F. fayyaz Jahani sr. and A. sA.madani 

Medical, Tonekabon Azad University of Medical Sciences, Tonekabon, Iran. 

2301 

EFFECT oF a SYnBioTiC miXTUrE on aToPiC DErmaTiTiS in CHilDrEn: a ranDomiZED-ConTrollED Trial 

H. Ahanchian ii1 , r. Farid2 , F. Jabbari2 and t. moghiman2 1 2 Pediatric Allergy and Immunology, Mashhad University of Medical Sciences, Mashhad, Iran. Mashhad University of Medical 

Sciences, Mashhad, Iran. 

2302 

EFFiCaCY oF omaliZUmaB monoTHEraPY in THE managEmEnT oF aToPiC DErmaTiTiS 

E. syrigou 1 , A. sinaniotis 1 , J. Paraskevopoulos 2 and P. Psarros 3 

1 Department of Allergy, “Sotiria” General Hospital, Athens, Greece. 2 Department of Allergy, 401 Army Hospital, Athens, Greece. 

3 Department of Allergy, Naval Hospital, Athens, Greece. 

2303 

EFFECTiVEnESS oF omaliZUmaB in THE TrEaTmEnT oF ColD UrTiCaria 

A. sinaniotis 1 , P. Psarros 2 , g. Paraskevopoulos 3 and E. syrigou 1 

1 Department of Allergy, “Sotiria” General Hospital, Athens, Greece. 2 Department of Allergy, Athens Naval Hospital, Athens, Greece. 

3 Department of Allergy, 401 Army Hospital, Athens, Greece. 

2304 

THE aCTiVE Form oF D ViTamin, CalCiTriol 1,25(oH)2D3 anD naTUral PPrgamma agoniST, -3 PolYUnSaTUraTED 

FaTTY aCiDS (PUFaS) migHT SErVE aS a nEgaTiVE FEEDBaCK looP To PrEVEnT EXCESSiVE inFlammaTion in PaTiEnTS 

WiTH SEVErE aToPiC DErmaTiTiS 

t. Zaharov 1 , A. Chaynava 2 , B. A. Kamenov 3 and s. Kamenov 4 

1 Pediatrics, Regional Hospital Næstved, Naestvad, Denmark. 2 Pediatrics, Regional Hospital Næstved, Naestved, Denmark. 3 Pediatric 

Clinic, Clinical Centre of Nis, Nis, Serbia and Montenegro. 4 Pediatric, Helth Centre of Nis, Nis, Serbia and Montenegro. 


FinAl PrOgrAm

POstErs 



2305 

mETHoTrEXaTE For UrTiCarial VaSCUliTiS anD angioEDEma WiTH CrYogloBUlinEmia 

A. Butt, m.D., m. Alkhalil, m.D., D. ledford, m.D. and r. F. lockey, m.D. 

Division of Allergy & Immunology, University of South Florida and James A. Haley Veterans’ Hospital, Tampa, FL. 

2306 

anTi-igE (omaliZUmaB) EFFECTiVE aS SinglE-DrUg THEraPY For CHroniC iDioPaTHiC UrTiCaria 

J. gonzález-Cervera 1 , B. rodríguez-Domínguez sr. 1 , D. Antolín-Amérigo 2 , A. Henríquez-santana 2 , F. J. ruiz Hornillos 2 and D. manzano 1 

1 Allergy, Hospital General de Tomelloso, Tomelloso, Spain. 2 Allergy, Hospital de Valdemoro (Madrid), Madrid, Spain. 

2307 

PaTiEnT WiTH VaSCUliTiC aUToimmUnE anD PrESSUrE UrTiCaria SUCCESSFUllY TrEaTED WiTH omaliZUamB 

s. Diez, J. sanchez, l. tamayo, m. restrepo and r. Cardona 

Allergology, Universidad de Antioquia, Medellín, Colombia. 

2308 

oPEn-laBEl USE oF nanoFilTErED C1 ESTEraSE inHiBiTor (HUman) For THE TrEaTmEnT oF HErEDiTarY angioEDEma 

(HaE) aTTaCKS 

t. J. Craig, DO 1 , B. Zuraw 2 , W. lumry 3 , J. Baker 4 , r. levy 5 , D. Hurewitz 6 , m. White 7 , m. riedl 8 , P. Busse 9 , l. Bielory 10 , J. A. grant 11 , i. 

Kalfus 12 , C. Broom 13 , s. Villano 13 , m. Uknis 13 , g. tillotson 13 and t. Cinryze study group 14 

1 Penn State University, Hershey, PA. 2 The Scripps Research Institute, La Jolla, CA. 3 Allergy and Asthma Specialists, Dallas, TX. 

4 University of Michigan, Ann Arbor, MI. 5 Family Allergy and Asthma Center, PC, Atlanta, GA. 6 Allergy Clinic of Tulsa, Inc., Tulsa, OK. 

7 Institute for Asthma and Allergy, Wheaton, MD. 8 UCLA Medical Center, Los Angeles, CA. 9 Mount Sinai School of Medicine, New York, 

NY. 10 UMDNJ - New Jersey Medical School, Newark, NJ. 11 University Texas Medical Branch, Galveston, TX. 12 Lev Pharmaceuticals, 

Plymouth Meeting, PA. 13 ViroPharma Incorporated, Exton, PA. 

2309 

oPEn-laBEl USE oF nanoFilTErED C1 ESTEraSE inHiBiTor (HUman) For THE ProPHYlaXiS oF HErEDiTarY 

angioEDEma (HaE) aTTaCKS 

B. Zuraw 1 , J. Baker 2 , D. Hurewitz 3 , m. White 4 , A. Vegh 5 , l. Bielory 6 , W. lumry 7 , m. riedl 8 , m. Davis-lorton 9 , r. levy 10 , J. A. grant 11 , P. 

Busse 12 , A. Banerji 13 , H. H. li 14 , i. Kalfus 15 , C. Broom 16 , s. Villano 16 , m. Uknis 16 , g. tillotson 16 and t. Cinryze study group 17 

1 The Scripps Research Institute, La Jolla, CA. 2 University of Michigan, Ann Arbor, MI. 3 Allergy Clinic of Tulsa, Inc., Tulsa, OK. 4 Institute 

for Asthma and Allergy, Wheaton, MD. 5 Puget Sound Allergy Asthma and Imm., Tacoma, WA. 6 UMDNJ - New Jersey Medical School, 

Newark, NJ. 7 Allergy and Asthma Specialists, Dallas, TX. 8 UCLA Medical Center, Los Angeles, CA. 9 Winthrop - University Hospital, 

Mineola, NY. 10 Family Allergy and Asthma Center, PC, Atlanta, GA. 11 University Texas Medical Branch, Galveston, TX. 12 Mount Sinai 

School of Medicine, New York, NY. 13 Massachusetts General Hospital, Boston, MA. 14 Institute for Asthma & Allergy, Chevy Chase, MD. 

15 Lev Pharmaceuticals, Plymouth Meeting, PA. 16 ViroPharma Incorporated, Exton, PA. 

2310 

oPEn-laBEl USE oF nanoFilTErED C1 ESTEraSE inHiBiTor (HUman) (nF-C1inH) For TrEaTmEnT oF aCUTE aTTaCKS oF 

HErEDiTarY angioEDEma (HaE) in PEDiaTriC SUBJECTS 

t. J. Craig, DO 1 , W. lumry 2 , J. Baker 3 , m. Davis-lorton 4 , m. manning 5 , i. Kalfus 6 , C. Broom 7 , s. Villano 7 , m. Uknis 7 , g. tillotson 7 and t. 

Cinryze study group 8 

1 Penn State University, Hershey, PA. 2 Allergy and Asthma Specialists, Dallas, TX. 3 University of Michigan, Ann Arbor, MI. 4 Winthrop - 

University Hospital, Mineola, NY. 5 Allergy and Immunology Associates, Scottsdale, AZ. 6 Lev Pharmaceuticals, Plymouth Meeting, PA. 

7 ViroPharma Incorporated, Exton, PA. 

2311 

oPEn-laBEl USE oF nanoFilTErED C1 ESTEraSE inHiBiTor (HUman) (nF-C1 inH) For THE ProPHYlaXiS oF aTTaCKS oF 


D. Hurewitz 1 , J. A. grant 2 , P. Busse 3 , m. Davis-lorton 4 , J. Baker 5 , m. riedl 6 , A. Banerji 7 , r. levy 8 , t. J. Craig, DO 9 , i. Kalfus 10 , C. 

Broom 11 , s. Villano 11 , m. Uknis 11 , g. tillotson 11 and t. Cinryze study group 12 

1 Allergy Clinic of Tulsa, Inc., Tulsa, OK. 2 University Texas Medical Branch, Galveston, TX. 3 Mount Sinai School of Medicine, New York, 

NY. 4 Winthrop - University Hospital, Mineola, NY. 5 University of Michigan, Ann Arbor, MI. 6 UCLA Medical Center, Los Angeles, CA. 

7 Massachusetts General Hospital, Boston, MA. 8 Family Allergy and Asthma Center, PC, Atlanta, GA. 9 Penn State University, Hershey, 

PA. 10 Lev Pharmaceuticals, Plymouth Meeting, PA. 11 ViroPharma Incorporated, Exton, PA. 


FinAl PrOgrAm 

POstErs

POstErs 

POstErs 



2312 

oPEn-laBEl USE oF nanoFilTErED C1 ESTEraSE inHiBiTor (HUman) For TrEaTmEnT or ProPHYlaXiS oF aCUTE 

aTTaCKS oF HErEDiTarY angioEDEma (HaE) in PrEgnanT SUBJECTS 

J. Baker 1 , m. riedl 2 , A. Banerji 3 , D. Hurewitz 4 , r. levy 5 , t. J. Craig, DO 6 , i. Kalfus 7 , C. Broom 8 , s. Villano 8 , m. Uknis 8 , g. tillotson 8 and t. 

Cinryze study group 9 

1 University of Michigan, Ann Arbor, MI. 2 UCLA Medical Center, Los Angeles, CA. 3 Massachusetts General Hospital, Boston, MA. 

4 Allergy Clinic of Tulsa, Inc., Tulsa, OK. 5 Family Allergy and Asthma Center, PC, Atlanta, GA. 6 Penn State University, Hershey, PA. 7 Lev 

Pharmaceuticals, Plymouth Meeting, PA. 8 ViroPharma Incorporated, Exton, PA. 


FinAl PrOgrAm

POstErs 



Wednesday, 8 December 2010 – Poster Session 3 

9:30 – 10:30 PO3-1: immune mechanisms of allergy sheikh rashid F 


Chairpersons: robert lemanske 

Jung Wong Park 

3100 

an UnUSUal PrESEnTaTion oF PUlmonarY maSS liKE lESionS SEConDarY To an allErgiC CaUSE 

m. rafique, Pulmonologist and B. mahboub, Head, of, Pulmonary, medicine 

Department of Pulmonary Medicine, Rashid Hospital, Dubai, United Arab Emirates. 

3101 

ForgoTTEn ParaSiTES in allErgY PraCTiCE 

P. Kumar, mD 

Medicine, Louisiana State University Health Sciences Center, New Orleans, LA. 

3102 

CHaraCTEriSTiCS oF rHinoVirUS-inDUCED PBmC immUnE rESPonSES in aSTHmaTiCS, From inFanCY To aDUlTHooD 

i. Katsuhito 1 , t. Katsunuma 1 , H. saito, mD, PhD, Director 2 and K. matsumoto, mD, PhD, laboratory, Head 2 

1 Pediatrics, Jikei University, school of medicine, Tokyo, Japan. 2 Laboratory for allergy, Department of Allergy and Immunology, 

National Research Institute for Child Health and Development, Tokyo, Japan, Tokyo, Japan. 

3103 

CUrCUmin maY inHiBiTS T CEll aCTiVaTion THroUgH STorE-oPEraTED Ca2+ EnTrY CHannElS anD K+ CHannElS 

W. K. Kim, Doctor1 and J. H. nam2 1 2 Asthma & Allergy, Dongguk University Ilsan Hospital, Goyang, South Korea. Physiology, Dongguk University collage of medicine, 

Kyung Ju, South Korea. 

3104 

nano-SiZED WElDing FUmE inCrEaSES inFlammaTorY CYToKinES, aPoPToSiS anD g2 arrEST in HUman T CEll linE 

Y. m. Chiung 1 , P. s. liu 2 , Y. Y. Chen 2 , J. B. lin 1 and C. J. tsai 3 

1 Division of Medicine, Institute of Occupational Safety & Health, Taipei County, Taiwan. 2 Department of Microbiology, Soochow 

University, Taipei, Taiwan. 3 Institute of Environmental Engineering, National Chiao Tung University, Hsinchu. 

3105 

THE EFFiCaCY oF a naSal anTiHiSTaminE oloPaTaDinE For THE TrEaTmEnT oF SEroUS oTiTiS mEDia in CHilDrEn 

s. nsouli, m, D. 

Asthma and Allergy, DANVILLE ASTHMA AND ALLERGY CLINIC, DANVILLE, CALIFORNIA, USA, Danville, CA. 

3106 

ComBinaTion oF a naSal anTiHiSTaminE oloPaTaDinE anD a naSal CorTiCoSTEroiD, momETaSonE For THE 

TrEaTmEnT oF SEaSonal allErgiC rHiniTiS PaTiEnTS noT CUrrEnTlY ConTrollED on monoTHEraPY inTranaSal 

anTiHiSTaminE or inTranaSal CorTiCoSTEroiD 

s. nsouli, mD, AnD, sEniOr, CliniCAl, rEsEArCH, AssOCiAtE 

Asthma and Allergy, DANVILLE ASTHMA AND ALLERGY CLINIC, CALIFORNIA, USA, Danville, CA. 

3107 

EXPErimEnTallY UnraVEling THE aToPiC marCH 

m. s. Wilson, PhD 

Molecular Immunology, NIMR, MRC, London, United Kingdom. 

3108 

a noVEl rolE For THE ComPlEmEnT rEgUlaTor CD46 in EPiTHElial TigHT JUnCTion FormaTion/rEgUlaTion 

s. t. Al-shouli1 and C. Kemper2 1 2 Clinical Immunology and Allergy., King’s College London Guy’s and S’t Thomas’ Hospital, London, United Kingdom. MRC Centre for 

Transplantation, London, United Kingdom. 


FinAl PrOgrAm 

POstErs

POstErs 

POstErs 



3109 

THE rolE oF EXTErnal PHYSiCal ForCES in TriggEring THE allErgiC rEaCTionS 

r. r. Athota, Dr1 , r. r. K. reddy, Dr2 , K. B. neerupudi, mr1 and r. A. sam, Dr3 1 2 3 Biochemsitry, Andhra University, Visakhapatnam, India. Department of Physics, S K University, Anantapur, India. Internal Medicine, 

Christian Medical College, Vellore, India. 

3110 

THE STaTiSTiCS TaKE iT all: ComParaTiVE analYSiS oF THE gEnomiC BaCKgroUnD oF CHilDHooD aSTHma in 

CaUCaSian PoPUlaTion 

E. Hadadi 1 , i. Ungvari 1 , V. Virag 1 , Z. nemeth 2 , g. Hullam 3 , P. Antal 3 , A. Falus 1 and C. szalai 1 

1 Genetics, Cell and Immunbiology, Semmelweis University, Budapest, Hungary. 2 Csertex Kft, Budapest, Hungary. 3 Department of 

Measurement and Information Systems, Budapest University of Technology and Economics, Budapest, Hungary. 

3111 

PrEValanCE oF HUman-mETaPnUEmoVirUS inFECTion in WHEEZY aDmiTTED CHilDrEn 

s. Alyasin Jr. 1 and A. moatari2 1 2 Pediatric, Shiraz University of Medical Science, Shiraz, Iran. Influenza Research Center, Shiraz University of Medical Science, 

Shiraz, Iran. 

3112 

SEroPrEValEnCE oF aniSaKiaSiS analiSYS rESiDEnTS From “alDEa DE PESCaDorES” ToWn, PUErTo la CrUZ, 

anZoaTEgUi 2010 

m. naime, Estudiante, m. sofia and P. Elizabeth 

Escuela De Ciencias De La Salud, Universidad de oriente, Puerto La Cruz, Venezuela. 

3113 

EFFECTS oF VarioUS rESPiraTorY VirUSES on DEr F-SEnSiTiZED moUSE moDEl oF aSTHma 

H. H. Kim, Y. H. Chun, J. s. Yoon, J. t. Kim and J. s. lee 

Pediatrics, The Catholic University of Korea, Pucheon-si, South Korea. 

3114 

igg4 aS THE PrEDominanT aUToanTiBoDY in SEra From PaTiEnTS WiTH aCTiVE STaTE oF PEmPHigUS VUlgariS 

m. Entezam1 and m. Ayatollahi2 1 2 Genetic Department, Shiraz University of Medical Sciences, Shiraz , Iran. Transplant Research Center, Shiraz University of Medical 

Sciences, Shiraz, Iran. 

9:30 – 10:30 PO3-2: immunotherapy sheikh rashid F 


Chairpersons: nasser Al-Ahmed 

glenis scadding 

3200 

EFFiCaCY oF SUB-lingUal immUnoTHEraPY in PollEn allErgiC aSTHma 

A. Khoury, r. Al-Fadel and K. sawas 

Chest Diseases, Aleppo Faculty of Medicine, Aleppo, Syria. 

3201 

SaFETY anD EFFiCaCY oF CarBamYlaTED monomEriC DErmaToPHagoiDES allErgoiD DEPoT FormUlaTion giVEn BY 

SUBCUTanEoUS roUTE 

P. Fancello1 , i. Atzeni1 , m. Bruno2 and P. Falagiani3 1 2 Allergology Service, “San Gavino Monreale” Hospital - ASL 6, Sanluri (CR), Italy. Medical Service, Lofarma S.p.A., Milan, Italy. 

3Scientific Direction, Lofarma S.p.A., Milan, Italy. 

3202 

CliniCal EFFiCaCY oF SUBCUTanEoUS immUnoTHEraPY giVEn aS a SinglE anD miXTUrE oF TWo non-CroSS 

rEaCTiVE allErgEnS in PaTiEnT WiTH SEaSonal allErgiC rHiniTiS 

n. A. Arifhodzic, mD, PhD 

Department of Allergy Clinical Immunology, Kuwait Allergy Centre, Kuwait city, Kuwait. 


FinAl PrOgrAm

POstErs 



3203 

ComPariSon BETWEEn THE EFFECT oF BoTH SUBCUTanEoUS anD SUBlingUal immUnoTHEraPY on CUTanEoUS 

rEaCTiViTY 

n. Al-Ahmed, m.D., ABim, FrCPC1 , n. Arifhodzic, Phd2 , m. Al-Ahmad1 and A. Al-Enezi1 1 2 Department of Allergy, Al-Rashed Allergy Centre, Ministry of Health, State of Kuwait, Kuwait, Kuwait. Allergy, AL-Rashed allergy 

Centre, Kuwait, Kuwait. 

3204 

KinD oF SEnSiTiZaTion in SUBJECTS UnDErgoing allErgoiD SUBlingUal immUnoTHEraPY. a rETroSPECTiVE STUDY 

(ParT i) 

P. simone1 and P. Amboni2 1 2 USC Pneumologia, Ospedali Riuniti di Bergamo, Bergamo, Italy. USC Patologia Clinica e Laboratorio Analisi, Ospedali Riuniti di 

Bergamo, Bergamo, Italy. 

3205 

CliniCal CHaraCTEriSTiCS oF PaTiEnTS UnDErgoing allErgoiD SUBlingUal immUnoTHEraPY. a rETroSPECTiVE 

STUDY (ParT ii) 

P. simone1 and P. Amboni2 1 2 USC Pneumologia, Ospedali Riuniti di Bergamo, Bergamo, Italy. USC Patologia Clinica e Laboratorio Analisi, Ospedali Riuniti di 

Bergamo, Bergamo, Italy. 

3206 

a SUrVEY oF allErgEn SPECiFiC immUnoTHEraPY in KorEa 

g. Y. Hur 1 , t. B. Kim 2 , m. Y. Han 3 , D. H. nahm 4 and J. W. Park, mD., PhD. 5 

1 Internal Medicine, Korea University College of Medicine, Seoul, South Korea. 2 Department of Allergy and Clinical Immunology, 

Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 3 Pediatrics, Pochon CHA University College of 

Medicine, Seoul, South Korea. 4 Allergy & Rheumatology, Ajou University School of Medicine, Seoul, South Korea. 5 Division of Allergy 

& Immunology Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. 

3207 

SUCCESSFUl gamma-inTErFEron THEraPY in a CaSE oF rEFraCTorY VaCCinE-aSSoCiaTED aBSCESS in a CgD PaTiEnT 

m. nabavi 1 , s. maherbanai 1 and m. H. Bemanian 2 

1 Semnan Medical University, Tehran, Iran. 2 Yazd medical university, Yazd, Iran. 

3208 

FloW CYTomETrY aS a Tool For DElaYED DrUg allErgY rEaCTionS DiagnoSiS: oUr EXPEriEnCE 

s. Ardito 1 , m. De Donno 2 , V. Aiello 2 , m. l. iaia 1 and g. maietta 2 

1 Allergy Department, Perrino Hospital, Brindisi, Italy. 2 Cellular Immunology, Pignatelli Institute, Lecce, Italy. 

3209 

CliniCal CHaraCTEriSTiCS oF oral TolEranCE inDUCTion oF non-igE mEDiaTED FooD allErgY USing iFn-gamma 

J. H. lee sr. and g. noh 

Department of Pediatrics, School of Medicine, Chungnam National University, Taejeon, South Korea. 

3210 

THE rolE oF immUnoTHEraPY in aSTHma anD rHiniTiS 

l. Hwejeh, mD 

Chest Department, ALASAD UNIVERSITY HOSPITAL IN DAMASCUD, Damascus, Syria. 

3211 

CHroniC aSTHma in aDUlTS 

D. Aguilar 

MEDICINE DIVISION, JUAREZ HOSPITAL, Mexico DF, Mexico. 


FinAl PrOgrAm 

POstErs

POstErs 

POstErs 



3212 

SUBCUTanEoUS immUnoTHEraPY For TrEE PollEn allErgY WiTH a PrEParaTion WiTH oPTimiSED allErgEn 

alUminiUm HYDroXiDE raTio: an oPEn laBEl oBSErVaTional STUDY inVESTigaTing TolEraBiliTY anD 

EFFECTiVEnESS in THE roUTinE USE in DailY PraCTiSE 

U. neumann 1 , H. Wolf 2 , J. schnitker 3 and E. g. Wuestenberg 4 

1 ENT-Physician, Wolmirstedt, Germany. 2 Clinical Development, ALK-Abelló, Wedel, Germany. 3 Institut für angewandte Statistik, 

Bielefeld, Germany. 4 Medical and Regulatory Affairs, ALK-Abelló, Wedel, Germany. 

3213 

immUnomoDUlaTorY PoTEnTial oF mESEnCHYmal STEm CEll ProViDE a PromiSing alTErnaTiVE For TrEaTmEnT oF 

liVEr TranSPlanTaTion 

m. Ayatollahi 1 , m. Entezam 2 and B. geramizadeh 3 

1 Transplant Research Center, Stem Cells & Transgenic Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. 2 Genetic 

Department, Shiraz University of Medical Sciences. 3 Transplant Research Center, Shiraz University of Medical Sciences. 

9:30 – 10:30 PO3-3: Pediatric allergies sheikh rashid F 


Chairpersons: Alessandro Fiocchi 


3300 

STUDY oF THE rElaTionSHiP BETWEEn ToTal anD SPECiFiC igE in SCHool agE aSTHmaTiC CHilDrEn 

O. A. Al Janabi 

Allergy, Allergy And Asthma Center Baghdad, Baghdad, Iraq. 

3301 

a STaTiSTiCal STUDY oF THE moST Common allErgEnS in CHilDrEn, WHo SUFFEr From DiSEaSES or allErgiC 

rEaCTionS in THE CiTY oF laTaKia (SYrian CoaST) 

g. s. Did 

department of pediatric – faculty of medicine – Tishreen University – Lattakia - Syria, Lattakia, Syria 

3302 

ConnECTionS oF aSTHma anD rESPiraTorY inFECTionS in BoSnian CHilDrEn 

A. Bajraktarevic, Prim, Dr, med1 , A. Hadzimurtezic1 , V. Pavlovic1 , m. miokovic1 , A. mahinic1 , A. selimovic2 , i. suljevic3 , Z. 

Hadzimurtezic4 and l. sporisevic5 1 2 Pediatrics Department, Public Health Insitution of Canton Sarajevo, Sarajevo, Bosnia. Pulmonology Pediatrics Department, 

Pediatrics Clinic Sarajevo, Sarajevo, Bosnia. 3Department for Biochemistry, Clinical Medical Center Sarajevo, Sarajevo, Bosnia. 

4 5 Asthma Department, UMC Sarajevo- Clinic for Pulmology, Sarajevo, Bosnia. Pediatrics Department, First Medical Aid Sarajevo, 

Sarajevo, Bosnia. 

3303 

CHilDHooD aSTHma anD oPPorTUniSTiC inFECTionS oF HiV PoSiTiVE CHilDrEn in BoSnia anD HErZEgoVina 

A. Bajraktarevic, Prim, Dr, med1 , A. Hadzimurtezic1 , m. Omerovic1 , A. mahinic1 , Z. Hadzimurtezic2 , A. Djurdjevic Djulepa3 , l. 

sporisevic4 , A. selimovic5 , B. Vranic6 and i. suljevic7 1 2 Pediatrics Department, Public Health Insitution of Canton Sarajevo, Sarajevo, Bosnia. Asthma Department, UMC Sarajevo- Clinic 

for Pulmology, Sarajevo, Bosnia. 3Perinatology Department, General Hospital Sarajevo, Sarajevo, Bosnia. 4Pediatrics Department, 

First Medical Aid Sarajevo, Sarajevo, Bosnia. 5Pulmonology Pediatrics Department, Pediatrics Clinic Sarajevo, Sarajevo, Bosnia. 

6 7 Pulmonology Pediatrics Department, Infectious Clinic Sarajevo, Sarajevo, Bosnia. Department for Biochemistry, Clinical Medical 

Center Sarajevo, Sarajevo, Bosnia. 

3304 

THE EFFECT oF CEllUloSE PoWDEr (naSalEZE) on THE CoUrSE oF SEaSonal allErgiC rHiniTiS 

m. Kherkheulidze, n. Kavlashvili, E. Kandelaki and n. Adamia 

Pediatrics, State Medical University, Tbilisi, Georgia. 


FinAl PrOgrAm

POstErs 



3305 

EPiDEmiologY oF rHiniTiS in SEConDarY SCHool CHilDrEn USing mSYPQ (moDiFiED Sino-naSal oUTComE TEST-20 

YoUng PErSon QUESTionnairE) anD ComPariSon WiTH moDiFiED SnoT-20 USED in aDUlT CommUniTY BaSED SUrVEY 



3306 

SEVErE aToPiC DErmaTiTiS ComPliCaTED WiTH FooD ProTEin-inDUCED gaSTroinTESTinal SYnDromE, CaSE rEPorT 

oF 5 inFanTS 

K. Yamamoto, i. nomura, t. shoda, Y. tsumura, K. Yoshida, K. Horimukai, t. Fukuie, m. Futamura, m. narita and Y. Ohya 

Division of Allergy, National Center for Child Health and Development, Tokyo, Japan. 

3307 

THE PrEValEnCE oF CHilDHooD aSTHma, allErgiC rHiniTiS anD aToPiC DErmaTiTiS in YErEVan 

s. s. gambarov, l. V. Kostanyan and A. s. Zakharyan 

Clinical Immunology and Allergy, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia. 

3308 

PrEVEnTaBlE imPaCT oF SUPlaTaST ToSilaTE DoSagE on aSTHma onSET in inFanTS 

O. norifumi 1 , O. norifumi 2 , m. Kentaro 3 , O. Hiroaki 4 , i. Atsushi 5 , K. Yutaka 5 , s. toshiaki 2 and n. takeshi 2 

1 Pediatrics, Chiba Aiyukai Memorial Hospital, Chiba, Japan. 2 Pediatrics, Kitasato University School of Medicine, Japan.. 3 Department 

of Pediatrics, Chiba Aiyukai Memorial Hospital, Chiba, Japan. 4 Department of Pediatrics, Tokyo Kousei-Nenkin Hospital, Japan. 

5 Department of Pediatrics, Yokohama City Minato Red Cross Hospital, Japan. 

3309 

EValUaTion oF Small airWaYS oF JaPanESE CHilDHooD aSTHma BY HrCT anD iTS aSSoCiaTion WiTH SnPS 

m. tomikawa, m.D. 1 , t. Oguma, m.D. 2 , A. niimi, m.D., Ph.D. 2 , E. matsui, m.D., Ph.D. 3 , n. Kondo, m.D., Ph.D. 3 and m. Ebisawa, m.D., 

Ph.D. 1 

1 Pediatrics, Sagamihara National Hospital, Sagamihara, Japan. 2 Respiratory Medicine, Graduate School of Medicine, Kyoto 

University, Kyoto, Japan. 3 Pediatrics, Graduate School of Medicine Gifu University, Gifu, Japan. 

3310 

riSK FaCTorS For CHilDHooD aSTHma 

n. Kavlashvili, m. Kherkheulidze, E. Kandelaki, n. Adamia and i. Chkhaidze 


3311 

allErgiC ProFilE oF aSTHmaTiC CHilDrEn in a CoaSTal CiTY in THE WEST oF algEria 

A. Benyounes sr. 

ANAP, Algiers, Algeria. 

3312 

THE rolE oF CHiTinaSE-liKE ProTEinS in allErgiC inFlammaTion on PEDiaTriC aDEnoiD TiSSUE 

s. Y. shin 1 , Y. m. Ye 2 , K. H. lee 1 , s. W. Kim 1 , J. s. Cho 1 and H. s. Park 2 

1 Otorhinolaryngology-Head and Neck Surgery, Kyung Hee University, Seoul, South Korea. 2 Department of Allergy & Rheumatology, 

Ajou University School of Medicine, Suwon, South Korea. 

3313 

PaSSiVE SmoKing iS a maJor DETErminanT oF EXHalED niTriC oXiDE lEVElS in allErgiC aSTHmaTiC CHilDrEn 

Y. laoudi 1 , l. nikasinovic 2 , F. sahraoui 1 , A. grimfeld 1 , i. momas 2 and J. Just 1 

1 Department of Asthma and Allergic Diseases, Armand Trouseau Children University Hospital, Paris, France. 2 Laboratory of Public 

health and Environment, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris-Descartes, EA 4064, Paris, France. 

3314 

PrEValEnCE oF allErgiC rHiniTiS in SCHool CHilDrEn PoPUlaTion oF TBiliSi anD WESTErn gEorgia 

m. Kherkheulidze, n. Adamia, E. Kandelaki and n. Kavlashvili 



FinAl PrOgrAm 

POstErs

POstErs 

POstErs 



3315 

aDiPonECTin lEVElS in oBESE anD nonoBESE CHilDrEn WiTH aSTHma 

s. s. Zivanovic, l. m. saranac, D. r. Djordjevic, s. P. Kovacevic and B. A. Kamenov 

Pediatric Clinic, Clinical Centre of Nis, Nis, Serbia and Montenegro. 

3316 

rElaTionSHiP oF EoSinoPHil CoUnT anD igE WiTH THE SEVEriTY oF PErEnnial allErgiC rHiniTiS in CHilDrEn 

Y. H. rha1 and m. s. Kim2 1 2 Department of Pediatrics, Kyung Hee University Hospital, Seoul, South Korea. Department of Pediatrics, Aigumteo Children’s 

Hospital, Daegu, South Korea. 

3317 

rolE anTEnaTal anD PoSTnaTal FaCTorS in oCCUrrEnCE oF an allErgiC DiaTHESiS aT CHilDrEn WHo HaVE BEEn 

Born in CiTY loCaTED nEar To nUClEar EnTErPriSE 

n. Petrushkina 

Departament of physiology, Ural State Univercity Physical Culture, Chelyabinsk, Russia. 

3318 

an ESTimaTion oF THE rESPTaTorY’S FUnCTion CHilDrEn WHo liVE nEar aTomiC PlanT 

n. Petrushkina ii 

Departament of Physiology, Ural State Physical Culture, Chelyabinsk, Russia. 

3319 

PUlmonarY FUnCTion TEST in HEalTHY CHilDrEn 7 To 9 YEarS aFTEr rESPiraTorY Viral inFECTionS 

C. B. Kartasasmita iV, Prof/PhD, s. sudarwati, D. A. Wulandari, A. U. suwardi, W. saptaputra, i. nuradi, m. Kuswandewi and E. A. 

simoes 

Department of Child Health, Hasan Sadikin/School of Medicine Padjadjaran University, Bandung, Indonesia, Bandung, Indonesia. 

3320 

CliniCal ProFilE anD riSK FaCTorS in HoSPiTaliZED CHilDrEn WiTH BronCHioliTiS 

i. Kirovski, l. nikolovski, A. sazdovski, V. micevska and l. seckova 

Department of Pulmonology and Allergology, University Children’s Hospital, Skopje, Macedonia. 

3321 

aSSoCiaTion BETWEEn THE oVErWEigHT anD allErgiC DiSEaSES in SCHool agE CHilD PoPUlaTion oF TBiliSi 

m. Kherkheulidze, n. Kavlashvili, E. Kandelaki and n. Adamia 


3322 

aSTHma anD iTS CorrElaTES in CHilDrEn 

n. takzaree 1 , n. Daneshvar 2 and A. takzaree 3 

1 Dept of Anatomy, Tehran university of Medical Sciences, Faculty of Medicine., Tehran, Iran. 2 Dapt of Histology, Amam khomnei 

Hospital, Tehran, Iran. 3 General Medicine, Amam khomnei Hospital, Tehran. 

3323 

CrEaTiVE agEnTS oF aSTHma in CHilDHooD 

n. takzare 1 , n. Daneshvar 1 , A. takzare 1 and H. Forutan 2 

1 Tehran university of Medical Sciences, Faculty of Medicine., Tehran, Iran. 2 Amam khomeine Hospital, Tehran, Iran. 

3324 

EValUaTion oF USing VBg inSTEaD oF aBg in aSTHma EXaCErBaTion 

m. Fatemi Khorasgani1 , E. niazi1 and s. Farzaneh2 1 2 Pediatrics, Islamic Azad University-Najafabad branch, Isfahan, Iran. Anesthesiology, Islamic Azad University-Najafabad branch, 

Isfahan, Iran. 


FinAl PrOgrAm

ABstrACts 

ABstrACts 

PoSTEr SESSion 1-1: allergens and risk factors 

1100 

allErgiC aSTHma in SYrian aDUlTS 

Khoury, A., merrawi, m. and Joukaji, A. 

Chest Diseases, Aleppo Faculty of medicine, Aleppo, syria. 

objective the interest of our study was to investigate the most important Allergens responsible for Atopic Bronchial Asthma in 

syrian Adults. 

methods :76 Adults asthmatics aging (16-45 y.) consulting our Department between January 2008- January 2009, with 37 male 

patients (48.6%), and 39 Female patients (51.3%), all patients had a skin Prick tests (sPts-stAllErgEnEs lab.)and specific and 

total igE measurements using the ClA-sYstEm method(multiple Allergens sensibility test). 

results the Prevalence of Allergic Asthma is more common in the town (70.3%) than in the Country (29.7%).there was a history 

of positive smoking in 18.5%of our group, with a 70.8%of patients had positive familial history of Asthma. there was an Allergic 

rhinitis(30.4%) , Allergic Conjunctivitis(15.3%) ,and Urticaria(10.7%) in our patients. 

the most common Allergens in the sPts were:Dpt+Df(59%),grass Pollens(50.66), Cats&Dogs(19.2%),Fungi(8.2%)and tree 

Pollens(4.6%). 

the most common Allergens in the mAst were: Dpt+Df(57.7%0,grassPollens(49.3%),Cats&Dogs(23.5%),Fungi(11.2%),and tree 

Pollens(3.9%). 

Conclusions Bronchial Asthma is a common disease in our Country. Allergy to House Dust mite and to grass Pollens were 

comparable to western European Countries, but Allergy to pets and tree pollens were lower 

1101 

oCCUPaTional aSTHma in PETroCHEmiSTrY WorKErS WiTH PErSiSTanT EXPoSUrE 

Eatemadi, A. 

immunology & infectious disease, Ahvaz univrsity of medical siences, Ahvaz, iran. 

Background: to evaluate the effect of treatment with Fluticasone / salmeterol combination on respiratory symptoms and 

pulmonary function tests ( PFt ) in petrochemistry workers with occupational asthma (OA) and persistant exposure in work place. 

method: 40 workers with known history of OA enrolled in this study.twice daily inhalation therapy with Fluticasone propionate (500 

mcg ) and salmeterol ( 50 mcg ) was initiated. At the enrollment and every 3 months, PFt and respiratory symptom score (rss) 

were checked for one year period. need for emergency use of salbutamol also was recorded . 

results: mean baseline FEV1 was 80% of predicted values, but no statistically significant differences in FEV1 and rss were seen 

compare to baseline values after one year treatment. 

Conclusion : regular use ofcombination therapy with inhaled corticosteroids and long-acting bronchodilators can prevent 

respiratory symptoms deterioration over one year period in petrochemistry workers with occupational asthma and persistant 

exposure in work place. 

1102 

SPECiFiC igE SEnSiTiZaTion To CEPHaloSPorinS in HoSPiTal PErSonnEl 

Kim, J. , Kim, s. , Jin, H. , Kim, J. , Ye, Y. and Park, H. 

Department of Allergy & rheumatology, Ajou University school of medicine, suwon, south Korea. 

Background: Cephalosporins can induce occupational allergies including asthma, urticaria, and anaphylaxis. this study evaluates 

the sensitization rate and the risk factors for sensitization to cephalosporins in hospital personnel. 

method: A total of 167 hospital personnel, including 128 nurses working at wards (currently being exposed group), 14 nurses 

working at outpatient clinics or at offices (not currently but previously exposed group), and 25 pharmacists (unexposed group) were 

enrolled. We also enrolled 86 unexposed non-atopic healthy controls. the questionnaire contained items including the work place, 

intensity of exposure, duration of employment, cephalosporin associated work related symptoms (Wrs), and past history of allergic 

diseases including bronchial asthma, allergic rhinitis, atopic dermatitis, chronic urticaria, and experiences of internal or parenteral 

antibiotic use and antibiotic allergy after those. skin prick tests (sPts) to commonly used intravenous cephalosporins including 

cefotiam, ceftriaxone, and ceftizoxime and sPt to common inhalant allergens were performed. serum specific igE antibodies to 

each cephalosporin-HsA conjugate were measured by ElisA. total igE level was measured by immunoCAP system. the binding 

specificities were confirmed by ElisA inhibition tests. 


FinAl PrOgrAm

ABstrACts 

results: the prevalence of cephalosporin associated Wrs was 17.0%. Ceftriaxone was the only cephalosporin which responded 

to sPt and the sensitization rate using sPt to ceftriaxone was 3.1%. the sensitization rate using serum specific igE antibody to any 

cephalosporin-HsA conjugate was 17.0%, where the sensitization rate was the highest to cefotiam (9.1%) followed by ceftriaxone 

(6.7%) and ceftizoxime (3.6%). the past history of antibiotic allergy was a risk factor for cephalosporin associated Wrs (Or, 24.9; 

95% Ci, 2.6-238). On the other hand, the past history of atopic dermatitis was a risk factor for high serum specific igE antibody (Or, 

6.5; 95% Ci, 1.2-34.6) to cefotiam-HsA conjugate. 

Conclusion: Cephalosporins can be sensitized through the skin contact as well as inhalation in hospital personnel. Atopic dermatitis 

would be a risk factor for sensitization to cefotiam. monitoring of serum specific igE to cephalosporin-HsA conjugate would be more 

useful to detect the sensitized subjects than sPt. 

1103 

HoUSE DUST miTE allErgY – inDian PErSPECTiVE 

saha, g. K. 

Zoology, Department of Zoology, University of Calcutta, Kolkata, india. 

Background : An increasing trend in the prevalence of allergic diseases has been noticed from the developing countries due to 

many factors like metamorphic change in ambient air quality due to rapid urbanization and industrialization, subsequent increase 

in air pollution, change in living and dietary habits etc. mites being in house dust represent a major source of allergens resulting 

various allergic manifestations and information regarding the house dust mites (HDms) is of great importance to provide the 

patients with best possible diagnosis and management. As expected, information in this regard is mostly available from western 

and developed countries. 

methodology : the present study represents a comprehensive information on their diversity, habitat preference, seasonal 

occurrence in Kolkata metropolis and their probable role in nasobronchial allergic manifestations through allergy skin test, 

quantification of total igE antibody and detection of allergen specific igE antibodies. 

results & Discussion : During last ten years study period, a total of 54 species of mites belonging to 34 genera and 13 families 

under 3 orders have been identified, of which 5 species are new to science. Dermatophagoides pteronyssinus is the most 

predominant mite species, comprising 47% of total acarine fauna. species diversity index indicates that the maximum number and 

variety of mites are found in Pre-monsoon period and minimum in Winter. Patients’ bed contains higher mite population than the 

corresponding bed-room floor dust. results of skin Prick test (sPt) revealed that sensitivity towards house dust and house dust 

mites are 96% and among them more than 75% patients are sensitive to Dermatophagoides pteronyssinus, 63% to D. farinae and 

72% to Blomia tropicalis mite allergens. information regarding sensitivity to Blomia tropicalis mite is new to indian population. the 

difference between patients and control mean serum igE level is statistically significant (p< 0.05) and 93.5% patients are with 

elevated (300 iU/ml) serum igE level. identification of allergen specific igE antibodies by immuno CAP syatem shows that 79.77% 

patients respond to HD allergen, 71.91 % to DP and 88.76% to DF allergens while 90% patients respond to Bt allergen which 

further confirms the result of sPt. 

1104 

SEnSiTiZaTion raTE anD riSK FaCTorS For SEnSiTiZaTion To DigESTiVE EnZYmES in HoSPiTal PErSonnEl 

Kim, J. , Jin, H. , Kim, J. , Ye, Y. and Park, H. 

Department of Allergy & rheumatology, Ajou University school of medicine, suwon, south Korea. 

Background: Hospital personnel can be sensitized by the inhalation of digestive enzymes and develop occupational asthma and 

rhinitis. Our previous reports demonstrated a high prevalence of serum specific igE antibodies to digestive enzymes in exposed 

subjects with work related symptoms. this is a follow up study 3 years after the first intervention to evaluate the change of the 

sensitization rate and risk factors in hospital personnel. method: A total of 167 hospital personnel, including 25 pharmacists (higher 

exposure group) and 142 nurses (lower exposure group), in a tertiary hospital were enrolled. We also recruited 86 unexposed nonatopic 

healthy controls. the questionnaire contained items including the workplace, intensity of exposure, duration of employment, 

digestive enzyme-associated work related symptoms (Wrs), and past history of allergic diseases such as bronchial asthma, allergic 

rhinitis, atopic dermatitis, chronic urticaria, and drug allergies. skin prick tests (sPts) using biodiastase, the most commonly 

prescribed digestive enzyme, and common inhalant allergens were performed. serum specific igE antibodies to biodiastase and 

porcine α-amylase were measured by ElisA. the total igE level was measured by the immunoCAP system. results: the prevalence 

of digestive enzyme-associated Wrs was 36.0% in pharmacists and 4.2% in nurses. the sensitization rates in pharmacists using 

the sPt to biodiastase (37.5%) and serum specific igE antibodies to biodiastase and/or porcine α-amylase (25.0%) increased over 

the previous report (both 16.7%). the sensitization rate in nurses using the sPt to biodiastase (9.6%) was similar to that of the 

previous report (9.6%), while the sensitization rate using serum specific igE antibodies to biodiastase and/or porcine α-amylase 

(3.5%) decreased from that of the previous report (8.9%). Past history of atopic dermatitis (Or, 28.6; 95% Ci, 4.1-200.4) and drug 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

allergies (Or, 6.9; 95% Ci 1.2-39.6) were found to be risk factors for the sensitization to digestive enzymes. Conclusion: the 

sensitization rate to digestive enzymes in pharmacists increased after the first intervention performed 3 years ago. the sPt to 

digestive enzymes would be more useful in the detection of sensitized subjects than the monitoring of serum specific igE antibodies 

to digestive enzymes. skin contact as well as inhalation could be a route for sensitization to digestive enzymes in hospital 

personnel. 

1105 

SKin TEST rEaCTiViTY in THE EaSTErn ProVinCE oF SaUDi araBia 

KHOUQEEr, r. 

Allergy and immunology, saad specialist Hospital, Alkhobar, saudi Arabia. 

Background: Allergic disease prevalence and incidence are increasing worldwide for unknown reasons, with the steepest rise 

occurring in industrialized societies. Allergic diseases affect more than 20% of the U.s. population and are the sixth leading cause 

of chronic disease in the United states. However in saudi Arabia still there are (scanty) data on the incidence and the prevalence 

of the allergic diseases. saudi Arabia has a fast growing population with an estimated population around 30 millions people, the 

majority of them in the young-middle age group 

there were conflicting data published earlier on the most common allergen in saudi Arabia with small size studies 

objective: to investigate the pattern of skin reactions among the Eastern Province population of the Kingdom of saudi Arabia 

methods: this is a cross sectional data analysis of standard prick and intradermal tests, which were performed to our patients, 

visited saad specialist Hospital in Al-Khobar city in saudi Arabia between 

results: A total of 217 subjects 192 saudi and 19 non-saudis age between July2006 -July2009 were tested, 181 of them had only 

Pst and 36 an iD skin test was done after the initial Pst, 27 of them tested to foods and 192 patients to aeroallergens, thee most 

common food allergen found was to Eggs 29.6% followed by milk 22.2% then Peanut 14.8%, the most frequent aeroallergens 

found were HDm (23.7%), cat (12%), russian thistle (11%), Kochia (8.6%), lambs Quarter (8%), followed by cockroach (6.6%) then 

mesquite (6%) 

Conclusion: Our food skin reactivity was consistent with that of the literature; on the aeroallergen we noticed a change in the 

pattern of the previously published data, which could be multifactorial in origin including environmental changes, a long with 

changes in the living habits of individuals. 

1106 

QUanTiFiCaTion oF a 24 KD maJor allErgEn oF CULEX QUINQUEFASCIATUS WHolE BoDY EXTraCT BY immUnologiCal 

TECHniQUES 

Kausar, m. A. 1 , Vijayan, V. 2 , Bansal, s. 3 , Vermani, m. 4 , siddiqui, W. 5 and Agarwal, m. 6 

1 2 Departments of respiratory Allergy and Applied immunology, VP Chest institute, University of Delhi, new Delhi, india. Department 

of respiratory medicine, V.P. Chest institute, Delhi, india. 3Department of Biochemistry, V.P. Chest institute, Delhi, india. 4Department of respiratory Allergy and Applied immunology, V.P. Chest institute, Delhi, india. 5Department of Biochemistry, Jamia Hamdard,, new 

Delhi, india. 6Department of respiratory Allergy and Applied immunology, Formerly at V.P. Chest institute, Delhi, india. 

introduction: 

in an earlier study, we have reported the identification, isolation and purification of a 24 kd major allergenic protein of crude 

mosquito (Culex quinquefasciatus; Cq) extract1 . We further quantified this 24 kd purified protein in crude Cq extract which may 

serve as a reference reagent for the quality control of commercially available Cq extract. 

methods: 

ElisA and ElisA inhibition assays were developed for quantification of 24 kd purified protein in crude Cq extract. 

results: 

Dose-related inhibition was obtained in Cq-Frib ElisA with the purified protein (24 kd) as well as crude Cq WBE. Dose of purified 

protein and crude Cq WBE required for 50% inhibition (calculated from inhibition curves) was 144 ng and 1145 ng, respectively; 

i.e. 125.8 μg/mg of crude lyophilized Cq WBE. since, 1 ml of 1:20 w/v Cq WBE solution contains 3.7 mg of crude Cq WBE, it is 

recommended that the amount of purified protein in this solution should be 465.5 μg/ml of 1:20 w/v mosquito extract. Further, 

for performing iD tests (1:500 w/v), the Cq extract solution should contain 18.6 μg/ml of the purified protein. Accordingly, the 

concentration of purified protein in the Cq WBE for various dilutions of immunotherapy vaccine may be also calculated for quality 

control purposes. 

Conclusion: 

the 24 kd purified major allergenic proteins of Cq may be used as a reference reagent for the standardization of Cq extract used for 


FinAl PrOgrAm

ABstrACts 

effective diagnosis and efficacious immunotherapy of millions of patients of respiratory allergy in our country. it is recommended 

that this purified protein may be used as a reference reagent for quality control of commercially available mosquito WBE. 

reference: 

1. Kausar mA, Vijayan VK, Bansal sK, Vermani m and Agarwal mK. isolation and purification of a 24 kd major allergen of Culex 

quinquefasciatus whole body extract. Annals of Allergy, Asthma and immunology 2009;102:23. 

1107 

PrEValEnCE oF aSTHma in ElEmEnTarY SCHool STUDEnTS aFTEr an oil lEaK in THE WESTErn CoaST oF KorEa 

Jee, Y. 1 , Kim, K. 1 , Kim, D. 1 , Kim, Y. 1 , Park, J. 1 , Jeong, W. 2 , Hur, J. 2 , Jung, s. 3 and roh, s. 3 

1 2 internal medicine, Dankook University College of medicine, Cheonan, south Korea. taean institute of Environmental Health, taean, 

south Korea. 3Occupational and Environmental medicine, Dankook University College of medicine, Cheonan, south Korea. 

objective 

the aim of this study was to investigate the impact of the exposure to oil leak on pulmonary function and prevalence of asthma in 

the elementary school students in taean, where were located in the western coast of republic of Korea and exposed to offshore oil 

leak on December 7th , 2007 

Subjects and methods 

Of 662 eligible students, 477 (72.1%) subjects who agreed to and completed the health assessment were enrolled on June 2009. 

A Questionnaire developed by the international study of Asthma and Allergic diseases in Children (issAC) was modified and used. 

methacholine bronchial provocation tests (mBPt) were performed in 109 (22.9%) subjects who reported asthmatic symptoms in 

the questionnaire. Participants were stratified into two exposure groups (high vs. low). general characteristics and asthma-related 

symptoms, and prevalence of asthma were compared. 

results 

there were no statistically significant differences in sex, age, Bmi, and family history of asthma between the two groups. the 

number of children who was previously diagnosed asthma, began wheezing after oil leak or had current asthma symptoms was 

significantly higher in the high-exposure group than that in the low-exposure group (previously diagnosed asthma; 20.6% vs 

11.6%, P=0.008, wheezing after the oil leak; 6.7% vs 1.0%, P=0.01, current asthma symptoms; 30.6% vs 18.6%, P=0.00). FEV1 was significantly lower in the high-exposure group than that in the low-exposure group (82.6±10.8% vs 85.2±10.3%, P=0.01). 

those who showed positive (PC20°Â16mg/ml) response in the bronchial provocation test was significantly higher in the highexposure 

group than that in the low-exposure group (18.2% vs 7.6%, P=0.00). logistic regression on asthma indicated increased 

odds for male (Or: 1.88, 95%Ci: 1.04-3.41), children with family history of asthma (Or: 4.02, 95%Ci: 1.38-11.71), and highexposure 

group (Or: 3.26, 95%Ci: 1.79-5.92) adjusting for age, sex, and Bmi. 

Conclusion 

the study suggest that exposure to oil leak can be a risk factor in the development of asthma in elementary school students 

although the causality is not certain. Follow-up studies and further analyses with biologic exposure index will elucidate the 

relationship between oil leak and asthma. 

1108 

PrEValEnCE oF CHroniC oBSTrUCTiVE PUlmonarY DiSEaSE anD iTS aSSoCiaTion WiTH ToBaCCo SmoKing anD 

EnVironmEnTal ToBaCCo SmoKE EXPoSUrE among rUral PoPUlaTion 

B g, P. 1 , Huliraj, n. 2 , s P, P. K. 1 , B m, r. 1 , Dr, g. 1 , n r, r. m. 1 and C r, s. B. 3 

1 2 Department of Community medicine, Kempegowda institute of medical sciences, Bangalore, india. Department of thoracic 

medicine, Kempegowda institute of medical sciences, Bangalore, india. 3Department of radiology, Kempegowda institute of medical 

sciences, Bangalore, india. 

Background: the prevalence of COPD is increasing in india. Only few studies have been conducted in rural areas of india to find 

out the prevalence of COPD and its relationship with tobacco smoking, environmental tobacco smoke (Ets) exposure and type of 

cooking fuel used. Hence the present study was undertaken with the following objectives:i) 

to find out the prevalence of COPD in adult subjects of 35 years and above. 

ii) to determine the tobacco smoking, Ets exposure and type of cooking fuel used as an associated risk factor with COPD. 

material and methods: Field survey was conducted for COPD epidemiology in the rural field practice area of Kempegowda institute 

of medical sciences, Bangalore, india which covers a population of 44,387 residing in 71 villages using cluster sampling technique 

with the help of previously validated and standardized translated kannada (local language) version questionnaire for diagnosis of 

COPD among subjects of age 35 years and above. spirometry was performed to all those who gave positive response to COPD and 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

they were graded according to gOlD criteria. results: Among 1400 subjects aged above 35 years, 693 (49.5%) were males and 

707 (51.5%) were females. the overall prevalence of COPD was 4.36%. the prevalence among males and females were 5.32% 

and 3.41% respectively. the prevalence was found to be increasing with increase in age [p

ABstrACts 

mWCnts on OVA-asthma model were analyzed by airway hyperreactivity (AHr) measurement, bronchoalveolar lavage fluid (BAlF) 

analysis, intracellular rOs production and histological analysis in lung tissue. 

Results: intranasally administrated-mWCnts easily loaded in alveolar macrophage, but did not result in significant lung 

inflammation and intracellular rOs production of the OVA-induced asthma model. in histological analysis, mWCnts exacerbated 

collagen deposition within the lung parenchyma of naïve mice and pre-existing allergic mice. 

Conclusion: these results suggest that combined OVA sensitization and mWCnts administration did not affected pre-existing 

allergic, but increased collagen deposition in lung parenchyma. 

1111 

PollEn CoUnTS ProFilE in gEorgia EValUaTED BY THE BUrKHarD PollEn TraP 

Chikhladze, m. V. 1 and sepiashvili, r. i. 2 

1 2 national institute of Allergology, Asthma & Clinical immunology, georgian Academy of sciences, tskhaltubo, georgia. Department 

of Allergology and Clinical immunology, institute of immunophysiology, moscow, russia. 

Aim and Methodology: the pollen counts in georgia were studied in 2006-2009 using the vacuum Burkhard Pollen trap (great 

Britain) donated by the World Allergy Organization (WAO) to the national institute of Allergology, Asthma and Clinical immunology 

in tskhaltubo (georgia). the dependence of allergic diseases prevalence on the geographic location and some other factors (air 

temperature, humidity, height above the sea level, spectrum of regional plants) were also studied. 

Results: it was stated that allergy to mold fungi and other bacteria more often occurred in the areas with high humidity and the 

morbidity level with hay fever and bronchial asthma was much higher than in dry areas. in cities situated on the Black sea (Batumi, 

Kobuleti, Poti), ragweed is widely distributed, which in the period of blossom caused numerous allergic diseases (allergic rhinitis, 

conjunctivitis, urticaria etc.). When ragweed blossom, the quantity of pollen in the air is extremely high and as it is a strong allergen 

it causes exacerbation and allergic disease in people sensitized to ragweed pollen. the highest percentage of allergy morbidity 

fall at plants allergens caused by pollen of numerous weeds and plants (pollen of ragweed, alder, birch, maple, walnut, mallow, 

cotton-plant etc.). in different areas of georgia people are more sensitive to various plants. in imeretia region, it is ragweed pollen, 

in Kakhetia and Kartli – platan and wheat. graphic chart of hay fever and bronchial asthma morbidity as a rule have two peaks – 

spring–summer and autumn–winter. it is the season of plants blossom and the quantity of pollen in the air is most high. 

Conclusion: the pollen counts obtained using the Burkhard Pollen trap allowed us to make a pollen calendar for different regions 

of georgia thus enabling to perform treatment and prophylactic measures in advance. 

1112 

air PUriFiEr THaT USES PHoTo CaTalYTiC oXiDaTion rEDUCED THE PoPUlaTion oF mrSa 

ghosh, n. 1 , Pratt, C. 1 , Bennert, J. 2 , Chudasama, J. 2 and Das, A. B. 3 

1 2 3 life, Earth and Environmental sciences, West texas A&m University, Canyon, tX. Air Oasis, Amarillo. Dept. of Agricultural 

Biotechnology, College of Agriculture, Orissa University of Agriculture & technology, india. 

the air surrounding us plays an extremely important role in our well being and efficiency. Breathing pure and clean air allows us to 

think more clearly, sleep more soundly, and stay healthier. studies show that we receive 56% of our energy from the air we breathe, 

more than from water and food combined. On average we breathe 37 pounds of air a day. the quality of the environment within 

buildings is a topic of major importance for public health and indoor Air Quality (iAQ) is a major concern at work places. the objective 

of the present study was to assess two negative ion purifiers - Xtreme 3000 and luna induct air purifiers on the net reduction of 

bacteria in the microbiology and mycology laboratories of Baptist saint Anthony’s Hospital (BsA) in Amarillo, texas and the specific 

effect on methicillin resistant Staphylococcus aureus, mrsA. mrsA has become a serious public health issue. luna induct air units use 

an advanced hydrated Photo-Catalytic Oxidation (PCO) filtration system. it produces a broad spectrum high intensity UV light targeted 

on a quad metallic catalyst in a low-level ozone and moist atmosphere. Bacteria isolated from petri plates exposed to the room air 

were gram positive bacilli such as Bacillus, Coryneform (diptheroids), coagulase negative Staphylococcus and Micrococcus spp., and 

encapsulated gram negative bacilli. in every case there was reduction in airborne pathogen with variable room sizes when the air 

purifiers were used. tsA plates with 5% sheep blood were placed for exposure rooms at different distances and intervals. Plates were 

evaluated for the total number of bacterial and fungal colonies at intervals of 24, 48, 72 and 120 hours. We plated the mrsA strains 

from the stock culture after dilution 10-4 to investigate the effect of air-purifiers on the production of number of colonies of mrsA. tsA 

plates were inoculated with the strain after serial dilutions as follows. 5 ml of stock culture was diluted to 10-4 after incubation at 37o C for 24 hours and were plated onto tsA petri plates. ‘t-test’ results show that there was a significant difference in the air purifier 

treated sets and a gradual reduction in the number of colonies. the reduction of latent bacteria in the air could possibly reduce the 

transmission of airborne disease. 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

1113 

inCrEaSing oF allErgY PoTEnCY oF PollEn grainS in HElianTHUS annUUS l. UnDEr BEnZo(Á) PYrEnE (BaP) 

EXPoSUrE 

Baghali, Z. 1 , majd, A. 2 , Chehregani, A. 3 , Pourpak, Z. 4 and Vatanchian, m. 3 

1 2 3 Dept. of Biology, tarbiat moallem University, Hamedan, iran. Dept. of Biology, tarbiat moallem University, tehran, iran. Dept. of Biology, 

Bu-Ali sina University, Hamedan, iran. 4immunology, Asthma and Allergy research institute, tehran University, tehran, iran. 

Background: Allergy prevalence was increased in recent years dramatically. the reason of this phenomenon was not clear but there is 

a scientific attention to air pollution. Diesel exhaust particles (DEP) are a major part of air pollutants that express both adjuvant activity 

for sensitization against common allergens and enhancing sensitized individuals. Benzo(α) Pyrene (BAP) is considered as the most 

important part of DEP. the aim of this research was study of the effect of BAP on allergenecity of pollen grains in Helianthus annuus l. 

method: in this research, H. annuus l. Var. record plants were grown from seed in green house controlled condition and shoots treated 

by different concentration of BAP solutions in phosphate buffer saline (PBs) (0.002, 0.02, 0.04 g/l) daily. Controls were sprayed by 

PBs. Pollen grains were collected and allergy potency of pollen grains was compared in different experimental groups and controls. 

Allergenecity of pollens was studied by means of skin prink test, determination of blood cells and evaluation of total igE in studied 

groups using sensitized guinea pigs as an experimental model. Pollen proteins were also studied by sDs-PAgE and immuno-blotting 

method for BAP-induced changes in protein profile and detection of allergen bands. 

result: Comparing of allergy potency of different pollen extracts showed that allergic skin reactions in animals that treated by polluted 

pollen grains was 2-3 times more than the groups treated by normal pollen extract and 5-6 times more than BAP treated group. 

Eosinophil number and igE level, as allergy indicators, were also increased considerably in the blood of the groups treated by BAP 

exposed pollen grains than control ones. results of sDs-PAgE showed that there are two additional bands in the BAP treated pollen 

grains. immuno-blotting study of pollen proteins showed that new bands act as allergens that are reacted with igE strongly. 

Conclusion: results of this research work concluded that BAP could increase the allergy potency of H. annuus pollen grains and 

also cause to formation of new protein bands that act as new allergens. 

1114 

rElaTionSHiP BETWEEn ToTal SErUm igE anD BoDY maSS inDEX in PaTiEnTS WiTH nonaToPiC rESPiraTorY allErgY 

Kim, s. , lee, W. Y. , Yong, s. J. , shin, K. C. , lee, s. n. , lee, s. J. and lee, m. K. 

Department of internal medicine, Yonsei University Wonju College of medicine, Wonju, south Korea. 

Background : Allergy skin test is a major tool in the diagnosis of atopy. some of the patients with respiratory allergy such as rhinitis 

and asthma show often no sensitization for common inhalant allergens when skin prick test is performed. Previous literature on 

the relationship between serum total igE and body mass index (Bmi) has been inconsistent. it is not known how this relationship is 

in patients with nonatopy. objective : We sought to examine the relationship of serum total igE and body mass index in respiratory 

allergy patients with nonatopy. methods : skin prick tests were performed with 33 common inhalant allergens on 934 respiratory 

allergy patients from January 2007 through December 2007 at a University hospital and total serum igE was measured. Atopy 

was determined by a positive skin prick test response to at least one common inhalant allergen. Among the studied subjects, 526 

patients were nonatopy. We excluded the cases with more than 500 iU/ml of total serum igE because which levels of igE were 

more associated with other causes, such as parasite infections. results : the subjects with nonatopy and less than 500 iU/ml of 

total igE level were 468 patients consisted of 169 male and 299 female. When the cutoffs were used for underweight, overweight, 

and obesity corresponding to Bmi of 18.5, 23.0, and 25.0 kg/m2 , the levels of mean total igE in female patients were 41.1±41.0 

in underweight (n=14), 64.6±87.3 in normal weight (n=104), 78.9±99.9 in overweight (n=57), and 85.5±87.6 iU/ml in obese 

patients (n=124), respectively. mean total igE levels were significant higher among obese and overweight patients than among the 

others (83.4 vs. 61.8 iU/ml, p=0.036). no statistical significance was observed in male patients. Conclusion : Obesity may be a 

contributor to the increased level of total serum igE in female patients with nonatopic respiratory allergy diseases. 

1115 

PollEn STUDY in inDonESia 

rengganis, i. 

Department of internal medicine, Faculty of medicine, University of indonesia, Jakarta, indonesia. 

Allergy is a human immediate hypersensitive reaction to allergens. it occurs when the body produces an excess of igE antibody 

as response to allergen. Pollens are important environmental allergens in subtropical countries which contribute to significant 

morbidity especially during the pollination period. Despite the all year long of plants flowering in indonesia, pollen allergy has not 

been well studied. the objectives of this study were to identify pollen from plants in a given area in indonesia which may cause 


FinAl PrOgrAm

ABstrACts 

allergy in human. A Burkard spore trap was set for seven days sampling in lebak Bulus, district in south Jakarta, while a passive 

collectors with adhesive object glass were placed in Darmaga Bogor, Pasar minggu and Jagakarsa in south Jakarta. Using light 

and scanning electron microscopes (sEm), pollens that were trapped and identified were acacia (Acacia auriculiformis), cogon 

grass (Imperata cylindrica), coconut (Cocos nucifera), palm trees (Elaeis guineensis), maize (Zea mays), rice (Oryza sativa), and 

pine (Pinus merkusii). molecular weight of protein profiles from those pollen extract using sodium dodecyl sulfate-polyacrylamide 

gel electrophoresis analysis (sDs-PAgE) were dominated by 10-70 kD bands. Allergenicity in human to those pollen commercial 

grasses mix extract was also included in the test to people with and without history of allergy, 69 people each, using the skin prick 

test method. the seven pollen of plants trapped in indonesia are allergenic. Human sensitivity to Cogon grass and acacia pollen 

are more severe than to the rest of other pollen, however, the sensitivity was most found to commercial allergens of grasses mix. 

People with respiratory allergy was more sensitive than people without history of allergy. meanwhile, human sensitivity to acacia 

was the same in those two groups of people. Pollen of Cogon grass and acacia are potential allergens to be used for skin prick test 

in indonesia. Acacia trees are not recommended to be utilized as a shading tree since their pollen showed sensitivity reaction in 

human. 

Keywords: pollen, allergen, sensitivity, skin prick test. 

1116 

inHalanT allErgEnS SEnSiTiZaTion in PaTiEnTS WiTH aSTHma anD allErgiC rHiniTiS; rEViEW oF SKin TEST rESUlTS 

oVEr TWo YEarS PErioD aT SUlTan QaBooS UniVErSiTY HoSPiTal, mUSCaT – oman 

sharef, s. W. and Al-tamemi, s. H. 

Department of Child Health, sultan Qaboos University Hospital, muscat, Oman. 

Background: there are geographical variations with respect to allergens presence, and therefore identification of relevant allergens 

in each environment is important that may have diagnostic and therapeutic implications. 

method: A review of allergy skin prick tests during (April 2008 – march 2010) is performed at sultan Qaboos University Hospital, 

muscat - Oman. A new panel of inhalant allergen extracts was introduced in April 2008. Pediatric and adult patients with a 

diagnosis of Asthma or Allergic rhinitis (Ar) are referred by physicians for allergy skin tests. the skin prick tests were performed 

according to standard method. the data were collected and analyzed using sPss. the frequencies of positive allergens sensitization 

were calculated. 

results: there were a total of 561 patients with asthma and allergic rhinitis. the number of patients with asthma was 103 

(44.7% males and 55.3 % females). in these patients, the most common allergen sensitization is Dermatophagoides pteronyssinus 

(44.7%), followed by Dermatophagoides farinae (40.8%), Cat fur (21.4%), Dog Hair (18.4%), russian thistle (14.6%), Bermuda 

grass (13.6%), mosquite (11.7%), Feather mix (7.8%), 5 grasses mix (5.8%), Aspergillus mix (5.8%), Chenopodiaceous (5.8%), 

Penicillium mix (4.9%), Compositae (4.9%), Date Palm (4.3%), Wheat pollen (3.9%), Cladosprium mix (3.9%), Cattle Hair & Epithelia 

(1.7%). the number of patients with allergic rhinitis was 458 patients (53.9% males and 46.1 % females). in these patients, the 

most common allergen sensitization is Dermatophagoides pteronyssinus (33.8%), followed by Dermatophagoides farinae (30.1%), 

russian thistle (24.7%), Chenopodiaceous (16.6%), Dog Hair (14.6%), Cat fur (12.9%), mosquite (12.9%), Bermuda grass (12.4%), 

Date Palm (9.8%), Compositae (7.6%), 5 grasses mix (5.5%), Feather mix (5%), Wheat pollen (4.4%), Cattle Hair & Epithelia (4.3%), 

Aspergillus mix (3.3%), Cladosprium mix (2.6%), Penicillium mix (2.4%). 

Conclusion: the above data identified House dust mite as the commonest allergen sensitization (which is consistent with published 

data from other countries), other significant allergens are identified including date palm pollens. this will help physicians to manage 

allergic asthma and Ar patients. Ultimately pollen count may be necessary to identify other significant environmental allergens in 

Oman. 

1117 

SKin PriCK TEST in CHilDrEn rESiDing in a rUral CommUniTY in BanDUng, WEST JaVa, inDonESia 

sapartini, g. 1 , B.Kartasasmita, C. 1 , setiabudiawan, B. 1 , majangsari, r. g. D. 1 , saptaputra, W. 2 and irwan, n. 2 

1 2 Department of Child Health, school of medicine Padjadjaran University, Bandung, indonesia. Health research Unit, school of 

medicine Padjadjaran University, Bandung, indonesia, Bandung, indonesia. 

Background skin prick test (sPt) is a fast, safe, and efficient method to diagnose igE-mediated allergy that provides optimal 

information as long as it performed and interpreted correctly. it is important that the allergens tested for should be adjusted to 

the patient’s clinical condition and residential. the aim of this study is to report the result of sPt in children residing in a rural 

community in Bandung, West Java, indonesia. 

methods this study was a part of a nested case control study entitled, “rsV and recurrent wheezing in indonesia: 7-9 years 

follow-up study with lung function studies.” this study was conducted in Department of Child Health, Hasan sadikin Hospital from 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

December 2009 to July 2010. Demographic data and history taking on the basis of standardized questionnaires were collected 

from all participants. the skin prick test was performed with 12 common allergens. 

results there were 218 subjects, 111 (50.9%) boys and 107 (49.1%) girls, age 8.4 to 13.4 years old, mean of age 10.4 ± 1.05 

years old, enrolled in the study. Positive sPt were found in 175 subjects (80.3%), negative sPt in 31 subjects (13.8%) and severe 

dermatographism in 13 subjects (6%). the positive rates of inhaled and food allergens were 33.1% and 6.3% respectively whereas 

positive rate to both allergens was 60.6%. the most common inhaled allergens were house dust mites i.e. Blomia tropicalis (58%), 

Dermatophagoides farinae (55%), and Dermatophagoides pteronyssinus (49.5%), followed by cockroach (32.6%), cat dander 

(26.6%), Alternaria alternata (24.3%), and Aspergillus mix (18.3%). Yolc egg was the most common food allergen (31.7%), followed 

by chocolate (30.7%), shrimp (22.5%), and soya (11.5%). 

Conclusion the percentage of positive sPt is high. the most common allergen is house dust mite (Blomia tropicalis). 

Keywords: Allergen, house dust mites, igE-mediated allergy, skin prick test 

1118 

ProTEin EXPrESSion ProFilE oF inDigEnoUS anD CommErCial EXTraCTS oF amaranTHUS PollEn in allErgY 

PaTiEnTS 

Hasnain, s. m. 1 , Al sini, H. 1 , Al-Qassim, A. 1 , Al Frayh, A. 2 , gad-El-rab, m. O. 3 and Alaiya, A. 1 

1 2 Biological and medical research, King Faisal specialist Hospital and research Centre, riyadh, saudi Arabia. king saud University 

&King Khalid Hospital riadh K s Ariyadh, riyadh. 3College of medicine, King saud University. 

Background: Amaranthus viridis and Amaranthus lividus, pollen are the most prevalent in various parts of saudi Arabia. 

Amaranthus species are allergenic and potential cause of respiratory allergy. However, neither are commercially available for 

diagnostic or therapeutic purposes. 

method: sPt was applied in this study. Five allergy patients were skin tested with locally prepared (indigenous and commercial 

pollen) as well as commercial extracts. Amaranthus pollen was collected from various indigenous sources. A. palmeri, A. retroflexus, 

A. hybridus, A. tuberculatus were acquired from greer and A. retroflexus, A. tamariscinus were acquired from Allergon. the raw 

pollen from these species was extracted in buffered saline PH 8.1. Protein patterns of eight different types of Amaranthus samples 

as well as serum samples from patients were analyzed using two-dimensional polyacrylamide gel electrophoresis (2-DE)/sDs PAgE 

and computer-assisted image analysis (PDQUEst). 

results: We have generated and characterized the expression of multiple proteins in human serum samples of patients exposed 

to 7 different types of Amaranthus allergens. two patients demonstrated similar high expression changes to 2 types of Amaranthus 

allergens and were classified as group 1 while three samples showed low expression to Amaranthus and were referred to as group 

2 of the Amaranthus allergens. Changes in the expression of 12 proteins were observed between groups 1 and group 2 samples. 

Conclusion: there appear to be proteins diversity in six major Amaranthus species and similarities in the two indigenous species. 

While the reactive and cross-reactive proteins between the indigenous and commercial species are being investigated, the available 

commercial extracts appear to have different protein profile and may not be fully relevant to this region for the diagnosis of inhalant 

pollen allergy and subsequent specific immunotherapy. Further validation of observed protein spots is warranted in order to support 

their usefulness as potential Amaranthus biomarkers for the diagnosis and therapy monitoring of allergy patients. 

1119 

naTUral rUBBEr laTEX-rElaTED oCCUPaTional aSTHma: SUCCESSFUl SUBlingUal DESEnSiTiZaTion 

D. schiavino, A Buonomo, t De Pasquale, V Pecora, V sabato, A Colagiovanni, A rizzi, A Aruanno, l Pascolini, E nucera. 

Allergy Department, Catholic University, rome, italy. 

Background: Occupational Asthma (OA) has become the most common work-related lung disease in industrialized countries. the 

most common triggers are wood dust, grain dust, latex (especially among health care workers associated with use of gloves) or 

other chemicals (especially diisocyanates). specific desensitization represents an important therapeutic tool in the management of 

patients with latex allergy. the aim of the study is to evaluate the safety and effectiveness of sublingual desensitization in patients 

with latex-induced asthma and its impact on patient capability to reintegrate at the previous work. 

method: We selected 13 patients affected by occupational latex-induced asthma. the diagnosis of nrl allergy was based on 

a positive allergological work-up, included execution of allergological tests (skin prick test and in vitro laboratory tests) and 

provocation challenges (glove-wearing, conjunctival, bronchial and sublingual provocation test) to confirm clinical latex allergy. 

Based on clinical history and positive allergological work-up, we decided to carry on a rush sublingual desensitization with latex, 

performed in 4 days with increasing doses of latex extract under patient’s tongue until the highest dose of 500 μg of undiluted latex 

solution. A maintenance therapy (10 drops of undiluted solution three times a week) was recommended. After 1-year treatment 

challenges were repeated and those with negative bronchial test underwent a 8-hour work place challenge in an operating room. 


FinAl PrOgrAm

ABstrACts 

Patients with all negative challenges were reintegrated at the previous work and followed up for 1 year for the occurrence of 

modification of respiratory parameters. 

results: the treatment was tolerated by all patients and in 12 out of 13 bronchial challenge turned negative. they did not 

experience symptoms or modification of respiratory parameters during the workplace challenge and 10 were reintegrated at the 

previous work, being followed up for 1 year. 

Conclusion: sublingual immunotherapy with nrl has proven to be safe and efficacious for the management of patients affected by 

nrl-related occupational asthma. Our results are really encouraging even though they should be confirmed by further large casecontrolled 

1120 

ToTal igE SEnSiTiViTY ComParED WiTH SPECiFiC igE rESUlTS againST miTES anD molDS For THE SCrEEning oF TYPE 

1 allErgY in WorKErS oF a PoliCE inSTiTUTE in CaraCaS, VEnEZUEla 

silva, n. A. , monterrey, C. , Camacho, n. and nirsen, g. 

laboratory of Production and Quality Control, Corpodiagnostica, Caracas, Venezuela. 

igE mediated Allergies (type i) are chronic diseases that affect more than 20% of the population in some countries. We analyzed 

55 blood samples from workers of Universitary institute of scientific Police, iUPOlC Caracas, Venezuela, that presented Allergies 

related symptoms at the moment of the study. We used a specially designed survey to register that information. We tested serum 

total igE by ElisA method and a specific igE using an immunoblott nitrocellulose panel composed with mites and molds allergens 

of well know local prevalence, in order to calculate the diagnostic sensitivity of serum total igE as a marker for screening type 

i Allergies compared with allergen sensitivities detected on the individuals. We selected the most common reference values for 

serum total igE used in Venezuela. the sensitivity obtained for serum total igE was 66,67%,, specificity 100%, Positive Predictive 

Value 100%, and negative Predictive Value 61,29% . We discussed the possibility that the sensitivity obtained for total igE could 

be even lower if more number of allergens and skin tests were included on the study. We conclude that the use of total igE as 

screening diagnostic tool for Allergies must be used together with clinical history of the patient and other assays like i.e. specific 

igE. local Clinical laboratories should promote of better interpretation schemes (reference values) for total igE that actually helps 

to a better diagnosis of this disease. (1, 2). 

1.Bousquet J., Khaltaev n., Cruz A. A., Denburg J., Fokkens W. J., togias A., Allergic rhinitis and its impact on Asthma (AriA) 2008 

Update, in collaboration with the World Health Organization, gA2lEn and Allergen, Allergy 2008: 63 (suppl. 86): 8–160. 

2.Comité nacional de Alergia, Comité nacional de neumonología y Comité de Otorrinolaringología de sAP Filial Córdoba, Consenso 

nacional de rinitis Alérgica en Pediatría, Arch Argent Pediatr 2009:107,1,67-81. 

PoSTEr SESSion 1-2: asthma education and management 

1200 

omaliZUmaB ProVing To BE EFFECTiVE in PaTiEnTS WiTH normal igE lEVElS & rEFraCTorY aSTHma, 

B. mahboub1 , mohamed, r. 2 and mohamed, n. 3 

1 2 ,rashid hospital, Dubai, United Arab Emirates. Department of Pulmonary medicine, rashid hospital, Dubai, United Arab Emirates. 

3 ,Department of Pulmonary medicine ,rashid hospital, Dubai, United Arab Emirates. 

Backgroundto assess the response of Omalizumab in patients with normal igE levels regards asthma control & quality of life 

methodsA 38yr old female physician with childhood asthma from 5yrs, later developing into adulthood as severe uncontrolled 

asthma on high dose salmeterol/fluticasone 500mcg BD,anti-cholinergics,aminophylline,on nasal steroids & antihistamines 

for rhinitis control,antireflux measures with frequent need for nebulizations & subcutaneous sympathomimetics during severe 

attacks with high doses of 80mg to 60 mg of oral steroids.there is H/o atopy, eczema, allergic rhinitis & asthma in family. 

Work up for ABPA, carcinoid & endocrinopathies was negative. H/o intubation thrice since2002& steroid reduction not possible. 

in 2006methotrexate 20-25mg weekly achieved a steroid reduction of up to 10mg/day after 6mths.in 2008 she developed 

methotrexate alveolitis by HrCt which was treated with iv methylprednisolone & high oral steroids with resolution in subsequent 

follow up Ct after stopping methotrexateresults inspite of normal igE levels & negative specific igE to common aeroallergens 

Omalizumab started at a moderate dose of 225mg sc every 2weeks for 6months, showed a significant improvement in asthma 

control & rhinitis, no nocturnal symptoms, only once needed prn salbutamol, modest improvement in lung function, asthma control 

test scores up from 5 to 22 with half dose of oral steroids, eczema disappeared. After 6 months, omalizumab stopped due to 

economic reasons during which her symptoms recurred, to resolve again after a month when it was restarted Conclusionthis 

beneficial effect of omalizumab may be attributed to either long-term steroid use suppressing igE or to the production of local 

igE complexes in the pulmonary system and local pulmonary steroid resistance .this expands the role of Omalizumab & modifies 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

the indication from the use of the drug based on purely igE levels as a parameter to patients symptoms and clinical improvement 

as an important factor.references1.Omalizumab (Xolair) in patients with steroid-resistant asthma:lessons to be learnt ,Philip 

j.thompson,neil l.misso & john woods respirology (2007) 12 (suppl.3),s29–s34. ref no2.Benefits of omalizumab as add-on 

therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (ginA 2002step 4 

treatment)innOVAtE, m.Humbert,r.Beasley,J.Ayres, r.slavin,J.H bert,J.Bousquet,Allergy 2005:60:309–316 

1201 

From TEmPEramEnT To PErSonaliTY: DoES aSTHma aFFECT DEVEloPmEnT? 

grønnerød, C. 

Department of Psychology, University of Oslo, Oslo, norway. 

this paper examines the relationship between temperament, personality and asthma in a longitudinal sample. A previous study 

have pointed to possible links between temperamental mismatch between parents and children, and asthma. Other studies have 

found links between asthma and negative emotionality, while some have not found such relationships. in the longitudinal PrAD 

study (lilljeqvist, smørvik & Faleide, 2003), 100 children with and without asthma were followed from birth to adolescence. no 

link was found between asthma and temperamental traits at 7-9 years of age, nor of asthma and personality traits at 15-17 years. 

the data did reveal a link between asthma at 7-9 years of age and elevations in the personality trait of neuroticism at 15-17 years. 

Possible etiological links are discussed. 

1202 

THE TrEaTmEnT oF PaTiEnTS WiTH BronCHial aSTHma anD arTErial HYPErTEnSion 

latysheva, E. A. 1 , Kurbacheva, O. m. 1 and gendlin, g. E. 2 

1 2 Allergology and Clinical immunology, institute of immunology FmBA russia, moscow, russia. Cardiology, russian medical 

University. 

the course and the prognosis of the bronchial asthma (BA) depend not only on the correct antiasthmatic treatment, but on the 

comorbid conditions. Cardiovascular diseases have a great impact and may complicate the treatment of the patients with BA. the 

influence of the cardiovascular pathology on the course of BA can be caused both with the illness itself and applied medications. 

Antihypertensive treatment sometimes is associated with direct negative influence on the bronchial resistance, sputum production, 

bronchial hyperreactivity and the quality of life. the purpose: to estimate the effectiveness and safety of angiotensin-converting 

enzyme inhibitors (ACEi) and their combination with calcium antagonists (CA) in patients with BA. methods: 60 patients with 

a controlled BA and not controlled arterial hypertension (AH) were selected. All patients underwent a complex examination, 

including spirography and bodypletismography, arterial blood pressure (BP) monitoring, echocardiography and quality of life (Ql) 

questionnaires. Afterwards they were randomized into 2 groups of similar age and gender. 1st group was treated with ACEi (enalapril 

2.5-20mg) and the 2nd received the combination of ACEi and CA in a fixed combination (verapamil + trandolapril 180/2). After 6 

month of treatment the complex examination was repeated. results: 3 (5%) patients were excluded because of cough after the 

beginning of ACEi treatment. the normal levels of BP were achieved in 100%. the antihypertensive treatment did not lead to the 

BA exacerbations (the reasons of the exacerbations were viral and bacterial infections of the respiratory tract). the treatment with 

enalapril decreased the hypertrophy of the left ventricle (p

ABstrACts 

both gender, suggesting a marked co-morbidity between asthma and ADHD. the association between AE and ADHD is modified 

by sleeping problems which are, in itself, known risk factors to rtAs. given the significant morbidity and mortality of rtAs, atopic 

disorders, and adult ADHD, the co- morbidity between these disorders should gain more attention from us. methods: 

the aim of this presentation is to shed the light on the black spot in managing the aforementioned co- morbidity. the author 

reviewed all publications investigating this co-morbidity in several databases. 

results and conclusion: 

then he would display in his 15 minutes oral presentation a black spot program to manage it. 

1204 

THE QUaliTY oF liFE in aSTHmaTiC PaTiEnTS TrEaTED WiTH omaliZUmaB 

della torre, F. 1 , limonta, A. 1 , gaffuri riva, V. 1 and Della torre, E. 2 

1 2 general Pneumology, inrCA-irCCs, milan, italy. internal medicine, san raffaele Hospital, milan, italy. 

introduction 

it is well known that some patients with severe persistent asthma remain inadequately controller despite receiving best available 

treatment and optimal management efforts. such patients, who have exhausted the therapeutic options available to them , are at 

risk of experiencing serious exacerbations and asthma related mortality 

We present two cases treated with omalizumab 

Case 1 

35 years old female brasilian, ,work as housekeeper, with rhinitis and asthma since age 12. she experienced several hospital 

admissions, frequent use of nebulizer, asthma worsening with numerous courses of iv and oral corticosteroids. skin prick tests 

were positive to dermatophagoides, grass, birch, plantago. Fev1= 25% ( of predicted) reversing to 42%, total serum igE = 91 iU/ml. 

she started Xolair in 2007 and after few months she improved her symptoms, reduced drugs and stopped with oral corticosteroids. 

in 2009 she had no hospitalizations, can work normally. igE = 281 iU/ml, FEV1= 57% reversed to 71%. Her health has improved 

and they are not so worried any more when she is out and about work and free time. 

Case 2 

severe persistent allergic asthma, 67 years old , severe asthma symptoms and exacerbations since 1980, ex smoker, ex 

bricklayer, obesity, hypertension, diabetes mellitus. He had rhinitis and asthma due to allergy to mite and was treated with 

subcutaneous specific immunotheraphy for 10 years with symptoms’ disappeared. since 2005 started with frequent asthma 

exacerbations ( 5 times per year ) required emergency treatment or hospitalization. Exacerbations and symptoms limited his 

activities of daily living, nocturnal symptoms, poor control despite maintenance oral steroids, inhaled steroids, salmeterol, 

cromoglycate, theophylline trials and need long term oxygen theraphy. 

in July 2007 skin prick test were positive for dermathophagoides, igE= 435 U/ml, FEV1 =70%. He started with Xolair treatment 

and after two months stopped oral corticosteroids and after fourth months stopped oxygen therapy. in January 2010 FEV 1 =75%, 

total serum igE : 494 iU/ml. improved symptoms, reduced wheezing shortness of breath, nocturnal symptoms uncommon. sleeps 

through the night. Fewer exacerbations. no hospitalizations since starting xolair 

Xolair doses were determined by serum total igE levels measured before treatment initiation and patient’s body weight. Dosing 

tables were used to calculate the appropriate dose. 

no side effects were reported. 

1205 

aToPiC aSTHma anD BronCHiECTaSiS 

Khoury, A. 1 and Ahmed, F. 2 

1 2 Chest Diseases, Aleppo Faculty of medicine, Aleppo, syria. Pulmonology Department, Faculty of medicine of Aleppo, Aleppo, syria. 

Background:investigations using high-resolution Ct scan show that bronchiectasis is found in many patients with Asthma. 

materials and methods: in our study we had investigated the presence of Bronchodilatation in 80 patients with stable atopic 

Asthma and 20 healthy control subjects. 

results: At least one dilated bronchus was present in 35 Patients(43,8%) and 1 control subject(5%). 

Conclusion: We suggest to do HrCt-scan in Difficult to treat atopic asthma. 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

1206 

EFFECT oF omaliZUmaB in JaPanESE PaTiEnTS WiTH SEVErE allErgiC aSTHma anD rHiniTiS 

nishihara, F. , takaku, Y. , nakagome, K. , masumoto, A. , Yamaguchi, t. and nagata, m. 

Allergy Center , Department of respiratory medicine, saitama medical University, moroyama-machi, Japan. 

Background : 

there is evidence that humanized monoclonal antibody against igE (Omalizumab) is effective in mainly north American and or 

European population of severe allergic asthma. in this study, we examined the effectiveness of omalizumab on clinical symptoms, 

pulmonary function, and airway inflammation in Japanese patients with severe allergic asthma. 

method : 

We conducted a prospective open-label study that enrolled patients with severe allergic asthma in adult who visited Allergy 

Center, saitama medical University in Japan. All patients were uncontrolled despite medication including high-dose inhalational 

corticosteroids, long-acting beta agonist, leukotriene receptor antagonist, theophylline, and oral predonisolone. Omalizumab was 

added on their treatments and we evaluated symptoms using Asthma Contol test(ACt), peak expiratory flow rate(PEFr), exhaled 

nitric oxide (enO), sputum eosinophils, and nasal symptoms before and 12-16 weeks after administering omalizumab. 

results : 

seven patients were enrolled, and administered with omalizumab for 12-16 weeks. the mean age was 52 years and four patients 

(57%) were female. All patients had allergic comorbidities (7 had rhinitis, 3 had dermatitis, 2 had conjunctivitis). the five patients 

(71%) were taking the oral corticosteroid as controller. Omalizumab significantly improved ACt scores especially dose of rescue 

use of short-acting beta2-agonist (p

ABstrACts 

1208 

THE rolE oF inTErlEUKin-13 in aSTHma 

Vafa, A. 

Azerbaijan medical University, Baku, Azerbaijan. 

Background: interleukin-13 (il-13), the most recently identified cytokine to join the th2 cytokine family, is distantly related to il-4. 

the aim of this study was to identify the role of il-13 in asthmatic children. 

method: With purpose to study the parameters of cytokine profile, the clinical and laboratorial indicators of 62 patients with halfserious 

and serious atopic bronchial asthma were examined. 

the study included 3 groups. group A consisted of 10 children with serious atopic bronchial asthma (age 1-16 years), group B of 

52 children with half-serious atopic bronchial asthma and group C (Control group) of 15 healthy children without asthma or other 

atopic disease. 

results: the results of serum igE, il-13, il-17, il-4 and il-5 are shown in the table: 

table 1: 

igE and Cytokines group A group B group C 

igE 524,4 335,4 213,8 

il-13 6,53 4,28 1,74 

il-17 10,65 7,04 3,14 

il-4 7,08 5,25 1,37 

il-5 40,5 29,7 10,4 

Conclusions: the asthmatic phenotype in humans is accompanied by elevated expression of il-13. the latter is a key factor in the 

asthmatic phenotype but its role remains elusive. the anti-inflammatory cytokine il-17, as well as th-2 cytokines il-4 and il-5 

may be useful markers of chronic inflammation in childhood asthma without helping to determine the state of the disease. Further 

studies are required to elucidate the exact role of the above cytokines in children with asthma 

1209 

imProVED HEalTH oUTComES For aDolESCEnTS WiTH aSTHma in JorDan: a ClUSTEr ranDomiZED ConTrollED 

Trial 

Al-sheyab, n. A. 1 , gallagher, r. 2 , Crisp, J. 2 and shah, s. 3 

1 2 maternal and Child Health, Jordan University of science and technology, irbid, Jordan. University of technology, sydney, sydney, 

Australia. 3University of sydney, Westmead, Australia. 

oBJECTiVE. the objective of this study was to determine the effect of a peer related outcomes in students with asthma-program on 

health led asthma education attending high schools in Jordan. 

mETHoDS. in this cluster-randomized controlled trial, 4 high schools in irbid, Jordan, were randomly assigned to receive the 

Adolescent Asthma Action (triple A) program or standard practice. trained bilingual health workers facilitated the triple A, which 

uses a three-step cascade process to train peers from years 10 and 11 over a three week period. this peer training aims at 

delivering asthma education for the school community, with the aid of well-established resources including peer training manuals, 

videos and props. students with asthma (n = 261) in years 8, 9 and 10 were surveyed at baseline in December 2006 and three 

months post-intervention. the main outcomes were asthma-related quality of life, knowledge of asthma management, and selfefficacy 

to resist smoking. 

rESUlTS. statistically and clinically significant improvements at three months in the intervention group in comparison to the 

control group for quality of life (mean difference = 1.35, 95% Ci 1.04 – 1.76), asthma-related knowledge (mean difference = 1.62, 

95% Ci 1.15 – 2.19), and self-efficacy to resist smoking (mean difference = 4.63, 95% Ci 2.93 – 6.35). 

ConClUSionS. this randomized controlled trial demonstrated the success of a school-based, peer-led education program in 

improving important outcomes for adolescents with asthma. Furthermore, it is clear that triple A can be readily adapted to suit 

different cultures and contexts. Adolescents can teach their peers about managing asthma and avoiding smoking and also be 

capable allies and responsible partners in health promotion programs when they are given an opportunity. Finally, school-based 

peer-led health education programs have strong potential to be used for other adolescent health issues such as smoking and 

obesity prevention. 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

1210 

imPlEmEnTaTion oF gUiDElinES in rEal-WorlD UK aSTHma managEmEnT 

ryan, D. 1 , Haughney, J. 2 , thomas, m. 2 , Pinnock, H. 3 , Price, D. 2 , Ellis, s. 4 and Chisholm, A. 4 

1 2 Woodbrook medical Centre, loughborough, United Kingdom. Centre of Academic Primary Care, University of Aberdeen, Aberdeen, 

United Kingdom. 3Allergy and respiratory research group, Centre for Population Health sciences: gP section, the University of 

Edinburgh, Edinburgh, United Kingdom. 4research in real life, Cawston, United Kingdom. 

Background: Current asthma guidelines suggest use of add-on therapy (i.e. leukotriene receptor antagonists (ltrAs), theophylline 

(theo), oral beta -agonists) in patients whose asthma control remains inadequate despite daily high-dose inhaled corticosteroid 

2 

(hdiCs) and long-acting beta -agonist (lABA) therapy. 

2 

objectives: to evaluate the proportion of patients on daily hdiCs/lABA therapy experiencing exacerbations (1, 2 and ≥3 

exacerbations annually), but who have not received a trial of additional add-on therapy. 

methods: retrospective study using the general Practice research Database (gPrD) to identify inadequately controlled hdiCs/lABA 

patients (average iCs daily dose of ≥800mcg beclometasone dipropionate equivalent in the prior year and ≥1 lABA prescription 

in the prior 2 years) and the proportion prescribed appropriate “additional add-on therapy” (namely ≥1 month of: ltrA, or theo, or 

oral beta -agonists ever). We used a history of exacerbations (1, 2, ≥3 exacerbations) as evidence of poor control. High risk patients 

2 

were those with ≥2 exacerbations in the prior year, detected using a composite measure based on the American thoracic society / 

European respiratory society exacerbation definition, namely records of: acute oral steroid prescriptions, hospital admissions and 

Accident & Emergency attendance for asthma. 

results: Of 96,964 asthma patients in the dataset, 21,994 (23%) were prescribed hdiCs+lABA. Of these, 17,971 (82%) had 

never received additional add-on therapy. Although patients experiencing exacerbations were more likely to have been prescribed 

additional add-on therapy (p

ABstrACts 

of oral steroids in last year) and asthma control (defined according to ginA guideline definitions: Controlled, Partly controlled and 

Uncontrolled). 

results: 11 gP practices from surrey Primary Care trust were reviewed. 5134 asthma patients, from a patient population of 

112,272, were identified (prevalence: 4.57%). 4451 were adults (aged ≥18 years), of which 720 (16%) were receiving high 

dose iCs and lABA, and 8 (0.2%) were also receiving long term oral steroids. 41 were considered high risk. results using the 

ginA guideline definitions of control are shown in table 1. Extrapolating to PCt level (1,154,068 patients), 1696 (226 High risk), 

uncontrolled patients would require referral to a severe asthma service. 

table 1: results for ginA definition of Control 

Patients High risk 

ginA definition of Control 

n (%) n (%) 

Controlled 25 (4.3%) 1 (2.63%) 

Partly Controlled 391 (67.3%) 15 

(39.5%) 

Uncontrolled 165 (28.4%) 22 

(57.9%) 

total with available data 581 (100%) 38 (100%) 

Data Unavailable 147 3 

Conclusion: in the practices reviewed, there is an unmet need for referral to a severe asthma clinic. Use of ginA criteria for asthma 

control are dependent upon data collection. 

1http://www.goldcopd.com/download.asp?intid=554 2http://www.britthoracic.org.uk/Portals/0/Clinical%20information/Asthma/guidelines/sign101%20revised%20June%2009.pdf 1212 

CHooSing ComBinaTion THEraPY For aSTHma: rESUlTS oF a Pan-EUroPEan aTTiTUDinal SUrVEY 

Price, D. 

Centre of Academic Primary Care, University of Aberdeen, Aberdeen, United Kingdom. 

Background. A recent Delphi consensus found that the factors considered to be most important in the selection of inhaled 

corticosteroids (iCss) and long-acting β -agonists (lABAs) as part of a stepped approach to asthma management are: flexibility 

2 

of dosing (88% agreement), long-term safety of the iCs and lABA (81%), clinical efficacy (81%), lABA speed of onset (69%) and 

iCs potency (69%). An attitudinal research survey was subsequently developed to evaluate whether physician attitudes in reallife 

practice are similar to the expert consensus. the aim of this study was to evaluate physician attitudes towards combination 

therapies for asthma and to identify important factors influencing treatment in the real-world setting. 

methods. Based on the responses of the Delphi consensus group, an attitudinal questionnaire was developed, translated and 

pilot-tested in face-to-face interviews. Computer-assisted web interviews were then conducted by Kantar Health in 13 European 

countries. Physicians who treated fewer than 15 asthma patients a month or who had responded to previous surveys on asthma in 

the past 3 months were excluded. 

results. Of 1861 respondents, 1007 (54%) were eligible for inclusion; 85% of eligible respondents were respiratory specialists 

and 15% were primary physicians with a specialist interest in asthma, treating a mean of 59 asthma patients per month. Half 

(50%) of the patients with asthma were being treated with iCs/lABA fixed combinations, 15% with iCs alone, 10% with iCs/lABA 

free combinations, 10% with short-acting β -agonists alone, other therapy (10%) and 5% with lABAs alone. When choosing an 

2 

iCs/lABA combination, the factors considered the most important (ranked 1 or 2 out of 5) were symptom improvement (71%), 

iCs potency (55%), improvement in fixed expiratory volume in 1 second (FEV ; 50%), safety and tolerability (43%), speed of onset 

1 

(42%), flexibility of dosing (40%) and duration of action (37%). 

Conclusion: in this pan-European survey, physician attitudes to iCs/lABA therapy differed from those observed in the Delphi 

consensus in terms of the importance given to specific treatment attributes. However, both initiatives indicated that clinical efficacy, 

safety and tolerability, speed of onset of the lABA, potency of the iCs, and flexibility of dosing influence the choice of treatment in 

real-life practice. 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

1213 

ComBinaTion THEraPY For aSTHma: rESUlTS oF a DElPHi ProCESS 

Price, D. 1 and Bousquet, J. 2 

1 2 Centre of Academic Primary Care, University of Aberdeen, Aberdeen, United Kingdom. University of montpellier, montpellier, France. 

Background. international guidelines recommend combination therapy with an inhaled corticosteroid (iCs) and a long-acting 

β -agonist (lABA) as part of a stepped approach to asthma management, but do not provide guidance on how to choose specific 

2 

combinations. We report here the findings of an initiative undertaken under the auspices of the global Allergy and Asthma 

European network (gA2lEn) to reach agreement on which factors are the most important to consider when choosing an iCs/lABA 

combination for asthma. 

methods. A Delphi process was used to elicit three rounds of structured feedback from a panel of European respiratory experts 

from primary and secondary care who had a specialist research interest in the management of asthma. in round 1, panel members 

recommended factors to consider using free text. responses were then coded and grouped for voting in round 2 using a 5-point 

anchored likert scale (from 0 [not important] to 4 [very important]). the factors rated most important were included in statements 

circulated to the panel, who then voted their level of agreement in round 3. Consensus was defined a priori as ≥ 66% agreement. 

results. thirty-two experts from 9 European countries (Austria, Finland, France, germany, italy, spain, sweden, switzerland and 

the UK) were invited to participate; response rates were 59.4% in round 1, 84.2% in round 2 and 84.2% in round 3. Fifteen factors 

were identified through the free-text responses in round 1. nine of these were rated as important or very important by ≥ 75% of 

the panel in round 2. in the final round, the panel reached consensus that the most important factors were: availability of a range of 

doses; clinical efficacy of the combination and long-term safety and tolerability of the components; speed of onset of the lABA and 

potency of the iCs. 

Conclusion. in the absence of clear recommendations from international guidelines regarding the criteria that should inform the 

selection of an iCs/lABA combination therapy for asthma, the results of this Delphi process may help to guide the evaluation and 

assessment of these treatments. 

1214 

CorrElaTion BETWEEn aSTHma-rElaTED QUaliTY oF liFE anD aSTHma ConTrolS in aDUlT aSTHmaTiCS 

Anıl, B. , Yıldız, P. , Aynacı, E. , Yıldırım, E. , Şahin, F. and seçik, F. 

Pulmonology, Yedikule Chest Disease and surgery training and research Hospital, İstanbul, İstanbul, turkey. 

Asthma has a multiface nature that results in a functional and emotional impairments. 

Aim: the purpose of the present study was to evaluate relationship between the Asthma Control test (ACt), Asthma Control 

Questionnaire (ACQ) and Asthma-related Quality of life Questionnaire (AQlQ) in adult asthmatics. 

PAtiEnts AnD mEtHODs: 91 patients (72 female, 19 male; mean age 35.91 yrs) included in this prospective study. Patients were 

followed-up for 3 months. they were completed the ACt and ACQ in order to assess disease control and AQlQ at 2 physician visits. 

Pulmonary function was measured in each visit and asthma specialist rated asthma control and decided for treatment according to 

the global initiative for Asthma (ginA) quideline. 

rEsUlts: Uncontrolled patient ratio was 79% (72/91) before treatment. significant decreases to the 26 % (24/91) has been 

shown with the 3 months asthma medication according to ginA guideline (p

ABstrACts 

1215 

aSTHma ComPliCaTion in PrEgnanCY 

Al shammari, n. H., O. randa, K. muna 

Al Qassimi Hospital, sharjah, United Arab Emirates. 

A case presentation: 

status asthmatic complicated by emphysema and pneumomediastinum during pregnancy A 25 y old 30 week pregnant, p3+2, 

known asthmatic on steroids, she stopped her medication during pregnancy thinking that its harmful to the baby,developed sever 

attack due to acute exacerbation after exposure to allergen , intubated .then, she developed emphysema &pneumomediastinum 

,she had emergency caserean section ,the baby Apgar scor was very poor and unfortunately died after few days due to fetal 

hypoxia. 

sever & poorly controlled asthma has been associated with numerous adverse perinatal outcome including preeclampsia , 

pregnancy induce hypertension ,uterine haemorrhage, pretermlabour, congenital abnormalities, fetal growth restriction & low birth 

weight. 

review of pathophysiology of asthma & the effect of the physiological changes of pregnancy on asthma. 

the clinical assessment of asthma include both subjective evaluation & pulmonary function test & how to do that properly? 

goals of management: 

is to reduce hospitalization, emergency room admission, prevent work loss& chronic disability. 

the key of treatment is by frequent assessment of the patients, the severity of the attack and the patient response to treatment. 

Both number & dosage of medications can be increased as asthma severity increased. 

Hypoxia, acidosis, hypercapniea & pneumothorax is a warning sign of sever exacerbations 

the medication: 

B2 agonist is the mainstay of treatment; budesonide is the preferred inhaled steroid. 

Early systemic steroid,,theophylline, antihistamin oxygen supply, intravenous fluid, avoids tranquilizer& sedative. 

Discussing the criteria for hospital admission & iCU admission &ventilation setting. 

the prognosis; great risk in the last portion of pregnancy. 

Patient education: 

it is important because of most complication were due to under medication, 

Prevention & avoidance of triggers, allergens & irritant 

Home use of metered dose inhalers& pulmonary function test, using written diary to record PEFr 

Use a written guideline for management of exacerbation. 

1216 

THE ValUE oF aSPirin DESEnSiTiSaTion in THE managEmEnT oF aSTHma anD rHinoSinUSiTiS: EViDEnCE–BaSED 

Arafa, E. 1 and Howarth, D. P. 2 

1 2 Allergy Department, n m C specialty Hospital, Dubai, United Arab Emirates. infection,inflammation and immunity research 

division,school of medicine, southampton general Hospital, southampton, United Kingdom. 

Background: Aspirin is one of the gold standard medications used in a wide range of therapeutic and preventive indications. 

Aspirin hypersensitivity is a non-direct immunological mediated allergic reaction. it is responsible for aspirin exacerbated 

airway disease (AErD) and can cause asthma, rhinosinusituis, nasal polyps, urticaria and angioedema. the prevalence of aspirin 

hypersensitivity is 2.5 % (1) Aspirin Desensitisation (AD) has to be used for treating such cases. aim : in this review, we evaluated 

and rated the available evidence-based data for the value of AD on asthma and rhinosinusitis. methods: An electronic search 

of databases; Pubmed, Cochran’s database and American college of physicians. results: 393 publications were relevant to AD. 

Duplicated, non-human and non-English language references were excluded. Papers of unclear objectives and outcomes were 

excluded. the remaining 44 papers have evidence on the value of AD for management of asthma and rhinosinusitis. the evaluation 

was based on diagnosis, efficacy, failure, safety and cost-effectiveness. level of evidence (l) was rated according to a new scheme 

of oxford Centre of Evidence-based medicine (CEBm) (2) . According to EACCi/gA2lEn 2007 guidelines for diagnosis of aspirin 

hypersensitivity, aspirin provocation challenge tests are recommended for diagnosis of aspirin induced asthma, and rhinosinusitis. 

AD is an effective treatment option and may alter the course of the ArED in patients with ArED who require aspirin for other 

therapeutic indications. Evidence is from five randomised controlled trials (lii), one small retrospective, one prospective study, three 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

systematic review of non-randomised trials and one cross over study (liii), 21 case reports, expert opinion and clinical experience 

(lV). AD is a safe treatment with low aspirin dosage (lV, liii) and high dose (lii). it is a cost effective option in cardiovascular 

diseases (liii). in spite of the confirmed efficacy of AD, there is some failures (lV).Conclusion: AD has a small evidence data base, 

however, based on current available evidence AD is effective, safe and an alternative option for AErD patients. AD might be a cost 

effective option for cardiovascular diseases. more randomised multicentre controlled trials are needed in AErD. 

1217 

ESoPHagEal CanDiDiaSiS SUCCESSFUllY TrEaTED WiTH rEPlaCEmEnT oF inHalED CorTiCoSTEroiD 

Castro-Coelho, A. P. , Aun, m. V. , montenegro, F. g. , Borges, D. B. , Agondi, r. C. , Kalil, J. and giavina-Bianchi, P. 

Clinical immunolgy and Allergy, sao Paulo University, sao Paulo, Brazil. 

Background: Over the last few decades, inhaled corticosteroids (iCs) became the cornerstone in the treatment of persistent 

asthma. Esophageal candidiasis is a rare complication resulting from iCs administration, but it is probably underdiagnosed. We have 

recently described a prevalence of 5.7% in severe asthma patients. it was also shown that the device and type of iCs used can 

influence the occurrence of this complication. 

methods: We describe two patients who recovered from esophageal candidiasis after replacing budesonide dry powder with 

ciclesonide pressurized metered-dose inhaler (HFA). 

results: We report two cases of female patients aged 65 and 46 years with difficult-to-control asthma who had to use budesonide 

aeroliser 2000mcg/day associated with formoterol 60mcg/day to maintain asthma partially controlled. the patients complained of 

abdominal pain and heartburn and therefore underwent EgD, which revealed esophageal candidiasis. the diagnosis was confirmed 

by esophagus biopsy. they were both treated with fluconazole, with no improvement of the symptoms and the endoscopic lesions. 

We repeated the antifungal treatment once more, but it was again ineffective. Budesonide was then replaced with ciclesonide 

1280mcg/day. the asthma continued stable and the infection was healed, without antifungal administration. 

Conclusion: Ciclesonide is delivered as an inactive prodrug, which is cleaved to the active molecule by intracellular esterases 

located in the lungs. this and other pharmacodynamic and pharmacokinetic properties may limit the amount of active molecule 

outside the lung and may reduce the incidence of side effects. this could explain why our patients recovered from esophageal 

candidiases. We showed that replacement of budesonide aeroliser with ciclesonide aerosol without antifungal treatment can be 

enough to eliminate Candida infection. 

1218 

DEmograPHiC anD CliniCal CHaraCTEriSTiCS aSSoCiaTED WiTH THE aTTriTion in a CoHorT oF aDUlT aSTHma 

Kim, s. 1 , Kim, t. 2 , Chang, Y. 3 , Kim, s. 3 , Park, H. 4 , Park, s. W. 5 , Cho, Y. s. 2 , Park, J. 6 , nahm, D. 7 , Cho, Y. J. 8 , Cho, s. 4 , Choi, B. 9 , 

moon, H. 2 and Yoon, H. J. 1 

1 2 Department of internal medicine, Hanyang University College of medicine, seoul, south Korea. Department of Allergy and Clinical 

immunology, Asan medical Center, University of Ulsan College of medicine, seoul, south Korea. 3Department of internal medicine, 

seoul national University Bundang Hospital, seongnam, south Korea. 4Department of internal medicine, seoul national University 

College of medicine, seoul, south Korea. 5Division of respiratory and Allergy medicine, soonchunhyang University Hospital, College 

of medicine, Bucheon, south Korea. 6Division of Allergy & immunology Department of internal medicine, Yonsei University College of 

medicine, seoul, south Korea. 7Allergy & rheumatology, Ajou University school of medicine, seoul, south Korea. 8Allergy and Clinical 

immunology, internal medicine, Ewha Womans University mockdong Hospital, seoul, south Korea. 9Department of internal medicine, 

Chung-Ang University College of medicine, seoul, south Korea. 

Background in observational studies, unexpected attrition of patients can significantly reduce statistical power and comprise study 

objectives. in this study, we aimed to assess the factors predicting attrition in a cohort of adult asthma. 

methods in an adult asthma cohort (COrEA) from 11 university hospitals in Korea, we estimated the proportion of completers and 

dropouts among the patients who enrolled more than 18 months ago. Completers were defined as the patients who had one or 

more visit records in the next 12-18 months after registration. Demographic and clinical features were compared between dropouts 

and completers. 

results Of 1,499 patients, 670 (44.7%) patients dropped out in the study period. the dropouts showed lower mean age (43.1 ± 

15.8 vs. 51.1 ± 14.3, P

ABstrACts 

to allergens, lower severity of asthma, and less use of HCU for asthma. these findings suggest the factors predicting attrition in the 

management of asthma. 

Keywords: attrition, drop-outs, asthma, characteristics 

1219 

EFFECT oF anTirEFlUX TrEaTmEnT on CoUgH FrEQUEnCY in STaBlE aDUlT aSTHmaTiCS 

Hamed, m. n. 1 , sliem, H. 2 and Hassan, m. 3 

1 2 Chest Diseases, suez Canal University, Faculty of medicine, isamilia, Egypt. internal medicine, suez Canal University, Faculty of 

medicine, ismailia, Egypt. 3infectious and tropical diseases, suez Canal University, Faculty of medicine, ismailia, Egypt. 

Background: gastroesophageal reflux disease (gErD) is common in patients with asthma, but the target population for antireflux 

treatment, are not precisely defined. 

The purpose of the study: to assess the effect of the proton pump inhibitor omeprazole and prokinetic domperidone on cough 

frequency, in patients with stable asthma of different severity (persistent mild to severe asthma) with chronic cough. 

Methods: in this case – control study, 45 adult stable asthmatics, received omeprazole 40 mg twice daily, with domperidone 5 

mg half an hour before meal three times daily for 4 weeks, and followed for cough frequency (score of 5[no=0, rare =1, usual =2, 

common =3, frequent =4] ) according to patient daily records . According to gErD esophageal symptoms, subjects were divided 

into two matched groups: with gErD group (25 patients) and without gErD group (20 patients). 

Main Results: there were statistically highly significant (P < .0001) improvements in cough frequency, in the overall study 

population (35/45patients [77.8%], Z=-5.11), and in both groups (gErD19/25patients [76. %] Z= -3.72, without gErD 16/20 

patients [80%] Z= -3.64). 

But there was no statistically significant difference, as regard cough frequency improvement, between groups. 

According to cough frequency score ≥ 2, the probability (the positive predictive value) that a subject has gErD -assessed by cough 

improvement on antireflux treatment- was 85.7% in the 45 patients, 88.23% in gErD group, and 81.8% in without gErD group. 

Conclusions: omeprazole combined with domperidone improved cough frequency in 45 subjects with stable asthma either with or 

without gErD esophageal symptoms, which makes the possibility of hidden gErD (without esophageal symptoms) high in patients 

without gErD esophageal symptoms; the high positive predictive value of cough frequency 

(≥ 2) in predicting gErD in such patients, nominate it as a possible guide for prescribing antireflux treatment in such stable 

asthmatics, even in patients without esophageal gErD symptoms. 

1220 

PoTEnTial maSKing oF airWaY inFlammaTion BY ComBinaTion THEraPY in aSTHma 

lee, B. , lee, J. and Choi, D. 

Allergy and Clinical immunology, Department of medicine, samsung medical Center, sungkyunkwan University school of medicine, 

seoul, south Korea. 

Background: there is a concern about safety of long-acting beta2 agonists (lABA), because lABA might mask ongoing 

bronchial inflammation and thereby leave the asthmatic patient at risk for more severe exacerbations. We compared the effect of 

combination therapy including low dose of inhaled corticosteroids (iCs) and lABA with the effect of medium dose of iCs alone on 

airway inflammation in asthma. methods: twenty-four patients whose asthma is not controlled by low dose iCs (400 ug a day of 

budesonide) were enrolled in this prospective crossover study. Participating patients were randomized into two treatment phases: 

one receiving higher dose (800 ug a day) budesonide (iCs phase), and the other receiving a combination therapy of budesonide/ 

formoterol (360 ug/9 mg a day) delivered by a single inhaler (lABA phase). Each treatment phase was lasted for 6 weeks then 

crossed over. Asthma symptoms, lung function, and airway inflammation were compared between the two phases. results: Among 

23 patients who completed the study, adequate sputum for the analysis was available in 17 patients. Asthma symptoms and lung 

function remained similar in the two phases. By contrary, the mean sputum eosinophil percentile was significantly higher in lABA 

phase than iCs phase (5.07 ± 3.82 % vs. 1.02 ± 1.70 %, p < 0.01). sputum eosinophilia (≥3 %) remained in six subjects during 

the lABA phase, but in two subjects during the iCs period. Conclusion: Combination therapy of low dose iCs and lABA may mask 

airway eosinophilic inflammation in asthmatic patients compared to medium dose iCs alone. 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

1221 

THE USEFUlnESS oF Pram SCorE in aSSESSing THE SEVEriTY anD oUTComE oF an aCUTE EXaCErBaTion oF WHEEZE 

in CHilDrEn 

nagaraju, m. K. , r, D. , n, s. and r, g. 

Pediatric allergy and immunology, Kanchi Kamakoti CHilDs trust Hospital, Chennai, india. 

Background: 

Clinical scores are valuable tools to assess asthma severity in children. Among the available scores the Pediatric respiratory 

Assessment measure (PrAm) score is very useful one . 

aims of study: 

to study the usefulness of PrAm score in assessing the severity and outcome of an acute exacerbation of wheeze in children aged 

1-17yrs.to identify the PrAm score predicting the need for hospitalization and iCU care. Period of study: 

August 2008 to Dec 2009 

Study design: 

this is a prospective cohort study 

Sample size: 

127 children was calculated based on the pilot study from the initial 20 children. Assuming an alpha error of 5% and 80% power. 

methodology : 

Children diagnosed to have asthma based on ginA guidelines 2008 came with acute exacerbation of wheeze were enrolled in the 

study ,had PrAm scores done at admission and following each treatment administered in the Er. All children were triaged and 

treated as mild, moderate, severe exacerbation and appropriate treatment was given in the emergency room and the outcome 

was recorded. statistical Analysis done using sPss – 15 version. relationship between admission scores and the outcome 

were evaluated using paired t tests and one way AnOVA f test. receiver operator curve analysis(rOC)was used to identify score 

predicting admission and need for iCU care. 

results : 

Of the 127 children 52% were aged 1 - 3 years, 27.6% between the ages of 3 – 6 years and 20.4% between the ages of 6 - 17 

years . the mean PrAm scores at admission and discharge in all the 3 age groups was 7.3 and 4.1 respectively ,this difference is 

statistically significant. rOC score of 5.5 and above had 89% sensitivity and 64% specificity for admission. 

Conclusion: 

PrAm scores is a useful score to assess asthma severity in children and a score of 6 predicted the need for hospitalization and 

score of 9 predicted the need for iCU care . 

PoSTEr SESSion 1-3: asthma epidemiology and mechanisms 

1300 

rElaTion oF PErimEnSTrUal aSTHma WiTH DiSEaSE SEVEriTY anD oTHEr allErgiC Co-morBiDiTiES-THE FirST 

rEPorT oF PErimEnSTrUal aSTHma PrEValEnCE in SaUDi araBia 

sabry, E. Y. 

Chest OPD- internal medicine, saudi german Hospital, riyadh, saudi Arabia. 

Background: Perimenstrual asthma (PmA) has been documented in 30% to 40% of asthmatic women; however, there have been 

few epidemiological investigations of PmA in practice. 

objectives: in this study, we analyzed PmA prevalence and relation to disease severity based on direct questions carried out in taif- 

KsA and compared the results with those of studies reported previously. 

results: the prevalence of PmA and its’ relation to asthma severity and to other allergic co-morbidities were studied. Prevalence 

was 8.2% and asthma severity was found to be significantly related to PmA (p

ABstrACts 

1301 

non-EoSinoPHiliC aSTHma: imPorTanCE anD PoSSiBlE mECHaniSmS 

raj, s. and shah, r. 

Bioinformatics, sathyabama University, Chennai 73, india. 

Aim: to study the aetiology of asthma including the underlying inflammatory profiles. introduction: Asthma is a common chronic 

inflammatory disease of the airways characterized by variable and recurring symptoms, airflow obstruction, and bronchospasm. 

symptoms include wheezing, cough, chest tightness, and shortness of breath. there is increasing evidence that inflammatory 

mechanisms other than eosinophilic inflammation may be involved in producing the final common pathway of enhanced bronchial 

reactivity and reversible airflow obstruction that characterises asthma. A review of the literature has shown that, at most, only 50% 

of asthma cases are attributable to eosinophilic airway inflammation. it is hypothesised that a major proportion of asthma is based 

on neutrophilic airway inflammation, possibly triggered by environmental exposure to bacterial endotoxin, particulate air pollution, 

and ozone, as well as viral infections. if there are indeed two (or more) subtypes of asthma, and if non-eosinophilic (neutrophil 

mediated) asthma is relatively common, this would have major consequences for the treatment and prevention of asthma since 

most treatment and prevention strategies are now almost entirely focused on allergic/eosinophilic asthma and allergen avoidance 

measures, respectively. it is therefore important to study the aetiology of asthma further, including the underlying inflammatory 

profiles. 

Conclusion: Asthma is thus an inflammatory disease caused by the inflammation of bronchioles. Also asthma cases are attributable 

to eosinophilic airway inflammation. 

Keywords: Asthma, eosinophilic inflammation, bronchioles. 

1302 

aSTHma inCiDEnCE aFTEr agE 6 YEarS BY gEnDEr anD aToPiC STaTUS in THE CHilDHooD allErgY STUDY 

Ahmed, s. 1 , Wegienka, g. 1 , Havstad, s. 1 , Johnson, C. 1 , Ownby, D. 2 , nageotte, C. 1 and Zoratti, E. 1 

1 2 Allergy and immunology, Henry Ford Health system, Detroit, mi. Allergy and immunology, medical College of georgia, Augusta, gA. 

Background: Asthma is more prevalent in males before adolescence, yet more common among adult women. later-onset asthma 

is often perceived to be less associated with atopy. We explored gender-specific asthma incidence in a birth cohort, stratifying by 

atopic status. 

method: We used data from the Detroit Childhood Allergy study to analyze the role of atopy during the period of apparent transition 

from male to female asthma predominance (i.e. between age 6 and 20). self or parental report of physician-diagnosed asthma was 

used to define incident asthma. Atopy was defined as a specific igE ≥ 0.35 for at least 1 of 7 common allergens. A log-rank test 

was performed to determine the association of time to asthma among atopic and non-atopic males and females. A Cox regression 

analysis was done with the male, non-atopic group as the reference group. 

results: Of the 565 subjects included, 53% were female and 47% male. Females overall developed asthma after age 6 at a rate 

1.73 times higher than males, hazard ratio (Hr)=1.73 (1.04, 2.85), p=0.033. the proportion of atopy among asthmatic females 

was 69% versus 70% among asthmatic males. Atopic females were more than twice as likely to develop asthma compared to nonatopic 

females, Hr=2.27 (1.21, 4.27); p=0.011. 

Conclusion: Between the ages of 6 and 20 years, females developed asthma at a higher rate than males and associated atopy 

was common among new onset asthma in females. in young adults atopic asthma was equally prevalent in males and females and 

more than twice as common as non-atopic asthma. 

1303 

PrEVElanCE, TrEaTmEnT PaTTErnS anD riSK FaCTorS oF aSTHma anD rHiniTS among aDUlTS in THE UaE 

mahboub, B. 1 , Pawankar, r. 2 , rafique, m. 3 , sulaiman, n. 4 , Al Hammadi, s. 5 and ibrahim, A. 6 

1 2 Department of Pulmonary medicine, rashid Hospital, Dubai, United Arab Emirates. Allergy and rhinology, niPPOn mEDiCAl 

sCHOOl, tokyo, Japan. 3Pulmonologist ,Dept of Pulmonary medicine, rashid Hospital, Dubai, United Arab Emirates. 4Dept of family 

& community medicine& Behavioural sciences, sharjah University, sharjah, United Arab Emirates. 5UAE University, United Arab 

Emirates. 6Otorhinolaryngology, Al barha Hospital, Dubai, United Arab Emirates. 

objective to assess the prevalence of symptoms of Chronic respiratory diseases like asthma, and allergic rhinitis especially in 

adults in the UAE. due to lack of epidemiological data methods 1,225 direct interviews were conducted (in English and Arabic) 

on randomly selected people of all age groups, throughout the 7 emirates (males :66.5%, females: 33.5%). modified European 

Community respiratory Health survey (ECrHs)ii Questionnaire, both the short screening & main ones were used with changes to 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

reflect environmental & cultural nuances of the UAE. results From the screening questionnaire the prevalence of wheezing in the 

past 1yr was 10.1%. Of those interviewed, 8.1% had asthma attacks in the last 1yr, 7.9%are were currently on asthma drugs, 6.9% 

had nasal allergies. the key findings in known 188 asthmatics were 58.5% claimed to have asthma. more asthma attacks were 

seen in Jan/Feb (26.1%) and (19.1%) in nov/Dec, Fewer attacks were reported in march/April. About, 36.2% had nasal allergies 

and 23.4% took treatment for it.. About 10.1% had eczema or skin rash and 47.9% took asthma medications. Of the asthmatics, 

19.1% woke up less than twice a month because of their asthma in past 3months and 10.5 workdays were lost due to asthma 

in past 1yr. Average age when they first experienced an asthma attack was 13.5 years. the average no of attacks experienced in 

the past 1yr was 9.5.short acting beta agonist inhalers (41.5%) was the most used followed by long acting beta agonist inhalers 

(6.9%.onl) Approximately, 3.7% were on inhaled steroids alone and 8.5% were using oral beta agonists followed by methyxanthines 

(2.1%) and antileukotrienes (1.6%). Only 9.6% had a spirometry or laboratory test done. Alternative remedies comprised of 9% on 

breathing exercises, 6.9% on diet control, 4.3% on swimming/other exercises & 3.7% homeopathy. About 18.1% of asthmatics 

were regularly exposed to tobacco smoke in the past 1yr Conclusion A high prevalence of asthma symptoms and nasal allergies in 

adults was found. Environmental factors had an important role. the level of annoyance by outdoor air pollution was 6.4. there was 

more use of short acting beta agonist as the main stay of asthma treatment with underutilisation of spirometry, peak flow meters, 

allergy tests, xrays in diagnosis and increasing dependence on alternative remedies (19.7%). reference Asthma insights and 

reality in the gulf and the near East. Khadadah m, mahboub B, Al-Busaidi nH, sliman n, soriano JB, BahousJ ,int J tuberc lung Dis. 

2009 Aug;13(8):1015-22 

1304 

PollEn rElaTED aSTHma: THE moST FrEQUEnT aSTHma PHEnoTYPE in KUWaiTi SCHoolCHilDrEn 

Al-Ahmad, m. s. 1 , Arifhodzic, n. 2 , Al-Ahmed, n. 1 , Al-Onizi, A. 1 , Panicker, r. 1 and Fakim, n. 1 

1 2 Allergy Department, Kuwait Allergy Center, Kuwait, Kuwait. Allergy, Al-rashed allergy Centre, Kuwait, Kuwait. 

introduction: indoor allergens (house dust mites) are the leading cause of allergic asthma in children worldwide. However, a desert 

climate does not provide optimal conditions for mite thriving. 

The aim of study: to evaluate the relationship between sensitization to indoor vs. outdoor inhalant allergens in asthma 

development in Kuwaiti schoolchildren. 

methods: in a cohort of 246 randomly selected asthmatic children, both gender, aged 8-15 years old. Patients were recruited from 

september 2006 - October 2007 from Kuwait allergy center. All patients completed disease history questionnaire, underwent PFt 

and skin prick test (sPt) with the battery of inhalant allergens (stellergenes, France), including those typical for desert climate. One 

hundred eleven healthy, age and gender matched children served as control 

results: majority of asthmatic children, 86.9 %,( mean age of 11.3 ± 2.9 years) had positive sPt to one or more inhalant allergens 

in comparison to 26.1% of healthy control. sensitization to outdoor allergens prevailed in all asthmatic children, (44, 3% vs. 15.6% 

to house dust mites; p 0.05) in asthma severity between children sensitized to either indoor or outdoor allergens was found. 

(indoor allergens: mild intermittent: 44.1%, mild - moderate persistent: 55.9%; Outdoor allergens: 42.6% and 57.3 % respectively). 

Co - morbid allergic rhinitis was found in more than 50% of our patients. 

Conclusion: Unlike other countries, where asthma is most frequently related to exposure to indoor allergens, it is not the case in 

our region. Pollen allergens a major cause of asthma of Kuwaiti asthmatic school children. Extremely long pollination season in 

Kuwait region characterized by two typical, almost constant peaks, (spring and autumn) has important impact on pollen related 

asthma development. Harsh desert climate with drastic environmental changes, have a major impact on asthma phenotype. 

Key words: indoor allergens, outdoor allergens, asthma development. 

1305 

CYSTEinYl-lEUKoTriEnS oVErProDUCTion anD THE aSTHma SEVEriTY in PaTiEnTS WiTH aSPirin-inDUCED aSTHma 

mitsui, C. , taniguchi, m. , Higashi, n. , Ono, E. , Kajiwara, K. , Hukutomi, Y. , tsuburai, t. , sekiya, K. , tanimoto, H. , ishii, t. , mori, A. , 

mita, H. , Hasegawa, m. and Akiyama, K. 

Clinical research Center for Allergy and rheumatology, national Hospital Organization sagamihara national Hospital, 

sagamihara,Kanagawa, Japan. 

Background: the unique pathophysiology of aspirin-induced asthma (AiA) is cysteinyl-leukotriens (Cyslt) overproduction. Almost 

patients with AiA show severe asthma, but some of them have mild asthma. the mechanisms underlying asthma severity in AiA 

patients remain unclarified. We hypothesized that Cyslt overproduction is related to the asthma severity of AiA and tried to clarify 

the correlation between Cyslt production and asthma severity in AiA patients. 

methods: Forty AiA patients, whose aspirin sensitivity was determined by the aspirin challenge test, and twenty healthy subjects 


FinAl PrOgrAm

ABstrACts 

participated in this study. We measured urinary leukotrien E4 (U-ltE4) level under stable asthma condition, using Cayman’s EiA 

kit after purification by HPlC, as we reported previously. AiA patients were classified into three groups, 1) patients with mild to 

moderate asthma which was controlled at less than ginA step 3 treatment,2) patients with stable but severe asthma which was 

well controlled at ginA step 4 treatment, and 3) patients with difficult-to-treat asthma which was not controlled at ginA step 4 

treatment. 

results: the AiA groups 1-3 showed median U-ltE4 concentrations 108, 259, and 582 pg/mg creatinine, respectively. there was no 

significant difference between patients with mild to moderate asthma and healthy controls. On the other hand, the concentrations of 

U-ltE4 in patients with severe but stable AiA patients and difficult-to-treat AiA patients significantly increased according to asthma 

severity as compared with AiA patients with mild to moderate asthma. 

Conclusion: Cyslt overproduction may be related to the asthma severity in AiA patients. 

1306 

CorrElaTion BETWEEn SPiromETrY rESUlTS anD BoDY maSS inDEX in PaTiEnTS WiTH aSTHma 

Agondi, r. C. , Bisaccioni, C. , ribeiro, m. , Kalil, J. and giavina-Bianchi, P. 


Background: studies have suggested that asthma in obese individuals differs from the classic asthma phenotype, presenting as 

a disease that is more difficult to control and that does not respond as well to inhaled corticosteroids. the objective of the present 

study was to determine whether obesity, age or a combination of the two are associated with abnormal spirometry results in 

patients with asthma. 

method: this was an observational, cross-sectional, retrospective study involving patients over 18 years of age who had been 

diagnosed with asthma. We evaluated the results of spirometric tests conducted between February of 2009 and August of 2009. 

the patients were classified in accordance with two criteria: body mass index (Bmi) and age. 

results: We evaluated 453 patients and 453 corresponding sets of spirometry results. in the present study, the pulmonary function 

parameters were negatively correlated with Bmi. in the obese group, the mean FEV value was 17.4% lower than that observed in 

1 

the normal-weight group. Within that group, the number of abnormal spirometry results was significantly higher among the patients 

≥ 60 years of age than among those 18-59 years of age. the proportion of females was also higher in the obese group. 

Conclusion: Our results indicate that FEV and FVC decrease significantly in proportion to increases in Bmi and age. Because 

1 

obesity is yet another factor that makes asthma control difficult, the weight of asthma patients should be closely monitored. 

1307 

PrEValEnCE oF BronCHial aSTHma anD iTS aSSoCiaTion WiTH SmoKing HaBiTS among aDUlT PoPUlaTion in rUral 

arEa 

Parasuramalu, B. g. 1 , Huliraj, n. 2 , B m, r. 1 , s P, P. K. 1 , Dr, g. 1 and n r, r. m. 1 

1 2 Department of Community medicine, Kempegowda institute of medical sciences, Bangalore, india. Department of thoracic 

medicine, Kempegowda institute of medical sciences, Bangalore, india. 

Background: Only few studies have been conducted in rural areas in india to study the relationship of active tobacco smoking in 

bronchial asthma. Hence the present study was conducted with the objectives: 1. to find out the prevalence of bronchial asthma. 2. 

to find out the association between tobacco smoking and bronchial asthma. materials and methods: A cross sectional study was 

conducted in the rural field practice area of Kempegowda institute of medical sciences, Bangalore. totally 3194 adult individuals 

(18-70years) were selected from 30 villages (clusters) using cluster-sampling technique. On visiting each house, previously 

validated and standardized translated Kannada version questionnaire was administered. individuals with symptoms suggestive of 

asthma were subjected for clinical examination for the diagnosis of asthma. the data was compiled and analyzed. results: Among 

the 3194 respondents, 1518 (47.5%) were males & 1676 (52.5%) were females. the prevalence of bronchial asthma was 2.88%. 

the prevalence of asthma was higher among those reporting a history of current smoking. Among current smokers the number of 

cigarettes/ bidis/ hookah smoked daily did not differ (p>0.05) between individuals without asthma and with asthma, whereas the 

mean number of years of smoking did differ (p

ABstrACts 

ABstrACts 

1308 

analYSiS oF PUBmED- inDEXED aSTHma rESEarCH From THE araB WorlD in THE laST TEn YEarS 

Afifi, m. 1 and Hameed, W. A. 2 

1 2 Primary Health Care, ministry of Health (HQ), Dubai, United Arab Emirates. Primary Health Care, ministry of Health, Ajman, United 

Arab Emirates. 

oBJECTiVES: We aimed to identify the gaps in asthma research in the Arab world and suggest recommendations for untapped 

areas. Hence we analyzed ten- years Pubmed- indexed publications related to bronchial asthma, produced by authors affiliated to 

the Arab countries. 

mETHoDS: a medline search was performed on 1st July 2010 to have the total number of citation from the 22 Arab countries 

during the ten years prior to the search. Another search in the mesH database of the medline for citations under “asthma” 

Or “ bronchial asthma” category was followed. the two search strategies were then combined by “AnD” and inspected for 

validation. the search was then saved in medline format text file, which was converted into Excel file and captured as a new 

database query via sPss software. the methodology of capturing research of the Arab countries and converting a medline search to 

an sPss data file was discussed in more details in previously published research by the first author. 1,2 

rESUlTS: the number of asthma related publications affiliated to the Arab countries over the last 10 years totaled 275 articles. 

the number of research was doubled in 2010 relative to 2000. However, only three countries- namely KsA, Egypt and Kuwaitpublished 

63% of the total publications. the three major areas studied were the epidemiological issues of asthma, its management, 

and its immunological issue (32%, 18.55%, and 18.05% respectively of total publications). Health system research constituted 

only 11.27% of publications. Areas as asthma in primary care and gender differences in morbidity and response to treatment are 

relatively neglected. the majority of publications were journal articles (82.9%), whereas clinical trial articles and evaluation studies 

constituted only 1.1 % and 3.6 % respectively. the saudi med J followed by J Asthma and Ann thorac med came on top of the list 

of 131 journals that published asthma research (12 %, 5.09% and 4.37% respectively). 

ConClUSion: Despite the increase in asthma publications, the outcome of some Arab countries was not satisfactory. Areas as 

health system research, asthma in primary care, and gender differences should have more consideration from Arab researchers. 

references: 

1: Osman Ot, Afifi m. troubled minds in the gulf: mental health research in the 

United Arab Emirates (1989-2008). Asia Pac J Public Health. 2010 Jul;22(3 

suppl):48s-53s. 

2: Afifi mm. mental health publications from the Arab world cited in Pubmed, 

1987-2002. East mediterr Health J. 2005 may;11(3):319-28. 

1309 

THE imPaCT oF ConComiTanT allErgiC rHiniTiS anD aSTHma on QUaliTY oF liFE in iTalian PaTiEnTS oF gEnEral 

PraCTiTionErS: arga STUDY 

maio, s. 1 , Baldacci, s. 1 , Borbotti, m. 1 , Angino, A. 1 , martini, F. 1 , Piegaia, B. 1 , silvi, P. 1 , sarno, g. 1 , Cerrai, s. 1 , simoni, m. 1 , Di Pede, 

F. 1 and Viegi, g. 2 

1 2 institute of Clinical Physiology, national research Council, Pisa, italy. Cnr institute of Biomedicine and molecular immunology, 

Palermo, italy. 

Background: epidemiological studies show that allergic rhinitis is very common in patients with asthma, and that the co-presence 

of these two diseases can worsen the patients’ quality of life. 

aims: to evaluate the impact of the concomitance of asthma and rhinitis (Ar) on quality of life in italian patients of general 

practitioners (gP). 

methods: prospective observational study in different italian areas. 107 gP enrolled patients with asthma/rhinitis diagnosis and 

with anti-asthmatic or anti-rhinitic therapy or symptoms in the last 12 months. Questionnaires were used to collect data on 

respiratory allergic diseases. the rhinasthma questionnaire was used to assess the patients’ quality of life. 

Univariate analyses were used to assess the relationship between presence of only asthma, Ar or Ar and any one among other 

allergic diseases (sinusitis, conjunctivitis, atopic dermatitis and nasal polyposis) (ArOAD) and quality of life, disease severity levels 

and asthma symptoms. linear regression analysis was used to assess the relationship between quality of life and presence of Ar or 

ArOAD adjusting for age, gender, smoking habits and asthma severity levels. 

results: 46.8% of 936 subjects had only asthma, 36.2% Ar and 17.0% ArOAD. Univariate analyses showed a significantly higher 

frequency of moderate-severe asthma (36.0% vs 33.8%) and asthma symptoms (95.4% vs 89.9% for wheeze, 93.5% vs 88.7% 


FinAl PrOgrAm

ABstrACts 

for attacks of shortness of breath, 92.8% vs 85.4% for asthma symptoms in the last 12 month) in subjects with ArOAD with 

respect to those with only asthma; the presence of Ar or ArOAD, with respect to only asthma, was associated with a significantly 

worse quality of life (mean values of global score derived from rhinasthma questionnaire: 19.8±14.6, 20.2±14.3, 29.9±16.3, 

respectively). the multivariate linear regression analysis confirmed that the presence of Ar or ArOAD is an independent risk factor 

for a worse quality of life (beta coefficient: 0.253, p-value

ABstrACts 

ABstrACts 

uptake, dominated the disease with medium-severe course. Conclusion: Epidemiological studies can provide reliable information 

on the prevalence, structure and severity of AD. monitoring of the true prevalence of AD shows hypodiagnostics of all forms of AD in 

the Cis-C, related to the underestimation of mild forms of the disease. Accounting for the structure and expression of sensitization 

to allergens, taking into account climate and geographic features, allows to plan the work of allergic services and to organize 

preventive and curative interventions. 

1312 

gUiDElinES aPPliCaTion For aSTHma anD rHiniTiS managEmEnT: arga (rESPiraTorY allErgiC DiSEaSES: 

moniToring STUDY oF gina anD aria gUiDElinES) ProJECT 

Baldacci, s. 1 , maio, s. 1 , Cerrai, s. 1 , sarno, g. 1 , Borbotti, m. 1 , Angino, A. 1 , martini, F. 1 , Carrozzi, l. 1 , Di Pede, F. 1 and Viegi, g. 2 

1 2 institute of Clinical Physiology, national research Council, Pisa, italy. Cnr institute of Biomedicine and molecular immunology, 

Palermo, italy. 

Background: in italy, a big effort has been made to disseminate ginA and AriA guidelines (gl) for asthma and rhinitis management 

within the setting of specialist and general practice. Despite a general good knowledge of gl, their implementation within the 

clinical practice seems still poor. 

Objective: to assess the level of application of gl for asthma and rhinitis management within general practitioners (gP). 

methods: cross-sectional italian survey (2007-10); 107 gP (89% of the expected sample) enrolled patients with asthma/rhinitis 

diagnosis and pharmacologic treatment and/or rhinitis/asthma symptoms in the last 12 months. 

For each patient (n=1820), a questionnaire was filled in by gPs on: diagnosis of allergopathies, asthma and rhinitis severity 

according to gl, instrumental tests used for diagnosis/monitoring, educational activity, drug prescriptions for asthma/rhinitis. 

results: patients are: 47% rhinitic (7% moderate-severe persistent), 25% asthmatics (2% severe persistent) 28% with both asthma 

and rhinitis (Ar) (8% with moderate-severe persistent rhinitis, 6% with severe persistent asthma). 

the prevalence of prescribed instrumental tests for rhinitis diagnosis/monitoring ranges between 32% (objective nasal test) and 

62% (prick test) while for asthma is between 6% (exhaled nitric oxide) and 87% (spirometry). Ar increases the prevalence of 

prescribed instrumental tests for rhinitis and decreases that for asthma instrumental investigations. 

58% of rhinitic patients, 68% of asthmatics and 68% of Ar subjects receive a specific education (regular controls, written 

therapeutic plans, auto-monitoring education, support groups). 35% of rhinitic, 29% of asthmatics and 26% of Ar patients receive 

general information. 6% of rhinitic, 3% of asthmatics and 5% of Ar patients do not receive any educational intervention. 

Considering the prescribed pharmaco-therapeutic categories, 43% of rhinitic, 77% of asthmatic and 54% of Ar subjects do not 

receive an appropriate treatment in relation to the severity level. 

Conclusions: contrary to gl recommendations, use of instrumental tests for asthma and rhinitis diagnosis/monitoring appears still 

incomplete as well as use of specific educational support for the patients. Anyway, it is the pharmacologic treatment for rhinitis and 

even more for asthma that presents the lower level of implementation within the general practice. 

Work supported by the italian medicines Agency (AiFA), contract no. FArm5JYs5A. 

1313 

inHalED SoDiUm CromoglYCaTE rEDUCES THE EXPrESSion oF aSTHma-rElEVanT CYToKinES BY PEriPHEral BlooD T 

CEll in CHilD aSTHma. THiS SUPPorTS iTS PoSSiBlE USE aS PrEVEnTaTiVE THEraPY in CHilD aSTHma 

gemou-Engesaeth, V. 1 , Hamid, Q. 2 , roedland, E. A. 3 , Heier, H. E. 4 , gaarder, P. i. 4 , grogaard, J. B. 1 , Halvorsen, s. 1 and Corrigan, C. J. 5 

11Dept. of Pediatrics, Oslo Univers. Hospital5King’s College london school of medicine and 6Athens University, A Pediatric Clinic, 

Oslo, norway. 2mcgill University, meakins-Christie laboratories, montreal, QC, Canada. 33institute of medical microbiology, 

rikshospitalet, molecular Biology, Oslo, norway. 4Dept. of immunology and transfussion medicine, Oslo University Hospital, Oslo, 

norway. 5Centre for Allergic mechanisms of Asthma, King’s College london school of medicine and mrC and Asthma, Centre for 

Allergic mechanisms of Asthma, london, United Kingdom. 

We addressed the in vivo anti-inflammatory effects of inhaled sodium cromoglycate (sCg) in childhood asthma. Ethical approval 

was granted by the regional ethics committee. All patients and their parents received written information concerning the purpose of 

the study, and parents provided written consent. 

seven asthmatic children aged 7-13 years needing regular preventative therapy for the first time for asthma control were followed 

for 4-6 (mean 4.8) months after commencing sCg at a dosage of 10 mg 4 times daily by metered-dose inhaler. Just prior to 

commencing therapy and at the end of follow-up, CD4 and CD8 t cells were isolated from peripheral blood samples and the 

percentages of these cells expressing mrnA encoding interleukin-4 (il-4) and il-5 determined using in situ hybridisation with 

specific, anti-sense riboprobes. Clinical improvement was accompanied by significant reductions in the percentages of peripheral 


FinAl PrOgrAm

ABstrACts 

blood CD4+ t cells expressing mrnA encoding il-5 and il-4, and CD8+ t cells expressing il-5 mrnA. the data are compatible 

with the hypothesis that clinical improvement associated with inhaled sCg therapy in childhood asthma results at least in part from 

inhibition of elevated th2 cytokine synthesis by t cells. 

1314 

EConomiC CoST oF aDUlT aSTHmaTiCS in THE TErTiarY HoSPiTal oF KorEa 

lee, s. 1 , Kim, t. 1 , Kang, H. 1 , Kim, s. 2 , Kim, s. 1 , lee, Y. 3 , Kim, t. 4 , Kim, s. 5 , Park, H. 1 , Park, s. W. 6 , Chang, Y. 2 , Cho, Y. s. 4 , Park, J. 7 , 

Cho, Y. J. 8 , Yoon, H. J. 5 , Cho, s. 1 , Choi, B. 9 , moon, H. 4 and min, K. 1 

1 2 Department of internal medicine, seoul national University College of medicine, seoul, south Korea. Department of internal 

medicine, seoul national University Bundang Hospital, seongnam, south Korea. 3Department of internal medicine, Yonsei University 

College of medicine, seoul, south Korea. 4Department of Allergy and Clinical immunology, Asan medical Center, University of Ulsan 

College of medicine, seoul, south Korea. 5Department of internal medicine, Hanyang University College of medicine, seoul, south 

Korea. 6Division of respiratory and Allergy medicine, soonchunhyang University Hospital, College of medicine, Bucheon, south 

Korea. 7Division of Allergy & immunology Department of internal medicine, Yonsei University College of medicine, seoul, south 

Korea. 8Allergy and Clinical immunology, internal medicine, Ewha Womans University mockdong Hospital, seoul, south Korea. 

9Department of internal medicine, Chung-Ang University College of medicine, seoul, south Korea. 

Background: the prevalence of asthma is increasing and asthma cause a considerable socioeconomic burden worldwide. 

However, few studies were conducted to evaluate the risk factors associated with economic cost of asthma in Korea. this study 

was aimed to evaluate asthma cost according to severity and patients’ factors in the Korean tertiary hospital. 

methods: Direct and indirect cost was assessed in the 314 physician-diagnosed adult asthmatics randomly recruited in eight 

tertiary hospitals in Korea. Official direct medical cost was derived from the analysis of one-year(2009) expenditure related with 

asthma-related hospital care utilization and medication. non-official direct cost(oriental medicine, instrument, and alternative 

medicine) and indirect cost(productivity loss cost caused by hospital care utilization, work day loss and activity limitation) were 

analyzed using a questionnaire designed for the study. 

results: mean direct and indirect cost of the total subjects was estimated at 1,690 dollars and 1,503 dollars respectively. 

multivariate analysis revealed that the most important risk factor affecting economic cost was asthma severity. Direct and indirect 

cost were significantly higher in the severe persist asthma than in the mild to moderate persistent asthma (2,825 vs. 1,246 

dollars, p=0.001, 3,734 vs. 594 dollars, p

ABstrACts 

ABstrACts 

1316 

CHLAMYDOPHILA PNEUMONIAE-inFECTED HUman PEriPHEral mononUClEar CEllS rESiST CorTiCoSTEroiD- inDUCED 

SUPPrESSion oF mETalloProTEinaSE-9 anD TiSSUE inHiBiTor mETalloProTEinaSE-1 SECrETion 

Park, C. s. 1 , Kim, t. 2 , moon, K. 3 , Bae, Y. 2 , lee, Y. s. 2 , Jang, m. K. 3 , moon, H. 2 and Cho, Y. s. 2 

1 2 Department of internal medicine, inje university Heaundae Paik Hospital, Busan, south Korea. Department of Allergy and Clinical 

immunology, Asan medical Center, University of Ulsan College of medicine, seoul, south Korea. 3Asan institute for life science, 

seoul, south Korea. 

Background: it has been suggested that Chlamydophila pneumoniae infection contributes to the development of severe asthma. 

the major characteristics of severe asthma include a reduced response to corticosteroid treatment and progressive airway 

remodeling in which an imbalance of metalloproteinase-9 (mmP-9) and tissue inhibitor metalloproteinase-1 (timP-1) is believed 

to have an important role. We hypothesized that C. pneumoniae infection affects the secretion of mmP-9 and timP-1 and induces 

altered responsiveness to corticosteroids in inflammatory cells. 

methods: Human peripheral blood mononuclear cells (PBmCs) were cultured in vitro in the presence or absence of C. pneumonia 

infection. Dexamethasone was used in each experiment to assess the responsiveness to the corticosteroid. the values of secreted 

mmP-9 and timP-1 were measured by ElisA. to evaluate the underlying mechanism, the expression of human glucocorticoid 

receptor (gr)-β, known as an endogenous antidote for gr, was observed in PBmCs with or without C. pneumoniae infection using 

immunohistochemistry. 

results: the secretion of mmP-9 and timP-1 was remarkably suppressed by corticosteroid treatment in PBmCs without 

C. pneumoniae infection. in C. pneumoniea-infected PBmCs, the suppressed secretion of mmP-9 by the corticosteroid was 

significantly inhibited, while the level of timP-1 secretion did not change compared with those levels in untreated PBmCs. 

therefore, the molar ratio of secreted mmP-9/timP-1 was decreased by C. pneumonia infection and was more exaggerated under 

corticosteroid treatment. the expression of gr-β was significantly increased in C. pneumoniae-infected PBmCs. 

Conclusion: C. pneumoniae infection in inflammatory cells may induce altered secretion of tissue enzymes associated with airway 

remodeling through a decreased responsiveness to corticosteroids and may be linked to the pathogenesis of severe asthma. 

Key words: Asthma, Chlamydophila pneumoniae, Peripheral blood mononuclear cells, mmP-9, timP-1, glucocorticoid receptor (gr) 

- β 

1317 

EFFECTS oF TraFFiC air PollUTion on rESPiraTorY HEalTH anD allErgiES in EgYPTian SCHoolCHilDrEn 

shamssain, m. 1 , Al Qerem, W. 2 , mcgarry, K. 1 and neshat, l. 1 

1 2 Pharmacy, Health and Wellbeing, University of sunderland, U.K, sunderland, United Kingdom. Pharmacy, Health and Wellbeing, 

University of sunderland, sunderland, United Kingdom. 

Background 

studies suggest that traffic exposures can influence asthma and allergic symptoms among children; air pollution is associated with 

exacerbation of asthma symptoms in children with asthma. there has been few studies about the susceptibility of subgroups and 

on new onset asthma.the objective of the study is to investigate the effects of traffic air pollution on allergies with emphasis on 

gender differences in the respiratory effects of air pollution. 

methods 

We studied 1400 schoolchildren from two locations in Egypt: Cairo with high level of air pollution and shbeen Al Koom in the 

Delata with low level of air pollution. lung function testing was done by the Vitalograph spirometer. the Arabic version of isAAC 

questionnaire was used (the international study of Asthma and Allergies in Childhood). Air pollution measurements were collected 

from the government sites in both locations. 

results 

mean values of sO2, nO2, Ozone, CO, and Pm10 in Cairo were significantly lower than shbeen Al Koom (39.0 vs 17.0;62.8 vs 

55.8 ug/m3; 93.0 vs 28.8 ug/m3; 3.0 vs 1.3 mg/m3; and 263.5 vs 94.0 ug/m3, respectively. Forced vital capacity (FVC), forced 

expiratory volume in the first second (FEV1) and peak expiratory flow rate (PEFr) were lower in children in Cairo compared to shben 

Al Koom (1.99 vs 2.03 l; 1.70 vs 1.79 l; and 204.4 vs 207.4 l/min, respectively. the prevalence rates of current wheeze, asthma, 

rhinitis, hay fever and eczema in Cairo were higher than shbeen Al Koom (6.9 vs 5.6% ; 5.5 vs 3.3%; 24.2 vs 17.9; 9.5 vs 6.4%; 

and 9.1 vs 5.6% , respectively. the prevalence rates of ever rhinitis were 6.0% and 3.0% higher in boys and girls in Cairo compared 

to shbeen Al Koom, respectively. Children who developed rash less than 2 years of age were 2.0% and 5.0% higher in boys and 

girls in Cairo compared to shbeen Al Koom, respectively. 


FinAl PrOgrAm

ABstrACts 

Conclusion 

Air pollution is associated with increased prevalence of asthma and allergies in these children. the present study illustrates that 

there is an adverse respiratory effects of exposure to traffic air pollution on children showing gender differences. the present study 

will help to implement strategic health intervention programmes to improve the respiratory health of these children. 

1318 

aSSoCiaTion BETWEEn aToPiC ECZEma anD CHilDHooD aSTHma in SCHoolCHilDrEn From THE norTH EaST oF 

EnglanD 

shamssain, m. 

Pharmacy, Health and Wellbeing, University of sunderland, U.K, sunderland, United Kingdom. 

Background respiratory epidemiologists have special international interest in the sequential progression of multiple allergic 

conditions (allergic march). individuals who develop an allergic disease are at increased risk of developing further allergic 

conditions.many large studies have estimated the prevalence of eczema, asthma and allergic rhinitis which are common and 

useful in reducing the co-morbidity associated with these disorders. However, the progression and the association between these 

conditions remain understudied. the aims of the study is to investigate the association between atopic eczema and childhood 

asthma. methods We studied 600 schoolchildren, aged 6-7 and 13-14 years, from the north east of England. We used the 

international study of Asthma and Allergies in Childhood (isAAC) questionnaire and illustrative manual of childhood eczema 

developed by isAAC group. results Atopic eczema was the most common allergic disease of girls, with a lifetime prevalence 

of 27%. there was a negative association between maternal smoking and eczema (p

ABstrACts 

ABstrACts 

1320 

il-17 DriVES THE rECrUiTmEnT oF B CEllS To THE BronCHial TiSSUE oF SEVErE aSTHmaTiC PaTiEnTS 

Halwani, r. 1 , Al-muhsen, s. 2 and Hamid, Q. 3 

1Asthma research Chair and Prince naif Center for immunological research, College of medicine, King saud University., riyadh, 

saudi Arabia. 2Department of Pediatrics, College of medicine, King saud University. 3mcgill University, meakins-Christie laboratories, 

montreal, Canada. 

Background: B-cells play an important role in asthma development mostly via the production of igE. A number of reports have 

shown local production of igE in B cells present in lung tissues of mild allergic asthmatics. However, it is not clear whether there 

is an increase in the number of B cells in severe asthma and how do B cell migrates to the mucosal site. Our objective in this 

study was to determine the number and pattern of infiltrated B cells into lung tissues in severe compared to mild asthma and to 

investigate the mechanism behind this infiltration. 

methods: Bronchial biopsies from severe versus mild asthmatics were stained for B cells marker (CD20) using 

immunohistochemistry. moreover, migration towards il-17 gradient was determined using Boyden chamber. 

results: the number of CD20 positive cells in severe asthmatic biopsies was significantly higher than those in mild asthmatics. 

interestingly, we have also observed lymph follicles in 40% of severe compared to 15% of mild asthmatic airways. most of 

the cells in the lymph follicles were CD20 positive cells. these lymph follicles were very close to the epithelial surface. We 

have recently reported high expression of il-17 in severe asthma. We tested the hypothesis that il-17 is involved in migration 

of B cells to the mucosal surface of the airways. Although B cells were shown to migrate towards both il-17A and il-17F, 

much lower concentrations of il-17F, compared to il-17A, were sufficient to induce migration. moreover, B cells within airway 

mucosa of severe asthmatics were shown to express higher level of il-17r compared to those of mild asthmatic patients using 

immunohistochemistry as well as qPCr. 

Conclusion:il-17 might drive the migration of B cells in the lung tissues and could play a critical role in the formation of lymphoid 

follicles in severe asthmatic airways. 

1321 

EoSinoPHilS EnHanCE airWaY SmooTH mUSClE CEll ProliFEraTion 

Halwani, r. 1 , Al-muhsen, s. 2 and Hamid, Q. 3 

1Asthma research Chair and Prince naif Center for immunological research, College of medicine, King saud University., 

riyadh, saudi Arabia. 2Department of Pediatrics, College of medicine, King saud University. 3mcgill University, 2meakins-Christie laboratories, montreal, Canada. 

Background: Asthma is a chronic inflammatory disorder of the lung airways that is associated with airway remodeling and 

hyperresponsiveness. its is well documented that the smooth muscle mass in asthmatic airways is increased due to hypertrophy 

and hyperplasia of the Asm cells. moreover, eosinophils have been proposed in different studies to play a major role in airway 

remodeling. Here, we hypothesized that eosinophils modulate the airways through enhancing Asm cell proliferation. the aim of this 

study is to examine the effect of eosinophils on Asm cell proliferation using eosinophils isolated from asthmatic and normal control 

subjects. 

methods: Eosinophils were isolated from peripheral blood of 6 mild asthmatics and 6 normal control subjects. Asm cells were 

incubated with eosinophils or eosinophil membranes and Asm proliferation was estimated using thymidine incorporation. the 

mrnA expression of extracellular matrix (ECm) in Asm cells was measured using quantitative real-time PCr. the effect of 

eosinophil-derived proliferative cytokines on Asm cells was determined using neutralizing antibodies. 

results: Co-culture with eosinophils significantly increased Asm cell proliferation. However, there was no significant difference in 

Asm proliferation following incubation with eosinophils from asthmatic versus normal control subjects. Co-culture with eosinophil 

membranes had no effect on Asm proliferation. moreover, there was no significant change in the mrnA expression of ECm proteins 

in Asm cells following co-culture with eosinophils when compared with medium alone. 

Conclusion: Eosinophils induces Asm cell proliferation independent of direct cell to cell contact or ECm synthesis. Eosinophils may 

induce Asm proliferation via the secretion of proliferative cytokines. 


FinAl PrOgrAm

ABstrACts 

1322 

EPiTHElial CEll DEriVED CHEmoKinES EnHanCE THE ProliFEraTion anD SUrViVal oF airWaY SmooTH mUSClE CEllS 

Via THE aCTiVaTion oF ErK1/2 Signaling PaTHWaY 

Al-muhsen, s. 1 , Halwani, r. 2 , Al-Jahdali, H. 3 and Hamid, Q. 4 

1 2 Department of Pediatrics, College of medicine, King saud University. Asthma research Chair and Prince naif Center for 

immunological research, College of medicine, King saud University., riyadh, saudi Arabia. 3King saud University for health sciences, 

riyadh, saudi Arabia. 4mcgill University, meakins-Christie laboratories, montreal, Canada. 

Background: the increase in AsmC mass is a major structural change described in asthma. this increase has been attributed to 

AsmC hyperplasia and hypertrophy. recent studies have suggested a role of chemokines in smC migration toward the epithelium. 

the objective of the current study is to test the hypothesis that chemokines (Eotaxin, rAntEs, il-8 and miP-1α) can increase the 

rate of proliferation and enhance the survival of Asm cells. 

methods: AsmCs were exposed to different concentrations of eotaxin, rAntEs, il-8 or miP-1α. to test for proliferation, stimulated 

AsmC were pulsed with 3H-thymidine or AsmCs were stained with BrdU and then analyzed with flow cytometry. Apoptosis was 

measured using Annexin-V and flow cytometry. 

results: in a concentration-dependent manner, chemokines such as Eotaxin, rAntEs, il-8 and miP-1α increased AsmCs 

3H-thymidine incorporation and DnA synthesis. this increase, however, was inhibited using ErK1/2 phosphorylation inhibitors. il-8, 

Eotaxin, and miP-1α decreased the number of apoptotic AsmCs compared to the matched controls. 

Conclusion: We conclude that chemokines might contribute to airway remodeling seen in asthma by increasing Asm mass through 

enhancing AsmCs proliferation and survival. 

1323 

TH-17 CYToKinE moDUlaTion oF STEroiD inSEnSiTiViTY in PEriPHEral BlooD mononUClEar CEllS 

Vazquez tello, A. 1 , Halwani, r. 2 , Al-muhsen, s. 3 and Hamid, Q. 4 

1Asthma research Chair and Prince naif center for immunology research, College of medicine, King saud University, riyadh, saudi 

Arabia. 2Asthma research Chair and Prince naif Center for immunological research, College of medicine, King saud University., 

riyadh, saudi Arabia. 3Department of Pediatrics, College of medicine, King saud University. 4mcgill University, meakins-Christie 

laboratories, montreal, QC, Canada. 

Background. inhaled corticosteroids represent the most common treatment for asthma. Although most asthmatic patients respond 

well, a significant proportion of severe asthmatic patients either require high doses or even fail to respond to oral or inhaled 

corticosteroids. We have previously reported that glucocorticoid receptor-beta is associated with corticosteroid resistance. We 

have also shown that in severe asthmatic patients, th-17 cytokines increase steroid insensitivity in airway epithelial cells via a 

mechanism involving gr-beta upregulation. 

objective. to investigate whether il-17A and F cytokines enhance steroid unresponsiveness in PBmCs isolated from normal and 

severe asthmatic subjects via the upregulation of gr-beta isoform. 

methods. PBmCs were isolated from the blood of healthy and severe asthmatics subjects and cultured for 48 hours in the presence 

or absence of il-17A, il-17F, il-17A+il-17F, or il-2+il-4 cytokines. inhibition of proliferation by Dexamethasone (iC50) was then 

assessed on PHA-treated cells using 3H-thymidine pulse labeling. Expression of gr-alpha, gr-beta, gilZ and il-6 was determined 

using real time rt-PCr and/or Western blotting. 

results. treatment of PBmCs with il-17A+F cytokines significantly decreased the level of expression of gr-alpha m-rnA while 

the of expression of gr-beta m-rnA was significantly upregulated. moreover, while treating PBmCs with il-2+il-4 had a more 

remarkable decrease in gr-alpha expression, this cytokine combination had no effect on gr-beta receptors. Both cytokine 

combinations significantly decreased the inhibitory effect of Dexamethasone on PBmC proliferation (il-17A+F, iC50=190 nm Dex; 

il-2+4, iC50=1060 nm Dex); no significant differences were observed between the PBmCs from normal subjects and severe 

asthmatics. treatment with il-2+4, but not il-17A+F, inhibited the dexamethasone-induced expression of the glucocorticoidinducible 

leucine zipper gene (gilZ) in PBmCs from both normal (60%) and asthmatics (45-50%). 

Conclusion. il-17A, il-17F, il-2 and il-4, which are known to be upregulated in the blood and lung tissue of asthmatics, contribute 

to steroid insensitivity of severe asthmatic patients by modulating the expression of gr-alpha and gr-beta receptors on peripheral 

blood PBmCs. Furthermore, the increased gr-beta/gr-alpha ratios by both il-17A+F and il-2+4 cytokines correlates with the 

decreased inhibitory effect of Dexamethasone on PHA-induced PBmC proliferation. 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

1324 

molD allErgEnS SEnSiTiZaTion in aSTHma PaTiEnTS iS aSSoCiaTED WiTH SEVEriTY oF DiSEaSE 

Bisaccioni, C. , Aun, m. V. , Castro-Coelho, A. P. , montenegro, F. g. , Agondi, r. C. , Kalil, J. and giavina-Bianchi, P. 


Background: mold allergens can induce hypersensitivity reactions, including igE-mediated disease. Exposure to mold, which are 

considered indoor and outdoor allergens, is associated with asthma. Furthermore, proteases produced by fungi can act as adjuvants 

to promote tH2 responses, disrupt the airway epithelium and increase hyperresponsiveness. Environmental control to mold is 

limited and, despite the pharmacological treatment available for asthma control, patients with sensitivity to mold appear to have 

increased risk of potentially fatal asthma exacerbations. Our objective was to evaluate mold allergens sensitization in patients with 

allergic asthma and correlate this with severity of disease. 

method: this was a retrospective observational study. We evaluated patients with persistent allergic asthma who were at followup 

in our clinic. Data were extracted from our electronic medical record (PrOntmED), between 2005 and 2010. sensitization was 

determined by skin prick test or in vitro specific igE detection (immunoCAP). We studied the following allergens: dust mites, cat, 

dog, cockroaches, pollen and molds (Aspegillus fumigatus, Cladosporium herbarum, Alternaria alternata, Penicillium notatum and 

Candida albicans). the severity of asthma was classified using ginA criteria. We excluded patients who met diagnostic criteria for 

ABPA. 

results: We studied 352 patients: 58 classified as mild asthma, 79 as moderate asthma and 215 as severe asthma. mold 

sensitization was found in 18.96%, 18.98% and 35.34%, respectively. We did not find patients with mild or moderate asthma 

sensitized only to molds, but there were six patients monossensitized to mold (five to Aspergillus fumigatus). 

Conclusion: Our study corroborates data recently published in the literature showing association between mold sensitization and 

asthma severity. However, much remains to be studied about the sources and degrees of fungal exposure, the role of exposure in 

the clinical outcome of asthmatic patients and the most effective measures to prevent this contact. 

1325 

imPaCT oF allErgiC rHiniTiS on PaTiEnTS WiTH BronCHial aSTHma in aBU DHaBi 

Bodi, s. g. 1 , Ohri, m. 2 , mn, J. 2 , tn, B. 2 and Khare, m. 2 

1 2 Pulmonology, AHAliA HOsPitAl, ABU DHABi, United Arab Emirates. Ent, AHAliA HOsPitAl, ABU DHABi, United Arab Emirates. 

introduction: 

respiratory allergies are rapidly increasing , with more than 300 million people affected by Asthma worldwide.many studies 

have shown a strong link between Asthma and Allergic rhinitis . there are few studies in the gulf region on asthma and allergic 

rhinitis and hence we made an attempt to study the impact of allergic rhinitis on asthmatics in a respiratory department of a 

multispeciality hospital in Abu Dhabi . 

objective: 

to study the impact of Allergic rhinitis in patients of Bronchial asthma. 

methods: 

study design : retrospective study . 

setting : respiratory department of a 50 bedded multi speciality hospital in Abu Dhabi , (Ahalia Hospital). 

subjects : 94 out of 161 patients of Asthma fulfilled the study criteria for Allergic rhinitis (AriA guiidelines). 

results: 

94 out of 161 patients of Asthma( 58.4%)had associated Allergic rhinitis.the mean age of these patients was 34.56 among 

females and 35.28 among males.71.4% of female asthmatics as compared to 53.8 % males have associated Allergic rhinitis(. 

p

ABstrACts 

1326 

analYSiS oF gEnE EXPrESSion ProFilES oF PEriPHEral BlooD B lYmPHoCYTES in VarioUS CliniCal PHEnoTYPES oF 

aSTHma 

Ahmad, n. E. Q. 1 , Harun, r. 2 and Othman, r. 2 

1 2 institute of medical science technology (mEstECH), Universiti Kuala lumpur (UniKl), Kajang, malaysia. UKm medical molecular 

Biology institute (UmBi), Universiti Kebangsaan malaysia (UKm), Cheras, malaysia. 

Background B lymphocytes play important roles in the inflammatory response in asthma including igE production, antigen 

presentation and secretion of certain cytokines. However the exact molecular pathways are still largely unknown. the objectives of 

this study were to identify gene expression profiles of peripheral blood B lymphocytes and subsequently determine gene signatures 

that were associated with different clinical phenotypes of asthma. in addition we aimed to identify biological processes and 

pathways involved in the molecular mechanisms of asthma. 

method Peripheral blood B cells were isolated from subjects with different manifestations of asthma: mild (n=8), moderate 

controlled (n=8), moderate uncontrolled (n=10), severe steroid dependant (n=7), severe steroid resistant (n=7) and normal 

control (n=8). total rnA were extracted from the B lymphocytes, reverse transcribed and amplified linearly before being labelled 

and hybridized on illumina Humanref-8 Expression BeadChips that had 24,355 elements. microarray data was analysed using 

genespring gX 10.0.02 software and real-time PCr was performed to validate the microarray gene expression. 

results Data were analysed according to several conditions including asthma control status, steroid response, asthma severity and 

disease status. Differential gene analyses, corrected for multiple testing, revealed 7 (p

ABstrACts 

ABstrACts 

recognized cause of COPD, most of sri- lankan women are non smokers. therefore females having COPD become an important 

group to study aetiology of COPD other than smoking.the aim of this study is to identify causes of COPD in females of Kandy, sri 

lanka. 

method: the study consisted of 54 patients who were diagnosed of having COPD on the basis FEV1/ FEC ratio of below 70% 

and had bronchodilator reversibility of less than 12%. the cohort of patients was selected from patients investigated for cough 

and dyspnoea presented to the Chest Clinic, Kandy for a period of 9 months from 01 Jul 2008 to 31 mar 2009 the study group 

of patients was interviewed using a prepared questionnaire .their demographic data including social status was recorded . the 

aetiologies of smoking recurrent chest infections in early childhood and indoor air pollution were recorded 

results: the age range of the patients was 48y to 82y with a mean age of 69.8y. All the patients were life time nonsmokers. 26% 

reported to have inhaling secondhand smoke from one or more household smokers. Only 7% had recurrent chest infections 

in childhood. 82% of patients had exposure to indoor air pollution in the form of using firewood for cooking in under ventilated 

kitchens. 88% of the patients were form suburban and rural areas and 68% belonged to poorer social classes. in spite of the high 

literacy ratio of srilana 5.2% of the study population was illiterate. 

Conclusion: indoor air pollution is a significant cause of COPD in women of Kandy, sri lanka COPD .affects women of poorer social 

strata. since around 80% of sri lankan households use firewood for cooking, it is very important to improve standards of cooking 

and ventilation in kitchens,and to empower women with knowledge in causative factors and prevention of COPD. 

PoSTEr SESSion 1-4: rhinitis, rhinosinusitis and conjunctivitis 

1400 

SElECT ParamETErS rElaTing To THE maXimal inSPiraTorY anD EXPiaTorY FloW raTE among THE rUral 

PoPUlaTionS inHaBiTing THE arEaS aroUnD ZamoSC, PolanD – a FolloW-UP To THE mUlTi-CEnTEr STUDY ECaP 

(EPiDEmiologY oF allErgiC DiSEaSES in PolanD) 

Krzych-Falta, Jr., E. 1 , samoliñski, B. 2 , lusawa, A. 1 , rojek, B. 1 and Kapalczynski, W. 3 

1Department of Prevention of Environmental Hazards and Allergology, Warsaw medical University, Department of Clinical Allergol, 

medical Uniwersity of Warsaw, Warsaw, Poland. 2Department of Prevention of Environmental Hazards and Allergology, Warsaw 

medical University, Department of Clinical Allergol, m, medical Uniwesity of Warsaw, Warsaw, Poland. 3University of louisville school 

of medicine, louisville, United states, University of louisville school of medicine,, United states. 

the objective of this study is to determine the average value of various upper and lower respiratory tract parameters (PniF, FEV1, 

FEV1/VC) as they relate to a patient’s clinical diagnosis. All diagnoses were made during medical examination by a physician based 

on specific criteria. the study encompassed 288 ECAP participants (96 participants 9-10 years of age, 84 participants 16-17 years 

of age, and 108 participants 23-47 years of age) residing in the areas surrounding Zamoœæ. research methods employed included 

spirometry and the measurement of peak nasal inspiratory flow in l/min using a specially constructed mask. For analysis of the 

results, the participants were divided into three groups: 

- Patients diagnosed with seasonal rhinitis- mean values: PniF: 90.23 l/min, FEV1: 99.27%, FEV1/VC: 101.95% 

- Patients diagnosed with perennial rhinitis- mean values: PniF: 99.93 l/min, FEV1: 98.77%, FEV1/VC: 98.83% 

- Patients with diagnosed asthma including: 

- light asthma- mean values: PniF: 86.15 l/min, FEV1: 90.31%, FEV1/VC: 96.15%. 

- moderate asthma- mean values: PniF: 92.5 l/min, FEV1: 89%, FEV1/VC: 93.25%, 

- Severe asthma- mean values: PniF: 87.23 l/min, FEV1: 87.73%, FEV1/VC: 95.45%. 

in conclusion, the lowest values for the selected upper and lower respiratory tract parameters were obtained from the group of 

patients diagnosed with bronchial asthma, especially severe asthma. 

1401 

THE aSSoCiaTion BETWEEn DEgrEE oF SEnSiTiZaTion To allErgEn anD SEVEriTY oF allErgiC rHiniTiS 

mohd Ashari, n. s. , Wm, W. m. , Y, n. K. , sah, s. and CH, C. m. 

immunology, Universiti sains malaysia, Kota Bharu, malaysia. 

Allergic rhinitis is the most common allergic disease affecting an estimated four million people in malaysia. Although allergic 

rhinitis is not usually severe diseases, it significantly alters the social life of patients and affects school learning performance as 

well as work productivity. this study was done to determine the levels of allergen specific immunoglobulin E assay in allergic 


FinAl PrOgrAm

ABstrACts 

rhinitis patients in Hospital Universiti sains malaysia (HUsm), malaysia before proceed with evaluation of possible association 

between this parameter with severity of allergic rhinitis. 

in this cross sectional study, total and specific igE to 28 types of allergens were measured in serum samples from 128 allergic 

rhinitis patients. the interviewer guided questionnaire was used to evaluate the severity of symptoms using AriA criteria. 

in this study, we found that among the aeroallergens, Dermatogoides farinae (97%) was the most common followed by 

Dermatogoides pteronyssinus (83%) and house dust mite (43%). Among the food allergen group, shrimp (28.9%) was the most 

common implicated food followed by soybean (26.6%), crab (23.4%), clam (22.7%), wheat (21.9%), peanut (20.3%), yolk egg 

(18.8%), cow’s milk (18.0%), citrus mix (18.0%), beef(14.1%), white egg (12.5%), tuna (11.7%) and chicken (11.7%). For fungal 

allergen, aspergillus spp (23.4%) was found to be the most common fungal followed by candida spp (20.3%), altenaria spp (16.4%), 

mucor spp (14.8%), penicillium spp (12.5%) and clasdosporium spp (10.9%). Cockroach (49.2%) was the most common animal 

allergen. Cat (44.5%), dog (43.0%), latex (42.2%), Bermuda (28.9%) and Johnson (21.9%) grass were also common. in this study, 

we also found a significant association between the specific igE levels and the severity of allergic rhinitis for Dermatogoides farinae 

(p=0.024), Dermatogoides pteronyssinus (p=.039), cockroach (p = 0.038), cat (p = 0.042) and latex (p = 0.044). 

in conclusion this study revealed a significant association between specific igE levels and the severity of allergic rhinitis symptoms 

for Dermatogoides farinae, Dermatogoides pteronyssinus, cockroach, cat and latex. 

1402 

Co-aDminiSTraTion oF CHEnoPoDiUm alBUm allErgEnS anD CPg oligoDEoXYnUClEoTiDES EFFECTS on PEriPHEral 

BlooD mononUClEar CEllS oF PaTiEnTS WiTH allErgiC rHiniTiS TrEaTED WiTH inTranaSal CorTiCoSTEroiDS anD 

anTiHiSTaminES 

Farrokhi, sr., s. 1 , mousavi, t. 1 , Arshi, s. 1 , salekmoghadam, A. 1 , Varasteh, A. 2 and rezaei, n. 3 

1 2 Department of immunology, iran University of medical sciences, tehran, iran. 6. immunobiochemistry lab, immunology research 

Center, Avicenna research institute, 6. immunobiochemistry lab, immunology research Center, Avicenna research institute, 

mashhad, iD, iran. 3growth and Development research Center, Children’s medical Center, tehran, iran. 

Objective. Allergic rhinitis (Ar) is one of the most common chronic diseases in the developed countries, associated with substantial 

economic burden and morbidity. this study was performed to investigate the effect of Cpg-ODn in alteration of t-helper (th)1/th2 

balance of patients with Ar treated with intranasal corticosteroids (inCs) and antihistamines. 

methods. Peripheral blood mononuclear cells (PBmCs) of 20 patients with Ar were isolated before and after 45 days treatment 

with inCs and antihistamines. Cytokine production (il-4, il-10, il-13, iFn-γ) and specific Ch.a igE in response to Cpg-ODn 

co-administration of natural chenopodium album (Cpg/Ch.a) or recombinant Ch.a (Cpg/rCh.a) allergen were investigated using 

ElisA method. intracellular il-10 was also assessed in CD4 + cells using flow cytometry. For statistical analysis sPss 16 software 

packagresults. significant increases in production of iFn-γ and il-10 and a significant decrease in production of il-4 were found 

in PBmCs stimulated with either Cpg/Ch.a or Cpg/rCh.a compared to stimulated cells with allergens alone, before and after therapy 

of patients. After therapy, only iFn-γ production with Cpg/Ch.a stimulant was significantly increased in comparison with before 

treatment (237 vs. 44 pg/ml, p=0.001). iFn-γ and il-10 production with Cpg/rCh.a stimulant was significantly increased after 

therapy compared to before (407.6 vs. 109 pg/ml, p=0.01 for iFn-γ; 171.7 vs. 52.6 pg/ml, p=0.008 for il-10), whilst production 

of il-4 was significantly decreased (2.1 vs. 5.8 pg/ml, p=0.02). intracellular il-10 expression was also significantly increased 

in response to either Cpg/Ch.a or Cpg/rCh.a. Altogether, the comparison of all results obtained from il-10 assay with either 

intracellular or secreted form showed that intracellular assay could be more sensitive than ElisA. specific igE was significantly 

decreased after therapy in response to either Cpg/Ch.a or Cpg/rCh.a stimulant. 

Conclusion. treatment of PBmCs from Ar patients with Cpg/Ch.a or Cpg/rCh.a inhibits th2 cytokine responses and induces th1biased 

immune responses. Also, treatment with intranasal corticosteroids and antihistamines could enhance this Cpg effect, in vitro. 

However, further clinical studies are recommended to confirm these findings. 

1403 

TrEaTmET oF CHroniC allErgiC rHiniTiS:inTranaSal VS. oral THEraPY? 

Eatemadi, A. 


Background:Allergic rhinitis is common among iranian people.the aim of this study was compare the efficacy of intranasal vs. oral 

therpy for chronic allergic rhinitis( CAr). method: A randomised controlled study was conducted in 51 patients with diagnosis of 

CAr who divided to received either intranasal budesonide 256 mg ( group 1) or combination therapy wih 10 mg cetirizine plus 10 

mg montelukast( group 2) daily for two months. results: At the end of treatment, group 1 had significantly better total nasal score 

and subjective symptoms than group 2, but did not have any diffrences in post nasal drip. Conclusion: intranasal budesonide is mor 

effective than cetirizine plus montelukst for treatment of chronic allergic rhinitis. 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

1404 

EFFiCaCY oF FEXoFEnaDinE in DiFFErEnT DoSagES For TrEaTmnET oF SEaSonal allErgiC rHiniTiS 

Eatemadi, A. 


Background: the aim of this study was to determine the efficacy of fexofenadine in different dosages for treatment of seasonal 

allergic rhinitis ( sAr).method: A placebo-controlled, double blind study was conducted in 114 patients with diagnosis of sAr. 

they were randomly assigned to received either 60 mg, 120 mg , 180 mg once daily fexofenadine or placebo for one month. 

Patients were evaluated by using total symptom score ( tss ) and total nasal score ( tns ) during and at the end of treatment. 

results: Fexofenadine 120-180 mg was significantly more effective than placebo for improvement of sAr signs and symptoms. 

no statistically significant difference was seen between two dosages ( 120 mg vs. 180 mg ). Conclusion: Once dail 120 mg 

fexofenadine is an effective and safe treatment for seasonal allergic rhinitis. 

1405 

THE moDiFiED SnoT-20 QUESTionnairE: rEPEaTaBiliTY anD aPPliCaBiliTY To rHiniTiS 

sami, A. s. 

Ent, royal national throat, nose and Ear Hospital, london, United Kingdom. 

Background 

rhinitis is a clinically prevalent disease, symptomatically characterised by nasal itch, sneezing and difficulty breathing through the 

nose. Patients with rhinitis often suffer from associated symptoms related to posterior nasal, sinus and ear disease. Other effects on 

the psychological well being are also accountable to rhinitis. 

A number of these features are encompassed in disease specific quality of life (Qol) questionnaires. However, the modified snOt- 

20 (msnOt-20) questionnaire aims to correspond to the requirements for a complete and comprehensive assessment of rhinitis 

and its impact. it uses a six-point scale to identify clinical severity (0=no problem, 5=very severe problem). method 

the msnOt-20 questionnaire was evaluated in a pilot study of disease and non-disease and then used to assess the prevalence of 

rhinitis and associated features in a community based survey. Following a successful pilot project, 2000 postal questionnaires were 

sent to randomly selected adults from the electoral register in Farnborough. Differences in housing, social class and environment 

were balanced with repeat questionnaires sent for non-respondents. results 

in the pilot study, there were significant differences (p < 0.001) in symptom reporting between rhinitics and non-rhinitics, with 

92.67% of the healthy controls responding on all 20 questions either 0=no problem (85.67%) or 1=very mild problems (7%) in 

comparison to 42.07 % in the rhinitis group (28.7 % of responses no problem, 13 % very mild problems). A score of 0 or 1 was thus 

taken as normal and 2-5 taken as abnormal. 

in the community survey in Farnborough, 68% of 1580 evaluable respondents (79.8 % response rate) had a total snOt-20 score of 

0-20 (max 100) with 32% scoring 21 + (max 88). there were significant correlations between the rhinitis domain and the 4 other 

domains (paranasal [sinus and ear], sleep, social and emotional). the repeatability of these responses was evaluated in a follow-up 

evaluation in a subpopulation. Conclusion 

msnOt-20 questionnaire is a disease-related Qol rhinitis questionnaire, which is valid for the evaluation of rhinitis and the impact 

of disease on quality of life. it identified a high prevalence of nasal and paranasal problems within the community with significant 

co-morbidity caused by rhinitis. 

1406 

a CommUniTY BaSED SUrVEY on THE PrEValEnCE oF rHiniTiS 

sami, A. s. 


Background 

rhinitis is an increasingly common condition although there is limited information as to its true prevalence within the community. 

this study aimed to obtain a current prevalence of rhinitis within the community and to explore its impact on social and emotional 

functioning. A survey of 2000 adults in the Farnborough area was devised and carried out using the modified snOt-20 (msnOt-20) 

questionnaire for this study. 

method 

A postal survey of rhinitis was conducted in the Farnborough area with 2000 msnOt-20 questionnaires being sent to randomly 


FinAl PrOgrAm

ABstrACts 

selected adults from the electoral register. there were 1595 returned (79.8%) of which 1580 were evaluable. 58% of respondents 

were female and 41.9% male. 

results 

the population age range was 16.9 to 92.4 years (mean 48.6 years). A score of 0-1 on a six-point rating scale was taken as normal 

for each question and a score of 2-5 taken as abnormal. 32.5% of the population had an abnormal score for “needing to blow their 

nose”, 31.4% for “sneezing”, 25.4% for “runny nose’ and 30.1 % for “blocked nose”. the combined nasal sub-score (sum of 4 

questions, max score 20) identified a score of 4 or less in 62.1 % (39.9 % abnormal rhinitis score). 

those with rhinitis were more likely to score abnormally on the other domains in comparison to those with normal scores; 

paranasal (55.5% vs. 28.8%), sleep (41.5% vs. 22.1%), social and emotional (38.9 vs. 19.6%). 

Conclusion 

this study identifies the common prevalence of rhinitis and the associated morbidity, with over 30% of the population experiencing 

nasal blockage, sneezing and need to blow their nose. 

A total msnOt-20 score does not provide information exclusively on Ent disease; due to the wide range of conditions affecting 

quality of life. subdivision into separate symptom clusters does, however, permit exploration of disease prevalence. Using symptom 

clusters, this study identified that there is also a high prevalence of Ent morbidity within the community. 

1407 

EFFiCaCY oF mUlTiFaCETED aVoiDanCE mEaSUrES in THE managEmEnT oF PaTiEnTS WiTH PErSiSTEnT allErgiC 

rHiniTiS anD HoUSE DUST miTE allErgY 

Chao, s. s. and Wang, D. Y. 

Department of Otolaryngology Head and neck surgery, national Univeristy of singapore, singapore, singapore. 

Background 

in patients with persistent allergic rhinitis (PAr) and allergy to house dust mites (HDm), the use of HDm avoidance measures is 

logical. there is however, uncertainty in the literature regarding its efficacy. single intervention methods were felt to be ineffective. it 

was proposed that multifaceted interventions may be necessary. We hence designed a study to evaluate the efficacy of multifaceted 

avoidance measures in patients with PAr and confirmed allergy to HDm. 

method 

newly diagnosed adults with PAr and skin prick test positive to HDm were randomized to receive multifaceted dust mite avoidance 

measures (group 1, n=51) or no intervention (group 2, n=48). the avoidance measures used were dust mite impermeable bedding 

covers, ascaricides, removal of dust collecting items and regular cleaning of beddings and bedrooms at stipulated intervals. the 

study was conducted over 6 weeks. the end points were changes in the total symptoms score (tss, average of scores for nasal 

congestion, rhinorrhoea, sneezing, itch and eye symptoms) and the rhinoconjunctivitis Quality of life Questionnaire (rQlQ) scores. 

results 

Of the 89 patients recruited, 27 were excluded from the analysis as they either did not comply with the multifaceted measures 

or used 15 days or more of rescue medication. the final number in group 1 was 47 and group 2 was 25. there was a significant 

reduction in dust mite load in group 1 (16.88 ng/ml ± 6.61 (P=0.02)), but not in group 2 (10.21ng/ml ± 7.88 (P=0.21)). statistically 

significant improvements were seen in both tss and rQlQ scores in patients receiving multifaceted avoidance measures. the 

improvements in tss were 2.86 + 0.48 and 1.15 ± 0.46 (p

ABstrACts 

ABstrACts 

ragweed, dust mites, grasses, and/or trees. subjects were asked to rate their ocular itching on a scale of 0 to 4 in increments of 

0.5, with 0 = none and 4 = severe. All subjects were required to have zero itching bilaterally (both scores = 0) at baseline. this 

analysis focused on a subset of 40 subjects who were dosed in one eye with olopatadine 0.2% and in the contralateral eye with 

placebo. Eligible subjects were challenged with antigen at 27 minutes after dosing with drug or placebo. this post hoc efficacy 

analysis evaluated the ability of the drug to reduce itching scores to zero.. the safety analysis was based on an evaluation of the 

exposure to study drug, adverse events, visual acuity, ocular signs, and fundus parameters. 

results: the 40 subjects had an average age of 39 ± 11 years; 65% were women and 35% were men. At 3 minutes after the 

antigen challenge, 63% of subjects (25 of 40) reported having zero itching in their olopatadine-treated eyes, while only 3% of 

subjects (1 of 40) reported having zero itching in their placebo-treated eyes. At 5 minutes after the antigen challenge, 63% of 

subjects (25 of 40) reported having zero itching in their olopatadine-treated eyes, while only 5% of subjects (2 of 40) reported zero 

itch in their placebo-treated eyes. At 7 minutes after the antigen challenge, 65% of subjects (26 of 40) reported zero itch in their 

olopatadine-treated eyes, while only 10% of subjects (4 of 40) reported zero itch in their placebo-treated eyes. the percentages 

of eyes with zero itch scores were significantly higher in the olopatadine group than in the placebo group at every time point (p < 

0.05). no treatment-related adverse events were reported during the study. 

Conclusion: in this placebo-controlled, contralateral-designed, double-masked conjunctival antigen challenge study, olopatadine 

HCl ophthalmic solution 0.2% prevented any allergen-induced ocular itching response in a majority of eyes. the percentages of 

eyes with zero itch scores were significantly higher in the olopatadine group than in the placebo group at every analysis time point. 

1409 

momETaSonE FUroaTE naSal SPraY inCrEaSES THE nUmBEr oF DaYS WiTH minimal SYmPTomS in PaTiEnTS WiTH 

aCUTE rHinoSinUSiTiS 

Danzig, m. 1 , meltzer, E. O. 2 , gates, D. 1 and gopalan, g. 3 

1 2 schering-Plough research institute (now merck research laboratories), Kenilworth, nJ. Allergy and Asthma medical group & 

research Center, san Diego, CA. 3merck & Co., Kenilworth, nJ. 

Background: Acute rhinosinusitis is a potentially serious inflammatory disease triggered by viral or, rarely, bacterial infections, 

causing symptoms for up to 4 weeks. We studied therapeutic effects of mometasone furoate nasal spray (mFns) vs amoxicillin and 

placebo on increasing number of minimal symptom days. 

methods: Double-blind, parallel-group, placebo- and active-controlled 15-day study randomized subjects ≥12 old to mFns 200 

mcg QD, mFns 200 mcg BiD, amoxicillin 500 mg tiD, or placebo. subjects maintained daily symptom diaries. Qualified subjects 

had major rhinosinusitis symptom score (sum of rhinorrhea, postnasal drip, congestion, sinus headache, facial pain) ≥5 and ≤12 

(maximum score, 15) for ≥7 but

ABstrACts 

nasal Olopatadine led to more significant resolution of the postnasal-drip syndrome due to the possible synergistic effect of the 

combination drug regimen. 

1411 

USEFUlnESS oF PEaK EXPiraTorY FloW raTE aSSESSmEnT in THE SCrEEning For BronCHial HYPEr rESPonSiVEnESS 

in CHilDrEn WiTH allErgiC rHiniTiS 

nagaraju, m. K. , r, iii, m. , n, s. and r, g. 

Pediatric allergy and immunology, Kanchi Kamakoti CHilDs trust Hospital, Chennai, india. 

Background: the unified airway hypothesis explains the sequence in onset of atopic march from Allergic rhinitis(Ar) to bronchial 

hyper responsiveness (BHr) and subsequently to asthma in most of the children with Ar. BHr better identified with Peak expiratory 

flow rate (PEFr) assessment . 

aim identifying BHr in children with Ar with PEFr and to determine the effect of treatment of Ar on BHr. 

methodology : 

study design :Prospective observational study 

study Period : October 2007 – september 2008 

setting : Allergy clinic Kanchi Kamakoti CHilDs trust Hospital 

inclusion criteria : children > 5 yrs fulfilling Allergic rhinitis and its 

impact on Asthma (AriA) criteria were included in the study and classified as 

A.mild intermittent 

B.mild Persistant 

C.severe intermittent 

D.severe persistant. 

Exclusion Ceriteria : 

Children aged < 5 yrs and Unable to perform PEFr 

sample size : 82 was arrived with confidence interval of 95% 

Prevalence of 10% based on previous studies 

method: same Postgraduate will confirm the inclusion ,exclusion 

Criteria. Detailed history ,complete examination and investigations (ig E levels ,Absolute eosinophil count and PEFr will be done 

after obtaining informed consent. treatment (oral Antihistamines and or inhaled nasal steroids ) as per AriA CritEriA for various 

subgroups . Follow up done. 

results: total 85 children were included and 58.8% were males and majority were in 6-9 yrs age group. mild intermittent ,mild 

Persistant ,severe intermittent, severe persistant Allergic rhinitis were observed in 48,28,5,4 children respectively.As severity 

increases PEFr declined (P

ABstrACts 

ABstrACts 

for these cells. to evaluate the role of regulatory t cells (treg) in the pathogenesis of nasal polyposis, we analyzed the numbers of 

FOXP3+ cells in nasal polyps versus nasal mucosa from patients with allergic rhinitis (Ar). 

materials and method FOXP3 expression in the nasal mucosa of 15 patients with Ar and nasal polyp tissue from 17 patients 

with chronic rhinosinusitis with nP were analyzed by immunohistochemistry. results are expressed as the number of positively 

stained cells in the epithelial and subepithelium layer. statistical Data analysis was done using the student t-test at 95% interval 

and a P value of less than 0.05 was accepted as indicating a statistically significant differresults the number of FOXP3+ cells in 

the subepithelium of nasal polyps was significantly lower than that in the nasal mucosa of Ar patients (2.79 and 5.99 respectively, 

p=0.002). no difference was noted in the number of FOXP3+ cells in epithelium ( 3.60 and 2.35 respectively) of nasal polyps and 

nasal mucosa (p=0.130). therefore, the numbers of t reg cells were significantly lower in nasal polyps than in the nasal mucosa of 

patients with Ar. 

Conclusion nasal polyps have lower numbers of t reg cells (FOXP3 expression) as compared to the nasal mucosa of Ar patients. 

since the severity of eosinophilic, th2 type inflammation and levels of inflammatory mediators are much higher in nP than in the 

nasal mucosa of Ar patients, this may reflect an inverse co-relation with these factors and could explain at least in part the more 

pronounced structural alterations in nP. Further studies are needed to confirm this. 

1413 

DoES THE SinUS mUCoSa rESPonD To allErgEn ProVoCaTion? 

El Hassan, E. 1 , mösges, r. 2 and Kleiner, m. 1 

1Faculty of medicine, University of Cologne, institute of medical statistics, informatics und Epidemiology, University Hospital of 

Cologne, Cologne, germany. 2imsiE, Cologne, germany. 

Background: in the common cold infection, the nose and sinus mucosa react as one entity to the virus, both simultaneously 

demonstrating the typical inflammatory changes (gwaltney 1994). little is however known about whether a similar phenomenon 

exists in other pathological settings. 

Aim: Our study examines the behaviour of the mucosa of the paranasal sinuses in comparison to the nasal mucosa, when the 

subject is exposed to the accused allergen. 

methods: the allergen applied was birch pollen, to which the patient had a known allergy but however took no medications and 

was asymptomatic at the experiment baseline. An Ent specialist examined the nasal mucosa at two visits, one before, the other 

after an allergen provocation tests, for signs of a nasal mucosal reaction. to assess changes in the mucosal lining of the sinuses, its 

thickness was measured at different points on 3 sections taken from mri images taken at the same two visits. the area enclosed 

by the maxillary sinus mucosa was also measured, as well as the volume it contains, which was done by devising two different 

methods devising 3D reconstructions, in order to indirectly assess any possible mucosal thickness changes. 

results: there was no change detectable in the inner lining of the frontal, sphenoidal, ethmoidal and maxillary sinuses. the mean 

change in mucosal thickness at the different points taken was 0.45 ± 0.32 mm. All values before and after provocation lie within 

the physiological range for normal sinus mucosal thickness. the area enclosed by the maxillary mucosa changed by a mean value 

of only 1.82%. the volume measured inside each of the sinuses (right, left) changed on average by 1.035 ml, from initial volumes 

of 20.68 ± 1.61 ml. meanwhile the Ent examination reported the expected typical nasal mucosal reaction, the slight variations in 

sinus mucosal thickness measured were considered not significant. 

Conclusion: Our study reports for the first time that there is no relationship in the behaviour and response of the nose and sinus 

mucous membrane to test allergen exposure. When the former is provoked by an allergen, the thickness of the latter remains 

anatomically unchanged. 

PoSTEr SESSion 2-1: Clinical immunology 

2100 

a rarE CaSE oF aTaXia TElangiECTaSia in malaYSia 

mohd Ashari, n. s. , Ar, K. s. and Wah, W. Z. 

immunology, Universiti sains malaysia, Kota Bharu, malaysia. 

Ataxia-telangiectasia is a rare multisystem neurodegenerative genetic disorder due to mutation of Atm gene. the disease 

is characterized by progressive neurologic impairment, cerebellar ataxia, variable immunodeficiency with susceptibility to 

sinopulmonary infections, impaired organ maturation, ocular and cutaneous telangiectasia and a predisposition to malignancy. We 

report a rare case of ataxia telangieectasia who was diagnosed only at the age of 14. the patient presented to Hospital Universiti 

sains malaysia (HUsm), malaysia, 12 years ago with motor developmental delay at the age of 2 years. Diagnosis made at that 

time was dyskinetic cerebral palsy secondary to ? kernicterus. Patient was then referred for rehabilitation and occupational 


FinAl PrOgrAm

ABstrACts 

therapy. However, patient defaulted followed up on and off after that. Eight years later during followed up at the paediateric clinic, 

a doctor noted that the patient not only having learning difficulty but also recurrent chest infection for the past 2 years. there was 

also presence of unsteady gait, telangiectasia at the conjunctivae, nystagmus, multiple healed infected skin lesion, generalized 

crepitations in both lungs and positive cerebellar sign. serum iggAm was 8.8/5.63/2.09 g/l. Based on the patient complaint and 

physical findings, the final the diagnosis of ataxia telangiectasia was made. 

2101 

CHroniC EoSinoPHiliC PnEUmonia in PaTiEnT WiTH DiFFiCUlT-To-TrEaT aSTHma 

Pauk, n. 

3rd Faculty of Charles University, Dept of Pneumology, Faculty Hospital na Bulovce, Prague, Czech republic. 

introduction 

idiopathic chronic eosinophilic pneumonia (iCEP) is a rare disorder of unknown cause characterised by subacute or chronic 

respiratory and general symptoms, alveolar and /or blood eosinophilia, and peripheral pulmonary infiltrates on chest imaging . 

interestingly, some but not all patients diagnosed with iCEP have a history of asthma, whilst others may develop asthma after a 

dignosis of iCEP has been made. 

Case presentation 

An 66-year-old woman with a history of asthma and chronic rhinitis with polyps , nonsmoker, history of allergies negative, formerly 

farming work.. 

she received antiasthmatic treatment with salmeterol/fluticasone propionate (50/500) bid since 2005, no other drugs. she suffered 

from frequent exacerbations of asthma .On 1st .of september 2006 she had sudden fever, weight loss, malaise and impaired 

dyspnea with productive cough, mild chest pain on sternum and respiratory failure. A chest radiograph demonstrated bibasilar 

infiltrates. 

Peripheral blood smear showed a newly developed, marked eosinophilia (20%), and a chest X-rays and HrCt scan revealed a 

diffuse patchy nodular infiltrate in all lung fields. 

Discussion 

We present this case, because iCEP is a rare complication of asthma, although it is seldom mentioned in reviews ant textbooks on 

asthma. Asthma in patients with iCEP is relatively severe and get worse after diagnosis of iCEP . 

the presence of asthma at the time of diagnosis of iCEP, is associated with less relapses of iCEP, possibly because of a higher 

frequency of long-term inhaled corticosteroids use in asthmatics . 

in our case no clinical relevant relaps of iCEP has occurred during 4-year follow-up. 

Conclusion 

Clinicians should consider pulmonary eosinophilia in the differential diagnosis of patients treated for asthma who develop 

pulmonary infiltrates with dyspnea. 

2102 

CliniCal CHaraCTEriSTiCS oF EoSinoPHiliC organ inVolVEmEnT DiSTingUiSHing From mETaSTaSiS in CanCEr 

PaTiEnTS WiTH EoSinoPHilia 

Kim, t. , lee, t. , lee, Y. s. , Bae, Y. , Cho, Y. s. and moon, H. 

Department of Allergy and Clinical immunology, Asan medical Center, University of Ulsan College of medicine, seoul, south Korea. 

Background: Eosinophilic organ involvement should be differentiated from metastasis of primary cancer, when space occupying 

lesions were newly developed together with peripheral blood eosinophilia in a patient who has been diagnosed with cancer, 

because further chemotherapy may be needed. 

objective: to investigate clinical characteristics of eosinophilic organ involvement compared with distant metastasis in patients 

with primary cancer. 

methods: We retrospectively reviewed medical records of thirty cancer patients who newly developed hepatic or pulmonary 

nodules with peripheral blood eosinophilia from January, 2005 to February, 2010 in Asan medical Center in seoul. Eosinophilic 

infiltration or distant metastasis was defined by pathologic findings and radiologic features. mann-Whitney U test or Kruskal-Wallis 

test were used for statistical analysis. 

results: twenty patients (66%) were diagnosed with eosinophilic infiltration, 5 (17%) with cancer metastasis, and 5 (17%) 

with undetermined. History of raw food diet, high serum levels of total igE, normal liver function test, fewer and smaller nodules 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

were significantly associated with eosinophilic infiltration rather than metastasis. Causes of eosinophilic infiltration were parasite 

infection (n=15), drug (n=1) and undetermined (n=14). 

Conclusion: Our results suggest that eosinophilic organ infiltration has distinguished clinical characteristics compared with 

cancer metastasis. moreover, physicians need to have more efforts to find the causes of organ involvement with peripheral blood 

eosinophilia, especially in cancer patients. 

2103 

oPPoSiTE EFFECT oF ETanErCEPT anD inFliXimaB on THE DEVEloPmEnT oF CUTanEoUS VaSCUliTiS 

Kim, J. 

Pediatrics, seoul national University College of medicine and rheumatology research institute, snU Hospital, seoul, south Korea. 

We report here a case that showed opposite effect of two tnF-α antagonists, etanercept and infliximab, on cutaneous vasculitis 

in a patient with JrA. three tnF-α antagonists, etanercept, infliximab, and adalimunmab are now available for the treatment of 

JrA in Korea. As JrA is a chronic condition, increase of adverse effects by long-term use is a major obstacle in tnF-α antagonists 

therapy. these include injection-site reaction, infusion-related reactions, infections, lymphoma, and lupus-like symptoms. 

recently, development of cutaneous vasculitis has been observed in patients receiving tnF-α antagonists. We experienced 

a JrA patient treated with etanercept(25~50mg/week) for 2 1/2 years developed cutaneous vasculitis on both of lower legs. 

Pathological examination of skin biopsy revealed leukocytoclastic vasculitis. thus, etanercept therapy was discontinued due to 

the extent and severity of vasculitis. After cessation of treatment for 4 months, the patient’s disease activity developed again and 

infliximab(100mg/8weeks) was administered with remission of disease activity. Unexpectedly, however, we found that cutaneous 

vasculitis was improved effectively by infliximab. this observation indicates that cutaneous vasculitis developed after introduction of 

one tnF-α antagonist(etanercept) can be improved with administration of another tnF-α antagonist(infliximab) and suggests that 

the opposite effect of these agents is probably associated with their ability to bind to tnF- α. 

2104 

BronCHoalVEolar laVagE anD SErUm EoSinoPHil CaTioniC ProTEin lEVElS in CHroniC aSTHma anD BronCHial 

CarSinoma 

Kose, s. 1 , Arici, m. 2 , Cavdar, g. 1 , Yavas, s. 1 and Camci, g. 1 

1infectious Diseases and Clinical microbiology, Clinical Allergy and immunology, tepecik Educational and research Hospital, izmir, 

turkey. 2Pulmonery Diseases, tepecik Educational and research Hospital, izmir, turkey. 

inTroDUCTion 

immunoglobuline E (igE) and eosinophil cationic protein (ECP) are important markers for atopy and allergic inflamation. Elevated 

ECP levels may be found in the serum as well as the bronchoalveolar and nasopharyngeal secretions in many diseases, including 

asthma, bronchiolitis and infections. 

mETHoDS 

the ECP in bronchoalveolar lavage fluid and in serum was measured in 15 patients with chronic pulmonary diseases such as 

bronchial carsinoma (7 of patients) and asthma (8 of patients). 

rESUlTS 

ECP levels in BAl fluids were higher in the patients with asthma (mean ECP level : 1,75 mcg/l) than in the bronchial carsinoma 

group (mean ECP level : 4 mcg/l). serum ECP levels ; were found 8,5 mcg/l in asthmatic group, and 3,4 mcg/l in patients with 

bronchial carcinoma. 

DiSCUSSion 

in conclusion we can say that serum and BAl ECP levels are useful markers for predicting eosinophilic airways inflamation, and 

serum ECP concentrations may be helpful noninvasive markers of atopic asthma. 

2105 

SUlFaTED moDiFiCaTion oF lYCiUm BarBarUm PolYSaCCHariDE UnDEr miCroWaVE irraDiaTion anD THEir anTi-HiV 

aCTiViTiES 

Zhu, X. and Zhang, H. 

Beijing University of technology, Beijing, China. 

the sulfated Lycium barbarum polysaccharide (lBP) were prepared by chlorosulfonic acid–pyridine (Py-sO ) method according to 

3 

orthogonal l (3) 9 4 test under microwave irradiation. Eight sulfated slBP, with various degrees of sulfate (Ds) and the number average 

molecular weight (M ), were obtained and their anti-HiV activities were compared by mtt and ElisA assay. the results indicated 

w 


FinAl PrOgrAm

ABstrACts 

that when Ds within the scope of 0.2–0.5 and the M w in the range of 40–50 kDa, slBP exhibited significantly strong inhibition of 

HiV activity, and it was confirmed by real-time biomolecular interaction analysis (BiAcore). the optimum sulfation conditions were 

reaction temperature of 45°C, the molar ratio of Py-sO 3 to lBP of 2:1 and the reaction time of 6 min at the microwave power of 

45W in DmF. 

2106 

THE lEVEl oF THE TUmor nECroSiS FaCTor in PaTiEnTS WiTH FEmoral nECK FraCTUrES 

Popova, O. 1 , nurpeisov , t. 2 and Batpenov , n. 3 

1 2 laboratory, research institute of traumatology and orthopedy, Astana, Kazakhstan. research institute of Cardiology, Almaty, 

Kazakhstan. 3research institute of traumotology and orthopedy, Astana, Kazakhstan. 

Methods: We have investigated the dynamics of the tnF level in patients with femoral neck osteoporotic fractures. the main group 

of 132 patients aged 60–75 with fractures of the proximal section of the neck of femur and the controlling group of 78 patients of 

the same age without the fracture were the object of our investigation. 

Results: in assessing the tnF-a serum level in patients with femoral neck osteoporotic fractures we revealed its trustworthy 

growth. in the group of patients with femoral neck osteoporotic fractures we observed a sharp increase of tnF-a concentration 

(93,8 ± 5,9 pg/ml) which exceeded the indices of the controlling group of patients by 3,4 times (r < 0,5). the investigation of the 

tnF-a serum level before the operation in patients with femoral neck osteoporotic fractures according to the type of the fracture in 

comparison with the controlling group made it possible to state that the content of this cytokine in all the patients was heightened. 

the highest indices were recorded in patients with subcapital femoral neck fractures. 

Conclusions: We have revealed high rates of tnF-a in patients with femoral neck osteoporotic fractures which exceeded the 

indices of the controlling group of patients by 3,4 times (r < 0,5). moreover, during the first 24 hours after the operation a higher 

level was found in the group of patients with subcapital and pertrochanteric femoral neck fractures. later, on the 14-th day after the 

operation, we observed the tendency to reduction of the tnF-a rate by 1,4 and 2,1 times, accordingly. On the contrary, in patients 

with spit and transcervical fractures the tnF-a level reduced during the first 24 hours, but there was a tendency to augmentation 

on the 14-th day by 0,8 and 0,7 times, accordingly. the obtained data can serve as a prognostic criterion of the emergence of 

postoperative complications and the course of treatment. 

2107 

STUDY oF il-8 inDiCES in ElDErlY PEoPlE WiTH FEmoral nECK FraCTUrES 

Popova, O. 1 and nurpeisov , t. 2 

1 2 laboratory, research institute of traumatology and Orthopedy, Astana, Kazakhstan, Astana, Kazakhstan. research institute of 

Cardiology, Almary, Kazakhstan. 

this study the dynamics of il-8 rate in patients with osteoporotic femoral neck fractures (a group of patients with subcapital and 

pertrochanteric fractures). 

the level of il-8 has been studied in 112 patients with osteoporotic fractures of proximal one-third of femoral neck. in the group 

with subcapital fractures we have revealed a high concentration of il- 8, which exceeded the controlling group indices by 1.2 times. 

il-8 indices in the group of patients with pertrochanteric fractures have not reached statistically significant distinctions. 

During the first 24 post-operation hours we have observed in the group of patients with subcapital fractures a growth of il- 8 rate 

by 1,2 times (p > 0,05) in comparison with that before the operation. no significant difference with its content was revealed in 

patients with pertrochateric fractures as compared with the controlling group. 

By the 14th day there was registered a tendency to the further growth of il–8 indices up to 4,2 pg / ml, which was by 1,8 times 

higher than the level before the operation (p > 0,05). On the contrary, there was an il-8 decline to the lower level registered in the 

group with pertrochanteric fractures as compared to the controlling group indices (1,7 pg / ml). 

According to our research, patients with subcapital fractures of the neck of the femur proved to be the most vulnerable elderly 

patients. We have also registered the highest percentage of post-operation complications and a more lingering rehabilitation period 

in this group of patients. it should be noted that women showed higher il-8 indices (2,15 pg/ml), which were by 1,1 times higher 

than those of the controlling group. 

it has been determined that during the first post-operation day the il-8 level exceeded the indices of the controlling group by 1,6 

times and on the 14-th day the elevation was by 2,2 times higher, which amounted 2,93pg/ml and 4,2pg/ml accordingly. the fact 

in question may serve as a diagnostic criterion for the development, diagnosing and treatment of osteoporotic fractures in older and 

senile patients. 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

2108 

EXPrESSion oF il-17a anD il-17F CYToKinES in B lYmPHoCYTES 

Vazquez tello, A. 1 , Halwani, r. 2 , li, r. 3 , Bar-Or, A. 4 , mazer, B. 5 , Al-muhsen, s. 6 and Hamid, Q. 7 

1College of medicine, Asthma research Chair and Prince naif center for immunology research, King saud University, riyadh, saudi 

Arabia. 2Asthma research Chair and Prince naif Center for immunological research, College of medicine, King saud University., 

riyadh, saudi Arabia. 3montreal neurological institute and mcgill University, montreal, QC, Canada. 45 montreal neurological institute 

and mcgill University, montreal, QC, Canada. 5meakins-Christie laboratories and respiratory Division, Department of medicine, 

mcgill University, montreal, QC, Canada. 6Department of Pediatrics, College of medicine, King saud University. 7mcgill University, 

meakins-Christie laboratories, montreal, QC, Canada. 

introduction. il-17A and F cytokines are regarded as promoters of autoimmune conditions such as inflammatory bowel disease, 

rheumatoid arthritis, and multiple sclerosis. there is a body of evidence suggesting that il-17A and F are produced primarily by 

CD4 + th-17 lymphocytes. However, recent reports suggest that other cells including CD8+, nKt and treg cells also express il-17A 

and il-17F and may contribute to the production of these cytokines in immunologically-mediated diseases. B lymphocytes are 

known to be important cytokine sources in inflammation and play a significant role in a number of chronic immunological diseases 

including allergic and autoimmune diseases. We therefore investigated the potential of human B lymphocytes to produce il-17A and 

il-17F. 

methods. Highly purified B cells were obtained from tonsils or peripheral blood by using a multiple-step separation procedure 

which included rosette depletion, adherence depletion, CD3+ cell magnetic-activated depletion and CD19+ magnetic-activated 

positive cell selection. CD20+ purity was verified by flow cytometry. in these cells fractions, the percentage of double-labeled 

CD3+CD4+ cells (t lymphocytes) was negligible (0.2%); CD14+ cells (macrophages/monocytes) were also very low (

ABstrACts 

result 

the patient was diagnosed as relapsing polychondritis (rP) and treated with prednison 2 mg/kg of bodyweight/day. the next 

bronchoscopy showed that the patient’s airway became narrowed, so we added immunosupressive agent (methotrexate), started 

from 10 mg/week. After the patient got methotrexate for 6 weeks, there was a clinical improvement and the tracheoscopy 

examination showed that the karina, the right and left prime bronchus was opened, and no evidence of granulation. 

Conclusion 

steroids alone did not give good result as expected, but the combination with methotrexate in this patient was proved useful and 

gave better clinical improvement. 

Key word: Collagen type ii, laryngotracheomalacia, methotrexate, relapsing polychondritis 

2110 

PEriPHEral EoSinoPHilia 

restrepo, m. 1 , Diez, s. 1 , sanchez, J. 1 , Chinchilla, C. 2 and Cardona, r. 3 

1 2 Allergology, Universidad de Antioquia, medellín, Colombia. University of Antioquia - grupo de Alergología Clínica y Experimental 

(gACE), medellin, Colombia. 3University of Antioquia, medellin, Colombia. 

Background: the accumulation of eosinophils in a variety of tissues is not unique to host defense or as result of immune 

dysregulation, this buildup occurs as a strategy to maintain homeostasis in both states: health and disease. Eosinophilia is 

considered to occur when the total number of eosinophils in the periphery is significantly higher than considered normal for the 

general population 

objective: to present the clinical case of a patient with peripheral eosinophilia, which one did not show apparent trigger. 

medical history and monitoring: 5 years old male patient, evaluated by our allergy group for 3-month history of cervical 

lymphadenopathy associated with fever, current edema in hands and feet and itchy, his laboratory test revealed eosinophils 

between 1860 and 9500cell/ml. studies were conducted to rule out to rule out causes of peripheral eosinophilia. HiV, toxocara, CmV, 

toxoplasma antibodyes has done , cerebrospinal fluids cytology, igE, bone marrow biopsy, echocardiography, upper gastrointestinal 

endoscopy, colonoscopy and biopsies all within normal ranges. 

By peripheral eosinophilia, recurrent fever and swelling hands gleich syndrome was thought , which is characterized by recurrent 

episodes of angioedema, urticaria, itchy, fever, weight gain, elevated igm and leukocytosis with marked eosinophilia. requested 

to continue with the studios vit B12 levels, igm, skin biopsy with immunohistochemistry and serum levels of tryptase, Finding 

high levels of Vit B12: 1018 pg / ml, normal tryptase and igm. skin biopsy was not carried out because the skin symptoms and 

eosinophilia resolved. 

it highlights the need for diagnostic studies in patients with hypereosinophilia in order to reach an etiological diagnosis. in our 

patient suspected gleich syndrome, but the normalization of the eosinophil count four months after without drug treatment and 

the absence of physical signs, now ruled out the diagnosis and force us to make periodic checks. 

Bibliography: the eosinophilias, including the idiopathic hypereosinophilic syndrome. Briito Babapulle. J Haematol 2003. 

Eosinophilia and Eosinophil-related Disorders Peter F. Weller middleton’s Allergy: Principles and Practice, 7th ed.n 

PoSTEr SESSion 2-2: Drug and food allergy 

2200 

PoTEnTial aDVErSE rEaCTionS From ComPlEmEnTarY anD alTErnaTiVE mEDiCinE (Cam) anD DiETarY SUPPlEmEnT 

(DS) in norTH amEriCa 

Wong, H. g. 

Department of medicine, University of British Columbia & Vancouver general Hospital, Vancouver, BC, Canada. 

Background: Complementary and alternative medicine (CAm) and dietary supplement (Ds) being natural products, are usually 

considered harmless. Potential adverse reactions in four preparations are presented. 

method: Visits were made to Chinese herbal shops and health food stores in Vancouver, Canada, and new York, UsA. the 

ingredients of some CAm and Ds were carefully examined. 

results: Four preparations, two from Vancouver (1,2) and two from new York (3,4) were noted to have potential adverse reactions. 

1. ArtHO-ACE “pill for pain relief” with a label stating “this product is made from [ten] selected natural herbal [sic] and contains no 

toxin [sic] & chemicals.” Does it mean it may contain heavy metal or pharmaceutical product? 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

2. rAPiDCUts “a rapid fat burning catalyst”, to take 1 pack BiD, with ingredients in each pack including (i) magnolia bark extract 

(known to contain turbocurarine) and (ii) caffeine 298mg (less than 400mg of caffeine per day from all sources, recommended by 

Health Canada). 

3. CHinA tUng sHUEH Pills “pill for blood thinning”, containing “radix salvine miltiorrhizae [sic]” with potential herb-drug 

interaction with warfarin. 

4. FU Zi li ZHOng WAn “nausea extract for gastric bloating”, containing prepared aconite root (Aconitum carmichaeli) with potential 

adverse cardiac side effect. 

Conclusions: there are potential adverse reactions in CAm and Ds purchased in Chinese herbal shops and health food stores in 

north America. Physicians should inquire the use of CAm and Ds by patients. there should be higher standard in regulation in CAm 

and Ds in north America. 

2201 

inTErim FinDingS From ESTaBliSHing THE EFFECTiVEnESS, CoST-EFFECTiVEnESS anD SaFETY oF oral anD 

SUBlingUal immUnoTHEraPY For FooD allErgY: a SYSTEmaTiC rEViEW 

nurmatov, U. 1 , Devereux, g. 2 and sheikh, A. 1 

1Allergy & respiratory research group, Centre for Population Health sciences, the University of Edinburgh, Edinburgh, United 

Kingdom. 2Department of Child Health, royal Aberdeen Children’s Hospital, the University of Aberdeen, Aberdeen, United Kingdom. 

Background: the prevalence of food allergy in children has increased in recent decades. Oral and sublingual immunotherapy 

aims to desensitise people and induce immunological tolerance, enabling igE-mediated food allergic patients to consume increased 

quantities of the food(s) in question. this is a promising new therapeutic approach and a careful critique and synthesis of the 

literature will be an important contribution towards establishing the safety, effectiveness and cost-effectiveness of this approach. 

objectives: to identify and critically review the published and unpublished evidence for the effectiveness and safety of oral and 

sublingual immunotherapy in people with igE-mediated food allergy. 

methods: systematic review and meta-analysis of all interventional studies i.e. randomised controlled trials (rCts), quasi-rCts 

and controlled clinical trials (CCts) were identified from searching 11 electronic databases. the primary outcomes of interest are 

the recovery rate from food allergy as assessed by the ability to consume increased amount of the offending food allergen whilst 

on treatment (i.e. desensitisation) and success rates for complete tolerance to the causative food. secondary outcomes of interest 

include the frequency and severity of local/systematic adverse events, quality of life, health services use including emergency 

department contacts and hospital admissions, and data on cost-effectiveness both from the perspectives of patients/families and 

healthcare providers. 

interim findings: Our searches identified 721 potentially relevant papers; after de-duplication, 626 potentially eligible papers were 

included for screening. 606 studies were excluded for not meeting review criteria and another 20 potentially appropriate abstracts 

reviewed, of which 11 satisfied our inclusion criteria. there were seven rCts and four CCts; nine of these trials relate to oral 

immunotherapy and the remaining two are concerned with assessing sublingual therapy. Analyses are underway and results will be 

presented at the conference. 

implications: this work will clarify the evidence base for the use of oral and sublingual immunotherapy in people with igEmediated 

food allergy and will inform national and international deliberations on service provision. 

2202 

CiSPlaTin aDminiSTraTion FolloWing aCUTE HYPErSEnSiTiViTY To oTHEr PlaTinUm ComPoUnDS: a PHaSE ii STUDY 

syrigou, E. , makrilia, n. , Politi, K. , Kaklamanos, g. , manolopoulos, l. and syrigos, K. n. 

Oncology Unit, 3rd Department of medicine, sotiria general Hospital, Athens school of medicine, greece, Athens, greece. 

Platinum compounds are antineoplastic agents widely used in numerous malignancies. A high percentage of patients exhibit 

carboplatin-associated hypersensitivity, especially after their seventh course of chemotherapy. the purpose of this study was to 

determine how useful skin tests are in ruling out cross-reaction to cisplatin, especially when treating physicians wish to continue 

platinum-based chemotherapy in patients responsive to these drugs. Prick tests were performed on three patients with medium 

and severe hypersensitivity to carboplatin. these tests were followed by intradermal tests with a series of carboplatin and cisplatin 

dilutions. Prick tests were negative for both carboplatin and cisplatin, whereas, in all patients, intradermal tests were positive with 

carboplatin and negative with cisplatin. Cisplatin was administered instead of carboplatin and was well tolerated by all patients 

without administering premedication. We reach the conclusion that intradermal skin tests can be used to detect cross-reaction 

between platinum compounds in order that platinum-based therapy is safely continued with a different platinum agent. this method 

requires neither desensitization nor premedication. 


FinAl PrOgrAm

ABstrACts 

2203 

FooD allErgY anD aToPiC DErmaTiTiS 

Hekmatdoost, Jr., A. 

Dep Clinical nutrition and Dietetics, shahid Beheshti University of medical sciences, tehran, iran. 

Food allergy is one of the most important factor in children with atopic dermatitis (AD). in this study, we have measured any 

association existed between AD severity, quality of life, total igE, eosinophil counts, and the number of food items sensitized. 

specific igE of ten common food items was measured for a group of consecutive AD patients (n = 105) enrolled during a 

randomized trial and correlated the findings with eczema severity. twenty-nine patients were negative for any of the ten common 

food items. the most commonly sensitized foods were caw milk (51%), fish (49%), egg white (41%), and wheat (38%). Atopy to 

beef as a protein and orange as a fruit were least common among the food items studied, even among patients positive for 8-9 

igE items. Patients with severe AD (objective sCOrAD > 40) were more likely to be positive for at least one of the food items (Yates 

corrected p = 0.024 for >/=1 food-specific igE in severe vs. moderate AD, Or 3.42 and 95% Ci 1.15-10.32); and for at least seven 

of the food items (p = 0.001 for >/=7 food-specific igE vs. nil with Or 11.67 and 95% Ci 2.29-67.77), respectively. the spearman 

coefficients between the number of positive food-specific igE and total sCOrAD, objective sCOrAD, area of AD involvement, 

Children’s Dermatology life Quality index (CDlQi), total igE levels, and eosinophil counts were 0.42 (p < 0.001), 0.45 (p < 0.001), 

0.50 (p < 0.001), 0.17 (p = 0.116), 0.80 (p < 0.001), and 0.22 (p = 0.043), respectively. specific igE levels for beef correlated with 

all the other food-specific igE levels, including cow’s milk (rho = 0.061, p < 0.001) and soy (rho = 0.70, p < 0.001). the number of 

common food items sensitized correlated with disease severity, extent, and total igE levels. it seems that many atopic children could 

be treated by food limitations. 

2204 

CliniCal CHaraCTEriSTiCS oF raniTiDinE inDUCED HYPErSEnSiTiViTY 

Cho, Y. J. 

Allergy and Clinical immunology, internal medicine, Ewha Womans University mockdong Hospital, seoul, south Korea. 

Purpose: ranitidine is a widely used drug for gastrointestinal problem and is usually associated with a low incidence of adverse 

reactions. there have been only a few cases of immediate type hypersensitivity reactions to ranitidine. to see the characteristics of 

ranitidine induced hypersensitivity, we analyzed 10 cases of ranitidine induced hypersensitive reaction 

methods: Patient who is suspicious of ranitidine induced hypersensitivity was evaluated. skin test and oral provocation were 

performed. We also evaluated the cross reactivity of other drugs (cimetidine, famotidine and proton pump inhibitor) used for gastric 

protection. 

results: Eighty percent of patient was positive in ranitidine skin test and oral provocation test. mean age of these patients was 

35 ± 7 years old. male: female ratio was 4:6. two cases illustrates a severe anaphylactic reaction after a single intravenous dose 

of 50 mgs of ranitidine and three cases showed anaphylactic reaction after oral intake of dose of 150mg of ranitidine. Five cases 

illustrated only skin eruption after oral intake of 150mg of ranitidine. All of five cases who illustrated anaphylactic reaction showed 

positive reaction with skin prick test and/or intradermal skin tests. three patients who showed only skin reactions were positive in 

intradermal skin test with ranitidine. two of cases were negative for skin test with ranitidine and they showed mild skin eruption 

with itching sense in 2 hours and 3 hours each with 75mg of ranitidine of oral provocation test. All of the 10 cases showed 

negative reaction in skin test and oral provocation test with cimetidine, famotidine and proton pump inhibitor. 

Conclusion: Our case suggests that ranitidine may induce immunoglobulin E-mediated anaphylaxis but also non-immunological 

mechanisms may be involved in hypersensitivity reactions. 

ranitidine may have very rare cross-reactivity with other gastric protective drugs. Clinicians should therefore be aware of possible 

life-threatening adverse reactions to commonly used H2-receptor antagonists such as ranitidine. 

2205 

PangaSiUS HYPoPHTHalmUS HYPErSEnSiTiViTY 

Palomeque, sr., m. t. 1 , torrecillas, m. 1 , Bartolome, B. 2 , martínez Borque, n. 1 , gonzález mendiola, m. r. 1 , martín Casáñez, E. 1 , lara 

de la rosa, P. 1 , soto Vargas, g. 1 and martínez Bohigas, D. 1 

1 2 Alergología, Complejo Hospitalario Universitario Albacete, Albacete, spain. Departamento i+D, Bial-Arístegui, Bilbao, spain. 

introduction: Fish is a relatively common source of food allergens and its ingestion may cause fatal anaphylactic reactions. Fish 

allergic subjects usually present igE antibody to several fish species, although clinical cross reactivity may be more limited. We 

report a patient allergic to Pangasius hypophthalmus (Panga fish) but no to other fish. this exclusive sensitivity was confirmed by in 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

vivo and in vitro tests, and a unique Pangasius hypophthalmus allergen was detected. Panga is a fish from Vietnam rivers which is 

being exported to many countries (included spain) in the last years. 

Clinical case: A 18-year-old man reported five reactions a few minutes after eating panga fish; he had upper and lower respiratory 

tract dyspnea, laryngeal oppression, wheezing and heartburn. He declared that he did not suffer allergic symptoms with the 

ingestion of any other kind of fish or seafood. 

results: Prick-test with Anisakis simplex, seafood, panga fish and thirteen different commercial fish extracts (hake, cod, salmon, 

sole, trout, tuna, bream, bass fish, sardine, herring, south African Anchovy, anglerfish and bonito) was positive only to octopus, 

panga and bass fish. Prick-prick with panga fish was positive (cooked: 10x7; raw: 12x9) and negative with sardine, cod, hake, 

salmon, south African Anchovy, swordfish, sole, guilthead bream, squid, cuttlefish, octopus and shrimp. the open oral challenge test 

was negative with salmon, sole, trout, bass fish, guilthead bream, squid, cuttlefish, octopus and shrimp. 

specific igE against extracts from panga (cooked: 4.3 kU/l ; raw: 3.1 kU/l), sardine (2.1 kU/l), hake (0.7 kU/l), cod (0.6 kU/l) 

and shrimp (0,9 kU/l) was detected by means of EAst method (Enzyme Allergosorbent test). igE-immunoblotting with panga 

extracts (cooked and raw) revealed igE-binding bands of 14 kDa and 12 kDa, the same molecular mass as the ones appeared after 

incubation with a rabbit serum anti-sardine parvalbumin. 

Conclusion: We report a patient who is allergic exclusively to panga fish. Probably the allergen involved is parvalbumin. 

2206 

FiXED DrUg ErUPTion inDUCED BY iBUProFEn anD aCETaminoPHEn 

torrecillas, sr., m. , Palomeque, m. t. , martín, E. , martínez, n. , lara, P. , soto, g. , martínez, D. and gonzález, m. r. 

Alergología, Complejo Hospitalario Universitario Albacete, Albacete, spain. 

Fixed Drug Eruption is considered the only pathognomonic drug hypersensitivity dermatosis. the most frequently drugs involved are 

sulfonamides, pyrazolones, barbiturates, chemotherapeutic agents, psychotropic drugs, penicillins and tetracyclines, but it also has 

been reported for ibuprofen, paracetamol and other nsAiDs, usually with only one drug involved. 

We report the case of a 62 years old man, hypertensive, treated with amlodipine + valsartan who complains about having 

presented pruritic violaceous macules on the back of hands, face and abdomen 24 hours after taking ibuprofen or paracetamol 

which lasted four weeks. 

Patch test were performed with a battery of nsAiDs, ibuprofen 5% and acetaminophen 10% in vaseline in healthy skin, and 

ibuprofen and acetaminophen also in back of hands, with negative results. 

single-blind, placebo controlled oral challenge (sBPCOC) with acetaminophen was positive, reappearing the lesions on the back 

of hands at 45 minutes after administration of 500 mg (cumulative dose 1000 mg). sBPCOC with ibuprofen also was positive with 

lesions at two hours into the test (cumulative dose 600 mg). 

single-blind, placebo controlled oral challenge to therapeutic doses of aspirin (1000 mg) and metamizol (575 mg) was well 

tolerated 

We present a case of fixed drug eruption by ibuprofen and acetaminophen with good tolerance to other groups of nsAiDs, 

diagnosted by controlled exposure test, having been negatived patch testing with them. 

2207 

FrEQUEnCY oF immEDiaTE, laTE anD DElaYED TYPE FooD HYPErSEnSiTiViTY in ProVoCaTion TEST For Egg allErgY 

anD iTS CorrElaTion WiTH Egg-WHiTE igE raST SCorE 

noma, t. 1 , Ogawa, n. 1 , Ogawa, n. 2 , mikami, K. 2 , saeki, t. 1 , isozaki, A. 3 , Kawano, Y. 3 and Oshiba, H. 4 

1 2 3 Pediatrics, Kitasato Univ, sagamihara, Japan. Pediatrics, Chiba Aiyukai memorial Hospital, Japan. Pediatrics, Yokohama City 

minato red Cross Hospital, Japan. 4Pediatrics, tokyo Kousei-nenkin Hospital, Japan. 

in egg allergy the method to determine the serum level of a specific igE is associated with shortcomings such as a frequent lack 

of correlation between the symptoms and the presence of a specific igE ; furthermore, in an attempt to find an antigen responsible 

for food hypersensitivity, the development of symptoms in a provocation test does not necessarily guarantee test values that signify 

positivity (a low sensitivity). in the present study where the egg provocation test was conducted, the correlation of the time required 

for the symptoms to develop, with the egg white rAst score in egg allergy were examined. 

subjects: included 125 children with atopic dermatitis (AD), (mean 2 y 10 m, from 3 m to 15 y in age). 

the oral provocation test and result: Approximately 0.1 ml of the raw egg was given first, followed by several spoonfuls (0.15ml/ 

sp), until the entire quantity. in a one-week observation of the patients who were subjected to the egg-loading test, 75 among 125 

suffered immediate (type i, 1h>), late (type l, 24h>), or a delayed-type (typed, 1-7d) skin eruption or exacerbation of eczema, while 

50 exhibited negative responses to the test. For type i , the positivity and the rAst score was 50.7%, 1.71+/-0.36(95%Ci), 12.0%, 


FinAl PrOgrAm

ABstrACts 

1.11+/- 0.81 for type i alone out of them, 2.7%, 1.5+/-2.08 for type il, 4.0%, 0.33+/- 0.50% for type Di, and 32.0%, 2.17+/- 0.37 

for type ilD which is the higher value (P=0.049). 55.6% of type i alone exhibited negative- rAst score. 

in conclusion: the type ilD shows higher value of the rAst score, which likely reflects the pathogenesis of the disease such as 

allergic inflammation and the severity in the higher value group. 

2208 

anTi-igE anTiBoDY anD FooD igE-mEDiaTED DiSEaSES in SEVErE aSTHmaTiC PaTiEnTS 

Florio, g. 1 , Oricchio, C. 2 , Palmieri, m. 1 , marone, g. 3 and Patella, V. 1 

1 2 Division of Allergy and Clinical immunology, Agropoli general Hospital, Department of medicine Asl salerno, salerno, italy. Unit of 

transfusion medicine, Agropoli general Hospital, Asl salerno, salerno, italy. 3Division of Allergy and Clinical immunology and Center 

for Basic and Clinical immunology research (Cisi), University of naples Federico ii, naples, italy. 

BaCKgroUnD: it is now recognized that immunoglobulin E (igE) plays a central role in mediating the allergic response. 

Omalizumab, a recombinant humanized monoclonal antibody (Xolair®), has been currently used in the treatment of patients with 

allergic asthma with moderate to severe persistent allergic asthma with a serum igE. 

oBJECTiVE: to investigate the efficacy of anti-igE to treat igE-mediated hypersensitivity to foods. 

mETHoDS: in a court of 12 patients (9 females, 3 males; range 6-46 years old; mean 32 years) with severe attacks asthma and 

food allergy to igE-mediated, they were treated with omalizumab and monitored during the treatment. the appropriate dose and 

frequency of administration of Xolair® was determined by levels of igE basal (iU / ml), measured before starting treatment, and 

body weight (kg). 

rESUlTS: seven female patients and one male patient with severe attacks of igE-mediated asthma and food allergy to milk, while 

three female patients and two male patients with severe asthma and food allergy to egg proteins. All patients experienced allergic 

food reactions based on history of Anaphylaxis and Dermatitis. Before treatment with Omalizumab, they had asthma with a mean 

of symptom scores of 7.2 ± 2.1 [scale from 0 (least) to 9 (severe)]. the total igE concentrations were a mean 1046 ± 84.3 iU/ml. 

After 16 weeks of treatment with Xolair®, total igE were decreased with a mean of 440 ± 92.7 lU/ml. no access to intensive care 

unit was needed during the treatment and the asthma symptom score decreased with a mean of 3.7 ± 2.4 and peak expiratory 

flow (PEF) of the morning increased each four weeks in all patients. Whereas the introduction (after challange test), in their diet, 

after 16 weeks of treatment with Xolair®, of cow’s milk, egg and its derivatives: in nine patients no reactions (anaphylaxis and 

dermatitis); in one patient a mild reaction with angioedema;in two patients a episode of hives it was registered. 

ConClUSion: these new features suggest further prospective regarding the use of this biological drug for patients suffering of 

severe allergies such as the food allergy. 

2209 

EFFECTS oF DiETarY CoUnSElling on ProTEin inTaKE anD PlaSmaTiC ProTEin ProFilE in CHilDrEn WiTH FooD 

allErgY 

D’Auria, E. , mandelli, m. , Cagnoli, g. , lammardo, A. m. , Zuvadelli, J. , salvatici, E. and giovannini, m. 

Department of Pediatrics, san Paolo Hospital-University of milan, italy, milan, italy. 

Background: Elimination diet in children with food allergy (FA) could be responsible for inadequate dietary intake and protein 

imbalance. 

aim: to investigate the protein intake and plasmatic protein profile in children with FA on elimination diet. 

methods: the study included 40 children (19 boys and 21 girls, 3-36 months of age), all affected by FA on elimination diet for at 

least 30 days. measurement of total protein, albumin, prealbumin, plasma nonessential to essential amino acid ratio was carried out 

at enrollment (t ) and after 6 months (t ) of dietary counselling by registered dietician. 

0 1 

results: Protein intake in FA children exceeded the recommended intake, according to national dietary recommendations, as 

in non allergic children. the ratio between the mean value of protein intake (g/kg) in our children, assessed by a 3-day diary, 

and the recommended protein intake (g/kg) decreased significantly from t to t [t =1,60 (0,7-3), t =1,31 (0,9-2); p=0,05] after 

0 1 0 1 

nutritional counselling. the comparison of the measurements of plasmatic protein profile [mean (min-max)] observed in the study 

population during the 2 times of valutation showed no significative difference (significance with p

ABstrACts 

ABstrACts 

Conclusions: An unbalanced diet is a frequent feature in allergic children. this condition could be prevented and resolved by an 

adequate nutritional counselling. in particular, in our population the dietary intervention improved the quality of protein intake. 

Plasmatic non essential/essential aminoacids may be an useful marker of protein status. 

2210 

THE rolE oF SKin PriCK TEST in DiagnoSiS oF CroSS –allErgY 

Bartuzi, Z. 1 and napiórkowska, K. 2 

1Department Allergology, Clinical immunology and internal Diseases, Collegium medicum nicolaus Copernicus University, 

Bydgoszcz, Poland. 2Allergology, Clinical immunology and internal Diseases, Collegium medicum nicolaus Copernicus University, 


Background: Patients with birch pollen allergy frequently develop hypersensitive reactions to certain food e.g. apples, celery and 

carrots due to cross-reactivity reactivity between these allergens. these reactions result from the similarity of allergen proteins 

structure, which are sometimes unbound phylogenetically. the aim of this study was to investigate the role of cross-reactivity and 

the diagnostic value of skin prick test (using commercial and native extracts of allergens), total and specific igE in diagnosis such 

kind of allergy. 

material and methods: Fifty eight patients at the age above 16 were included in the study. the clinical history and the positive 

result of the skin prick test with the birch extract were the condition for qualifications. Patients were divided into two groups. 

Patients included in the first group were birch allergic without any symptoms after eating food (23 persons). Patients in the other 

group had birch pollen allergy and they had reported clinical symptoms after eating foods such as: apple, celery, carrot, tomato, 

banana, peach, peanut and hazelnut. (35 persons). the skin prick tests with pollen and food commercial extract and with native 

food allergens were determined for all individuals. 

results: All patients showed positive skin prick test with other pollen allergen extracts. Particularly a high percentage of positive 

skin reaction was find for hazel (78,3% in the first group vs. 97,1% in the second group) alder (82,6% vs. 97,1%). Patients included 

in the first group had positive skin reaction more often for grass and cereals (61% vs. 48,6%) and poplar (30,4% vs. 11,4%). 

Patients from the other group were characterized by a significantly higher percentage of positive skin tests with weeds. generally, 

skin prick tests with native allergens showed more positive skin reaction and a better agreement with clinical history than skin 

prick tests with commercial extracts. 

Conclusions: the skin prick tests with native allergens seems to be the method of verifying and supplementing other diagnostic 

tests in patients with food allergy. 

2211 

THE EFFECTiVEnESS oF THE mEaSUrEmEnT oF ToTal anD SPECiFiC igE in DiagnoSiS oF CroSS allErgY 

Bartuzi, Z. 1 and napiórkowska, K. 2 

1Department Allergology, Clinical immunology and internal Diseases, Collegium medicum nicolaus Copernicus University, 

Bydgoszcz, Poland. 2Allergology, Clinical immunology and internal Diseases, Collegium medicum nicolaus Copernicus University, 


Background: some patients with birch pollinosis frequently develop hypersensitive reactions to certain plant food (i.e. apples, 

celery and carrots). this phenomenon is caused by cross-reactivity between inhalant and food allergens. Exposure to inhalant 

allergens causes hypersensitivity to the other allergens. the aim of this study was to investigate the diagnostic value of 

measurement total and specific igE in diagnostic such kind of allergy. 

material and methods: Fifty eight patients at the age above 16 were included in the study. the clinical history and the positive 

result of the skin prick test with the birch extract were the condition for qualifications. Patients were divided into two groups. 

Patients included in the first group were birch allergic without any symptoms after eating food (23 persons). Patients in the other 

group had birch pollen allergy and they reported clinical symptoms after eating foods such as: apple, celery, carrot, tomato, banana, 

peach, peanut and hazelnut (35 persons). igE concentration (total and specific) were determined for all individuals. 

results: no difference in total igE levels was found between the two groups (271,5+/-403,8 iU/ml vs 242,5+/- 340,9 iU/ml). 

Patients with birch allergy and hypersensitivity to food allergens showed significantly higher birch pollen specific igE levels and it 

might be the predictive factor of developing cross allergy to distinct plant food which may develop later (11,8 +/- 14,1 iU/ml vs 4,1 

+/- 6,6 iU/ml). the measurement of total and specific igE was characterized by the lowest effectiveness in diagnostic of allergy in 

comparison with skin tests (with commercial and native extracts of allergens). 

Conclusions: the measurement of total and specific igE seems to be the valuable method of verifying and supplementing other 

diagnostic tests in patients with food allergy. igE may be an alternative in case of questionable or negative skin prick tests and 

when the sPt cannot be performed. 


FinAl PrOgrAm

ABstrACts 

2212 

aSSESSing PoTEnTial DETErminanTS oF PoSiTiVE ProVoCaTion TESTS in SUBJECTS WiTH nSaiD HYPErSEnSiTiViTY 

Viola, m. , rumi, g. , Valluzzi, r. l. , gaeta, F. , Caruso, C. and romano, A. 

Allergy Unit, Complesso integrato Columbus, rome, italy. 

Background: Provocation tests (Pts) with the suspected compounds are considered the “gold standard” for establishing or 

excluding a diagnosis of hypersensitivity to nonsteroidal anti-inflammatory drugs (nsAiDs) [1]. However, only a few studies have 

evaluated the potential determinants of positive responses to Pts. 

the aims of this study are to asses the reliability of clinical histories as indicators of nsAiD hypersensitivity, as well as the risk 

factors for a positive Pt. 

methods: 275 subjects with an unequivocal history of nsAiD hypersensitivity reactions underwent Pts with the suspected drugs. 

to establish the potential determinants of positive Pts, we examined the following variables: gender, age at the time of reaction 

(12 months), and inclusion in a category of the stevenson et al. classification [2]. 

results: 214 (77.8%) subjects tolerated the suspected drugs and 61 (22.2%) reacted. Age

ABstrACts 

ABstrACts 

2214 

EPiDEmiologiCal STUDY oF FooD allErgY in THE ToWn oF ConSTanTinE (algEria) 

Boughellout, H. and Zidoune, m. n. 

nutrition and Food tECHnOlOgY institute, UniVErsitY mEntOUri COnstAntinE, Constantine, Algeria. 

the epidemiological study of food allergy was performed by a questionnaire at three centers of maternal and child health care in 

the town of Constantine. it involved 770 children aged between 0-3 years. 

the study involved two different components: the first involves studying food allergy : symptomatology, age of onset of the 

disorder, confirmatory tests, atopic history of parents and type of feedings. the second part concerns the study of diet followed, the 

substitutes, tolerance to these products and the development of allergy. 

the prevalence of food allergy has reached a cumulative rate of 7.14%. 

the major allergen is cow’s milk 47.45% 11.86% followed by eggs and finally the olive oil and strawberries (8.47%). the allergic 

reaction has been in the cow’s milk, eggs and canned foods. 

the most noticed clinical manifestations are : skin symptoms 57.14%, 46.42% digestive and respiratory symptôms 25%. the rate 

of anaphylaxis is 14.28%. 

the family history represents a rate of 46.42%, mothers are more affected 28.57%. 

Food allergy (especially cow’s milk protein) usually appears during the first month of life 42.85% of cases, this rate reached 75% 

during the first 3 months. 

Allergy is a health problem, particularly in the absence of care centers for allergic children. 

2215 

anaPHYlaCTiC rEaCTion inDUCED BY HomEoToXiC DrUg 

naime, m. , sofia, m. and Elizabeth, P. 

Escuela De Ciencias De la salud, Universidad de oriente, Puerto la Cruz, Venezuela. 

Female patient, 57 years old, with nsAiDs allergy history, who after the homeopathic drug administration (reumatric®) presented: 

laryngeal stridor, generalized skin rash, severe respiratory distress which needed cardiopulmonary resuscitation, sphincter 

relaxation and loss of consciousness; she is moved by her family on 16/08/1910 to santa Ana medical center, the patient was 

admitted in poor general conditions, swollen, facial erythema, acrocyanosis and chest pain treated with sublingual isordil, with 

blood pressure: 159/89 mmHg, heart rate: 110 bpm, respiratory rate: 18 bpm, with paraclinical tests: Hb: 13,6 gr/dl, Wbc: 22400 

cells/μl, Het: 45%, lym: 55%, Plt: 182000, Pt and Ptt within normal limits, pH:7,44; PCo: 29,7; PO2: 150; HCO3: 20,5; satO2: 

99% (with O2 by mask to 6 l/min); fibrinogen: 291 mg/l; Urea: 47,6 mg/l; Creatinine: 1,23 mg/l; troponins: i: 0,06; t: 0,03. she was 

admitted to intensive care unit with this diagnosis: 1) anaphylactic shock, 2) hypersensitivity reaction, 3) ischemic cardiopathy. 

Advanced supportive measures were applied for 48 hours with satisfactory evolution. Paraclinical tests 18/08/10: Hb: 11,6 gr/dl, 

Wbc: 14100 cells/μl, Het: 81%, lym: 18%, Plt: 212000, Pt and Ptt within normal limits, Urea: 43,5 mg/l; Creatinine: 0,91 mg/l, 

glucose: 150,9 mg/dl, CK: 535 U/l; CKmB: 48 U/l; tgO: 79,6 U/l; tgP: 51,4 U/l; na: 131,5 mmol/l; K: 5,59 mmol/l; Cl: 106,2 mmol/l; 

troponins: i: 10,17; t: 0,40. she was under hospitalization for 3 days. 21/08/10 is discharged later to cardiology and immunology 

evaluation with this diagnosis: severe anaphylactic shock for homeotoxic drug (reumatric®), complicated with ischemic 

myocardial injury in recovery. 

2216 

anaPHYlaXiS aFTEr naSal ProVoCaTion TEST WiTH alTErnaria alTErnaTa EXTraCT 

gomez-garcia, C. 1 , sus-Carrizosa, s. 1 , Olivares, m. 1 , Chinchilla, C. 1 , ramirez, r. 1 , Cardona-Villa, r. 1 and restrepo, m. 2 

1 2 University of Antioquia - grupo de Alergología Clínica y Experimental (gACE), medellin, Colombia. Allergology, Universidad de 

Antioquia, medellín, Colombia. 

Background 

Alternaria alternata is an ascomycete mold. it is predominantly an outdoor allergen, even though it can be found indoor, mostly 

derived from outdoor sources. in sensitized individuals, exposure to Alternaria alternata can exacerbate respiratory (asthma, rhinitis) 

and cutaneous (atopic dermatitis) symptoms. For the diagnosis of allergic rhinitis, nasal provocation test (nPt) can be used in 

clinical practice, since it helps to determine a correct therapy. incidence of anaphylaxis after nPt is not known. 

Case report 

55 years old woman, retired school teacher, with moderate-severe persistent rhinitis since childhood. she had been receiving 


FinAl PrOgrAm

ABstrACts 

regular treatment with beclometasone dipropionate and an antihistaminic, with some relief of her symptoms. Frequently she 

required antibiotics for the treatment of bacterial sinusitis. negative family history for atopy. 

method 

skin prick test to aeroallergens was positive only to Alternaria alternata (4 mm – positive control 7 mm). We decided to perform a 

nPt in order to demonstrate clinical relevance of this allergen. 

Alternaria alternata extract used in this nasal provocation was provided at a concentration of 30 HEP/ml. Vital signs, peak nasal 

inspiratory flow and peak expiratory flow were normal. Challenge was initiated with placebo (0.9% saline solution), and after 30 

minutes Alternaria dilution 1:1000 was delivered into each nostril with a spray bottle. 

results 

thirty minutes later after dilution 1:1000 had been delivered, the patient presented with severe naso-ocular symptoms and wheals 

in the neck. Although she had moderate dry cough, pulmonary auscultation and pulse oximetry were normal. Blood pressure, peak 

nasal inspiratory flow and peak expiratory flow were also within normal range. standard treatment was administered, and the 

patient was admitted for inpatient observation and treatment period. After 24 hours the patient was discharged asymptomatic. 

SYmPTomS BaSal 

30 min 

aFTEr 0,9% 

SS 

Pruritus 1 2 5 

rhinorrhea 1 1 6 

obstruction 1 1 5 

Sneezing 0 0 1 

ToTal 3 4 17 

30 min 

aFTEr 

1:1000 

DilUTion 

Table 1. nasal symptoms score test. 

Conclusion 

We present a patient with anaphylaxis due to Alternaria alternata extract during a nPt. Although blood pressure remained normal, 

both upper respiratory tract and skin were compromised. standard treatment was successful. 

2217 

PaTiEnT WiTH PEanUT allErgY WiTH nEgaTiVE CUTanEoUS anD in ViTro TESTS, ConFirmED BY oral ConTrollED 

FooD CHallEngE 

Diez, s. 1 , restrepo, m. 1 , sanchez, J. 1 and Cardona, r. 2 

1 2 Allergology, Universidad de Antioquia, medellín, Colombia. University of Antioquia, medellin, Colombia. 

Background: the peanut allergy and dry fruit allergy in general is not very frequent in our country and its prevalence is ignored, 

being this more important in developed countries as United states where an increment is reported in the last years (1). their 

manifestations generally debut in the childhood what differs of the case that will be presented next, where the symptoms began to 

the 50 years of age. 

objective: to present the case of a 58 years-old woman with history of two previous episodes of angioedema caused by peanut 

consumption with negative cutaneous and in vitro tests whose clinical condition was confirmed by means of a oral controlled food 

challenge with peanut and whose has like comorbidity aspirin allergy. 

method: For the patient’s diagnostic approach was conducted a skin prick test with food extracts that included the peanut extract, 

we also did a prick by prick test with peanut. specific igE for peanut was requested, and finally we carry out a controlled oral food 

challenge. 

For the study of the reactions to the nsAiD a nasal challenge with aspirin and an oral controlled challenge with meloxicam was 

carried out to offer the patient an anti-inflammatory option in the event of needing it. 

results: the skin prick test, prick by prick test with peanut and specific igE in vitro test for peanut allergy was all negative, the 

controlled oral food challenge with peanut caused an episode of urticaria and angioedema, with an accumulated dose of 9 grams 

of peanut. the controlled nasal aspirin challenge was positive and in the controlled drug challenge with meloxicam the patient 

tolerated a total dose of 15 mg of medication without presenting adverse reactions. 

Conclusion: the most interesting fact in this case is that although it has been described a sensibility and negative predictive values 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

for peanut prick test over 95% (2) and a lower but not worthless diagnostic accuracy for in vitro test, we suggest that according 

with our patient, if there is a positive causal relationship in the medical interview a controlled oral food challenge must be carried 

out as the gold standard for food allergy diagnosis. 

references 

1. Scott H. Sicherer, mD,a anne muñoz-Furlong, Ba,c James H. godbold, PhD,b and Hugh a. Sampson, mDa . US 

prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up JaCi 2010; 125(6): 1322 

2. Saleh al-muhsen, ann E. Clarke, rhoda S. Kagan. Peanut allergy: an overview. CmaJ 2003; 168(10): 1529 

2218 

ECZEma inDUCED BY FooD allErgY: CoUlD iT mimiC an immUnE DEFiCiEnCY? 

Arshi, s. , nabavi, m. , Babaie, D. and ghalehbaghi, B. 

Allergy and Clinical immunology, hazrat-e rasool Hospital, iran University of medical sciences, tehran, iran. 

Absrtract: Food allergy occurs in 4–6% of young children, it is a major cause of life-threatening hypersensitivity reactions. A 19 

month girl was admitted to our hospital because of recurrent infections and ulcerative skin lesions on trunk, hands and legs 

predominantly on creases and diaper, which has been started since 2 month of age. she was born by nVD and went on formula 

after 2 month. she was febrile and ill. she was admitted for several times in Baku because of sever eczema and 2 episodes of 

infections and received iVig.On lab evaluations there were leukocytosis and neutrophilia. immunologic study (CD flowcytometery, 

immunoglubolones, phagocytosis, opsonozation, and chemotaxis ) was performed which was unremarkable. Although she received 

full doses of H1 and H2 blockers, suffered from sever pruritis. so the skin prick test wasn’t reliable . in history she drink a kind 

of herbal tea since 4 months of age and major foods of her diet were bread and potato. riDA test was performed and sever 

food allergy was detected. the child was hospitalized and went on appropriate treatment include restrict avoidance, hydration, 

moisturizing, local and systemic steroid, local and systemic antibiotic. After a few days of treatment his condition became so far 

better. this case report highlights the possible benefit exclusive breast feeding for infants under 6 months especially in atopic 

families. Considering the immunodeficiency syndromes in cases of sever eczema with infections is obviously necessary. Key words: 

food allergy, eczema, 

PoSTEr SESSion 2-3: Skin and other diseases 

2300 

ComParaTiVE EValUaTion oF EPiDEmiologiCal FaCTorS anD ComPliCaTionS oF CaTaraCT SUrgErY in DiaBETiC 

PaTiEnTS VErSUS non DiaBETiC PaTiEnTS 

fayyaz Jahani, sr., F. and sA.madani, A. 

medical, tonekabon Azad Univevercity of medical seinces, tonekabon, iran. 

introduction: in attention to prevalence of cataract as one of the most common disease in ophthalmology, also extraction with 

intraocular lens implantation as the most common surgery in ophthalmic surgery .this study was designed for comparison of 

epidemiologic factors and rupture of posterior capsule during surgery between diabetic and non diabetic patients. 

methods: the manner of this study was retrospective and information was prepared by extraction from the files of operated 

patients during of three years in tonekabon teaching hospital and information analyzed by sPss 11 software. 

results: from 199 patients that had been undergone cataract extraction and i.O.l implantation, 32 patients had diabetes (16/1℅) 

that 29 patients type 1 and 3 patients type 2 ,and 167 patients were non diabetic .factor of sexuality had not any role for producing 

of cataract in diabetic patients. tearing of posterior capsule during surgery was more common in diabetic patients versus non 

diabetic patients, and on the chi-square exam and Pierson coefficient equal to 0.000, meaningful relation was existed between 

diabetes and post capsular rupture .there was no meaningful relation between kind of sexuality and post capsular rupture. 

Conclusion: due to more chance of post capsular rupture in diabetic patients versus non diabetic patient .its better that cataract 

surgery in diabetic patients to be done with the best controls and equipments (vitrectomy machine).also prospective study for 

further evaluation of other complication of cataract surgery in diabetic patients to be proposed 

Key words : cataract ,posterior capsule rupture 


FinAl PrOgrAm

ABstrACts 

2301 

EFFECT oF a SYnBioTiC miXTUrE on aToPiC DErmaTiTiS in CHilDrEn: a ranDomiZED-ConTrollED Trial 

Ahanchian, ii, H. 1 , Farid, r. 2 , Jabbari, F. 2 and moghiman, t. 2 

1 2 Pediatric Allergy and immunology, mashhad University of medical sciences, mashhad, iran. mashhad University of medical 

sciences, mashhad, iran. 

Background: Atopic dermatitis (AD) is the most common chronic relapsing skin disease seen in infancy and childhood. the 

intestinal microbiota plays an important role in immune development and may play a role in the development of allergic disorders. 

manipulation of the intestinal microbiota by synbiotics may therefore offer an approach to the prevention or treatment of allergic 

diseases. 

objective: We studied the clinical and immunologic effects of a new symbiotic(a mixture of seven probiotic strains of bacteria and 

Fructooligosaccharide) in infants and children with AD. 

method: in a randomized, double-blind, placebo-controlled study, 40 infants and children aged 3months to 6 years with AD 

received either a synbiotic or placebo for 8 weeks. the severity scoring of Atopic Dermatitis (sCOrAD) index was recorded at 

baseline and also at 4 and 8 weeks of treatment.. 

results: the synbiotic group showed a significantly greater reduction in sCOrAD than did the placebo group (P= 0.001).no specific 

effect was demonstrated of the probiotics employed on cytokine profile. 

Conclusion: this study provides evidence that a mixture of seven strains of probiotics and Fructooligosaccharide can clinically 

improve the severity of AD in young children. Further studies are needed to investigate the effects on underlying immune responses 

and the potential long term benefits for patients with AD. 

Keywords: Atopic Dermatitis, synbiotic, Cytokine, Children 

2302 

EFFiCaCY oF omaliZUmaB monoTHEraPY in THE managEmEnT oF aToPiC DErmaTiTiS 

syrigou, E. 1 , sinaniotis, A. 1 , Paraskevopoulos, J. 2 and Psarros, P. 3 

1 2 Department of Allergy, “sotiria” general Hospital, Athens, greece. Department of Allergy, 401 Army Hospital, Athens, greece. 

3Department of Allergy, naval Hospital, Athens, greece. 

Background:Omalizumab is a unique biological therapeutic drug licensed for the treatment of atopic patients with moderate to 

severe persistent allergic asthma with a serum igE ranging from 30 to 700 iU/ml. this study was performed to examine the efficacy 

of omalizumab for the treatment of atopic dermatitis, a disease with significant morbidity. 

methods:We report the case of three young Caucasian men (16, 18 and 24 years old) who presented with chronic severe atopic 

dermatitis that only responded to oral corticosteroids. Failed treatments for these patients included topical corticosteroids, 

topical tacrolimus, oral prednisone, oral antibiotics and oral antihistamines. Only oral corticosteroids provided significant relief. 

All three patients had also moderate to severe persistent allergic asthma. All three patients had increased serum immunoglobulin 

E (igE) levels: 532 iU/ml, 11.860iU/ml and 13.340iU/ml respectively (reference range, 11-210 iU/ml). All three patients received 

omalizumab a humanized monoclonal anti-igE antibody currently indicated for patients 12 years and older with moderate to severe 

persistent asthma, administered suncutaneously, in a total dose of 450mg every 15 days. Atopic dermatitis severity was assessed 

at 0, 1, 3, 6 months with sCOrAD. 

results:All the three patients responded to a 12-week course of omalizumab, with significant improvement of their atopic 

dermatitis symptoms. no adverse events were reported throughout the course of treatment. 

Conclusion:We suggest that omalizumab may have a role in the treatment of atopic dermatitis in the adult population and further 

studies are needed to establish its therapeutic effect. 

2303 

EFFECTiVEnESS oF omaliZUmaB in THE TrEaTmEnT oF ColD UrTiCaria 

sinaniotis, A. 1 , Psarros, P. 2 , Paraskevopoulos, g. 3 and syrigou, E. 1 

1 2 Department of Allergy, “sotiria” general Hospital, Athens, greece. Department of Allergy, Athens naval Hospital, Athens, greece. 

3Department of Allergy, 401 Army Hospital, Athens, greece. 

Background: the effectiveness of the humanized monoclonal antibody omalizumab in the treatment of physical urticaria has been 

demonstrated by a number of small studies and case reports. in this case study we sought to assess the effects of omalizumab in 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

patients with acquired cold urticaria (ACU), unresponsive to standard treatment with high doses of antihistamines, montelukast and/ 

or corticosteroids. 

methods: Four patients with ACU (three males, one female, median age = 34 years) with a critical stimulation time threshold (Cstt) 

at 3 minutes. three out of the four cold urticaria patients had a history of systemic anaphylactic reactions after exposure to cold 

environment and episodes of urticaria-angioedema several times a week during the winter, spring and autumn. 

results: treatment with omalizumamb, resolved symptoms in three out four patients with cold urticaria (time to clinical response 

1.5 months). Only the patient with the lowest total igE (4.1 iU/ml) had a mild response to treatment, although the Csst became 

negative on the second month of treatment. Conclusion:treatment with omalizumab can be beneficial in selected patients with cold 

urticaria refractory to standard treatment with antihistamines and /or corticosteroids. Patients with low levels of total igE may not 

respond adequately to treatment with Omalizumab. 

2304 

THE aCTiVE Form oF D ViTamin, CalCiTriol 1,25(oH)2D3 anD naTUral PPrgamma agoniST, -3 PolYUnSaTUraTED 

FaTTY aCiDS (PUFaS) migHT SErVE aS a nEgaTiVE FEEDBaCK looP To PrEVEnT EXCESSiVE inFlammaTion in PaTiEnTS 

WiTH SEVErE aToPiC DErmaTiTiS 

Zaharov, t. 1 , Chaynava, A. 2 , Kamenov, B. A. 3 and Kamenov, s. 4 

1 2 3 Pediatrics, regional Hospital næstved, naestvad, Denmark. Pediatrics, regional Hospital næstved, naestved, Denmark. Pediatric 

Clinic, Clinical Centre of nis, nis, serbia and montenegro. 4Pediatric, Helth Centre of nis, nis, serbia and montenegro. 

the function of vitamin D is promoting cell differentiation, cell maturation and inhibiting (uncontrolled) cell proliferation. VDr is 

expressed by almost all immune cells, including activated CD4+ and CD8+ t cells, B cells, neutrophils, and APCs . 1,25(OH)2D 

inhibits th-1 type immune function in adult (memory) cells, induces t regulatory cells, and enhances phagocytosis by white blood 

cells. Vitamin D inhibits the activation of t cells, and promotes tolerance in dendritic cells.39,40 VDr has also been implicated in 

toll-like-receptor (tlr) signaling and regulation of the innate immune response in macrophages. Current evidence indicates that 

PUFAs can prevent the development of inflammatory diseases by affecting different steps of the immune response. 

Case reports: 

14 months old girl, known with severe atopic dermatitis, debuted at first days of life, had relapsed several staphylococci cutaneous 

infections, vasculitis like syndrome without positive verification of PCr/Antibody of Herpes family virus and was many times in 

treatment with per os and i.v. antibiotics. in the first 9 months of age exclusive breastfeedings, but due to event stimulation after 

mothers diet, stopped. started with diet restriction, only specific milk formula neocat, PUFAs , calcitriol and probiotics(lgg). 

results: 1) before immunomodulatory therapy, only with skin care and topical Cs, intermittent topical calcineurin inhibitors and 

pruritis control: very high igE over 5000, over 100 for cows milk, eggs and cross reaction almost of all, one that was normal was 

fish and shrimps igE, high Eo counts, 1.68, thrombocytosis and neu-peni. Calcitrol 204, normal levels of immunoglobulin’s, C1q 

concentration 77%, slightly below ref. intervals, reduced activity of complement via the mBl pathway and decreased concentration 

of B cells. 2) After: normalization of le and tr counts, especially nice response in Eo are decreasing to 0.53, reduction in igE level 

to 2500.EDtA blood for t, B and nK cell: normal proportions and concentrations of t and B / nK lymphocytes, nice response of 

virgin tcell, normal exposure of adhesions molecules, normal t cell proliferation by polyclonal stimulation, normal value of somatic 

mutation. there are no signs of maternal engraftment on the CD4/CD8 separated cells. there is not sign of stAt3 deficiency. 

Clinical benefit, much better without signs of acute infections and severe itching, almost normal skin without lesions, normal 

growth. 

2305 

mETHoTrEXaTE For UrTiCarial VaSCUliTiS anD angioEDEma WiTH CrYogloBUlinEmia 

Butt, A. , Alkhalil, m. , ledford, D. and lockey, r. F. 

Division of Allergy & immunology, University of south Florida and James A. Haley Veterans’ Hospital, tampa, Fl. 

Background: Cryoglobulinemia (Cg) is associated with a leukocytoclastic vasculitis primarily affecting the kidneys, skin and 

peripheral nerves. Urticaria, but not usually angioedema, is a potential presentation for Cg. Cryoglobulins are usually associated 

with infectious, autoimmune and lymphoproliferative disorders; therefore, treatment options are varied. We report a patient with 

corticosteroid (Cs)-dependent urticaria and angioedema (U/AE) who was able to discontinue Cs therapy following weekly oral 

methotrexate (mtX). 

results: 57-year- old Caucasian male presented with a seven month history of recurring symptoms of generalized urticaria and 

facial angioedema. the symmetrical rash initially developed after a dental procedure requiring penicillin therapy. the findings 

were attributed to penicillin, but persistence of the rash prompted a skin biopsy which demonstrated a leukocytoclastic vasculitis. 

Prednisone, 10 mg twice daily, resulted in minimal improvement of the rash, but arthritic pain in the hands and knees developed. 

An immunologic and rheumatologic evaluation showed type 3 mixed Cg without monoclonal protein, 2+ urinary protein, decreased 


FinAl PrOgrAm

ABstrACts 

C3 (50 mg/dl; normal 90 – 180 mg/dl) and CH50 (13 U/ml; normal 31-66 U/ml). negative studies included serum rheumatoid 

factor, hepatitis antibodies, anti-nuclear antibody, anti-neutrophil cytoplasmic antibody and Ct scan of the abdomen. 

treatment with daily doxepin, 100 mg, meloxicam, 7.5 mg, hydroxycloroquine, 400 mg, and prednisone, 20 mg, was ineffective for 

the U/AE. Exacerbations occurred when the dose of prednisone was reduced. Oral mtX, 25 mg weekly, facilitated a prednisone 

taper, which was discontinued completely within 6 months without U/AE exacerbations. the cryoglobulin quantification remained 

unchanged. 

Conclusion: the differential diagnosis of U/AE includes a variety of less common immunologic conditions. the mechanism of 

action of weekly, oral mtX is not completely understood. suppression of cell replication is probably not the primary mechanism of 

action. Weekly mtX is a minimally immunosuppressive therapy that may be effective for U/AE associated with Cg. Evaluation for 

Cg should be considered in subjects with U/AE requiring chronic Cs therapy or with features of leukocytoclastic vasculitis. 

2306 

anTi-igE (omaliZUmaB) EFFECTiVE aS SinglE-DrUg THEraPY For CHroniC iDioPaTHiC UrTiCaria 

gonzález-Cervera, J. 1 , rodríguez-Domínguez, sr., B. 1 , Antolín-Amérigo, D. 2 , Henríquez-santana, A. 2 , ruiz Hornillos, F. 2 and 

manzano, D. 1 

1 2 Allergy, Hospital general de tomelloso, tomelloso, spain. Allergy, Hospital de Valdemoro (madrid), madrid, spain. 

objective: report a clinical case in which Anti-IgE (omalizumab) effectiveness and security are pointed out evidencing omalizumab 

as a suitable alternative medication for Chronic idiopathic urticaria in non-responders to recommended conventional therapy 

(Antihistamines and corticosteroids). 

methods and material: *Case report: A 35 year-old caucasian male suffering from generalized and extremely pruritic 

erythematous infiltrative hives during the previous 6 years on a daily basis together with facial angioedema fortnightly was referred 

to our Allergy Division. Daily Levocetirizine, Hydroxicine and Ranitidine were insufficient to relieve his cutaneous lesions, requiring 

systemic corticosteroids monthly resulting in lack of effectiveness. Cutaneous eruption and swelling is not clearly related either to 

food/drug intake or physical agents. Complementary tests: Blood cell count, Biochemistry, total igE and specific igE to Anisakis, 

milk, egg, peanut and haddock, antithyroid autoantibodies, HBV, HCV and HIV serology; Urine analysis, stool ova and parasites exam 

as well as thorax radiography were performed. 

results: Blood Cell Count and Biochemistry taken from peripheral blood sample were both within normal range. total igE was 

115,2 Ui/ml. specific igE to Anisakis Simplex, milk, egg,peanut and haddock was

ABstrACts 

ABstrACts 

antihistamines, antileukotriene and immunomodulators like cloroquine, azatioprine, colchicine and steroids, the cyclosporine was 

contraindicated by its malignant hypertension. 

therefore we decided to begin treatment with omalizumab at doses of 150 mg monthly (total igE 18 Ui/ml) associated to 

antihistamine and antileukotriene. 

result: After 3 doses of this therapy hives and angioedema remission was obtained and lasted for two months. 

Conclusion: the omalizumab can be an option in patients with vasculitic, pressure and autoimmune urticaria resistant to others 

management lines, being even safer than steroids and immunomodulators. the low levels of our patient’s total igE make to think 

that the effect of this medication is not only ig E dependent as has been suggested by several authors. 

2308 

oPEn-laBEl USE oF nanoFilTErED C1 ESTEraSE inHiBiTor (HUman) For THE TrEaTmEnT oF HErEDiTarY angioEDEma 

(HaE) aTTaCKS 

Craig, t. J. 1 , Zuraw, B. 2 , lumry, W. 3 , Baker, J. 4 , levy, r. 5 , Hurewitz, D. 6 , White, m. 7 , riedl , m. 8 , Busse, P. 9 , Bielory, l. 10 , grant, J. A. 

11 12 13 13 13 13 , Kalfus, i. , Broom, C. , Villano, s. , Uknis, m. , tillotson, g. and the Cinryze study group 

1 2 3 Penn state University, Hershey, PA. the scripps research institute, la Jolla, CA. Allergy and Asthma specialists, Dallas, tX. 

4 5 6 University of michigan, Ann Arbor, mi. Family Allergy and Asthma Center, PC, Atlanta, gA. Allergy Clinic of tulsa, inc., tulsa, OK. 

7 8 9 institute for Asthma and Allergy, Wheaton, mD. UClA medical Center, los Angeles, CA. mount sinai school of medicine, new York, 

nY. 10UmDnJ - new Jersey medical school, newark, nJ. 11University texas medical Branch, galveston, tX. 12lev Pharmaceuticals, 

Plymouth meeting, PA. 13ViroPharma incorporated, Exton, PA. 

introduction: nf-C1 inH (Cinryze) is approved in the Us for routine prophylaxis against angioedema attacks in adolescent and adult 

patients with HAE. this study evaluated the efficacy and safety of repeat use of nf-C1 inH for the treatment of HAE attacks. 

methods: this open-label, multicenter (29 sites) study enrolled 113 subjects with a diagnosis of HAE. Approval was obtained 

from WirB and informed consent obtained from all subjects. subjects were eligible to receive nf-C1 inH 1000U iV for attacks of 

angioedema at any anatomic location. subjects could receive a second dose of nf-C1 inH 1000U if they had not improved by 60 

minutes. Documentation of attack occurred every 15 minutes by diary card. the presence of three consecutive assessments of 

improvement constituted relief. safety was monitored by recording AEs, vital signs, virology (HBV, HCV, HiV) and anti-C1 inhibitor 

antibody. 

results: Of the 113 subjects (aged 2-80 years) in this study, 101 received nf-C1 inH for an acute attack, and were included in the 

efficacy analysis. twelve received nf-C1 inH for short-term prophylaxis only. A total of 609 attacks in 101 subjects were treated. 

median time to beginning of relief of the first attack was 45 minutes. Of 84 laryngeal attacks, none required intubation after receipt 

of nf-C1 inH. no difference was observed in subject response between children and adults. in subjects treated for >1 attack the 

efficacy of nf-C1 inH was not reduced; of 15 subjects who had ≥ 10 attacks, the median time to beginning of relief of their 10th 

attack was 30 minutes. Adverse events were reported in 41% (46/113) of subjects. the majority (87%) were of mild or moderate 

intensity. the most common (3%-5% of subjects) were sinusitis, nasopharyngitis, streptococcal pharyngitis, HAE, constipation, 

cough, rash, and bronchitis. there were no severe hypersensitivity reactions, including anaphylaxis, related to nf-C1 inH. HBV, HCV, 

and HiV testing revealed no evidence of viral transmission. there was no evidence of development of clinically relevant anti-C1 inH 

antibodies. 

Conclusion: nf-C1 inH was safe and effective for the treatment of all HAE attacks. For subjects with >1 attack, the efficacy of nf-C1 

inH for the treatment of HAE did not diminish with subsequent repeated administration. 

2309 

oPEn-laBEl USE oF nanoFilTErED C1 ESTEraSE inHiBiTor (HUman) For THE ProPHYlaXiS oF HErEDiTarY 

angioEDEma (HaE) aTTaCKS 

Zuraw, B. 1 , Baker, J. 2 , Hurewitz, D. 3 , White, m. 4 , Vegh, A. 5 , Bielory, l. 6 , lumry, W. 7 , riedl , m. 8 , Davis-lorton , m. 9 , levy, r. 10 , 

grant, J. A. 11 , Busse, P. 12 , Banerji, A. 13 , li, H. H. 14 , Kalfus, i. 15 , Broom, C. 16 , Villano, s. 16 , Uknis, m. 16 , tillotson, g. 16 and the Cinryze 

study group 

1 2 3 4 the scripps research institute, la Jolla, CA. University of michigan, Ann Arbor, mi. Allergy Clinic of tulsa, inc., tulsa, OK. institute 

for Asthma and Allergy, Wheaton, mD. 5Puget sound Allergy Asthma and imm., tacoma, WA. 6UmDnJ - new Jersey medical school, 

newark, nJ. 7Allergy and Asthma specialists, Dallas, tX. 8UClA medical Center, los Angeles, CA. 9Winthrop - University Hospital, 

mineola, nY. 10Family Allergy and Asthma Center, PC, Atlanta, gA. 11University texas medical Branch, galveston, tX. 12mount sinai 

school of medicine, new York, nY. 13massachusetts general Hospital, Boston, mA. 14institute for Asthma & Allergy, Chevy Chase, mD. 

15 16 lev Pharmaceuticals, Plymouth meeting, PA. ViroPharma incorporated, Exton, PA. 


FinAl PrOgrAm

ABstrACts 

introduction : HAE is a genetic disease characterized by recurrent, painful and potentially life-threatening swelling episodes. this 

study evaluated the safety and efficacy of nf-C1 inH for routine prophylaxis of HAE attacks. 

methods: this open-label, multicenter study (47 sites) enrolled 146 subjects aged ≥1 year with HAE and ≥1 attack per month or 

history of laryngeal edema. Approval was obtained from WirB and informed consent obtained from all subjects. nf-C1 inH was 

administered prophylactically at 1000 U iV every 3 to 7 days. subjects were also eligible to receive treatment with nf-C1 inH for 

acute attacks. subjects were instructed to document all attacks on a daily basis. safety was monitored through the recording of 

AEs, vital signs, virology and anti-C1 inH antibody assessments. 

results: mean age was 37 years (range 3-82). Pre-enrollment, subjects had a median HAE attack rate of 3.0 per month (range: 

0.08-28.0). On nf-C1 inH prophylaxis, the median number of HAE attacks per month was 0.2 (range: 0 4.6) and 86% experienced 

an average of ≤1 attack per month; 35% reported no attacks during the study. Exposure to nf-C1 inH varied (range: 8 to 959 days), 

73% received nf-C1 inH over a period of at least 6 months. For subjects receiving therapy for at least one year, the median attack 

rate was consistently low at 0.3 per month (range 0-4.0). irrespective of age, laboratory analysis demonstrated persistent rise in 

C1 inH antigenic and functional levels following nf-C1 inH therapy. Of 74 subjects tested, there were no detectable anti-C1 inH 

antibodies following C1 inH administration. Adverse events most frequently reported related to nf-C1 inH were: headache 5.5%, 

nausea 4.1%, rash 2.7%, erythema 2.1% and diarrhea 2.1%. the most commonly reported sAE was HAE attack (11.6%). Five 

subjects experienced thrombotic sAEs: mi, DVt, PE, and 2 CVA; none of these was considered to be related to nf-C1 inH. there were 

no severe hypersensitivity reactions related to nf-C1 inH. there was no evidence of transmission of HBV, HCV, or HiV during this 

study. 

Conclusions: Administration of nf-C1 inH reduced the median monthly HAE attack rate. the distribution of monthly attack rates 

per subject over a 1-year period showed persistent effects of prophylactic nf-C1 inH. these data support the safety and efficacy of 

nf-C1 inH for routine prophylaxis of HAE attacks. 

2310 

oPEn-laBEl USE oF nanoFilTErED C1 ESTEraSE inHiBiTor (HUman) (nF-C1inH) For TrEaTmEnT oF aCUTE aTTaCKS oF 


Craig, t. J. 1 , lumry, W. 2 , Baker, J. 3 , Davis-lorton , m. 4 , manning , m. 5 , Kalfus, i. 6 , Broom, C. 7 , Villano, s. 7 , Uknis, m. 7 , tillotson, g. 7 

and the Cinryze study group 

1 2 3 4 Penn state University, Hershey, PA. Allergy and Asthma specialists, Dallas, tX. University of michigan, Ann Arbor, mi. Winthrop - 

University Hospital, mineola, nY. 5Allergy and immunology Associates, scottsdale, AZ. 6lev Pharmaceuticals, Plymouth meeting, PA. 

7ViroPharma incorporated, Exton, PA. 

introduction: HAE is an autosomal dominant disease of deficient functional C1 inhibitor (nf-C1 inH) manifested by attacks of 

angioedema commonly involving the gastrointestinal lining, extremities, face, larynx, and genitalia. HAE typically begins in childhood 

and worsens around puberty. Children have smaller airways complicating intubation during laryngeal attacks and are likely to suffer 

from upper respiratory infections which can trigger attacks, emphasizing the importance of appropriate treatment options for this 

age group. 

methods: Overall, this open-label, multicenter study evaluated subjects aged ≥1 year with a diagnosis of HAE; this subset analysis 

presents data on subjects aged

ABstrACts 

ABstrACts 

2311 

oPEn-laBEl USE oF nanoFilTErED C1 ESTEraSE inHiBiTor (HUman) (nF-C1 inH) For THE ProPHYlaXiS oF aTTaCKS oF 


Hurewitz, D. 1 , grant, J. A. 2 , Busse, P. 3 , Davis-lorton , m. 4 , Baker, J. 5 , riedl , m. 6 , Banerji, A. 7 , levy, r. 8 , Craig, t. J. 9 , Kalfus, i. 10 , 

Broom, C. 11 , Villano, s. 11 , Uknis, m. 11 , tillotson, g. 11 and the Cinryze study group 

1 2 3 Allergy Clinic of tulsa, inc., tulsa, OK. University texas medical Branch, galveston, tX. mount sinai school of medicine, new York, 

nY. 4Winthrop - University Hospital, mineola, nY. 5University of michigan, Ann Arbor, mi. 6UClA medical Center, los Angeles, CA. 

7 8 9 massachusetts general Hospital, Boston, mA. Family Allergy and Asthma Center, PC, Atlanta, gA. Penn state University, Hershey, 

PA. 10lev Pharmaceuticals, Plymouth meeting, PA. 11ViroPharma incorporated, Exton, PA. 

introduction: HAE is an autosomal dominant disease of deficient functional C1 inhibitor (nf-C1 inH) manifested by attacks of 

angioedema commonly involving the gastrointestinal lining, extremities, face, larynx, and genitalia. symptoms of HAE typically begin 

in childhood and worsen around puberty. stanozolol is FDA approved for pediatric prophylaxis but has undesirable AEs, such as 

masculinization, premature puberty, and premature epiphyseal plate closure. this subset analysis evaluates the use of nf-C1 inH for 

routine prophylaxis in pediatric subjects with HAE

ABstrACts 

PoSTEr SESSion 3-1: immune mechanisms of allergy 

3100 

an UnUSUal PrESEnTaTion oF PUlmonarY maSS liKE lESionS SEConDarY To an allErgiC CaUSE 

rafique, m. and mahboub, B. 

Department of Pulmonary medicine, rashid Hospital, Dubai, United Arab Emirates. 

Background:31yr old male referred for evaluation of pulmonary masses presents with symptoms of cough with expectoration 

for 3yrs,intermittent dyspnoea & hemoptysis.H/o use of frequent antibiotics.loss of appetite& weight present methodsCXr show 

perihilar & central pulmonary masses.Ct sugg of large nodular bilateral opacities in upper lobes,middle lobe,lingula close 

to hilum,few small nodules in both lower lobes with no adenopathy. Bronchoscopy (FOB) showed features of dilatation of rt 

Upper lobe,middle lobe bronchi with extrusion of impacted mucus balls sugg of Bronchiectasis with inspissated mucus with no 

endobronchial growth resultsBroncho alveolar lavage & washings grew pseudomonas & aspergillus fumigatus,negative for 

malignancy and negativeAFB smear & cultures,total igE70 iU/ml,Absolute eosinophil count 200,mantoux negative,allergy skin 

tests positive for A.fumigatus,High A.fumigatus Ab 2560,specific igE m3asp39,50 Kua/l.Pulmonary function showed moderate 

obstruction with significant reversibility sugg of asthma. treated with levofloxacin 2wk, Oral steroids 0.5mg/kg 2mth with tapering 

doses.Formeterol & Budesonide inhaler 160mcg 2puffs BD with Chest physiotherapy .His CXr& Ctscan showed complete clearance 

of pulmonary nodular masses in 2mths timeConclusion An Unsual presentation of Allergic Bronchopulmonary aspergillosis ABPA, 

which mimic tumour like opacities due to mucus plugging ,revealing underlying central bronchiectasis after clearance of mucus 

balls with background of undiagnosed asthma reference Allergic bronchopulmonary aspergillosis.Patterson strekmE Dept of 

medicine, section of Pulmonary and Critical Care medicine, the University of Chicago, Chicago, il 60637, UsA: 2010 may;7(3):237- 

44 Proc American thoracic society 

3101 

ForgoTTEn ParaSiTES in allErgY PraCTiCE 

Kumar, P. 

medicine, louisiana state University Health sciences Center, new Orleans, lA. 

BaCKgroUnD 

in UsA and other western countries, parasitic infestations are often overlooked as a cause of allergic diseases. in order to heighten 

awareness, the following three patients are being presented. 

PaTiEnTS mETHoDS & rESUlTS 

Case i: 26 year old female presented with two year history of generalized urticaria and periorbital angioedema. travel history 

included trip to india 6 months prior to onset of symptoms. she had elevated eosinophil count (518/mm3), elevated total igE 

(1376 K U/l). specific igE antibodies to ascaris were elevated at 9.29 K U/l (normal

ABstrACts 

ABstrACts 

3102 

CHaraCTEriSTiCS oF rHinoVirUS-inDUCED PBmC immUnE rESPonSES in aSTHmaTiCS, From inFanCY To aDUlTHooD 

Katsuhito, i. 1 , Katsunuma, t. 1 , saito, H. 2 and matsumoto, K. 2 

1 2 Pediatrics, Jikei University, school of medicine, tokyo, Japan. laboratory for allergy, Department of Allergy and immunology, 

national research institute for Child Health and Development, tokyo, Japan, tokyo, Japan. 

Background: Asthmatic patients have higher susceptibility to rhinovirus (rV) infection, the most common trigger of asthma 

exacerbations in children and adults. impaired iFn-alpha and lambda production in bronchial epithelial cells from asthmatic adults 

upon exposure to rV has been demonstrated in vitro. However, the mechanisms underlying the increased susceptibility to rV 

infection in asthmatic patients are not fully understood. the aim of the present study was to investigate the characteristics of the 

immune responses of peripheral blood mononuclear cells (PBmCs) from asthmatic patients to rV stimulation. 

methods: PBmCs obtained from three different age groups (1-6y: young children group; 7-19y: youth group; 20-y: adult group) 

of asthmatic patients and non-asthmatic control subjects were stimulated with rV14 for 72 h. Healthy adults with a history of 

childhood asthma were also enrolled. the concentrations of iFn-alpha, il-6, tnF-alpha, il-10 and soluble Fas ligand (sFasl) in the 

supernatant were measured by ElisA. 

results: When compared with age-matched control subjects, the level of iFn-alpha protein was significantly lower in the asthmatic 

youth group. the levels of il-6, tnF-alpha, il-10 and sFAsl proteins were significantly lower in both the asthmatic youth and adult 

groups. such impaired responses were not found in healthy adults with a history of childhood asthma. no significantly different 

responses were found between the asthmatic and control young children groups, whereas young asthmatic children with persistent 

wheeze after 2 years of follow-up showed significantly lower il-10 production than those without persistent wheeze. 

Conclusions: impaired production of both anti-viral and inflammatory cytokines by PBmCs upon rV stimulation may be involved in 

the higher susceptibility to rV infection that is seen in asthmatic patients. in addition, such immune responses–especially regulatory 

cytokine production–may play important roles in the development or disappearance of persistent wheeze in children with asthma. 

3103 

CUrCUmin maY inHiBiTS T CEll aCTiVaTion THroUgH STorE-oPEraTED Ca2+ EnTrY CHannElS anD K+ CHannElS 

Kim, W. K. 1 and nam, J. H. 2 

1 2 Asthma & Allergy, Dongguk University ilsan Hospital, goyang, south Korea. Physiology, Dongguk University collage of medicine, 

Kyung Ju, south Korea. 

Ca2+ -release activated Ca2+ channel (CrAC)-mediated increase in cytoplasmic Ca2+ concentration (D[Ca2+ ] ) is a critical early step of 

c 

signals for the activation of lymphocytes. Also, the voltage-gated K + channel (K ) and intermediate-conductance Ca v 2+ -activated K + 

channel (iKCa1/sK4) draw attention as pharmacological targets for regulating immune responses. since polyphenolic agents have 

various ranges of anti-inflammatory or immunomodulatory effects, here we compared the effects of curcumin, rosmarinic acid, 

resveratrol and epigallocatechin gallate on the ionic currents through CrAC (i ), Kv (i ), sK4 (i ), and on the D[Ca CrAC Kv sK4 2+ ] in Jurkat-t 

c 

cells, using fura-2 spectrofluorimetry and patch clamp technique. Curcumin (10 mm) inhibited both anti-CD3 Ab-induced D[Ca2+ ] 

c and thapsigargin-induced store-operated Ca2+ entry (sOCE) via CrAC. Ferulic acid and vanillin, the metabolites of curcumin, 

had no effect on sOCE. Dose-dependent inhibition of i by curcumin was confirmed in Jurkat t (iC , 5.9 mm) and the HEK-293 

CrAC 50 

cells overexpressing Orai1 and stim1 (iC , 0.6 mm). Also, curcumin potently inhibited both i (iC , 11.9 mm) and i (iC , 4.2 

50 Kv 50 sK4 50 

mm). the other polyphenols (rosmarinic acid, resveratrol and epigallocatechin gallate at 10 – 30 mm) had no effect on sOCE, and 

showed only a partial inhibition of the K + currents. in summary, among the tested polyphenolic agents, curcumin showed prominent 

inhibition of major ion channels in lymphocytes, which might contribute to the anti-inflammatory effects of curcumin when 

sufficient concentration is reached in vivo. 

3104 

nano-SiZED WElDing FUmE inCrEaSES inFlammaTorY CYToKinES, aPoPToSiS anD g2 arrEST in HUman T CEll linE 

Chiung, Y. m. 1 , liu, P. s. 2 , Chen, Y. Y. 2 , lin, J. B. 1 and tsai, C. J. 3 

1 2 Division of medicine, institute of Occupational safety & Health, taipei County, taiwan. Department of microbiology, soochow 

University, taipei, taiwan. 3institute of Environmental Engineering, national Chiao tung University, Hsinchu. 

the impact on inflammatory cytokine Production, apoptosis and g /g phases of human t lymphocyte induced by welding fume 

1 2 

was investigated to discuss the effects of different ranges of particle size. the on-site dusts were collected by micro orifice uniform 

deposition impactor (mOUDi). Human t cell line, Jurkat cell were treated by different sized dust particles which were classified to 

ten ranges of 8hr collected welding fumes under Pm , prepared as 0.2 % buffered solutions, respectively. inflammatory cytokine 

10 

il-6 and tnF-a production were measured at 24 hours by ElisA, and found both of the two were much higher by the particles 


FinAl PrOgrAm

ABstrACts 

smaller than 100 nm. Cell cycle and apoptosis were performed by flow cytometry. After 72hrs treatment, the viability decreased 

slightly related with the increasing ranges of size of the metal fume particles, counted by trypan Blue stain and Propidium iodide 

(Pi) uptake, and apoptosis was estimated by cytosolic caspase 3 activation. the rates of apoptosis in each treatment were about 

7~12% of the control. the increase rate of caspase 3, is according to the order of particle size reduction. Different size of welding 

fume particles also affect sub g cell cycle from 1~9 %, and 23~26% of g /m stage of the total cells. With the reduction of particle 

1 2 

size, we observed a decrease tendency of sub g1 phase and an increase tendency of g /m phase in total cell percentages. 

2 

We conclude nano-sized particles in metal fume increases the production of inflammatory cytokines of t cell in a short term 

treatment, and makes cells arrested at g /m phase and increases cell apoptosis in a long term exposure. statistical results support 

2 

the ultra-fine and nano-scale particles in welding fume cause larger effects on inflammatory cytokine production, Caspase 3 and 

g /m arrest (r = -0.425, P= 0.019). some metals, such as manganese, Copper (Cu) and nickel were analyzed by Atomic Absorption, 

2 

only the concentrations of smaller sized Cu particles exhibited significant correlation with Pi (r=-0.20, P=0.04). the mechanisms 

induce production of cytokines; apoptosis and g2 arrest with nano-sized welding fume remain to be clarified in future. 

3105 

THE EFFiCaCY oF a naSal anTiHiSTaminE oloPaTaDinE For THE TrEaTmEnT oF SEroUS oTiTiS mEDia in CHilDrEn 

nsouli, s. 

Asthma and Allergy, DAnVillE AstHmA AnD AllErgY CliniC, DAnVillE, CAliFOrniA, UsA, Danville, CA. 

Previously we have shown that the combination of a nasal Corticosteroid mometasone with an oral antibiotic may be more 

efficacious than monotherapy with an oral antibiotic in the treatment of serous otitis media in children. 

since chronic inflammation is the histopathologic landmark of otitis media with effusion, clinical observations have led us to believe 

that the combination of a nasal Antihistamine Olopatadine with an oral antibiotic may be more effective than monotherapy with an 

oral antibiotic in the treatment of serous otitis media. 

We studied forty pediatric patients (age 6 years to 11 years) in a randomized open labeled 2-week trial to compare the efficacy of 

the combination nasal Olopatadine 665 mcg/nostril twice daily with an oral antibiotic Amoxicillin/Clavulanate potassium (90mg/kg/ 

day in 2 divided doses every 12 house) for the treatment of otitis media with effusion 

the efficacy of the treatment options was assessed using pneumatic otoscopy, impedance tympanometry, and audiometry to 

monitor the clinical course of the middle ear effusion in both treatment groups. 

in the combination group nasal Olopatadine and oral antibiotic a resolution of otitis media with effusion occurred at the 7th day. in 

contrast in the group treated with monotherapy with the oral antibiotic the resolution of otitis media with effusion occurred on the 

14th day. 

in conclusion, the combination of nasal antihistamine Olopatadine plus an oral antibiotic is more effective than monotherapy with an 

oral antibiotic. the combination nasal antihistamine Olopatadine plus an oral antibiotic may be a safer and shorter therapy given the 

safety issues with long term use of system antibiotics. 

3106 

ComBinaTion oF a naSal anTiHiSTaminE oloPaTaDinE anD a naSal CorTiCoSTEroiD, momETaSonE For THE 

TrEaTmEnT oF SEaSonal allErgiC rHiniTiS PaTiEnTS noT CUrrEnTlY ConTrollED on monoTHEraPY inTranaSal 

anTiHiSTaminE or inTranaSal CorTiCoSTEroiD 

nsouli, s. 

Asthma and Allergy, DAnVillE AstHmA AnD AllErgY CliniC, CAliFOrniA, UsA, Danville, CA. 

For seasonal Allergic rhinitis (sAr) patients that remain symptomatic on an intranasal antihistamine, Olopatadine or intranasal 

corticosteroid, mometasone furoate, the combination of intranasal antihistamine, Olopatadine with an intranasal cortiscosteroid 

mometasone may provide additional efficacy in sub-optimally controlled seasonal Allergic rhinitis Patients. 

in this open labeled 8-week trial 40 patients with symptomatic sAr currently using Olopatadine 1330 mgc/nostril BiD or 

mometasone furoate, 100 mcg/nostril QD were randomized to receive the combination Olopatadine 1330 mcg/nostril BiD + 

mometasone, 100 mcg/nostril QD. the end points of the trial include: rhinomanometry, nasal symptom score (composite score of 

nasal congestion, rhinorrhea, sneezing post nasal drip and itching) and flexible rhinopharyngolaryngoscopy examination. 

mean efficacy measurements at the end of the 8-week trial revealed significant improvements in all parameters examined in the 

combination treatment group as compared to baseline measurements. 

in conclusion, the combination nasal Olopatadine plus nasal mometasone is more effective than monothereapy nasal Olopatadine 

or nasal mometasone. it appears that in the combination treatment Olopatadine and mometasone, the primary end points 

(rhinomanometry and symptom scores) are significantly improved. 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

3107 

EXPErimEnTallY UnraVEling THE aToPiC marCH 

Wilson, m. s. 

molecular immunology, nimr, mrC, london, United Kingdom. 

Experimentally Unraveling the atopic march. 

mark s. Wilson. molecular immunology Division. national instiutes for medical research, mrC. mill Hill. london. UK. 

the sequential progression of allergic symptoms from atopic eczema, food allergy, rhinitis and asthma have been widely reported 

and referred to as ‘the Atopic march’. Co-morbidities of allergic conditions and the over-dispersed distribution of allergic diseases 

within few individuals have also been identified. these data suggest that allergic diseases may be linked; however the relationships 

between allergic symptoms are unclear. to separate cause from consequence, we are investigating the immunological interactions 

between these disease phenotypes and have developed experimental models of allergic asthma, allergic rhinitis and food allergy. 

these models are used to ask whether food allergy, and/or upper airway rhinitis influence the development of lower airway 

asthma. mice sensitized and orally challenged with crude peanut antigen (CPA) are subsequently sensitized and challenged, in the 

lower airways, with house dust mite (HDm). A cohort of peanut-allergic mice will also be sensitized and challenged in the upper 

airways with ragweed (rW) prior to lower airway HDm challenge. We hypothesize that peanut allergy and rW-induced rhinitis will 

exacerbate HDm-sensitization (igE) and HDm-induced airway inflammation. the molecular mechanisms of such interactions will 

be investigated and tested. Our studies and latest observations will be presented. This work is supported by the Medical Research 

Council (MRC), UK. 

3108 

a noVEl rolE For THE ComPlEmEnT rEgUlaTor CD46 in EPiTHElial TigHT JUnCTion FormaTion/rEgUlaTion 

Al-shouli, s. t. 1 and Kemper, C. 2 

1 2 Clinical immunology and Allergy., King’s College london guy’s and s’t thomas’ Hospital, london, United Kingdom. mrC Centre for 

transplantation, london, United Kingdom. 

Background: the complement regulator CD46 has been shown to play a role in epithelial cell polarization and is overexpressed on 

epithelial tumor cells. it is clear that our understanding of the many functions of the complement system in health is growing but 

still not complete. it is therefore to be expected that complement will be connected in the future with additional human diseases. 

this research project focuses on just such a prediction: We have obtained data suggesting a novel role for CD46 in epithelial cell 

tight junction regulation and growth induction or restriction. these data suggest that complement may also play a previously 

unacknowledged role in another important human disease, colon cancer. Colon cancer is the third most common cancer in the 

UK with a poor prognosis because of a high mortality and recurrence rate, thus, there is a need to develop better treatments. 

methods: 1-Culture PtECs or Caco-2 cells for several days on 24 wells-plates to measure E-cadherin expression, CD46 expression, 

Cell-proliferation assessed and apoptosis induced in cells. 2- Culture the human kidney proximal tubular epithelial cells (PtECs) 

or the human intestinal cell line (Caco-2) for several days on transwells to measure transepithelial resistance (tEr) and Beads 

dextran. results: we found that CD46 interacts with E-cadherin and sPAK, both vital proteins in the maintenance of epithelial cell 

layer integrity. mutations in either protein cause colon cancer or iBD, respectively. Further, we observed that CD46 regulates tight 

junctions and by this transepithelial resistance and paracellular permeability. Based on these data we hypothesize that complement/ 

CD46 communicates with the E-cadherin/catenin network in epithelial cells (via interaction/activation of sPAK) and contributes to 

normal epithelial cell barrier integrity. Further, defects in CD46-mediated signals leading to disturbance in its crosstalk with the 

E-cadherin/catenin network may be a factor in malignant transformation. Conclusion: our study was conducted to ascertain the 

biological properties of CD46 in a cell-cell adhesion network. We believe that this study helped to further solidify this idea and set 

the ground for more detailed future studies. 

3109 

THE rolE oF EXTErnal PHYSiCal ForCES in TriggEring THE allErgiC rEaCTionS 

Athota, r. r. 1 , reddy, r. r. K. 2 , neerupudi, K. B. 1 and sam, r. A. 3 

1 2 3 Biochemsitry, Andhra University, Visakhapatnam, india. Department of Physics, s K University, Anantapur, india. internal medicine, 

Christian medical College, Vellore, india. 

Background: in the era of scientific advancements, the allergic population is increasing at an alarming rate in modern urban 

society. in this context, the influence of the external forces like humidity and other physical forces in triggering the allergic 

symptoms is investigated. 

methods: the humidity has been measured in two cities namely Visakhapatnam, a coastal city and Anantapur, a non-coastal 


FinAl PrOgrAm

ABstrACts 

and dry weather city of Andhra Pradesh state in india, and the number of allergic population has been determined basing on the 

appearance of allergic symptoms, and measuring the absolute esinophil count, peak expiratory flow rate and estimation of igE 

antibody. 

results: Visakhapatnam city with ~70% humidity is found to trigger about 30% migrants to develop allergic symptoms to that of 

Anantapur city with ~40% humidity to 10% migrants to be allergic. Physical forces/non-immunogenic agents like rainy season, 

onslaught of monsoon, dampness, odors, exposure to sun light at certain angles or direct exposure to air conditioned breeze could 

trigger the spontaneous allergic rhinitis/asthma. Furthermore, a small variation in humidity from room to room in the same building 

can trigger allergic reactions in susceptible individuals. these allergic symptoms can be prevented by regulating the fan speed, or 

air-conditioned breeze. And also, it is observed that allergic symptoms appear more frequently in indoors rather than in outdoors, 

this is due to humidity, soiled robes, the other agents like house dust mite, unhygienic conditions or combination of other facts. 

Conclusion: there are certain kinds of physical agents which can induce allergic symptoms and also certain perfumes can relieve 

off existing asthmatic symptoms. 

3110 

THE STaTiSTiCS TaKE iT all: ComParaTiVE analYSiS oF THE gEnomiC BaCKgroUnD oF CHilDHooD aSTHma in 

CaUCaSian PoPUlaTion 

Hadadi, E. 1 , Ungvari, i. 1 , Virag, V. 1 , nemeth, Z. 2 , Hullam, g. 3 , Antal, P. 3 , Falus, A. 1 and szalai, C. 1 

1 2 3 genetics, Cell and immunbiology, semmelweis University, Budapest, Hungary. Csertex Kft, Budapest, Hungary. Department of 

measurement and information systems, Budapest University of technology and Economics, Budapest, Hungary. 

Asthma is a complex pulmonary disease with genetic and environmental components. 

Our purpose with this work was to identify new genes and snPs implicated in pathomechanism of asthma. 

in this study we selected candidate genes described in the literature and from our previously completed whole genome gene 

expression microarray analysis of OVA induced mouse model of asthma. For further analysis we selected 308 genes. For the 

selection of snPs, we created a new web-based data-mining and data-analyzing platform with the integration of public datastores. 

the program performs model-based analysis on results of text and data mining processes, previous measurements and 

Bayesian statistical analyses. Out of the 2643 snPs in these genes 399 snPs were chosen and used for panel design. We designed 

four 48plex panels with Autoprimer software and the determination of snPs was carried out with single base extension assays 

(genomelab snPstream, Beckman Coulter). 

genotyping was performed in 349 asthmatic children and 461 controls. statistical analysis was carried out by conventional 

frequentist analysis (chi-square test and logistic regression) and a new method developed by our team for the Bayesian analysis 

of relevant variables based on Bayesian model averaging (using markov Chain monte Carlo methods) and complex properties of 

Bayesian networks such as markov Blanket sets and markov Blanket graphs. the developed methodology of “Bayesian, four-level, 

sequential analysis of relevance” is capable of incorporating diverse priors to facilitate knowledge-rich data analysis, effecting more 

reliable results on multidimensional genomic studies. 

According to conventional analyses (logistic regression and c2 test) 36 snPs appeared to be associated with asthma in Hungarian 

population while by Bayesian multilevel analysis (BmlA) only 16 snPs came to the front and from these 8 showed association 

with asthma. According to our understanding a multifactorial genetic background can be revealed only by complex and aggregate 

method which can filter out essential and cardinal elements and alleviate the ‘noise’ /statistical faults. in our further studies we 

would like to test and confirm this conception. 

3111 

PrEValanCE oF HUman-mETaPnUEmoVirUS inFECTion in WHEEZY aDmiTTED CHilDrEn 

Alyasin, Jr., s. 1 and moatari, A. 2 

1 2 Pediatric, shiraz University of medical science, shiraz, iran. influenza research Center, shiraz University of medical science, 

shiraz, iran. 

introduction: Viral infections such as parainfluenza, influenza and respiratory syncitial virus (rsV) contribute to the most of 

respiratory infections in children less than 5 year-old, yet causes for some 15-35% of children respiratory infections remained to be 

unknown. in recent years newly discovered human-metapnuemovirus (hmPV) showed to be one of the major causes for upper as 

well as lower respiratory tract infections especially in children. this virus also showed to be one of contributors in infants asthma 

exacerbation. 

method: in the present study, in one year, we examined 120 nasopharyngeal swaps from hospitalized children affected by 

wheezing for the presence of hmPV by rt-PCr technique. the datas are recorded in questionnaires. 

result: mean age for admitted children was 16 month-old .twenty out of 120 (16.6%) of 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

cases were positive for hmPV. HmVP prevalence among male was three times greater than female. All of the positive hmPV children 

were affected by wheezing. more over 31.3% were simultaneously affected by wheezing and asthma. significant correlation 

between clinical manifestation and more than 2 days of hospitalization and positivity of hmPV were detected. 

Conclusion: HmPV prevalence in children with asthma and wheezing was almost the same in shiraz in compare with the other part 

of the world. recent findindgs suggest a probable role of hmPV in asthma exacerbation and wheezing onset. 

3112 

SEroPrEValEnCE oF aniSaKiaSiS analiSYS rESiDEnTS From “alDEa DE PESCaDorES” ToWn, PUErTo la CrUZ, 

anZoaTEgUi 2010 

naime, m. , sofia, m. and Elizabeth, P. 

Escuela De Ciencias De la salud, Universidad de oriente, Puerto la Cruz, Venezuela. 

Anisakiosis is a zoonosis caused by nematodes Anisakidae family, of which there are many genres distinguished by their public 

health concern as: Pseudoterranova, Contracaecum, Hysterothylacium and Anisakis. Furthermore, there are four species recognized 

from Anisakis: A. simplex, A. physeris, A. typical and A. schupakovi. Anisakis simplex is being the most studied parasite in clinical 

practice, parasitizing marine mammals in its adult form, and in different larval stages affects fish and cephalopods. the humans, 

being an accidental host, it is acquired through the consumption of raw or undercooked fish. Anisakiosis could be a public health 

problem, especially in areas where the economy and feeding depend on fishing, causing health problems for the whole community. 

objectives: analyze the seroprevalence of anisakiasis in residents from “Aldea de Pescadores” town, sector i, Puerto la Cruz, 

Anzoátegui state. materials and methods: it was conducted an exploratory, field, prospective, cross-sectional research. there 

were taken samples of 93 local people from “Aldea de Pescadores” which were tested by Prick test and specific igE determination 

in order to detect positive Anisakiosis cases, to carried out a hypothesis test, analyzed by sPss 17.0. results: there was a (8.6%) 

of positive prick test to Anisakis simplex; 6.5% for the specific igE determination to the same parasite. However, verified the null 

hypothesis there were no differences in the prevalence of gastrointestinal, dermatological and/or breathing symptoms in those with 

skin and serological positive tests for Anisakis simplex. Conclusions: the results indicate that the Anisakis simplex infection is not 

a public health problem in “Aldea de Pescadores” town. nevertheless, there are a positive percentage of Anisakiasis cases in this 

town. For this reason, it is necessary the spread of information, and the application of prophylactic measures to avoid the increasing 

number of people affected by this disease. 

Keywords: Anisakiasis, Prick test, igE, Anisakis simplex. 

3113 

EFFECTS oF VarioUS rESPiraTorY VirUSES on DEr F-SEnSiTiZED moUSE moDEl oF aSTHma 

Kim, H. H. , Chun, Y. H. , Yoon, J. , Kim, J. t. and lee, J. s. 

Pediatrics, the Catholic University of Korea, Pucheon-si, south Korea. 

Purpose: respiratory viral infection is the main cause of acute asthma exacerbation in children and can be a confirmed viral 

infection in 85% of children who visit a hospital because of asthma exacerbation. Viruses related to acute asthma exacerbation are 

rhinovirus (rV), respiratory syncytial virus (rsV), parainfluenza virus (PiV), human metapneumovirus (hmPV) and influenza virus. 

Among the viruses, rV is the most well-known frequent cause virus of acute asthma exacerbation for children 2 years or more. 

some in vitro studies showed the immunologic responses after rV infection were different from other respiratory viruses. this 

may refer that the response to rV infection can be different to other respiratory viruses in patients with asthma. in this experiment, 

we determined cell counts and the level of cytokines in bronchoalveolar lavage fluid (BAlF) of asthma mouse model after being 

infected by rV, rsV, or influenza virus in order to evaluate that there are differences in the kind of virus. 

methods: Asthma mouse model is made by sensitizing BAlB/c mouse to house dust allergen Der f. the asthma mouse model is 

confirmed by measuring the airway resistance caused by methacholin inhalation, the eosinophil counts, interleukin (il)-4, il-5 and 

il-13 in BAlF, and by observing peribronchial eosinophilic inflammation of lung tissue through a microscope. After the prepared 

asthma mouse model is infected by rV, rsV, and the influenza virus respectively, the rt-PCr is used to confirm the existence of 

virus genes in lung tissue. We determined the number of eosinophils, neutrophils, lymphocytes and macrophages in BAlF and 

measured rAntEs and inF-γ in BAlF of the mice infected by the viruses. 

results in the case of the Der f-sensitized mouse model with rV infection, the airway resistance and eosinophil counts in BAlF 

increased, and inF-γ level did not increase by the virus. these findings were different from in the case of rsV or influenza virus 

infection. 

Conclusion: in the case of infecting a respiratory virus to the developed asthma mouse model with the sensitized house dust mite 

allergen, increased airway resistance and eosinophilic inflammation with no increase in th1 response were shown only with rV. 

these findings can be related to the phenomenon that rV is most frequently found to be the cause of acute asthma exacerbation. 


FinAl PrOgrAm

ABstrACts 

3114 

igg4 aS THE PrEDominanT aUToanTiBoDY in SEra From PaTiEnTS WiTH aCTiVE STaTE oF PEmPHigUS VUlgariS 

Entezam, m. 1 and Ayatollahi, m. 2 

1 2 genetic Department, shiraz University of medical sciences, shiraz , iran. transplant research Center, shiraz University of medical 

sciences, shiraz, iran. 

Background: Pemphigus vulgaris (PV) is an autoimmune blistering disease of the skin and mucous membranes caused by 

pathogenic antibodies. the aim of this study was to determine the antigen-specific subclasses of igg present in the sera of 

iranian patients with the active form of the disease and those in remission. methods: serum samples from 75 patients with 

the clinical presentation of PV and 50 normal healthy subjects were investigated after informed consent to use these samples 

for investigational use. Distribution of the igg subclass autoantibody was studied by using specific monoclonal antibodies to 

igg1, igg2, igg3 and igg4 in 17 patients with active form of disease, and 20 patients in remission with an indirect ElisA based 

method. results: the mean optical densities (OD) for igg1−igg4 (1.22, 0.63, 0.55, 1.11) versus the controls (0.38, 0.26, 0.37, 

0.41) showed significant differences (P = 0.0001) for igg1 and igg4 in all PV patients. the mean OD of specific igg1 autoantibody 

(0.52) compared with normal controls (0.38) was found to be significant in patients in remission (P = 0.02), while the titres of 

igg4 autoantibody were not significantly different between patients in remission and control individuals (OD = 0.46 versus 0.41) 

(P = 0.37). Conclusion: Elevated levels of igg4 in patients with active disease, and of igg1 in patients in remission, point to an 

important finding regarding the pathogenesis of autoantibodies in PV patients. the finding concludes that the detection of igg4 in PV 

patients is pathogenic and should be considered as a clinical marker, while elevated igg1 autoantibody may be produced within the 

repertoire of natural and non-pathogenic autoantibodies. 

Keywords: Autoimmune disease, Pemphigus vulgaris, igg4 

PoSTEr SESSion 3-2 immunotherapy 

3200 

EFFiCaCY oF SUB-lingUal immUnoTHEraPY in PollEn allErgiC aSTHma 

Khoury, A. , Al-Fadel, r. and sawas, K. 

Chest Diseases, Aleppo Faculty of medicine, Aleppo, syria. 

objective: the aim of this paper is to studying the efficacy of pollen sublingual immunotherapy in allergic asthmatic patients due to 

grass pollens in two consecutive seasons .methods: A randomized, double-blind, placebo-controlled search was done to evaluate 

the efficacy, carry-over effect and safety of grasses pollens with (slit).We enrolled 41 patients and 14 placebo patient with age 

rang was between ( 18 – 50 ) years . During a 11- day dose progression phase, the patients received a daily successively increased 

doses ( 10 – 20 – 40 – 60 – 80 – 100 – 300 – 600 – 1200 – 1800 – 2400 ir ) followed by 2400 ir three times every week in two 

consecutive seasons. Primary efficacy variables were symptoms and medication scores, and secondary variables included global 

evaluation of efficacy. results: there was a statistically improvement in slit treated patent in comparison with placebo group 

P(0,001).side effects were mainly local without any systemic side effects, five patients had sublingual itching and one patient had 

sneezing which was resolved with continuing therapy. Conclusion: sublingual swallow immunotherapy seems to be safe and 

efficacious for allergic asthmatic patients due to grass pollen even when started immediately or during pollen season. 

Key Words : Pollen , grasses . immunotherapy , treatments 

3201 

SaFETY anD EFFiCaCY oF CarBamYlaTED monomEriC DErmaToPHagoiDES allErgoiD DEPoT FormUlaTion giVEn BY 

SUBCUTanEoUS roUTE 

Fancello, P. 1 , Atzeni, i. 1 , Bruno, m. 2 and Falagiani, P. 3 

1 2 Allergology service, “san gavino monreale” Hospital - Asl 6, sanluri (Cr), italy. medical service, lofarma s.p.A., milan, italy. 

3scientific Direction, lofarma s.p.A., milan, italy. 

Background: immunotherapy with monomeric allergoid proved to be well tolerated, safe and effective in patients with respiratory 

allergy. Aim of this study was to assess the tolerability of a carbamylated monomeric allergoid given by subcutaneous route to 

patients with allergic rhinitis with or without asthma. method: We evaluated, in a prospective open-label phase ii study, lasting 

about 8 months, 15 patients (8m/7F, age: 15 - 45 years, mean age: 30 years), suffering from allergic rhinitis with (5) or without 

(10) asthma mainly due to house dust mites. the patients were given subcutaneously, during the first 5 weeks of the study, an 

increasing dose (0.1, 0.2, 0.4, 0.6 ml at 10,000 BU/ml) of the carbamylated monomeric allergoid (lofarma s.p.A., italy) and then, 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

during the 7 maintenance months, a dose of 0.8 ml (at 10,000 BU/ml) with a monthly cadence. the amount of major allergen 

was 4 μg of group 1 per ml. At each visit, they were evaluated for any local and/or systemic adverse reaction (Ar) related to the 

administration of the product. At baseline and at the end of the study a visual analogue scale (VAs) was performed as well. results: 

no Ars were observed in 7 out of 15 patient (46.6%). Eight patients (53.3%) showed Ars. they were nearly all local and all mild: 

pain at the arm (2 patients), local itching (3 patients), local reaction of the dimension of a walnut (2 patient) and fever the day after 

the injection (1 patient). none of these Ars caused either the interruption of the treatment or the hospitalisation of the patient. there 

was an improvement of VAs score from 2.8 ± 1.6 to 6.8 ± 2.4 (p

ABstrACts 

Conclusion: Our study demonstrates that after a 3-year course of treatment; both modalities for administering immunnotherapy, 

i.e: slit and sCit, result in a significant decrease in mean wheal size for pollen relevant to our desert country. this can be a 

confirmation for the role of both forms of sit in modifying the nature of igE-mediated diseases. 

Key words: sit= Allergen-specific immunotherapy, slit = sublingual immunotherapy, sCit= subcutaneous immunotherapy, sAr= 

seasonal allergic rhinitis. 

3204 

KinD oF SEnSiTiZaTion in SUBJECTS UnDErgoing allErgoiD SUBlingUal immUnoTHEraPY. a rETroSPECTiVE STUDY 

(ParT i) 

simone, P. 1 and Amboni, P. 2 

1 2 UsC Pneumologia, Ospedali riuniti di Bergamo, Bergamo, italy. UsC Patologia Clinica e laboratorio Analisi, Ospedali riuniti di 

Bergamo, Bergamo, italy. 

Background and method 

234 subjects living in a subalpine region underwent allergoid sublingual immunotherapy (lofarma s.p.A., italy) (slit) during 5 

years for allergic oculorinitis and/or asthma unresponsive to pharmacologic treatments. We describe relationships between sex 

(m–F), age, average prick tests (PK) antigens (Ag) reactivity, Ag)/histamine wheal (1+2), for perennial (Pr) or 

seasonal (ss) Ag, mono (ms) or polysensitivity (Ps), and formulations in tablets (tB) or drops (DP). results 

19 Ag were tested (mean 16; range 9-19) always including 7: birch, grass mix (gr), mugwort, Parietaria mix (PAr), Alternaria 

alternata, Dermatophagoydes farinae (DF) and cat dander (Ct). 

the 145 m (61.9%) and 89 F had similar age (28.3-29.8; range 6-56; ds12.6) and ms (20-14) (13.8-5.7%) (p>0.38).5 Ag reacted 

the more, average gr 2.5 + DF-Dermatophagoides pteronyssinus (DErm) (1.9-1.7+), hazelnut-birch (BEt) (1.3-1.4+), the same in 

m and F (p>0.05). BEt-PAr reactivity increases with age, DErm-gr decreases, lower only for gr in ms (0.7+) than in Ps (2.9+) 

(p0,05) too ; m-ms increases with age (odds 5.6; p=0.05), not F-ms or m-F Ps (p=0.7). reflecting PK reactivity ms-Ag (Pr) slit 

were higher, 19 DErm (55.9%), than (ss), 9 BEt (26.5%) and 6 gr (17.6%); but Ps-Ag (Pr) slit lower (p=0.2): 81 DErm (40.5%) 

and 4 Kt (2%), 93 gr (46.5%), including 40 (43%) BEt associations and 9 PAr (9.7%); BEt alone 16 (8%), 3 PAr, 2 Cupressus and 

1 each mugwort and ragweed. the total slit were 130 ss slit (55.6%), 114 (48.7%) gr and/or BEt, BEt globally 56 (23.9%), 100 

DErm slit (42.7%). tB-slit were 173 (73.9%): 98 DErm (56.6%), 46 gr (26.6%), 21 BEt (12.1%), 4 Kt (1.2%), than 2 PAr, and 1 

each mugwort and ragweed. the 61 DP slit were 40 associations: gr+BEt (65.6%), 9 gr+PAr (14.7%), 2 Cupressus (3.28%) and 

10 gr, BEt, DErm or PAr. Conclusions 

in a subalpine region trees and DErm are important antigens. the high need for gr+BEt slit lead to think to common antigens. 

tB are often prescribed while DP imply particular antigens or associations. 

3205 

CliniCal CHaraCTEriSTiCS oF PaTiEnTS UnDErgoing allErgoiD SUBlingUal immUnoTHEraPY. a rETroSPECTiVE 

STUDY (ParT ii) 

simone, P. 1 and Amboni, P. 2 

1 2 UsC Pneumologia, Ospedali riuniti di Bergamo, Bergamo, italy. UsC Patologia Clinica e laboratorio Analisi, Ospedali riuniti di 

Bergamo, Bergamo, italy. 

Background and method 

235 subjects underwent allergoid sublingual immunotherapy (lofarma s.p.A., italy) (slit) for rhinitis (ri), asthma (As) with or 

without conjunctivitis (OC+/-). We describe relationships between sex (m–F), pathology, mono (ms) or polysensitivity (Ps), seasonal 

(ss) or perennial (Pr) slit. results 

slit regarded 230 ri (98.3%) including 151 As (ri+As) (65.6%), and 4 As (1.7%): so 155 As (66.2%), 97.4 % ri+, 86 (ri+As) were 

OC+ (57%), 45 ri ( 57%) and 1 As (25%): OC links to ri. the 145 m (61.9%) and F, the 200 Ps (85.4%) and 34 ms, had similar 

age (28.3-32.3 ) and also similar ms in m-F (20-14;13.8-15.7%) (p>0.38). Considering casual the 4 As, 3 m Ps (OC-) and 1 F 

ms (OC+), higher m prevailed also in pathology and (ss) or (Pr) slit: 44/79 ri (55.7%), 98/151 (ri+As) (64.9%) being m-ri 4/8 

ms (50%) and 40/71 Ps (56.3%) and m-(ri+As), 16/25 ms (64%) and 82/126 Ps (65.1%). in the 235 slit, 1 double in a m Ps, 

m were 146/235 (62.1%), 20/34 ms (58.8%) and 126/201 Ps (62.7%) (p=0,68) being m ss slit, total or ms or Ps, respectively 

84/131(64.1%), 9/15 (60%) and 75/116 (64.6%) and m Pr-its respectively 62/104 (59.6%), 11/19 (57.9%) e 51/85 (60%). in 

ss slit were 131 (55,7%): 84/146 m (57.5%) and 47/89 F (52.8%); higher in Ps 116/201 (57.7%), m 75/126 (59.5%), F 41/75 

(54.7%), whereas in ms prevailed Pr slit, total 19/34 (55.9%), if m 11/20 (55%) or F 8/14 (57.1%) (p=0,2). Higher prevalence of 

ri+As interested both sexes: in 145 m, 20 ms e 125 Ps, respectively 98 (67.6%), 16 (80%) and 82 (65.6%), where ri was 44 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

(30.3%), 4 (20%) e 40 (32%); in 89 F, 14 ms e 75 Ps, respectively 53 (67.6%), 44 ( 80%) and 9 (65.6%), with ri 35 (39.3%), 4 

(38.6%) and 31 (41.3%): globally a little higher prevalence of m (ri+As), and of F ri particularly if ms. similar findings were found 

relating (ri+As) to ss or Pr slit if ms and Ps. Conclusions 

slit selection seems independent from sex, pathology and kind of sensitivity and is suitable for all seasonal antigens. 

3206 

a SUrVEY oF allErgEn SPECiFiC immUnoTHEraPY in KorEa 

Hur, g. 1 , Kim, t. 2 , Han, m. Y. 3 , nahm, D. 4 and Park, J. 5 

1 2 internal medicine, Korea University College of medicine, seoul, south Korea. Department of Allergy and Clinical immunology, 

Asan medical Center, University of Ulsan College of medicine, seoul, south Korea. 3Pediatrics, Pochon CHA University College of 

medicine, seoul, south Korea. 4Allergy & rheumatology, Ajou University school of medicine, seoul, south Korea. 5Division of Allergy 

& immunology Department of internal medicine, Yonsei University College of medicine, seoul, south Korea. 

Background; Allergen-specific immunotherapy (sit) has been used as the only curative and specific treatment for allergic 

diseases. there have been no data on sit in Korea. therefore, we carried out a survey to observe the prescription pattern of allergy 

specialists in Korea. 

methods; All 690 members of the Korean Academy of Asthma, Allergy, and Clinical immunology received an e-mail attaching a 

questionnaire on sit, and were required to return the answers. All returned answers were recruited between August 2009 and 

september 2009. 

results; the response rate was 21.0%. Among them, 42.8% was physicians, 32.4% was pediatricians, and 20.7% was 

otolaryngologists. Only 69% of respondents performed sit in practice. the methods used to detect causative allergens were skin 

prick test (46.1%) and serologic tests (44.1%) such as immunoCAP and mAst. the limitations to to start sit in their own practice 

were lack of equipment (21%) and practical experience (15.8%), no necessary because pharmacotherapy alone was enough to 

treat (14.5%), no good profit (14.5%), and its risks for adverse reactions (13.2%). the target diseases for sit were allergic rhinoconjunctivitis 

(46%), allergic asthma (38%), and atopic dermatitis (10%). ninety-two allergic specialists (82%) performed sit via 

subcutaneous route (sCit) and 18% via sublingual route (slit). the allergens used for sCit were house dust mites (42.5%), pollens 

(31.3%), and animal dander (10.2%). twenty-eight (30%) doctors have experienced anaphylactic reaction during sCit. About 40% 

of doctors have experienced any adverse reaction including local reactions during slit. 

Conclusion; in Korea, 69% of allergy specialists performed sit in practice. the prevalence of sCit was 82% and slit was 18%. 

lack of equipment and practical education were critical barrier to performing sit in doctors. therefore, proper practical educations 

to update information on sit will be necessary for allergy specialists. 

3207 

SUCCESSFUl gamma-inTErFEron THEraPY in a CaSE oF rEFraCTorY VaCCinE-aSSoCiaTED aBSCESS in a CgD 

PaTiEnT 

nabavi, m. 1 , maherbanai, s. 1 and Bemanian, m. H. 2 

1 2 semnan medical University, tehran, iran. Yazd medical university, Yazd, iran. 

CgD is a rare phagocyte defect with an incidence of four to five per million individuals, caused by genes affecting one X-linked and 

three autosomal recessive chromosomes. it is associated with recurrent abscesses of different size and locations. We present an 8 

year old girl who developed large abscesses at her thigh since 2 years of age. 

Case report: 

the patient is an 8 year old girl who developed a large abscess at her thigh just at the site of childhood vaccinations when she was 

2 years of age. the large 4×5-sized abscess contained voluminous yellow-greenish pus which led to persistent drainage. many 

topical and systemic antibiotics were used without any result and multiple courses of hospitalizations with intravenous use 

of wide-spread antibiotics had no benefits. gram stain and smear always showed a mixture of microbial agents for instance 

staphylococcus, either s. alba or s.aureus. the abscess had 2 to 4 stoma apart from each other and sometimes locolation of pus 

posed the need to incision and drainage of mutiple sites. Once acid fast bacilli were grown and anti tubercolosis medications 

were prescribed and used for at least 9 months without any significant relief. Because of refractoriness of abscesses , phagocyte 

defect were sugessted and an immunological consultation performed when she was 6 years of age. immunoglobulines were within 

normal limits. nitro Blue tetrazolium (nBt) and Di Hydro rhodamine test (DHr) was performed and showed a significant defect 

of respiratory burst and the patient regarded as “ Chronic granulomatous Disease”. long term therapeutic doses of trimetoprimsulfisoxazole 

followed by continous prophylaxis, resulted to some relief. introduction of gamma- interferon as an every-other-day 

schedule were terminally led to closure of abscess stoma and terminated the discharge. multiple scars of previously draining 


FinAl PrOgrAm

ABstrACts 

abscesses are visible at her thigh. there was no other site of local or systemic infection and the general status remained good 

during and after gamma- interferon therapy. 

3208 

FloW CYTomETrY aS a Tool For DElaYED DrUg allErgY rEaCTionS DiagnoSiS: oUr EXPEriEnCE 

Ardito, s. 1 , De Donno, m. 2 , Aiello, V. 2 , iaia, m. l. 1 and maietta, g. 2 

1 2 Allergy Department, Perrino Hospital, Brindisi, italy. Cellular immunology, Pignatelli institute, lecce, italy. 

introduction. 

the lymphocyte transformation test (ltt) is the only test to detect a sensitization of t cells to drugs in the peripheral blood of drugallergic 

patients, but it is often considered more of a research than a diagnostic tool. in a pilot study, Pichler et al. evaluated surface 

molecule CD69 expression as a marker of t-cell activation in a group of patients with t-cell-mediated drug allergic reactions. CD69 

was detectable after 48 hrs by flow cytometry in all patients tested. 

Aim of the study. 

We analysed 11 clinical cases of adverse drug reactions we observed in our department of allergy. in all cases clinical patterns and 

the time of reaction indicated a delayed type of immune mechanism. 

the patients underwent clinical evaluation, skin tests for the suspected drug and CD69 analysis with flow cytometry. 

methods. 

Clinical evaluation was made by allergy specialist doctor in agreement with the questionnaire of EAACi interest group on drug 

hypersensitivity. 8 patients experienced maculo-papular rush or generalized urticaria after amoxicillin intake, 1 patient after 

levofloxacin and 2 patients after ibuprofen or ketoprofen administration 

skin test were performed as described by torres mJ et al. (1). 

CD69 analysis were performed with flow cytometry by using monoclonal antibodies anti CD3, CD4, CD69, as described from 

Pichler et al. (2) and results were expressed as s.i. (stimulation index). 

results. 

in the group of 8 patients with delayed adverse reactions after amoxicillin intake, 3 patients showed positive intradermal skin tests 

with the drug, while 5 patients were negative. CD69 analisys was positive in 6 of the 8 patients. 

the patient with maculo-papular rush after levofloxacine intake showed positive patch tests and positive CD69 analisys. 

the 2 patients with adverse reactions to nsAiDs showed negative patch tests, but positive CD69 analisys. 

Conclusions. 

On the basis of our clinical experience, CD69 measurement seems to be a promising tool to detect drug-reactive t cells in the 

peripheral blood of drug allergic patients. 

references. 

(1) m.J. torres , m. Blanca, J. Fernandez , A. romano, A. Weck, W. Aberer , et al. Diagnosis of immediate allergic reactions to betalactam 

antibiotics. Allergy. 2003: 58(10):961-72. 

(2) A. Beeler, l. Zaccaria,t. Kawabata, B.O. gerber, W.J. Pichler CD69 upregulation on t cells as an in vitro marker for delayed-type 

drug hypersensitivity. Allergy 2008: 63: 181–188 

3209 

CliniCal CHaraCTEriSTiCS oF oral TolEranCE inDUCTion oF non-igE mEDiaTED FooD allErgY USing iFn-gamma 

lee, sr., J. H. and noh, g. 

Department of Pediatrics, school of medicine, Chungnam national University, taejeon, south Korea. 

Background: Food allergies are classified as igE-mediated (iFA)and non-igE-mediated (nFA). late eczematous reactions of the skin 

were found to be one of typical and diagnostic symptoms of nFA. Clinically, oral immunotherapy for food allergy has been tried to 

induce oral tolerance. 

Objective: recently, oral immunotherapy for food allergy has been successful in nFA using subcutaneous iFn-gamma injection. 

We are to characterize the clinical findings of nFA and the induction of the oral tolerance to food allergen in nFA after oral 

immunotherapy using iFn-gamma. 

methods: non-igE-mediated food allergies were diagnosed by food challenge, skin prick test and food-specific igE. total 77 nFA 

patients with atopic dermatitis that is characterized by late eczematous skin reaction were selected in this study. 37 subjets were 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

treated with a relevant Oit protocol for nFA. As a control group 10 subjets received only iFn-gamma without allergenic food. 10 

subjets receive only food without iFn-gamma, and 20 subjets with nFA did not receive treatment. Patients were evaluated clinically 

after treatment using subcutaneous iFn-gamma injection. 

results: All patients became successfully tolerized to previously offensive foods (changes in clinical severity scores by food 

challenge from 15.9 ± 3.6 to 1.8 ± 1.0 points, p 0.05) in a group of only iFn-gamma treatment 

without food, from 14.6 ± 3.6 to 14.1 ± 3.0 points (p>0.05) in a group of only food challenge without iFn-gamma treatment, and 

from 15.9 ± 3.7 to 15.4 ± 4.3 points (p >0.05) in a untreated group with neither iFn-gamma nor food. 

Conclusions: non-igE-mediated food allergy can be successfully treated by relevant oral immunotherapy using iFn-gamma. iFngammaƒnseemed 

to be necessary for the tolerance induction. 

3210 

THE rolE oF immUnoTHEraPY in aSTHma anD rHiniTiS 

Hwejeh, l. 

Chest Department, AlAsAD UniVErsitY HOsPitAl in DAmAsCUD, Damascus, syria. 

immunotherapy (sit ) is the only currently available treatment that deals with the main cause of allergic disease by modifying the 

immune response 

Our study is a retrospective study in alasad university hospital in Damascus syria to identify the causative allergens and to evaluate 

the efficacy of immunotherapy . 

We studied 345 patients with well-documented history of rhinitis(68%) , or asthma (47%). 

140 patients received either sublingual or subcutaneous immune therapy and followed the protocol of sit. 

results showed 65.9% improvement in asthmatic patients with pollen allergy , 

And 78% improvement in asthmatic patients with mites allergy. 

Patients with rhinitis due to mites allergy had 76.4% improvement 

While patients with rhinitis allergic to pollen had 70.1% improvement 

3211 

CHroniC aSTHma in aDUlTS 

Aguilar, D. 

mEDiCinE DiVisiOn, JUArEZ HOsPitAl, mexico DF, mexico. 

Alterations of forced vital capacity (FVC) and one-second forced expiratory volume (FEV1) forms part of the alterations present 

in chronic asthma. in an area that is aggressive for the health of the asthmatic patients as the city of mexico for its height, air 

pollution, overpopulation and migratory flows, the evolution of this disease to be different to other people living in other places 

with characteristics less damaging their environment. We used spirometry system to study 50 patients staying more than 5 years 

in the Valley of mexico 

with diagnosis of moderate persistent asthma. measurmenet made to that end of the values of FVC and FEVi in early morning 

without using bronchodilators and steroids systemic or topical. statistic : missing system. results: 35 females and 15 males, 

aged between 18 and 81 years old standard dev, in female 12.91, mean 39, standard dev. in male: 13.44, mean 35.5. He won 

the following most common pattern: Bronchial Hyperreactivity+ normal spirometry 39% in females. male sex in the peripheral 

moderate obstruction+ bronchial hyrresponsiveness in 33%. Conclusion: in both sexes the prevalence is the obstruction from mild, 

moderate and severe. most patients had bronchial hyperreactivity. 

3212 

SUBCUTanEoUS immUnoTHEraPY For TrEE PollEn allErgY WiTH a PrEParaTion WiTH oPTimiSED allErgEn 

alUminiUm HYDroXiDE raTio: an oPEn laBEl oBSErVaTional STUDY inVESTigaTing TolEraBiliTY anD 

EFFECTiVEnESS in THE roUTinE USE in DailY PraCTiSE 

neumann, U. 1 , Wolf, H. 2 , schnitker, J. 3 and Wuestenberg, E. g. 4 

1 2 3 Ent-Physician, Wolmirstedt, germany. Clinical Development, AlK-Abelló, Wedel, germany. institut für angewandte statistik, 

Bielefeld, germany. 4medical and regulatory Affairs, AlK-Abelló, Wedel, germany. 

Background: For subcutaneous immunotherapy (sCit) allergens usually are adsorbed to aluminium hydroxide (alum) for slow 


FinAl PrOgrAm

ABstrACts 

allergen release (depot effect). in addition alum also acts as an adjuvant that enhances the immunological effect. therefore, a sCit 

product with an optimised allergen/alum ratio allows reducing the maximum dose applied for maintenance therapy and shorter updosing 

schedules. in this open observational study the tolerability and effectiveness in the routine use in daily practise of a product 

with an optimised allergen/alum ratio with a five-injection up-dosing schedule was investigated. 

methods: Patients with rhinoconjunctivitis with/without asthma induced by birch/tree pollen were treated with a sCit depot 

preparation (Birch or tree-mix, AVAnZ, AlK-Abelló, Hørsholm, Denmark) containing 15% of the allergen content and 50% of the 

alum content compared with the widely used AlK allergen product for sCit (Alutard sQ, AlK-Abellò, Hørsholm, Denmark). therapy 

was initiated by up-dosing with 5 injections (300, 600, 3.000, 6.000, 15.000 sQ+) in weekly intervals and was continued by 

maintenance injections of 15.000 sQ+ with 14 and 28 days intervals. 

results: in total 409 patients were documented (Birch: 81, tree mix: 328 patients). the effectiveness of the treatment was rated as 

good or very good by 88.2% of the patients (Birch 85.1%, tree-mix 88.8%) and 90.7% by the investigators (Birch 87.2%, tree-mix 

91.5%). Adverse events were in general mild to moderate local reactions and occurred in 22.7% of the patients mostly at up-dosing 

(18.8% of patients). serious adverse events were reported in 5 patients (1.2%). Among them, the causality was rated as ‘possible’ 

in 3 patients. Overall the tolerability was assessed as good or very good by 96.8% of the patients (Birch 100.0%, tree-mix 96.1%) 

and 97.1% by the investigators (Birch 98.1%, tree-mix 96.6%). 

Conclusion: A sCit product with an optimised allergen/adjuvant ratio (AVAnZ) routinely used in the daily practise with 5 injections 

up-dosing was evaluated by patients and physicians to be effective and well tolerated. 

3213 

immUnomoDUlaTorY PoTEnTial oF mESEnCHYmal STEm CEll ProViDE a PromiSing alTErnaTiVE For TrEaTmEnT oF 

liVEr TranSPlanTaTion 

Ayatollahi, m. 1 , Entezam, m. 2 and geramizadeh, B. 3 

1 2 transplant research Center, stem Cells & transgenic research Center, shiraz University of medical sciences, shiraz, iran. genetic 

Department, shiraz University of medical sciences. 3transplant research Center, shiraz University of medical sciences. 

introduction: liver transplantation is the final treatment for the end stage of liver failure due to the hepatic dysfunction. 

Considering several limitations in this approach and based on the fact that mesenchymal stem cell (msC) do not elicit alloreactive 

lymphocyte to response due to immune modulations, this project was design to improve isolation, culture, characterization and in 

vitro differentiation of human msC into hepatocyte like-cell using different protocols and culture conditions. methods: Bone marrow 

of healthy donors was aspirated from the iliac crest after obtaining approval of Ethic Committee and informed consent to use 

these samples for investigational use. the adherent cells expanded rapidly and maintained with periodic passages until a relatively 

homogeneous population was established. the identification of these cells was carried out by differentiation potential into osteocyte 

and adipocyte. transdifferentiation of human msCs into hepatocyte-like cells was undertaken in response to a novel specific culture 

condition. results: the differentiation of msCs into osteoblast is determined by deposition of a mineralized extracellular matrix. 

Adipocytes are identified by their morphology and staining. Hepatic cells were demonstrated in vitro functions characteristic of liver 

cells. Conclusion: We have defined conditions under which human msCs can be isolated and expanded from human bone marrow. 

these cells can be amplified about 108-fold in 6 weeks, and were capable of transdifferentiation into liver-like cells. Understanding 

the cellular and molecular biology of msCs may be new insights into their clinical applications. 

Keywords: immunomodulatory Potential, Human mesenchymal stem cells, Clinical applications, liver transplantation 

PoSTEr SESSion 3-3: Pediatric allergies 

3300 

STUDY oF THE rElaTionSHiP BETWEEn ToTal anD SPECiFiC igE in SCHool agE aSTHmaTiC CHilDrEn 

Al Janabi, O. A. 

Allergy, Allergy And Asthma Center Baghdad, Baghdad, iraq. 

Asthma is a common and heterogeneous respiratory disease, usually associated with increased levels of total igE, even in subjects 

negative for specific igE to common aeroallergens. 

to identify the relationship between total and specific igE levels in school age Asthmatic children, determine the frequency of 

total igE in related to age, family history and gender in asthmatic children, clarify the relationship between specific igE levels and 

asthma, residence, and age, furthermore ; determine the frequency of asthmatic children in relation to family history, age, gender 

and residence. 

this study was conducted at the Allergy and Asthma Center – Baghdad, 499 children with mild intermitted asthma of both genders 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

included in this study, divided into 3 age groups (6-10, 11-14, and 15-19) years submitted to a questionnaire with evaluation of 

both total igE and specific igE antibodies to House Dust mite levels. 

the results were arranged in figures and tables and given as mean ± sD, values and data were analyzed using sPss version 14. 

the differences between the study’s groups were tested by using (AnOVA). P < 0.05 was accepted as statistically significant. 

male children were 270 (54%), 229 (46%) were female children, 290 of them live in urban area while only 209 live in rural area, 

there is a significant relationship between sD of specific igE levels and total igE in asthmatic children with a P value (0.000) and 

this relationship were significant in relation to positive family history with a p value= 0.003. 

Even many Population studies have shown an association between prevalence of asthma and total serum immunoglobulin E (igE) 

levels independent of specific reactivity to common allergens, this study found that there is a significant relationship between the 

total igE levels and the specific igE levels in asthmatic children and both total igE and specific igE levels are high in asthmatic 

children with positive family history of asthma. 

3301 

a STaTiSTiCal STUDY oF THE moST Common allErgEnS in CHilDrEn, WHo SUFFEr From DiSEaSES or allErgiC 

rEaCTionS in THE CiTY oF laTaKia (SYrian CoaST) 

Did, g. s. 

department of pediatric – faculty of medicine – tishreen University – lattakia - syria, lattakia, syria. 

this study was carried out in group of 639 children (298 girls and 341 boys), children aged 2 to 18 years . 

they were divided into 3 groups: 

1- (2 – 5 years old: 205 children) 

2- (> 5 – 13 years old: 289 children) 

3- (> 13 – 18 years old: 145 children) 

A sPt* used 6 aeroallergens: domestic moth, rot fungus (mould mixing**), grass mix pollen, cat dander, olive pollen, grain pollen***. 

521 (81.53 %) were reactive to at least one of the aeroallergens. Among the sPt-positive patients, a positive prick-test reaction to 

the house dust mites (87.33 %) was most common followed by mould (42.80 %) , 5 grasses mixing (34.35 %) , olive pollen (32.82 

%) , cat dander (30.13 %) , 4-cereals pollen (21.88 %). 

therefore, it appears that the prevelance of sPt reactivity to common aero allergens is high among lattakian allergic children, 

particularly in those with asthma and in all age groups. 

Dr. ghazal Dib: Assistant professor - department of pediatric – faculty of medicine – tishreen University – lattakia - syria 

* sPt: skin Prick test 

** mould mixing: Alternaria alternata, cladosporium, penicillium. 

3302 

ConnECTionS oF aSTHma anD rESPiraTorY inFECTionS in BoSnian CHilDrEn 

Bajraktarevic, A. 1 , Hadzimurtezic, A. 1 , Pavlovic, V. 1 , miokovic, m. 1 , mahinic, A. 1 , selimovic, A. 2 , suljevic, i. 3 , Hadzimurtezic, Z. 4 and 

sporisevic, l. 5 

1 2 Pediatrics Department, Public Health insitution of Canton sarajevo, sarajevo, Bosnia. Pulmonology Pediatrics Department, 

Pediatrics Clinic sarajevo, sarajevo, Bosnia. 3Department for Biochemistry, Clinical medical Center sarajevo, sarajevo, Bosnia. 

4 5 Asthma Department, UmC sarajevo- Clinic for Pulmology, sarajevo, Bosnia. Pediatrics Department, First medical Aid 

BACKgrOUnD: asthma is the most common chronic childhood illness. the kids patient exhibits prolonged expirations, increased 

use of accessory muscles for breathing, barrel chest, tachypnea, cyanosis, wheezing, exertional dyspnea, scattered rhonchi, coarse 

crackles and late-stage clubbing.Colds are caused by many types of viruses causing virtually the same symptoms. 

mEtHODs: the main issue in diagnosis is differentiating respiratory viruses, which cause most cases, from bacterial infection such 

as pneumonia comparing with asthma , which would benefit from treatment with antibiotics, and from influenza, for which antivirals 

are effective. gram stain of the sputum is necessary in all but the most severe cases of asthma and other respiratory diseases such 

as upper and lower respiratory infection . 

rEsUlts: the severity of the asthma will depend on the amount of lung tissue involved and type of pneumonia or severity chronic 

obstructive lung disease in children. During period 2005-2009, 8864 children with respiratory syncytial virus, 625 with influenza 

virus, 1813 with parainfluenza virus, and 1902 with adenoviruses were evaluated in connection with asthma at Primary Children’s 

medical Center sarajevo, First medical Aid and Pediatrics Clinic sarajevo. 

DisCUssiOn: the diagnostic labeling of presumed nonbacterial upper and lower respiratory tract infection is unclear. 


FinAl PrOgrAm

ABstrACts 

COnClUsiOns: Empiric treatment with antibiotics is to be considered only for critically ill kids asthmatic patients.. treatment 

is often empiric and based on history and examination. the rapid spread of antibiotic resistance in community pathogens has 

underscored the urgency for reducing unnecessary antibiotic use. Childhood asthma is a heterogeneous disease, which can start 

early or late in childhood and be transient or persistent. 

KEY WOrDs: Asthma , respiratory infections, Children, Diagnostic. 

3303 

CHilDHooD aSTHma anD oPPorTUniSTiC inFECTionS oF HiV PoSiTiVE CHilDrEn in BoSnia anD HErZEgoVina 

Bajraktarevic, A. 1 , Hadzimurtezic, A. 1 , Omerovic, m. 1 , mahinic, A. 1 , Hadzimurtezic, Z. 2 , Djurdjevic Djulepa, A. 3 , sporisevic, l. 4 , 

selimovic, A. 5 , Vranic, B. 6 and suljevic, i. 7 

1 2 Pediatrics Department, Public Health insitution of Canton sarajevo, sarajevo, Bosnia. Asthma Department, UmC sarajevo- Clinic 

for Pulmology, sarajevo, Bosnia. 3Perinatology Department, general Hospital sarajevo, sarajevo, Bosnia. 4Pediatrics Department, 

First medical Aid sarajevo, sarajevo, Bosnia. 5Pulmonology Pediatrics Department, Pediatrics Clinic sarajevo, sarajevo, Bosnia. 

6 7 Pulmonology Pediatrics Department, infectious Clinic sarajevo, sarajevo, Bosnia. Department for Biochemistry, Clinical medical 

Center sarajevo, sarajevo, Bosnia. 

intrODUCtiOn: Opportunistic infections are the most common complication of AiDs. increased understanding of the pathogenesis 

of HiV and associated opportunistic pathogens has led to effective prophylaxis for many of these infections. asthma (ginA) 

guidelines (modification for children) also recommend a measure of severity that is based on daily medication regimen and 

response to treatment. 

mEtHODs: HiV is present in body fluids especially blood and semen especially in the early and late phases of the disease in 

children. this was a randomized, double-blind controlled trial conducted between 2005 and 2009 in a primary, secondary and 

tertiary care pediatric pulmonology departments. 

rEsUlts: the rate of new HiV infections has fallen in our country. When CD4 + t cells drop below about 400 per μl, the kids patients 

immunity is sufficiently weakened that opportunistic infections begin. these are infections caused by organisms that ordinarily do 

not cause disease symptoms in immunocompetent children. 

DisCUssiOn: the epidemic of AiDs in Bosnia and Herzegovina is stabilizing but at an unacceptably high level. 

COnClUsiOns: asthma is the most common chronic childhood illness. the following opportunistic infections and conditions can 

frequently occur in children with AiDs as viral infections like herpes simplex virus, lymphoid interstitial pneumonia , shingles 

, cytomegalovirus infection , parasitic infections such as a pneumonia caused by Pneumocystis carinii, toxoplasmosis, serious 

bacterial infections such as bacterial meningitis, tuberculosis, salmonellosis and fungal infections. 

KEY WOrDs: HiV, Children, Opportunistic infections, treatment, Asthma. 

3304 

THE EFFECT oF CEllUloSE PoWDEr (naSalEZE) on THE CoUrSE oF SEaSonal allErgiC rHiniTiS 

Kherkheulidze, m. , Kavlashvili, n. , Kandelaki, E. and Adamia, n. 

Pediatrics, state medical University, tbilisi, georgia. 

the aim of the study was to assess the effectiveness of cellulose powder extract on prophylactic treatment of seasonal allergic 

rhinitis in children. We studied 38 patients with mean age 13,3±3,7 years, already diagnosed seasonal allergic rhinitis according 

to the isAAC and AriA criteria and at least double value of total igE immunoglobulin. All children received nasaleze inhaled powder 

once or twice a day based on symptom severity during one month. Before starting and at the end of the treatment all children had 

clinical examination. We evaluated nasal symptom score (0-4) according to their symptoms (nasal obstruction, rhinorrea, sneezing, 

itching), total igE, eosinophils of nasal secretion and quality of life (PrQlQ, published by E. Juniper). the study reveals that relief of 

symptoms was obtained within 0.1-3 hours after taking medication. the mean of the clinical nasal symptom score was 3,02±0,8 

at the beginning and 1,23±0,9 at the end of the treatment (p

ABstrACts 

ABstrACts 

3305 

EPiDEmiologY oF rHiniTiS in SEConDarY SCHool CHilDrEn USing mSYPQ (moDiFiED Sino-naSal oUTComE TEST-20 

YoUng PErSon QUESTionnairE) anD ComPariSon WiTH moDiFiED SnoT-20 USED in aDUlT CommUniTY BaSED SUrVEY 

sami, A. s. 


Background: 

rhinitis is significantly prevalent in the adult community but this research aimed to explore the prevalence of nasal and paranasal 

symptoms within the age group of 11-16 years while also assessing, within the same student population, the prevalence of 

impaired sleep, social and emotional function, time off school and visits to the family doctor. 

the sino-nasal Outcome test -20 (snOt-20) questionnaire, a valid disease related quality of life instrument, was modified for use 

on secondary school children for this project. the modified snOt-20 for Young Person Questionnaire, msYPQ was used in secondary 

school children in east london with the result compared to a similar adult survey. 

method 

the pilot project tested msYPQ according to EPOs criteria. EPOs positive showed significantly high score on msYPQ confirming the 

presence of the disease (rhinitis/rhinosinusitis), while EPOs negative had very low to zero score on msYPQ. this confirmed that 

msYPQ can identify subjects with rhinitic symptoms and is a good instrument to assess the effect on quality of life. 

the msYPQ was used in a face-to-face interview and postal survey for children aged between 11-16 years in three large east 

london schools. the data was collected and analysed for the prevalence of rhinitis, associated symptoms and effects on quality of 

life. 

results: 

the results showed that over 32% of secondary school children suffered rhinitic symptoms (cough was identified as one of the 

most significant symptoms). A similar prevalence of 30% was found in adults. 

more than 21% of secondary school students had their quality of life affected by rhinitis and more than 47% took between 2-15 

days off school due to rhinitic symptoms. in adults these values were 25% and 10% respectively. Conclusion: 

this analysis confirmed that rhinitis is a common problem in the 11-16 year age group. it affects quality of life and performance at 

school, as students have to take days off from the school and are frustrated by their symptoms. 

this study also confirms that msYPQ is a good tool for identifying the prevalence of rhinitis symptoms in 11-16 age group and their 

effect on quality of life. 

3306 

SEVErE aToPiC DErmaTiTiS ComPliCaTED WiTH FooD ProTEin-inDUCED gaSTroinTESTinal SYnDromE, CaSE rEPorT 

oF 5 inFanTS 

Yamamoto, K. , nomura, i. , shoda, t. , tsumura, Y. , Yoshida, K. , Horimukai, K. , Fukuie, t. , Futamura, m. , narita, m. and Ohya, Y. 

Division of Allergy, national Center for Child Health and Development, tokyo, Japan. 

Objective:sPlAD (severe Protein loss in Atopic Dermatitis), is an extreme form of atopic dermatitis in infants and their serum 

protein is lost through inflamed skin (Pediatr Allergy immunol 2002, 13(4):287-94). Food Protein-induced gastrointestinal syndrome 

(FPigs) is cell-mediated food allergy mainly involves gastrointestinal tract (Curr Opin Allergy Clin immunol. 2009;9(4):371-7). the 

prevalence of both sPlAD and FPigs has been increasing since the 1990’s in Japan. Co-existence of these two conditions in an 

infant may become a serious impact on health and growth. As we experienced 5 patients, we would like to clarify clinical features 

of these patients. 

method:A diagnosis of sPlAD was made if the patient showed; (1) severe atopic dermatitis, (2) total serum protein less than -2 sD 

of the normal value. FPigs was suspected if their gastrointestinal symptoms were stopped by the avoidance of offending food and 

confirmed by food challenge test. Five patients were enrolled and evaluated clinical features and biological markers (serum total 

protein, peripheral eosinophil count, total igE, specific igE antibodies, and stool cytology). 

result:two girls and 3 boys aged 4~6 months old showed severe AD (100%), serous skin discharge (100%), diarrhea (100%), 

bloody stool (100%) and vomiting (20%). Body weight was -3.2 ~ -1.6sD at the diagnosis. their serum total protein was 3.7 ~ 

4.9g/dl. Peripheral blood eosinophil count was 6~29 %. total igE was 32 ~ 1163kU/l. Dermatitis was treated with proper skin care 

and topical steroid therapy and responded well. serum total protein was recovered promptly. But diarrhea was persisted and food 

elimination was performed. Food challenge test revealed that wheat, rice and soy were the offending food. their body weight was 

recovered after treatment of both conditions. 


FinAl PrOgrAm

ABstrACts 

Conclusion:sPlAD and FPigs, both rare forms of allergic diseases, coexisted in 5 infants. this leads to an idea that there may be 

common factors concerning pathogenesis of those 2 conditions. 

3307 

THE PrEValEnCE oF CHilDHooD aSTHma, allErgiC rHiniTiS anD aToPiC DErmaTiTiS in YErEVan 

gambarov, s. s. , Kostanyan, l. V. and Zakharyan, A. 

Clinical immunology and Allergy, Yerevan state medical University after m. Heratsi, Yerevan, Armenia. 

aim-the aim of this research was to explore the prevalence of childhood asthma, allergic rhinitis and atopic dermatitis via 

standardized methods in Yerevan, which allow comparing our results with the international data. 

methods- We have delivered standardized questionnaires of ‘the international study of Asthma and Allergies in Childhood’ (isAAC) 

to 3079 parents of 6-7 years old pupils (73% response rate) and 3002 13-14 years old pupils (94% response rate) from a random 

sample of 52 schools of Yerevan in october-december 2008. During the second phase we have also investigated the respiratory 

function in the current wheezing group (98 and 105 pupils in 6-7 and 13-14 age groups respectively), transient wheezing group 

(122 and 116) and control group (30 in each age group) with the use of portable spirometer and bronchial reversibility test (two 

puffs of salbutamol àerosol were used to measure the reversibility). 

results-the lifetime prevalence of wheezing was 9% in 6-7 years old children and 8.4% in 13-14 years old children. Current 

wheezing (i.e. wheezing in past 12 months) was observed in 3.7% and 4% first and ninth grade schoolchildren, and self-reported 

doctor diagnosed asthma was observed in 0.5 and 0.8% respectively. 

in the younger age group the prevalence of lifetime rhinitis was 6.2%, current rhinitis-4.3%, and doctor diagnosed allergic 

rhinitis-1%.For the older group the data were-11.7%, 8.5% and 1.9% respectively. 

the prevalence of atopic eczema in the 6-7 old age group was 2.4% current eczema-1.4%, and diagnosed atopic eczema 0.6%. in 

the older age group the lifetime prevalence of eczema was 4.4%, current eczema-3.2% and diagnosed atopic eczema-1.1%. 

the spirometry results show that there is no statistically significant difference of forced expiratory volume in 1 second (FEV1) 

between the wheezing and control groups, but the bronchial reversibility was statistically higher in wheezing group (both age 

groups p=0.001 and p< 0.0005 for 6-7 and 13-14 age groups respectively). 

Conclusion-Our data conclude that Yerevan is a region of low prevalence of asthma and other atopic disorders, but since the 

prevalence of the symptoms of these diseases is several times higher than diagnosed diseases, we can conclude that allergies are 

underdiagnosed in Yerevan. 

3308 

PrEVEnTaBlE imPaCT oF SUPlaTaST ToSilaTE DoSagE on aSTHma onSET in inFanTS 

norifumi, O. 1 , norifumi, O. 2 , Kentaro, m. 3 , Hiroaki, O. 4 , Atsushi, i. 5 , Yutaka, K. 5 , toshiaki, s. 2 and takeshi, n. 2 

1 2 3 Pediatrics, Chiba Aiyukai memorial Hospital, Chiba, Japan. Pediatrics, Kitasato University school of medicine, Japan.. Department 

of Pediatrics, Chiba Aiyukai memorial Hospital, Chiba, Japan. 4Department of Pediatrics, tokyo Kousei-nenkin Hospital, Japan. 

5Department of Pediatrics, Yokohama City minato red Cross Hospital, Japan. 

Background: recent epidemiology suggests the increasing prevalence of allergic diseases including asthma in the industrialized 

countries, which necessitates the analysis of the mechanisms of allergic diseases and development of the effective treatment. 

suplatast tosilate (iPD) has been shown to be clinically effective for the treatment of hypersensitivity and childhood asthma, and it 

is a novel antiallergic agent that suppresses several processes, including the synthesis of il-4 and il-5 in both human and murine 

th2 cells. However, the effect of iPD to restrain the bronchial asthma onset of an infant having an established allergic factor has not 

been examined. Hence influence on asthma onset by the iPD dosage in patients who repeated 1-3 times wheeze after the life that a 

shift to the childhood asthma was observed. 

Objective and methods: the object is 39 patients who accepted 1-3 times wheeze after birth ranging from 6 months to 3 years in 

age. After an observation period of two weeks, they were divided into 3 groups; theophyline treated group (group A), theophyline + 

iPD group (group B), and iPD alone (group C). the clinical evaluation was performed concerning frequency of coughing and wheeze, 

and that of the β2-receptor agonist inhalation consumption in every four months with an asthma diary. in addition, allergic tests; 

peripheral blood eosinophile count and serum igE value were determined in every four months. 

results and Discussion: As for the coughing, the frequency fell not significantly 12 months later (the last four months) as compared 

to the first four months in all groups. Concerning the wheeze, the significant decrease in particular was examined in group B, C. As 

for the frequency of the β2-receptor agonist inhalation consumption, the significant decrease was observed in group B and C, but 

not in group A. the meaningful change of the peripheral blood eosinophile count was not observed in group A and C. However it 

increased 8 and 12 months later significantly in group B. the serum igE value increased 12 months later in group A and B, whereas 

such a meaningful increase was never recognized in group C. iPD likely restrains an increase of serum igE value. Conclusion: iPD 


FinAl PrOgrAm 

ABstrACts

ABstrACts 

ABstrACts 

regulates igE production and eosinophile count in patients who show 1-3 times wheeze after life, and has likely action to improve 

wheeze expression clinically. 

3309 

EValUaTion oF Small airWaYS oF JaPanESE CHilDHooD aSTHma BY HrCT anD iTS aSSoCiaTion WiTH SnPS 

tomikawa, m. 1 , Oguma, t. 2 , niimi, A. 2 , matsui, E. 3 , Kondo, n. 3 and Ebisawa, m. 1 

1 2 Pediatrics, sagamihara national Hospital, sagamihara, Japan. respiratory medicine, graduate school of medicine, Kyoto 

University, Kyoto, Japan. 3Pediatrics, graduate school of medicine gifu University, gifu, Japan. 

Objectives: the purposes of these studies were to evaluate small airways in childhood asthma by high-resolution computed 

tomography (HrCt) and to examine the association of single nucleotide polymorphisms (snPs) with small airways’ obstruction. 

methods: ten asthmatic patients (6 males & 4 Females) treated with iCs were recruited to the evaluation of small airways. By 

using HrCt, low attenuation area (lAA) % and mean lung density (mlD) % were examined. ninety three patients (70 males & 23 

females) were recruited to snPs study and were divided into %FEF50%≥80% group (n=34) and %FEF50%

ABstrACts 

autumn only in 13% of cases in spring and summer in 12 % of cases. the Pt was positive in 93% of cases, sensitization to dust 

mites is in first place (67%) followed by the olive tree (32%), cypress (29%), Parietaria (22%), 5 grasses (21%) , Alternaria (25%), 

dog (20%), cat (15%) and cockroach (15%). the monsensibisation was found in 20% of cases, the majority were polysensitized 

with mites. 

Discussion - comments: the mites are the main aero-allergen, in accordance with literature data. sensitization to pollen 

occupies the second place, this may be related with age bracket included in the study (children over 4 years). We note an important 

awareness to mold. Polysensitization is often encountered in older children. in some cases, there was a discrepancy between the 

history and results of skin prick tests based research to discuss specific igE. 

Conclusion: the diagnosis is mainly clinical allergy. the examination and skin tests constitute the cornerstone. they are sufficient 

in most cases to diagnose the cause. Clinical common sense and prudence of the findings are required in the interpretation of 

results. 

3312 

THE rolE oF CHiTinaSE-liKE ProTEinS in allErgiC inFlammaTion on PEDiaTriC aDEnoiD TiSSUE 

shin, s. 1 , Ye, Y. 2 , lee, K. 1 , Kim, s. 1 , Cho, J. 1 and Park, H. 2 

1 2 Otorhinolaryngology-Head and neck surgery, Kyung Hee University, seoul, south Korea. Department of Allergy & rheumatology, 

Ajou University school of medicine, suwon, south Korea. 

Chitin is an essential structural component of the fungal cell wall and is present in the exoskeleton of arthropods and the 

microfilarial sheath of nematodes. recent findings have not only demonstrated that mammals produce chitinases, but also that 

increased secretion of chitinases is closely associated with th2-dominated pathophysiological conditions including infection, 

fibrosis, allergy and asthma. the purpose of this study is to measure the level of chitinase-like proteins (ClPs) in adenoid tissues 

from atopic children, and to know its role in allergic inflammation on pediatric adenoid tissues. Forty atopic subjects, who were 

sensitized to more than one common aeroallergen, and 40 non-atopic subjects undergoing adenotonsillectomy, were recruited. 

the level of ClPs was measured by ElisA. immunoassays using adenoid tissue homogenate were performed to quantify the levels 

of total igE, eosinophil cationic protein (ECP), mast cell tryptase and Alternaria-specific igE. median level of ClPs was tend to be 

higher in atopics than in non-atopics (p = 0.056). median level of ECP was significantly higher in atopics than in non-atopics (p < 

0.001), while no difference was seen in tryptase. the level of ClPs in adenoid tissues strongly correlated with ECP or tryptase level. 

in addition, median level of ClPs was significantly higher in children showing positive response for Alternaria-specific igE than in 

children with negative response. in conclusion, chitinase showed close relationships with ECP or tryptase in allergic inflammation 

on pediatric adenoid tissues, and increased locally in fungal allergen sensitized children. 

3313 

PaSSiVE SmoKing iS a maJor DETErminanT oF EXHalED niTriC oXiDE lEVElS in allErgiC aSTHmaTiC CHilDrEn 

laoudi, Y. 1 , nikasinovic, l. 2 , sahraoui, F. 1 , grimfeld, A. 1 , momas, i. 2 and Just, J. 1 

1 2 Department of Asthma and Allergic Diseases, Armand trouseau Children University Hospital, Paris, France. laboratory of Public 

health and Environment, Faculté des sciences Pharmaceutiques et Biologiques, Université Paris-Descartes, EA 4064, Paris, France. 

Background: Fraction of exhaled nitric oxide (FenO), as a reflection of allergic bronchial inflammation, is considered to be a 

treatment follow-up parameter in allergic asthmatics. Factors such as active smoking can, however, influence FenO measurement 

and are thus taken into account in the interpretation of this parameter. in children, the evidence in favor of an impact of passive 

smoking (Ps) on FenO measurement is controversial. 

objective: to evaluate the impact of Ps on measurement of FenO in allergic asthmatic children. 

methods: 70 non-treated allergic asthmatic children over the age of 5 years underwent phenotype characterisation by 

measurement of on-line FenO, spirometry, and allergic tests (skin prick tests, total and specific igE levels, blood eosinophilia). 

Children were considered to be exposed to Ps when at least 5 cigarettes per day were declared by the family to be smoked at 

home. 

results: mean FenO in 48 children unexposed to Ps was 62.3 ± 29.1 ppb versus 30.3 ±17.6 ppb in 22 exposed children (p

ABstrACts 

ABstrACts 

3314 

PrEValEnCE oF allErgiC rHiniTiS in SCHool CHilDrEn PoPUlaTion oF TBiliSi anD WESTErn gEorgia 

Kherkheulidze, m. , Adamia, n. , Kandelaki, E. and Kavlashvili, n. 


the aim of the study was assessment of prevalence of allergic rhinitis in schoolchildren population of tbilisi and Western georgia 

region. the cross sectional research was conducted through questioning of the random and representative groups of population. 

schools and groups for study were selected by simple randomization. 

First stage of research covered 5569 children 53.7 % boys and 46.3 % girls aged from 6 to 16, who were divided into 2 groups – 

i group consist with 1049 child aged 6-10 years and ii group (1651 children ) aged 11-16 years. statistical data processing was 

provided by software package sPssv12. 

According to questioning, repeated sneezing episodes were identified in 14, 2 % of i group and 18, 7 % in elder group. the study 

reviled that most frequent symptom of allergic rhinitis is rhinorea and pruritus, while most disturbing symptom is nasal obstruction. 

Pruritus was indicated in 15.7 % elder group 20, 1 % in younger group. rhinorrhea was stated in 16.4, mostly among older 

schoolchildren. nasal obstruction was identified in 15.9 of respondents, with high frequency in younger schoolchildren. 

spread of the symptoms of Ar was reliably higher among boys (p

ABstrACts 

mEtHODs: ninety-six children aged 3 to 17 years old were recruited, including 80 with perennial Ar and 16 with non-Ar as 

controls. medical history was taken and physical examination, serum specific igE, total igE, peripheral blood eosinophil count, 

nasal smear were conducted. the nasal symptom score was calculated for each patient from a questionnaire and correlated with 

laboratory data. Bivariate correlation analysis and multiple linear regression analysis were done to compare the correlation among 

clinical markers and symptom score. 

rEsUlts: levels of all allergic markers in children with Ar were significantly different from those in non-allergic children. All of 

the markers were related to the severity of Ar in Pearson correlation analysis. On logistic regression analysis, only serum allergenspecific 

igE were independent predictors. 

COnClUsiOn: these results suggest that serum allergen-specific igE is correlated with the severity of perennial Ar in children. 

3317 

rolE anTEnaTal anD PoSTnaTal FaCTorS in oCCUrrEnCE oF an allErgiC DiaTHESiS aT CHilDrEn WHo HaVE BEEn 

Born in CiTY loCaTED nEar To nUClEar EnTErPriSE 

Petrushkina, n. 

Departament of physiology, Ural state Univercity Physical Culture, Chelyabinsk, russia. 

the purpose of research has consisted in an establishment antenatal and postnatal factors in occurrence of an allergic diathesis at 

children who have been born in city located near to nuclear enterprise. 

research included 335 children (the main group) at which parents worked at the nuclear enterprise and 466 children - the control. 

We applied a method logistic regression which have allowed to choose from set of attributes the most significant for occurrence of 

an allergic diathesis. 

Frequency of an allergic diathesis in the basic group was 12,6 on 100 children, in the control - 11,9 (distinctions are doubtful). the 

early sensitization on the first year of a life and to development of attributes of an allergic diathesis was promoted by such factors 

as medicamentous treatment in second half of pregnancy (0,65), threat of interruption (0,72 (0,84) and early placentation, and 

also mixed (0,72) and artificial feeding (0,73). For occurrence of this pathology significant there was a residing at adverse social 

conditions (0,71). the role of a parental professional irradiation is not established. 

thus occurrence of an allergic diathesis at children does not depend on a professional irradiation of parents and is defined 

(determined) by known non- radiation factors which promote early specialization. 

3318 

an ESTimaTion oF THE rESPTaTorY’S FUnCTion CHilDrEn WHo liVE nEar aTomiC PlanT 

Petrushkina, ii, n. 

Departament of Physiology, Ural state Physical Culture, Chelyabinsk, russia. 

Diseases of respiratory system one of conducting places in a pathology of children’s age. in this connection with the purpose of 

an estimation of a condition of respiratory system research of function of external breath at practically healthy 420 children is 

executed. 

investigation was carried out with use of the automated microprocessor a method of registration of parameters curve “stream - 

volume” of the forced exhalation. For an estimation of a condition of function of external breath studied the following parameters: 

frequency of breath 1 minute, vital volume of lungs (VVl), minute volume of breath (mVB), respiratory volume (rV), volume of the 

forced exhalation for 1 secund (VFE), the maximal volumetric speed at a level of 75%, 50%, 25% and 25-75% forced VVl, peak 

volumetric speeds of an exhalation and breath (ÏÎÑ), test tiffno attitude forced VVl for 1 s to VVl (%), resistance of respiratory ways. 

Absolute values of volume-speed parameters increase with the years. relative sizes did not depend on age and were above the 

bottom border of physiological norm. so VVl were within the limits of 90-107%. Parameters of bronchial passableness at a level 

75, 50, 25% FVVl laid from 96 up to 131%. With the years the increase on the average on 200-510 sm3 at boys is marked (higher 

than at girls). so, at girls of 9 years VVl it is equal 1950 sm3 , and 15 years - 3650 sm3 , at boys – 2320 and 4190 sm3 accordingly 

(Ð

ABstrACts 

ABstrACts 

3319 

PUlmonarY FUnCTion TEST in HEalTHY CHilDrEn 7 To 9 YEarS aFTEr rESPiraTorY Viral inFECTionS 

Kartasasmita, iV, C. B. , sudarwati, s. , Wulandari, D. A. , suwardi, A. U. , saptaputra, W. , nuradi, i. , Kuswandewi, m. and simoes, E. 

A. 

Department of Child Health, Hasan sadikin/school of medicine Padjadjaran University, Bandung, indonesia, Bandung, indonesia. 

Background. Pulmonary function test (PFts) provides an assessment of airflow limitation. it can be used for diagnosis of asthma in 

children over 6 years of age. Viral infections during infancy can cause wheezing (roberg et al. 2007) and abnormal lung function 

at 6 years of age (Anderson et al. 2008). the aim of this study is to determine the PFts in children 7 to 9 years after viral respiratory 

infections. 

materials and methods. this study is a part of a nested case control study entitled “rsV and recurrent wheezing in indonesia: 

7 – 9 year follow-up study with lung function studies”. the PFts were obtained from December 2009 to July 2010. All the 

children were healthy when the PFts were performed. to determine the obstructive impairment we analyzed FEV1 and FEV1/ 

FVC ratio. reversibility was measured in children with % predictive FEV1 < 80%, before and after administration of a short acting 

bronchodilator.the FEV1/FVC ratio > 80% showed normal lung function. 

results. A total 218 children, age 8.4 to 13.4 years old (mean 10.5 ± 1.05 years), consisted of 111 boys and 107 girls, were 

enrolled in the study. Fifty two cases with history of viral respiratory infections, and 166 controls. the viral pathogens found were: 

rsV (25), rV (19), mix rsV and rV (6), and hmPV (2). the mean ± sD of FEV1 in cases (2.12 ± 0.42) was slightly higher than 

control (2.04 ± 0.39), however, the difference was statisticaly not significant. the mean ± sD FEV1/FVC ratio in cases (90.76 ± 

9.15) and in control (92.28 ± 6.5) were also statisticaly no difference. in 14 out of 218 (6.4%) children the reversibility test were > 

12%. 

Conclusion: the PFts in children with history of viral respiratory infections are within normal limit, 7 to 9 years later. the rate of 

asthma is low. 

3320 

CliniCal ProFilE anD riSK FaCTorS in HoSPiTaliZED CHilDrEn WiTH BronCHioliTiS 

Kirovski, i. , nikolovski, l. , sazdovski, A. , micevska, V. and seckova, l. 

Department of Pulmonology and Allergology, University Children’s Hospital, skopje, macedonia. 

Bronchiolitis, potentially life-threatening respiratory condition is the most common reason for hospitalization in infancy. 

the aim of the study was to determine the risk factors and to describe the clinical profile in children who were admitted to the 

hospital with a diagnosis of bronchiolitis. 

methods: We studied 153 children, the analysis we conducted was restricted to first hospitalizations within the first 18 months. Data 

from their medical records were entered in a specially designed questionnaire. the following data were analyzed: age on admission, 

gender, gestational age, association of bronchiolitis with children’s nutritional status. Clinical factors such as chronic lung disease 

and congenital heart disease (CHD) were investigated. socioeconomic status, possible exposure to passive smoking, family history 

of atopy, number of siblings were also investigated. the respiratory rate, oxygen saturation, presence of chest wall retractions and 

cyanosis upon admission were noted. 

results: Of the 153 patients 85 were males and 68 females, giving a male to female ratio of 1,25:1. sixty-six percent were 

under 9 months of age and were previously healthy children. We could not find significant association between bronchiolitis and 

nutritional status. shorter or lack of exclusive breastfeeding was a risk factor for the hospitalization. 37% of the children were 

passive smokers. socioeconomic status was a factor in increasing the risk of hospital admission in our patients. Prevalence rate 

for bronchiolitis was higher in rural areas compared to urban ones. Other factors, such as a diagnosis of bronchodysplasia, CHD, 

and prematurity were not significantly associated with being hospitalized for bronchiolitis. the best method for initial assessment of 

bronchiolitis was oxygen saturation. 

Conclusion: the youngest infants and those who have been exposed to cigarette smoke after birth have the highest risk of 

bronchiolitis. the association between socioeconomic factors and hospitalization indicates that these factors may have a significant 

influence on the hospitalization rate in bronchiolitis during infancy. the promoting of exclusive breastfeed ing is for prevention of 

infectious diseases and also because of the lesser aggressive course of bronchiolitis in breastfed children. 


FinAl PrOgrAm

ABstrACts 

3321 

aSSoCiaTion BETWEEn THE oVErWEigHT anD allErgiC DiSEaSES in SCHool agE CHilD PoPUlaTion oF TBiliSi 

Kherkheulidze, m. , Kavlashvili, n. , Kandelaki, E. and Adamia, n. 


the study aims evaluation of relationship between Bmi indices and allergic disorders. Cross-sectional study was conducted 

through questioning of the random and representative groups of school age child population in tbilisi. in addition spirometry and 

measurement of weight was conducted. A written, self-completed questionnaire modified from the isAAC core questionnaire 

concerning symptoms and Bmi-per-age cut-off points based on WHO standard reference were used. Overweight status was 

defined as a Bmi greater than the age- and gender-specific 85th percentile. At all 1026 children from 10-14 years old were involved 

in study. the study reveled that Bmi was more then 85 % in 28, 1 % cases. 19.3% children reported a physician-diagnosed allergic 

disease, and 28.6% reported undiagnosed allergic symptoms the Overweight subjects more frequently reported ever having 

wheezing (27.7 vs. 16.2%, p

ABstrACts 

ABstrACts 

Conclution: our study confirmed that familial atopic diseases and exposure to smoking were significant predictors of childhood 

Asthma. 

3324 

EValUaTion oF USing VBg inSTEaD oF aBg in aSTHma EXaCErBaTion 

Fatemi Khorasgani, m. 1 , niazi, E. 1 and Farzaneh, s. 2 

1 2 Pediatrics, islamic Azad University-najafabad branch, isfahan, iran. Anesthesiology, islamic Azad University-najafabad branch, 

isfahan, iran. 

Background- Arterial blood gas (ABg) is the gold standard for blood gas analysis. in asthma exacerbation severity evaluation, 

ABg is important; however, it is somehow difficult and potentially dangerous. Using venous blood gas (VBg) sampling is easier for 

less expert personnel, with minimal damage for patient. in this research, we want to compare aBg & VBg indexes in asthma 

exacerbation. 

method-this prospective diagnostic study was done with convenience sampling of 50 admitted children, 36 boys and 14 girls, 

between 3 and 6 years (mean 4.18) in pediatric emergency ward in shariati hospital in isfahan with asthma exacerbation during 

2009 spring. they were normotensive and their temperature between 36-38.5. ABg sampling as routine in asthma management 

and VBg sampling along other venous tests were done without any excessive cost for patient. For both ABg and VBg test, we used 

an AVl compact1 analyzer few minutes after sampling. For data analysis, we utilized sPss ver. 14. 

results-From 17 patient with PO < 60 in ABg, 100% had PO 60, 80.77% had PO >60 in VBg 

2 2 2 2 

and for seven with normal PO in ABg 57.14% had normal value in VBg. For relationship between PO in ABg and VBg P-value was 

2 2 

0.04. 

From nine patients with PCO > 45 in ABg, 66.67% had PCO >45 in VBg.For 22 patients with PCO

sPEAKEr AnD CHAirPErsOn inDEX 

last name First name Session Page number 

Ababneh Hani PO2-1 45 

Ababneh Hani Ps5 49 

Ababneh Hani sY15 51 

Abdul rahman Hussain sY3 39 

Agarwal mK Ps5 49 

Al Ameri Hatem Pg11 35 

Al Frayh Abdulrahman Ps3 43 

Al Hammadi suleiman Pg7 34 

Al Hammadi suleiman PO2-2 45 

Al Kendi Hussain sY15 50 

Al nuaimi Asma sY9 44 

Al rawas Omar Pg1 33 

Al tamemi salem Pg13 35 

Al tamemi salem PO2-3 45 

Al Zaaibi Ashraf sY5 41 

Al-Ahmad mona sY5 41 

Al-Ahmed nasser PO3-2 49 

Al-Dhekri Hasan sY12 48 

Al-Dhekri Hasan sY16 51 

Al-Harfi Harb Kn3 51 

Al-Herz Waleed Ps3 43 

Al-muhsen saleh sY5 41 

Alrayes Hassan Ps1 38 

Al-sayegh mirza Ps6 52 

Alsowaidii shirina Ps2 40 

Ansotegui ignacio J. Pg9 34 

Arifhodzic nermina sY5 41 

Awad Zeinab sY2 39 

Baena-Cagnani Carlos E. Pg13 35 

Baena-Cagnani Carlos E. sY7 43 

Baena-Cagnani Carlos E. Css 46 

Bahna sami Pg16 36 

Bahna sami Pg22 37 

Baratawidjaja Karnen Ps4 46 

Barnes neil Pg6 34 

Barnes neil sY4 41 



Bateman Eric Pg11 35 

Bateman Eric sY1 38 

Bateman Eric PO1-2 42 

Bateman Eric sY9 44 

Bateman Eric Kn2 45 

Baz Zeina sY5 41 

Benyounes Abdenour sY15 50 

Blaiss michael s. Pg12 35 

Blaiss michael s. Pg13 35 

Blaiss michael s. sY13 49 

Blaiss michael s. Ps6 52 

Bonini sergio Pg15 35 

Bonini sergio sY2 39 

Bonini sergio sY13 50 

Bork Konrad special session 37 

Boulet louis-Philippe Pg6 34 

Boulet louis-Philippe sY4 41 



Boulet louis-Philippe Ps6 52 

Braido Fulvio Pg10 34 

Braido Fulvio Pg18 36 




Braido Fulvio sY6 42 

Braido Fulvio sY13 50 

Canonica g. Walter Pg8 34 

Canonica g. Walter Pg23 37 

Canonica g. Walter Ps2 40 

Canonica g. Walter Css 46 

Canonica g. Walter sY10 47 

Canonica g. Walter Kn3 51 

Casale thomas B. Pg1 33 

Casale thomas B. Pg24 37 

Casale thomas B. Ps4 46 

Chikhladze manana V. sY13 49 

Craig timothy J. special session 37 

Cua-lim Felicidad Ps4 46 

Custovic Adnan sY9 44 

Custovic Adnan sY12 48 

Custovic Adnan Ps5 49 

Douagui Habib sY2 39 

Ebisawa motohiro Pg16 36 

Ebisawa motohiro sY8 44 

Ehlayel mohamad sY1 38 

Elbousify Ahmed sY10 47 

El-gamal Yehia sY15 51 

Fiocchi Alessandro Pg16 36 

Fiocchi Alessandro sY11 47 

Fiocchi Alessandro PO3-3 49 

Fiocchi Alessandro Ps5 49 

Fiocchi Alessandro sY14 50 

gonzález-Díaz sandra Pg7 34 

gonzález-Díaz sandra Pg22 37 

gonzález-Díaz sandra sY8 44 

gonzález-Díaz sandra PO2-2 45 

gorski Pawel sY16 51 

greenberger Paul Pg12 35 

greenberger Paul PO1-3 42 

greenberger Paul Ps3 43 

greenberger Paul sY8 44 

Haahtela tari Pg9 34 

Haahtela tari Pg21 36 

Haahtela tari sY1 39 

Haahtela tari sY7 44 

Halwani rabih sY9 44 

Hanna Kamal sY12 48 

Hasnain syed m. sY5 41 

Hasnain syed m. PO1-1 42 

Holgate stephen t. Ps1 38 

Holgate stephen t. sY4 41 

Hossny Elham sY3 39 

Husain maitham sY13 49 

Hwejeh lubna sY8 44 

ibrahim Abdulla Pg4 33 

idrees majdi sY15 50 

irani Carla PO1-3 42 

irani Carla sY6 42 

Jee Young-Koo sY4 41 

Joo Cho Young Ps3 43 

Kalayci Omer Pg8 34 

Kalayci Omer Pg20 36 

Kalayci Omer sY11 47 

Kaliner michael A. Pg8 34 

KEY: Css – Company sponsored symposium Kn – Keynote lunch symposium Pg – Postgraduate Course 

PO – Poster session Ps – Plenary session sY – symposium 


FinAl PrOgrAm

sPEAKEr AnD CHAirPErsOn inDEX 


Kaliner michael A. Pg21 36 

Kaliner michael A. sY3 39 

Kaliner michael A. Ps2 40 

Kaliner michael A. PO1-4 42 

Kelkar Pramod Pg7 34 

Kelkar Pramod Pg17 36 

Kelkar Pramod sY16 51 

Khadadah mousa Kn2 45 

Kheder Ali Ben Ps1 38 

Kherallah nizar Pg9 34 

Kherallah nizar Pg24 37 

Kherallah nizar PO3-3 49 

Kherallah nizar sY14 50 

Kowalski marek l. Pg5 33 

Kowalski marek l. Pg24 37 

Kowalski marek l. sY3 40 

ledford Dennis Pg4 33 

ledford Dennis Pg14 35 

ledford Dennis sY2 39 


ledford Dennis Ps3 43 


lemanske robert Ps3 43 

lemanske robert sY7 43 

lemanske robert PO3-1 49 

lemanske robert sY14 50 

lockey richard F. Pg14 35 

lockey richard F. Pg19 36 

lockey richard F. Ps1 38 

lockey richard F. Kn1 40 

lockey richard F. sY6 42 

lockey richard F. Ps5 49 

lockey richard F. sY15 50 

lötvall Jan sY11 47 

mahboub Bassam Pg3 33 

makoto nagata sY10 47 

masjedi mohammad reza sY15 50 

mohamed Yousser sY4 41 

nelson Harold Pg18 36 

nelson Harold Pg23 37 

nelson Harold Ps3 43 

nelson Harold sY10 47 

nizam iqubal mohammed PO1-2 42 

O’Byrne Paul Pg6 34 

O’Byrne Paul Pg15 35 

O’Byrne Paul sY1 38 

O’Byrne Paul Ps4 46 

Park Hae-sim Pg5 33 

Park Jung-Won sY1 38 

Park Hae-sim sY3 40 

Park Jung-Won PO3-1 49 

Park Hae-sim sY16 51 

Pawankar ruby Pg4 33 

Pawankar ruby sY3 39 

Pawankar ruby Kn1 40 

Pawankar ruby Ps2 40 

Peters stephen Pg1 33 

Peters stephen Pg11 35 

Peters stephen sY9 45 

Peters stephen Ps4 46 




Polosa riccardo Pg3 33 

Polosa riccardo Pg17 36 

Polosa riccardo sY12 48 

reda shereen sY7 43 

rodriguez-Perez noel sY3 39 

rodriguez-Perez noel PO1-1 42 

rogala Barbara PO2-3 45 

rogala Barbara sY13 49 

rosenwasser lanny Pg20 36 

rosenwasser lanny special session 37 

rosenwasser lanny Ps1 38 

rosenwasser lanny sY2 39 

rosenwasser lanny PO2-1 45 

rosenwasser lanny Ps4 46 

rouadi Philip PO1-4 42 

saleh Fadhel sY4 41 

sallam Anwar Ps2 40 

sallam Anwar sY14 50 

sanchez-Borges mario Pg18 36 

sanchez-Borges mario Css 46 

sanchez-Borges mario Ps6 52 

sayah Zineb sY15 50 

scadding glenis Ps2 40 

scadding glenis sY10 47 

scadding glenis PO3-2 49 

sepiashvili revaz i. sY2 39 

shah Ashok Ps1 38 

singh meenu sY7 43 

slavyanskaya tatiana Pg21 36 

tadros Faheem Css 46 

Viegi giovanni Pg3 33 

Viegi giovanni Ps1 38 

Viegi giovanni Ps6 52 

Virchow Christian sY11 47 

Yoon Ho Joo sY6 42 

Zaitoun Fares Pg22 37 

Zitt myron Pg2 33 

Zitt myron Pg19 36 

KEY: Css – Company sponsored symposium Kn – Keynote lunch symposium Pg – Postgraduate Course 

PO – Poster session Ps – Plenary session sY – symposium 


FinAl PrOgrAm

POstEr AUtHOr inDEX 



author Poster # Session author Poster # Session author Poster # Session 

Adamia, n 3304 PO 3-3 




Afifi, m 1203 PO 1-2 

Afifi, m 1308 PO 1-3 

Agarwal, m 1106 PO 1-1 

Agondi, rC 1306 PO 1-3 



Aguilar, D 3211 PO 3-2 

Ahanchian, ii, H 2301 PO 2-3 

Ahmad, nEQ 1326 PO 1-3 

Ahmed, F 1205 PO 1-2 

Ahmed, s 1302 PO 1-3 

Aiello, V 3208 PO 3-2 

Akiyama, K 1305 PO 1-3 

Al Frayh, A 1118 PO 1-1 

Al Hammadi, s 1303 PO 1-3 

Al Janabi, OA 3300 PO 3-3 

Al Qerem, W 1317 PO 1-3 

Al shammari, nH 1215 PO 1-2 

Al sini, H 1118 PO 1-1 

Al-Ahmad, m 3203 PO 3-2 

Al-Ahmad, ms 1304 PO 1-3 

Al-Ahmed, n 1304 PO 1-3 

Al-Ahmed, n 3203 PO 3-2 

Al-Enezi, A 3203 PO 3-2 

Al-Fadel, r 3200 PO 3-2 

Al-Jahdali, H 1322 PO 1-3 

Al-muhsen, s 1320 PO 1-3 





Al-Onizi, A 1304 PO 1-3 

Al-Qassim, A 1118 PO 1-1 

Al-sheyab, nA 1209 PO 1-2 

Al-shouli, st 3108 PO 3-1 

Al-tamemi, sH 1116 PO 1-1 

Alaiya, A 1118 PO 1-1 

Alkhalil, m 2305 PO 2-3 

Alyasin, Jr., s 3111 PO 3-1 

Amboni, P 3204 PO 3-2 

Amboni, P 3205 PO 3-2 

Amin, D 1408 PO 1-4 

Anıl, B 1214 PO 1-2 

Angino, A 1309 PO 1-3 

Angino, A 1312 PO 1-3 

Antal, P 3110 PO 3-1 

Antolín-Amérigo, D 2306 PO 2-3 

Ar, Ks 2100 PO 2-1 

Arafa, E 1216 PO 1-2 

Aranda, A 1109 PO 1-1 

Ardito, s 3208 PO 3-2 

Arici, m 2104 PO 2-1 

Arifhodzic, n 1304 PO 1-3 

Arifhodzic, n 3203 PO 3-2 

Arifhodzic, nA 3202 PO 3-2 

Arshi, s 1402 PO 1-4 

Arshi, s 2218 PO 2-2 

Athota, rr 3109 PO 3-1 

Atsushi, i 3308 PO 3-3 

Atzeni, i 3201 PO 3-2 

Aun, mV 1324 PO 1-3 

Aun, mV 1217 PO 1-2 

Ayatollahi, m 3213 PO 3-2 

Ayatollahi, m 3114 PO 3-1 

Aynacı, E 1214 PO 1-2 

B g, P 1108 PO 1-1 

B m, r 1307 PO 1-3 

B m, r 1108 PO 1-1 

B.Kartasasmita, C 1117 PO 1-1 

Babaie, D 2218 PO 2-2 

Bae, Y 2102 PO 2-1 

Bae, Y 1316 PO 1-3 

Baghali, Z 1113 PO 1-1 

Bajraktarevic, A 3302 PO 3-3 

Bajraktarevic, A 3303 PO 3-3 

Baker, J 2308 PO 2-3 

Baker, J 2309 PO 2-3 

Baker, J 2310 PO 2-3 

Baker, J 2311 PO 2-3 

Baker, J 2312 PO 2-3 

Baldacci, s 1309 PO 1-3 

Baldacci, s 1312 PO 1-3 

Banerji, A 2309 PO 2-3 



Bansal, s 1106 PO 1-1 

Bar-Or, A 2108 PO 2-1 

Bartolome, B 2205 PO 2-2 

Bartuzi, Z 2210 PO 2-2 

Bartuzi, Z 2211 PO 2-2 

Batpenov , n 2106 PO 2-1 

Bemanian, mH 3207 PO 3-2 

Bennert, J 1109 PO 1-1 

Bennert, J 1112 PO 1-1 

Benyounes, sr., A 3311 PO 3-3 

Bielory, l 2308 PO 2-3 

Bielory, l 2309 PO 2-3 

Bisaccioni, C 1306 PO 1-3 

Bisaccioni, C 1324 PO 1-3 

Blagbrough, s 1211 PO 1-2 

Blaiss, ms 1408 PO 1-4 

Bodi, sg 1325 PO 1-3 

Boesoerie, sF 2109 PO 2-1 

Borbotti, m 1309 PO 1-3 

Borbotti, m 1312 PO 1-3 

Borges, DB 1217 PO 1-2 

Borick, m 2213 PO 2-2 

Boughellout, H 2214 PO 2-2 

Bousquet, J 1213 PO 1-2 

Britton, m 1211 PO 1-2 

Broom, C 2308 PO 2-3 

Broom, C 2309 PO 2-3 

Broom, C 2310 PO 2-3 

Broom, C 2311 PO 2-3 

Broom, C 2312 PO 2-3 

Bruno, m 3201 PO 3-2 

Busse, P 2308 PO 2-3 

Busse, P 2309 PO 2-3 

Busse, P 2311 PO 2-3 

Butt, A 2305 PO 2-3 

C r, sB 1108 PO 1-1 

Cagnoli, g 2209 PO 2-2 

Camacho, n 1120 PO 1-1 

Camci, g 2104 PO 2-1 

Cardona, r 2307 PO 2-3 



Cardona-Villa, r 2216 PO 2-2 

Carrozzi, l 1312 PO 1-3 

Caruso, C 2212 PO 2-2 

Castro-Coelho, AP 1324 PO 1-3 

Castro-Coelho, AP 1217 PO 1-2 

Cavdar, g 2104 PO 2-1 

Cerrai, s 1309 PO 1-3 

Cerrai, s 1312 PO 1-3 

CH, Cm 1401 PO 1-4 

Chang, Y 1314 PO 1-3 

Chang, Y 1218 PO 1-2 

Chao, ss 1407 PO 1-4 

Chaynava, A 2304 PO 2-3 

Chehregani, A 1113 PO 1-1 

Chen, YY 3104 PO 3-1 

Chikhladze, mV 1111 PO 1-1 

Chinchilla, C 2216 PO 2-2 

Chinchilla, C 2110 PO 2-1 

Chisholm, A 1210 PO 1-2 

Chiung, Ym 3104 PO 3-1 

Chkhaidze, i 3310 PO 3-3 

Cho, J 3312 PO 3-3 

Cho, s 1314 PO 1-3 

Cho, s 1218 PO 1-2 

Cho, Ys 2102 PO 2-1 

Cho, Ys 1314 PO 1-3 

Cho, Ys 1316 PO 1-3 

Cho, Ys 1218 PO 1-2 

Cho, YJ 2204 PO 2-2 

Cho, YJ 1314 PO 1-3 

Cho, YJ 1218 PO 1-2 

Choi, B 1314 PO 1-3 

Choi, B 1218 PO 1-2 

Choi, D 1220 PO 1-2 

Choi, i 1110 PO 1-1 

Chudasama, J 1109 PO 1-1 

Chudasama, J 1112 PO 1-1 

Chun, YH 3113 PO 3-1 

Corrigan, CJ 1313 PO 1-3 

Craig, tJ 2308 PO 2-3 




Crisp, J 1209 PO 1-2 

D’Auria, E 2209 PO 2-2 

Daneshvar, n 3322 PO 3-3 

Daneshvar, n 3323 PO 3-3 

Danzig, m 1409 PO 1-4 

Das, AB 1109 PO 1-1 

Das, AB 1112 PO 1-1 

Davis-lorton , m 2309 PO 2-3 



De Donno, m 3208 PO 3-2 

Della torre, E 1204 PO 1-2 

Della torre, F 1204 PO 1-2 

Devereux, g 2201 PO 2-2 

Di Pede, F 1309 PO 1-3 

Di Pede, F 1312 PO 1-3 

Did, gs 3301 PO 3-3 

Diez, s 2307 PO 2-3 


FinAl PrOgrAm





Diez, s 2217 PO 2-2 

Diez, s 2110 PO 2-1 

Djordjevic, Dr 3315 PO 3-3 

Djurdjevic Djulepa, A 3303 PO 3-3 

Dr, g 1307 PO 1-3 

Dr, g 1108 PO 1-1 

Eatemadi, A 1403 PO 1-4 



Ebisawa, m 3309 PO 3-3 

El Hassan, E 1413 PO 1-4 

Elizabeth, P 3112 PO 3-1 

Elizabeth, P 2215 PO 2-2 

Ellis, s 1210 PO 1-2 

Entezam, m 3213 PO 3-2 

Entezam, m 3114 PO 3-1 

Fakim, n 1304 PO 1-3 

Falagiani, P 3201 PO 3-2 

Falus, A 3110 PO 3-1 

Fancello, P 3201 PO 3-2 

Farid, r 2301 PO 2-3 

Farrokhi, sr., s 1402 PO 1-4 

Farzaneh, s 3324 PO 3-3 

Fatemi 

Khorasgani, m 3324 PO 3-3 

Fayyaz Jahani, sr., F 2300 PO 2-3 

Florio, g 2208 PO 2-2 

Forutan, H 3323 PO 3-3 

Fukuie, t 3306 PO 3-3 

Futamura, m 3306 PO 3-3 

gaarder, Pi 1313 PO 1-3 

gad-El-rab, mO 1118 PO 1-1 

gaeta, F 2212 PO 2-2 

gaffuri riva, V 1204 PO 1-2 

gallagher, r 1209 PO 1-2 

gambarov, ss 3307 PO 3-3 

gates, D 1409 PO 1-4 

gemou-Engesaeth, V 1313 PO 1-3 

gendlin, gE 1202 PO 1-2 

geramizadeh, B 3213 PO 3-2 

ghalehbaghi, B 2218 PO 2-2 

ghosh, n 1109 PO 1-1 

ghosh, n 1112 PO 1-1 

ghrahani, r 1327 PO 1-3 

giavina-Bianchi, P 1306 PO 1-3 



giovannini, m 2209 PO 2-2 

gomez-garcia, C 2216 PO 2-2 

gonzález, mr 2206 PO 2-2 

gonzález 

mendiola, mr 2205 PO 2-2 

gonzález-Cervera, J 2306 PO 2-3 

gopalan, g 1409 PO 1-4 

grant, JA 2308 PO 2-3 



grimfeld, A 3313 PO 3-3 

grogaard, JB 1313 PO 1-3 

grønnerød, C 1201 PO 1-2 

Hadadi, E 3110 PO 3-1 

Hadzimurtezic, A 3302 PO 3-3 

Hadzimurtezic, A 3303 PO 3-3 

Hadzimurtezic, Z 3302 PO 3-3 

Hadzimurtezic, Z 3303 PO 3-3 

Halvorsen, s 1313 PO 1-3 

Halwani, r 1320 PO 1-3 





Hamed, mn 1219 PO 1-2 

Hameed, WA 1308 PO 1-3 

Hamid, Q 1313 PO 1-3 

Hamid, Q 1320 PO 1-3 

Hamid, Q 1321 PO 1-3 

Hamid, Q 1322 PO 1-3 

Hamid, Q 1323 PO 1-3 

Hamid, Q 2108 PO 2-1 

Han, mY 3206 PO 3-2 

Harun, r 1326 PO 1-3 

Hasegawa, m 1305 PO 1-3 

Hasnain, sm 1118 PO 1-1 

Hassan, m 1219 PO 1-2 

Haughney, J 1210 PO 1-2 

Havstad, s 1302 PO 1-3 

Heier, HE 1313 PO 1-3 

Hekmatdoost, Jr., A 2203 PO 2-2 

Henríquez-santana, A 2306 PO 2-3 

Higashi, n 1305 PO 1-3 

Hiroaki, O 3308 PO 3-3 

Hong, C 1110 PO 1-1 

Horimukai, K 3306 PO 3-3 

Hossny, E 2213 PO 2-2 

Howarth, DP 1216 PO 1-2 

Hukutomi, Y 1305 PO 1-3 

Huliraj, n 1307 PO 1-3 

Huliraj, n 1108 PO 1-1 

Hullam, g 3110 PO 3-1 

Hur, g 3206 PO 3-2 

Hur, J 1107 PO 1-1 

Hurewitz, D 2308 PO 2-3 




Hwejeh, l 3210 PO 3-2 

iaia, ml 3208 PO 3-2 

ibrahim, A 1303 PO 1-3 

irwan, n 1117 PO 1-1 

irwan, n 1327 PO 1-3 

ishii, t 1305 PO 1-3 

isozaki, A 2207 PO 2-2 

Jabbari, F 2301 PO 2-3 

Jahromi, mm 1310 PO 1-3 

Jang, mK 1316 PO 1-3 

Jee, Y 1107 PO 1-1 

Jeong, W 1107 PO 1-1 

Jin, H 1102 PO 1-1 

Jin, H 1104 PO 1-1 

Johnson, C 1302 PO 1-3 

Joukaji, A 1100 PO 1-1 

Jung, s 1107 PO 1-1 

Just, J 3313 PO 3-3 

Kajiwara, K 1305 PO 1-3 

Kaklamanos, g 2202 PO 2-2 

Kalfus, i 2308 PO 2-3 





Kalil, J 1306 PO 1-3 

Kalil, J 1324 PO 1-3 

Kalil, J 1217 PO 1-2 

Kamenov, BA 2304 PO 2-3 

Kamenov, BA 3315 PO 3-3 

Kamenov, s 2304 PO 2-3 

Kandelaki, E 3304 PO 3-3 




Kang, H 1314 PO 1-3 

Kapalczynski, W 1400 PO 1-4 

Kartasasmita, iV, CB 3319 PO 3-3 

Kartasasmita, CB 1327 PO 1-3 

Kashwani , m 1215 PO 1-2 

Katsuhito, i 3102 PO 3-1 

Katsunuma, t 3102 PO 3-1 

Kausar, mA 1106 PO 1-1 

Kavlashvili, n 3304 PO 3-3 




Kawano, Y 2207 PO 2-2 

Kemper, C 3108 PO 3-1 

Kentaro, m 3308 PO 3-3 

Khare, m 1325 PO 1-3 

Kherkheulidze, m 3304 PO 3-3 




Khouqeer, r 1105 PO 1-1 

Khoury, A 1100 PO 1-1 



Kim, D 1107 PO 1-1 

Kim, HH 3113 PO 3-1 

Kim, J 1102 PO 1-1 

Kim, J 1104 PO 1-1 

Kim, Jt 3113 PO 3-1 

Kim, JY 1110 PO 1-1 

Kim, J 1102 PO 1-1 

Kim, J 1104 PO 1-1 

Kim, J 2103 PO 2-1 

Kim, K 1107 PO 1-1 

Kim, K 1315 PO 1-3 

Kim, m 3316 PO 3-3 

Kim, s 1314 PO 1-3 

Kim, s 1218 PO 1-2 

Kim, s 1114 PO 1-1 

Kim, s 1314 PO 1-3 

Kim, s 1218 PO 1-2 

Kim, s 1102 PO 1-1 

Kim, s 1314 PO 1-3 

Kim, s 3312 PO 3-3 

Kim, t 2102 PO 2-1 

Kim, t 3206 PO 3-2 

Kim, t 1314 PO 1-3 

Kim, t 1316 PO 1-3 

Kim, t 1218 PO 1-2 

Kim, t 1314 PO 1-3 

Kim, WK 3103 PO 3-1 

Kim, Y 1107 PO 1-1 


FinAl PrOgrAm





Kimura, s 1412 PO 1-4 

Kirovski, i 3320 PO 3-3 

Kleiner, m 1413 PO 1-4 

Knowles, V 1211 PO 1-2 

Kondo, n 3309 PO 3-3 

Kose, s 2104 PO 2-1 

Kostanyan, lV 3307 PO 3-3 

Kovacevic, sP 3315 PO 3-3 

Krzych-Falta, Jr., E 1400 PO 1-4 

Kumar, P 3101 PO 3-1 

Kurbacheva, Om 1202 PO 1-2 

Kuswandewi, m 3319 PO 3-3 

lammardo, Am 2209 PO 2-2 

laoudi, Y 3313 PO 3-3 

lara, P 2206 PO 2-2 

lara de la rosa, P 2205 PO 2-2 

latysheva, EA 1202 PO 1-2 

ledford, D 2305 PO 2-3 

lee, B 1220 PO 1-2 

lee, sr., JH 3209 PO 3-2 

lee, J 1220 PO 1-2 

lee, Js 3113 PO 3-1 

lee, K 3312 PO 3-3 

lee, mK 1114 PO 1-1 

lee, sJ 1114 PO 1-1 

lee, sn 1114 PO 1-1 

lee, s 1314 PO 1-3 

lee, t 2102 PO 2-1 

lee, WY 1114 PO 1-1 

lee, Y 1314 PO 1-3 

lee, Ys 2102 PO 2-1 

lee, Ys 1316 PO 1-3 

levy, r 2308 PO 2-3 

levy, r 2309 PO 2-3 

levy, r 2311 PO 2-3 

levy, r 2312 PO 2-3 

li, HH 2309 PO 2-3 

li, r 2108 PO 2-1 

limonta, A 1204 PO 1-2 

lin, JB 3104 PO 3-1 

liu, Ps 3104 PO 3-1 

lockey, rF 2305 PO 2-3 

lumry, W 2308 PO 2-3 

lumry, W 2309 PO 2-3 

lumry, W 2310 PO 2-3 

lusawa, A 1400 PO 1-4 

mahboub, B 1303 PO 1-3 



maherbanai, s 3207 PO 3-2 

mahinic, A 3302 PO 3-3 

mahinic, A 3303 PO 3-3 

maietta, g 3208 PO 3-2 

maio, s 1309 PO 1-3 

maio, s 1312 PO 1-3 

majangsari, rgD 2109 PO 2-1 

majangsari, rgD 1117 PO 1-1 

majd, A 1113 PO 1-1 

makrilia, n 2202 PO 2-2 

mandelli, m 2209 PO 2-2 

manning , m 2310 PO 2-3 

manolopoulos, l 2202 PO 2-2 

manzano, D 2306 PO 2-3 

marone, g 2208 PO 2-2 

martín, E 2206 PO 2-2 

martín Casáñez, E 2205 PO 2-2 

martínez, D 2206 PO 2-2 

martínez, n 2206 PO 2-2 

martínez Bohigas, D 2205 PO 2-2 

martínez Borque, n 2205 PO 2-2 

martini, F 1309 PO 1-3 

martini, F 1312 PO 1-3 

mascarenhas, l 1211 PO 1-2 

masumoto, A 1206 PO 1-2 

matsui, E 3309 PO 3-3 

matsumoto, K 3102 PO 3-1 

mazer, B 2108 PO 2-1 

mcgarry, K 1317 PO 1-3 

meltzer, EO 1409 PO 1-4 

merrawi, m 1100 PO 1-1 

micevska, V 3320 PO 3-3 

mikami, K 2207 PO 2-2 

min, K 1314 PO 1-3 

miokovic, m 3302 PO 3-3 

mita, H 1305 PO 1-3 

mitsui, C 1305 PO 1-3 

mn, J 1325 PO 1-3 

moatari, A 3111 PO 3-1 

moghiman, t 2301 PO 2-3 

mohamed, n 1200 PO 1-2 

mohamed, r 1200 PO 1-2 

mohd Ashari, ns 1401 PO 1-4 

mohd Ashari, ns 2100 PO 2-1 

momas, i 3313 PO 3-3 

montenegro, Fg 1324 PO 1-3 

montenegro, Fg 1217 PO 1-2 

monterrey, C 1120 PO 1-1 

moon, H 2102 PO 2-1 

moon, H 1314 PO 1-3 

moon, H 1316 PO 1-3 

moon, H 1218 PO 1-2 

moon, K 1316 PO 1-3 

mori, A 1305 PO 1-3 

mori, s 1412 PO 1-4 

mousavi, t 1402 PO 1-4 

mutyara, K 1327 PO 1-3 

mösges, r 1413 PO 1-4 

n, s 1411 PO 1-4 

n, s 1221 PO 1-2 

n r, rm 1307 PO 1-3 

n r, rm 1108 PO 1-1 

nabavi, m 2218 PO 2-2 

nabavi, m 3207 PO 3-2 

nagaraju, mK 1411 PO 1-4 

nagaraju, mK 1221 PO 1-2 

nagata, m 1206 PO 1-2 

nageotte, C 1302 PO 1-3 

nahm, D 3206 PO 3-2 

nahm, D 1218 PO 1-2 

naime, m 3112 PO 3-1 

naime, m 2215 PO 2-2 

nakagome, K 1206 PO 1-2 

nam, JH 3103 PO 3-1 

napiórkowska, K 2210 PO 2-2 

napiórkowska, K 2211 PO 2-2 

narita, m 3306 PO 3-3 

neerupudi, KB 3109 PO 3-1 

nemeth, Z 3110 PO 3-1 

neshat, l 1317 PO 1-3 

neumann, U 3212 PO 3-2 

niazi, E 3324 PO 3-3 

niimi, A 3309 PO 3-3 

nikasinovic, l 3313 PO 3-3 

nikolovski, l 3320 PO 3-3 

nirsen, g 1120 PO 1-1 

nishihara, F 1206 PO 1-2 

noh, g 3209 PO 3-2 

noma, t 2207 PO 2-2 

nomura, i 3306 PO 3-3 

norifumi, O 3308 PO 3-3 

norifumi, O 3308 PO 3-3 

nsouli, s 1410 PO 1-4 



nuradi, i 3319 PO 3-3 

nurmatov, U 2201 PO 2-2 

nurpeisov , t 2106 PO 2-1 

nurpeisov , t 2107 PO 2-1 

Ogawa, n 2207 PO 2-2 

Ogawa, n 2207 PO 2-2 

Oguma, t 3309 PO 3-3 

Ohri, m 1325 PO 1-3 

Ohya, Y 3306 PO 3-3 

Olivares, m 2216 PO 2-2 

Omerovic, m 3303 PO 3-3 

Ono, E 1305 PO 1-3 

Oricchio, C 2208 PO 2-2 

Oshiba, H 2207 PO 2-2 

Othman, r 1326 PO 1-3 

Ownby, D 1302 PO 1-3 

Palmieri, m 2208 PO 2-2 

Palomeque, sr., mt 2205 PO 2-2 

Palomeque, mt 2206 PO 2-2 

Panicker, r 1304 PO 1-3 

Paraskevopoulos, g 2303 PO 2-3 

Paraskevopoulos, J 2302 PO 2-3 

Parasuramalu, Bg 1307 PO 1-3 

Park, Cs 1316 PO 1-3 

Park, H 1102 PO 1-1 

Park, H 1104 PO 1-1 

Park, H 3312 PO 3-3 

Park, H 1314 PO 1-3 

Park, H 1218 PO 1-2 

Park, J 1107 PO 1-1 

Park, J 1110 PO 1-1 

Park, J 3206 PO 3-2 

Park, J 1314 PO 1-3 

Park, J 1218 PO 1-2 

Park, sW 1314 PO 1-3 

Park, sW 1218 PO 1-2 

Patella, V 2208 PO 2-2 

Pauk, n 2101 PO 2-1 

Pavlovic, V 3302 PO 3-3 

Pawankar, r 1303 PO 1-3 

Pawankar, r 1412 PO 1-4 

Petrushkina, n 3317 PO 3-3 

Petrushkina, ii, n 3318 PO 3-3 

Piegaia, B 1309 PO 1-3 

Pinnock, H 1210 PO 1-2 

Politi, K 2202 PO 2-2 

Popova, O 2106 PO 2-1 

Popova, O 2107 PO 2-1 


FinAl PrOgrAm





Pourpak, Z 1113 PO 1-1 

Prakash rao, m 1207 PO 1-2 

Pratt, C 1112 PO 1-1 

Price, D 1210 PO 1-2 

Price, D 1211 PO 1-2 

Price, D 1212 PO 1-2 

Price, D 1319 PO 1-3 

Price, D 1213 PO 1-2 

Psarros, P 2302 PO 2-3 

Psarros, P 2303 PO 2-3 

r, D 1221 PO 1-2 

r, g 1411 PO 1-4 

r, g 1221 PO 1-2 

r, iii, m 1411 PO 1-4 

rafique, m 1303 PO 1-3 

rafique, m 3100 PO 3-1 

raj, s 1301 PO 1-3 

ramirez, r 2216 PO 2-2 

randa, O 1215 PO 1-2 

reddy, rrK 3109 PO 3-1 

rengganis, i 1115 PO 1-1 

restrepo, m 2216 PO 2-2 




rezaei, n 1402 PO 1-4 

rha, YH 3316 PO 3-3 

ribeiro, m 1306 PO 1-3 

riedl , m 2308 PO 2-3 

riedl , m 2309 PO 2-3 

riedl , m 2311 PO 2-3 

riedl , m 2312 PO 2-3 

rodríguez- 

Domínguez, sr., B 2306 PO 2-3 

roedland, EA 1313 PO 1-3 

roh, s 1107 PO 1-1 

rojek, B 1400 PO 1-4 

romano, A 2212 PO 2-2 

roongrotwattanasiri, 

K 1412 PO 1-4 

rosifah, D 2109 PO 2-1 

ruiz Hornillos, F 2306 PO 2-3 

rumi, g 2212 PO 2-2 

ryan, D 1210 PO 1-2 

s P, PK 1307 PO 1-3 

s P, PK 1108 PO 1-1 

sA.madani, A 2300 PO 2-3 

saad, s 2213 PO 2-2 

saadeh, C 1109 PO 1-1 

sabry, EY 1300 PO 1-3 

saeki, t 2207 PO 2-2 

sah, s 1401 PO 1-4 

saha, gK 1103 PO 1-1 

ahin, F 1214 PO 1-2 

sahraoui, F 3313 PO 3-3 

saito, H 3102 PO 3-1 

salekmoghadam, A 1402 PO 1-4 

salvatici, E 2209 PO 2-2 

sam, rA 3109 PO 3-1 

sami, As 1405 PO 1-4 

sami, As 1406 PO 1-4 

sami, As 3305 PO 3-3 

samoliñski, B 1400 PO 1-4 

sanchez, J 2307 PO 2-3 



sapartini, g 2109 PO 2-1 



saptaputra, W 1117 PO 1-1 



saranac, lm 3315 PO 3-3 

sarno, g 1309 PO 1-3 

sarno, g 1312 PO 1-3 

sawas, K 3200 PO 3-2 

sazdovski, A 3320 PO 3-3 

schiavino, D 1119 PO 1-1 

schnitker, J 3212 PO 3-2 

seçik, F 1214 PO 1-2 

seckova, l 3320 PO 3-3 

sekiya, K 1305 PO 1-3 

selimovic, A 3302 PO 3-3 

selimovic, A 3303 PO 3-3 

senevirathne, K 1328 PO 1-3 

sepiashvili, ri 1311 PO 1-3 

sepiashvili, ri 1111 PO 1-1 

setiabudiawan, B 2109 PO 2-1 



shah, r 1301 PO 1-3 

shah, s 1209 PO 1-2 

shamssain, m 1317 PO 1-3 

shamssain, m 1318 PO 1-3 

sharef, sW 1116 PO 1-1 

shehab, A 2213 PO 2-2 

sheikh, A 2201 PO 2-2 

shin, KC 1114 PO 1-1 

shin, s 3312 PO 3-3 

shoda, t 3306 PO 3-3 

siddiqui, W 1106 PO 1-1 

silva, nA 1120 PO 1-1 

silvi, P 1309 PO 1-3 

simoes, EA 3319 PO 3-3 

simoes, EA 1327 PO 1-3 

simone, P 3204 PO 3-2 

simone, P 3205 PO 3-2 

simoni, m 1309 PO 1-3 

sims, EJ 1211 PO 1-2 

sinaniotis, A 2302 PO 2-3 

sinaniotis, A 2303 PO 2-3 

siribaddana, A 1328 PO 1-3 

slavyanskaya, tA 1311 PO 1-3 

sliem, H 1219 PO 1-2 

sofia, m 3112 PO 3-1 

sofia, m 2215 PO 2-2 

soto, g 2206 PO 2-2 

soto Vargas, g 2205 PO 2-2 

sporisevic, l 3302 PO 3-3 

sporisevic, l 3303 PO 3-3 

sudarwati, s 3319 PO 3-3 

sulaiman, n 1303 PO 1-3 

suljevic, i 3302 PO 3-3 

suljevic, i 3303 PO 3-3 

sus-Carrizosa, s 2216 PO 2-2 

suwardi, AU 3319 PO 3-3 

syrigos, Kn 2202 PO 2-2 

syrigou, E 2202 PO 2-2 



szalai, C 3110 PO 3-1 

takaku, Y 1206 PO 1-2 

takeshi, n 3308 PO 3-3 

takzare, A 3323 PO 3-3 

takzare, n 3323 PO 3-3 

takzaree, A 3322 PO 3-3 

takzaree, n 3322 PO 3-3 

tamayo, l 2307 PO 2-3 

taniguchi, m 1305 PO 1-3 

tanimoto, H 1305 PO 1-3 

thomas, m 1210 PO 1-2 

tillotson, g 2308 PO 2-3 





tn, B 1325 PO 1-3 

tomikawa, m 3309 PO 3-3 

torrecillas, m 2205 PO 2-2 

torrecillas, sr., m 2206 PO 2-2 

tort, m 1408 PO 1-4 

toshiaki, s 3308 PO 3-3 

tsai, CJ 3104 PO 3-1 

tsuburai, t 1305 PO 1-3 

tsumura, Y 3306 PO 3-3 

Uknis, m 2308 PO 2-3 

Uknis, m 2309 PO 2-3 

Uknis, m 2310 PO 2-3 

Uknis, m 2311 PO 2-3 

Uknis, m 2312 PO 2-3 

Ungvari, i 3110 PO 3-1 

Vafa, A 1208 PO 1-2 

Valluzzi, rl 2212 PO 2-2 

Varasteh, A 1402 PO 1-4 

Vatanchian, m 1113 PO 1-1 

Vazquez tello, A 1323 PO 1-3 

Vazquez tello, A 2108 PO 2-1 

Vegh, A 2309 PO 2-3 

Vermani, m 1106 PO 1-1 

Viegi, g 1309 PO 1-3 

Viegi, g 1312 PO 1-3 

Vijayan, V 1106 PO 1-1 

Villano, s 2308 PO 2-3 





Viola, m 2212 PO 2-2 

Virag, V 3110 PO 3-1 

Virchow, C 1319 PO 1-3 

Vranic, B 3303 PO 3-3 

Wah, WZ 2100 PO 2-1 

Wang, DY 1407 PO 1-4 

Wanigasekara, PC 1328 PO 1-3 

Wegienka, g 1302 PO 1-3 

White, m 2308 PO 2-3 

White, m 2309 PO 2-3 

Wilson, ms 3107 PO 3-1 

Wm, Wm 1401 PO 1-4 

Wolf, H 3212 PO 3-2 

Wong, Hg 2200 PO 2-2 

Wuestenberg, Eg 3212 PO 3-2 


FinAl PrOgrAm





Wulandari, DA 3319 PO 3-3 

Y, nK 1401 PO 1-4 

Yıldırım, E 1214 PO 1-2 

Yıldız, P 1214 PO 1-2 

Yagi, t 1412 PO 1-4 

Yamaguchi, t 1206 PO 1-2 

Yamamoto, K 3306 PO 3-3 

Yavas, s 2104 PO 2-1 

Ye, Y 1102 PO 1-1 

Ye, Y 1104 PO 1-1 

Ye, Y 3312 PO 3-3 

Yong, sJ 1114 PO 1-1 

Yoon, HJ 1314 PO 1-3 

Yoon, HJ 1218 PO 1-2 

Yoon, J 3113 PO 3-1 

Yoshida, K 3306 PO 3-3 

Yun, is 1110 PO 1-1 

Yutaka, K 3308 PO 3-3 

Zaharov, t 2304 PO 2-3 

Zakharyan, A 3307 PO 3-3 

Zhang, H 2105 PO 2-1 

Zhu, X 2105 PO 2-1 

Zidoune, mn 2214 PO 2-2 

Zivanovic, ss 3315 PO 3-3 

Zoratti, E 1302 PO 1-3 

Zuraw, B 2308 PO 2-3 

Zuraw, B 2309 PO 2-3 

Zuvadelli, J 2209 PO 2-2 


FinAl PrOgrAm

nOtEs 




FinAl PrOgrAm

nOtEs 




FinAl PrOgrAm

nOtEs 




FinAl PrOgrAm

Q411-10 

Allergic disease is a growing health issue in the world 

today compounded by environmental and socioeconomic 

problems and medical management. 

The World Allergy Organization Journal (WAO 

Journal)—the official publication of the World 

Allergy Organization, the only global umbrella 

organization for national and regional allergology 

and clinical immunology societies—provides a 

dynamic platform for the exchange of ideas and 

knowledge among researchers and practitioners 

from different regions of the world. 

World Allergy Organization Journal TM 

Official publication of the World Allergy Organization 

A Forum for Global 

Scientific Interactions 

Keep up with new advances in allergy, asthma and clinical immunology worldwide. 

EDITOR-IN-CHIEF 

Lanny J. Rosenwasser, MD 

Dee Lyons/Missouri Endowed Chair in 

Pediatric Immunology Research 

Professor of Pediatrics, 

Allergy-Immunology Division 

Children’s Mercy Hospital 

Professor of Pediatrics, Medicine 

and Basic Science 

University of Missouri-Kansas City 

School of Medicine 

Monthly ISSN: 1939-4551 

Free access for members of current WAO Member Societies 

Go to www.WorldAllergy.org. Click “Members Only” then “WAO Journal” 

Not a WAO member? Visit us at www.WAOJournal.org 

www.WAOJournal.org 

Visit www.WAOJournal.org and… 

✔ Examine new information that extends our 

understanding of pathogenesis and disease 

function 

✔ Learn new approaches for evaluation of disease 

and outcomes concerning treatments and 

interventions 

✔ Publish clinical reviews and editorials on basic 

and clinical translational science in allergy and 

clinical immunology 

✔ Sign up for eAlerts and receive the linked table 

of contents as soon as a new issue is posted 

Encompassing both translational research and 

clinical issues, the WAO Journal is dedicated to 

providing quality, up-to-date science to its readers, 

and a quick production schedule and worldwide 

recognition for its contributors.

DiAmOnD sPOnsOrs 

PlAtinUm sPOnsOrs 

gOlD sPOnsOr 

COllABOrAting PArtnErs 

sUPPOrting PArtnErs 

SMALL AIRWAYS 

WORKING GROUP 

sUPPOrting gOVErnmEnt PArtnErs 

Merck Sharp & Dohme (Italia) S.p.A. 

Via G. Fabbroni, 6 00191 Roma 

www.msd-italia.it www.univadis.it info@univadis.it 

Realizzato con il supporto non condizionato di Merck Sharp & Dohme (Italia) S.p.A. 

World allergy organization 

555 East Wells street, suite 1100 • milwaukee, Wi 53202 UsA 

Phone: +1 414 276 1791 • Fax: +1 414 276 3349 

WAO-1010-344

2010 WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE Final Program

Dubai Final-v20.indd - World Allergy Organization

Create successful ePaper yourself

Delete template?

Save as template?